var images_info;if (!images_info) images_info =[]; images_info["78"]={"78003":{"type":"graphic_table","displayName":"Indications for RF ablation","title":"Indications for radiofrequency (RF) ablation of cardiac arrhythmias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for radiofrequency (RF) ablation of cardiac arrhythmias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Arrhythmias cured by radiofrequency ablation</td> </tr> <tr> <td class=\"subtitle2_single\">Ablation preferred therapeutic modality</td> </tr> <tr> <td class=\"indent1\">Symptomatic Wolff-Parkinson-White (WPW) syndrome and variant preexcitation syndromes</td> </tr> <tr> <td class=\"indent1\">Selected patients with asymptomatic WPW</td> </tr> <tr> <td class=\"subtitle2_single\">Ablation indicated because of patient preference or refractoriness of arrhythmias to drug therapy</td> </tr> <tr> <td class=\"sublist2_start\">Paroxysmal supraventricular tachycardia</td> </tr> <tr> <td class=\"sublist2\">Atrioventricular nodal reentrant tachycardia</td> </tr> <tr> <td class=\"sublist2\">Accessory pathway-mediated tachycardia</td> </tr> <tr> <td class=\"sublist2\">Unifocal atrial tachycardia</td> </tr> <tr> <td class=\"indent1\">Common variety (type I) atrial flutter</td> </tr> <tr> <td class=\"indent1\">Idiopathic ventricular tachycardia</td> </tr> <tr> <td class=\"indent1\">Bundle-branch reentry tachycardia</td> </tr> <tr> <td class=\"subtitle2_single\">Ablation indicated for arrhythmias refractory to drug therapy</td> </tr> <tr> <td class=\"indent1\">Ablation of focal source of atrial fibrillation*</td> </tr> <tr> <td class=\"indent1\">Atypical atrial flutter</td> </tr> <tr> <td class=\"indent1\">Inappropriate sinus tachycardia</td> </tr> <tr> <td class=\"indent1\">Automatic junctional tachycardia</td> </tr> <tr> <td class=\"indent1\">Idiopathic ventricular premature depolarizations arising in the right ventricular outflow tract associated with severe symptoms</td> </tr> <tr> <td class=\"subtitle1_single\">Arrhythmias palliated by radiofrequency ablation; ablation indicated for arrhythmias refractory to drug therapy</td> </tr> <tr> <td>Atrial fibrillation with uncontrolled ventricular rate (atrioventricular-node ablation or modification)</td> </tr> <tr> <td>Sustained, hemodynamically stable, monomorphic ventricular tachycardia</td> </tr> <tr> <td>Sustained, hemodynamically stable, monomorphic ventricular tachycardia in patients with coronary artery disease</td> </tr> <tr> <td class=\"subtitle1_single\">Ablation procedures that are investigational or whose clinical indications are undefined</td> </tr> <tr> <td>Linear atrial lesions to eliminate atrial fibrillation</td> </tr> <tr> <td>Ablation of hemodynamically unstable monomorphic ventricular tachycardia</td> </tr> <tr> <td class=\"subtitle1_single\">Ablation not usually indicated</td> </tr> <tr> <td>Multifocal atrial tachycardia (can be palliated with atrioventricular-node ablation)</td> </tr> <tr> <td>Polymorphic ventricular tachycardia</td> </tr> <tr> <td>Ventricular fibrillation</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=5346&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Techniques and indications continue to be revised.</div><div class=\"graphic_footnotes\">* Some experts regard ablation for atrial fibrillation as the procedure of choice.</div><div class=\"graphic_reference\">Adapted from: Morady F. N Engl J Med 1999; 340:534.</div><div id=\"graphicVersion\">Graphic 78003 Version 7.0</div></div></div>"},"78005":{"type":"graphic_picture","displayName":"Eosinophilic folliculitis histology low power view","title":"Eosinophilic folliculitis histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic folliculitis histology</div><div class=\"cntnt\"><img style=\"width:292px; height:360px;\" src=\"images/PC/78005_Eosin_folliculitis_histol_l.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This low-power photomicrograph demonstrates spongiotic change with exocytosis extending from the sebaceous gland and its duct into the follicular epithelium of the infundibulum. For reasons which are not understood, the inflammatory process in HIV-associated eosinophilic folliculitis appears to be focused in these areas of the follicular apparatus.</div><div class=\"graphic_reference\">Courtesy of Whitney High, MD.</div><div id=\"graphicVersion\">Graphic 78005 Version 3.0</div></div></div>"},"78006":{"type":"graphic_picture","displayName":"Angioedema lip 1","title":"Angioedema lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angioedema lip</div><div class=\"cntnt\"><img style=\"width:396px; height:273px;\" src=\"images/ALLRG/78006_Angioedema_lip_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angioedema is a diffuse, nonpitting, tense swelling of the dermis and subcutaneous tissue. It develops over minutes to hours, and resolves over subsequent hours or days. Angioedema typically does not itch, unless it is associated with urticaria.</div><div class=\"graphic_reference\">Reproduced with permission from: Neville B, et al: Color Atlas of Clinical Oral Pathology, Lea &amp; Febiger, Philadelphia 1991. Copyright Â©1991 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78006 Version 2.0</div></div></div>"},"78008":{"type":"graphic_table","displayName":"Obstetrical gynecologic history","title":"Assessment of past obstetrical and gynecologic history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of past obstetrical and gynecologic history</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Past obstetrical history\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Date of delivery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Gestational age at delivery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Location of delivery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sex of child</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Birthweight and percentile for gestational age</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mode of delivery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Type of anesthesia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Length of labor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Outcome (miscarriage, stillbirth, ectopic, etc)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Details (eg, type of hysterotomy incision, forceps, etc)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Complications (maternal, fetal, child)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gynecologic history\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Age at menarche</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Date of last menstrual period</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Date of previous menstrual period</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cycle length and duration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Type of contraception</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Sexually transmitted infections</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Gynecologic surgery or disorders (eg, cervical, uterine, or ovarian surgery; endometriosis, fibroids, uterine anomalies)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=60124&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Obstetrical_gynecologic_his.htm</title></head></div><div id=\"graphicVersion\">Graphic 78008 Version 2.0</div></div></div>"},"78009":{"type":"graphic_figure","displayName":"Types of retinal vein occlusion","title":"Types of retinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Types of retinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:504px; height:585px;\" src=\"images/PC/78009_Types_retinal_vein_occl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black arrows show the sites of retinal vein occlusion.</div><div id=\"graphicVersion\">Graphic 78009 Version 3.0</div></div></div>"},"78010":{"type":"graphic_picture","displayName":"PAS stain of BAL fluid in alveolar proteinosis","title":"PAS stain of BAL fluid in pulmonary alveolar proteinosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PAS stain of BAL fluid in pulmonary alveolar proteinosis</div><div class=\"cntnt\"><img style=\"width:289px; height:192px;\" src=\"images/PULM/78010_BAL_in_alveolar_proteinosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cytocentrifuged bronchoalveolar lavage specimen stained with PAS shows large amounts of proteinaceous material.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 78010 Version 2.0</div></div></div>"},"78011":{"type":"graphic_table","displayName":"Inhaled GC doses for adults","title":"Estimated comparative daily doses for inhaled glucocorticoids in adolescents and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated comparative daily doses for inhaled glucocorticoids in adolescents and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Low dose</td> <td class=\"subtitle1\">Medium dose</td> <td class=\"subtitle1\">High dose</td> </tr> <tr> <td><strong>Beclomethasone HFA</strong><br /> (Qvar product available in United States)*</td> <td>80 to 160 mcg</td> <td>&#62;160 to 320 mcg</td> <td>&#62;320 mcg</td> </tr> <tr> <td class=\"indent1\">40 mcg per puff</td> <td>2 to 4 puffs</td> <td>&#182;</td> <td>&#182;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">80 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> <td>&#62;4 puffs</td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Beclomethasone HFA</strong><br /> (Qvar product available in Canada, Europe, and elsewhere)</td> <td>100 to 200 mcg</td> <td>&#62;200 to 400 mcg</td> <td>&#62;400 mcg</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">50 mcg per puff</td> <td>2 to 4 puffs</td> <td>&#182;</td> <td>&#182;</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td class=\"indent1\">100 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> <td>&#62;4 puffs</td> </tr> <tr> <td><strong>Budesonide DPI</strong><br /> (Pulmicort Flexhaler product available in United States)*</td> <td>180 to 360 mcg</td> <td>&#62;360 to 720 mcg</td> <td>&#62;720 mcg</td> </tr> <tr> <td class=\"indent1\">90 mcg per inhalation</td> <td>2 to 4 inhalations</td> <td>&#182;</td> <td>&#182;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">180 mcg per inhalation</td> <td>1 to 2 inhalations</td> <td>3 to 4 inhalations</td> <td>&#62;4 inhalations</td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Budesonide DPI</strong><br /> (Pulmicort Turbuhaler product available in Canada, Europe, and elsewhere)</td> <td>200 to 400 mcg</td> <td>&#62;400 to 800 mcg</td> <td>&#62;800 mcg</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">100 mcg per inhalation</td> <td>2 to 4 inhalations</td> <td>&#182;</td> <td rowspan=\"2\"> <p>&#182;</p> </td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">200 mcg per inhalation</td> <td>1 to 2 inhalations</td> <td>3 to 4 inhalations</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td class=\"indent1\">400 mcg per inhalation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>&#62;2 inhalations</td> </tr> <tr> <td><strong>Ciclesonide HFA</strong><br /> (Alvesco product available in United States, Europe, and elsewhere)*</td> <td>80 to 160 mcg</td> <td>&#62;160 to 320 mcg</td> <td>&#62;320 mcg</td> </tr> <tr> <td class=\"indent1\">80 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> <td>&#182;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">160 mcg per puff</td> <td>1 puff</td> <td>2 puffs</td> <td>&#62;2 puffs</td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Ciclesonide HFA</strong><br /> (Alvesco product available in Canada)</td> <td>100 to 200 mcg</td> <td>&#62;200 to 400 mcg</td> <td>&#62;400 mcg</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">100 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> <td>&#182;</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td class=\"indent1\">200 mcg per puff</td> <td>1 puff</td> <td>2 puffs</td> <td>&#62;2 puffs</td> </tr> <tr> <td><strong>Flunisolide MDI</strong><br /> (Aerospan product available in United States)*</td> <td>320 mcg</td> <td>&#62;320 to 640 mcg</td> <td>Insufficient data<br /> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">80 mcg per puff</td> <td>4 puffs</td> <td>5 to 8 puffs</td> <td>Insufficient data</td> </tr> <tr> <td><strong>Fluticasone propionate HFA</strong><br /> (Flovent HFA product available in United States)*</td> <td>88 to 220 mcg</td> <td>&#62;220 to 440 mcg</td> <td>&#62;440 mcg</td> </tr> <tr> <td class=\"indent1\">44 mcg per puff</td> <td>2 to 5 puffs</td> <td>&#182;</td> <td rowspan=\"2\"> <p>&#182;</p> </td> </tr> <tr> <td class=\"indent1\">110 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">220 mcg per puff</td> <td>&#916;</td> <td>2 puffs</td> <td>&#62;2 puffs</td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Fluticasone propionate HFA</strong><br /> (Flovent HFA product available in Canada, Europe, and elsewhere)</td> <td>100 to 250 mcg</td> <td>&#62;250 to 500 mcg</td> <td>&#62;500 mcg</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">50 mcg per puff</td> <td>2 to 5 puffs</td> <td>&#182;</td> <td rowspan=\"2\"> <p>&#182;</p> </td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">125 mcg per puff</td> <td>1 to 2 puffs</td> <td>3 to 4 puffs</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td class=\"indent1\">250 mcg per puff</td> <td>&#916;</td> <td>2 puffs</td> <td>&#62;2 puffs</td> </tr> <tr> <td><strong>Fluticasone propionate DPI</strong><br /> (Flovent Diskus product available in United States and Canada)*</td> <td>100 to 250 mcg</td> <td>&#62;250 to 500 mcg</td> <td>&#62;500 mcg</td> </tr> <tr> <td class=\"indent1\">50 mcg per inhalation</td> <td>2 to 5 inhalations</td> <td>&#182;</td> <td rowspan=\"2\"> <p>&#182;</p> </td> </tr> <tr> <td class=\"indent1\">100 mcg per inhalation</td> <td>1 to 2 inhalations</td> <td>3 to 5 inhalations</td> </tr> <tr> <td class=\"indent1\">250 mcg per inhalation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>&#62;2 inhalations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">500 mcg per inhalation (strength not available in United States)</td> <td>&#916;</td> <td>1 inhalation</td> <td>&#62;1 inhalation</td> </tr> <tr> <td> <p><strong>Fluticasone furoate DPI</strong><br /> (Arnuity Ellipta product available in United States)*</p> NOTE: Inhaled fluticasone furoate has a greater anti-inflammatory potency per microgram than fluticasone propionate inhalers. Thus, fluticasone furoate is administered at a lower daily dose and used only once daily.</td> <td>Not available for low dose</td> <td>100 mcg</td> <td>200 mcg</td> </tr> <tr> <td class=\"indent1\">100 mcg per inhalation</td> <td>Low dose not available&nbsp;in&nbsp;this preparation<br /> </td> <td>1 inhalation</td> <td>2 inhalations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">200 mcg per actuation</td> <td>Low dose not&nbsp;available in&nbsp;this preparation</td> <td>&#916;</td> <td>1 inhalation</td> </tr> <tr> <td><strong>Mometasone DPI</strong><sup>&#9674;</sup><br /> (Asmanex DPI product available in United States)*</td> <td>110 to 220 mcg</td> <td>&#62;220 to 440 mcg</td> <td>&#62;440 mcg</td> </tr> <tr> <td class=\"indent1\">110 mcg per inhalation</td> <td>1 to 2 inhalations</td> <td>&#182;</td> <td>&#182;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">220 mcg per inhalation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>&#62;2 inhalations</td> </tr> <tr> <td><strong>Mometasone HFA</strong><sup>&#9674;</sup><br /> (Asmanex HFA product available in United States)*</td> <td>100 to 200 mcg</td> <td>&#62;200 to 400 mcg</td> <td>&#62;400 mcg</td> </tr> <tr> <td class=\"indent1\">100 mcg per actuation</td> <td>1 to 2 inhalations</td> <td>&#182;</td> <td>&#182;&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">200 mcg per actuation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>&#62;2 inhalations</td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Mometasone DPI</strong><sup>&#9674;</sup><br /> (Asmanex Twisthaler product available in Canada, Europe, and elsewhere)</td> <td>200 mcg</td> <td>&#62;200 to 400 mcg</td> <td>&#62;400 mcg</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">200 mcg per inhalation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>&#62;2 inhalations</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"indent1\">400 mcg per inhalation</td> <td>&#916;</td> <td>1 inhalation</td> <td>&#62;1 inhalation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy.</strong> The clinician must monitor the patient's response on several clinical parameters and adjust the dose accordingly. The stepwise approach to therapy emphasizes that once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.<br />Depending on the specific product, total daily doses are administered once or twice daily.&nbsp;Some doses may be outside approved product information.</div><div class=\"graphic_footnotes\">DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant metered dose inhaler.<br />* Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States which may differ from how strengths are described for products available in other countries. Consult local product information before use.<br />Â¶ Select alternate preparation with higher mcg/puff to improve convenience.<br />Î Select preparation with fewer mcg/puff.<br />â&nbsp;Approved for once-daily dosing in mild asthma in some countries.</div><div class=\"graphic_reference\">National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma; 2007. NIH Publication 08-4051 available at <A href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report\" target=_blank>http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report</A>; updated with additional data from Global Initiative for Asthma (GINA); Global Strategy for Asthma Management and Prevention; 2014. Available at <A href=\"http://www.ginasthma.org/\" target=_blank>www.ginasthma.org</A>.</div><div id=\"graphicVersion\">Graphic 78011 Version 12.0</div></div></div>"},"78012":{"type":"graphic_diagnosticimage","displayName":"X-ray of sacroiliitis and hip injury in adult patient with psJIA","title":"Radiograph of sacroiliitis and hip injury in adult patient with juvenile-onset psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of sacroiliitis and hip injury in adult patient with juvenile-onset psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:376px; height:311px;\" src=\"images/ALLRG/78012_Xray_sacroil_hip_inj_psJIA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild unilateral sacroiliitis and marked left &gt; right hip injury in an adult patient with juvenile-onset psoriatic arthritis.</div><div class=\"graphic_reference\">Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78012 Version 1.0</div></div></div>"},"78013":{"type":"graphic_picture","displayName":"Methemoglobinemia","title":"Methemoglobinemia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Methemoglobinemia</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/78013_Methemoglobinemia_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the chocolate brown color of methemoglobinemia. Tube 1 and tube 2 have a methemoglobin concentration of 70 percent; tube 3, a concentration of 20 percent; and tube 4, a normal concentration.</div><div class=\"graphic_reference\">Image reprinted with permission from: Medscape.com, 2011. Available at: http://emedicine.medscape.com/article/956528-overview.</div><div id=\"graphicVersion\">Graphic 78013 Version 2.0</div></div></div>"},"78017":{"type":"graphic_waveform","displayName":"Para Hisian pacing ECG","title":"Para Hisian pacing ECG","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Para Hisian pacing ECG</div><div class=\"cntnt\"><img style=\"width:504px; height:263px;\" src=\"images/CARD/78017_Para_Hisian_pacing_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient #6. 12-lead surface electrocardiogram: (A) after atrioventricular node radiofrequency ablation: chronic atrial fibrillation with nodal escape rhythm (QRS 100 ms); (B) during direct His-bundle pacing: paced QRS duration 100 ms, with morphology and electric axis equal to the native QRS; (C) during right apical ventricular pacing: paced QRS duration 160 ms, with extreme left-axis deviation and &quot;left bundle block&quot; morphology.</div><div class=\"graphic_reference\">Reproduced with permission from: Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 2006; 47:1938. Copyright Â©2006 American College of Cardiology Foundation.</div><div id=\"graphicVersion\">Graphic 78017 Version 3.0</div></div></div>"},"78020":{"type":"graphic_picture","displayName":"Crescentic GN EM","title":"Electron micrograph in crescentic glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph in crescentic glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:394px; height:251px;\" src=\"images/NEPH/78020_RPGN_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in rapidly progressive glomerulonephritis (RPGN) showing characteristic breaks in the glomerular basement membrane (GBM) (arrows). These rents allow fibrin and cellular elements to enter Bowman's space and initiate crescent formation.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78020 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"78021":{"type":"graphic_table","displayName":"Broad- versus narrow-spectrum antiseizure drugs","title":"Therapeutic spectrum of antiseizure drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic spectrum of antiseizure drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Broad spectrum:</td> </tr> <tr> <td>Drugs&nbsp;used to treat a&nbsp;broad range of seizure types (both focal and generalized onset)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Brivaracetam&nbsp; </li> <li>Clobazam&nbsp; </li> <li>Felbamate </li> <li>Lamotrigine<sup>&#167;</sup> </li> <li>Levetiracetam </li> <li>Perampanel&nbsp;&nbsp; </li> <li>Rufinamide </li> <li>Topiramate </li> <li>Valproate </li> <li>Zonisamide </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Narrow spectrum (focal):</td> </tr> <tr> <td> <p>&nbsp;Drugs used primarily for focal-onset seizures (including focal evolving to bilateral convulsive seizures*)</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Carbamazepine<sup>&#182;</sup> </li> <li>Eslicarbazepine<sup>&#916;</sup> </li> <li>Gabapentin<sup>&#916; </sup></li> <li>Lacosamide </li> <li>Oxcarbazepine<sup>&#916;</sup> </li> <li>Phenobarbital<sup>&#182;</sup> </li> <li>Phenytoin<sup>&#182;</sup> </li> <li>Pregabalin&nbsp;&nbsp; </li> <li>Tiagabine<sup>&#916;</sup> </li> <li>Vigabatrin<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Narrow spectrum (absence):</td> </tr> <tr> <td>Absence seizures only (a type of generalized seizure)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ethosuximide </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note that although there is evidence to support the use of these medications for these seizure types, the medication may not be indicated for this use by the&nbsp;US Food and Drug Administration.</div><div class=\"graphic_footnotes\">*&nbsp;Previously referred to as secondary generalized seizures.<br />Â¶&nbsp;Some evidence of efficacy for generalized-onset tonic-clonic seizures, but may also worsen certain generalized seizure types.<br />Î&nbsp;Potential to worsen certain generalized seizure types.<br />Â§ May worsen or precipitate myoclonic seizures.</div><div id=\"graphicVersion\">Graphic 78021 Version 14.0</div></div></div>"},"78022":{"type":"graphic_table","displayName":"Endo biopsy recs","title":"The role of endomyocardial biopsy in fourteen clinical scenarios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The role of endomyocardial biopsy in fourteen clinical scenarios</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Scenario number</td>\n\t\t\t\t\t<td class=\"subtitle1\">Clinical scenario</td>\n\t\t\t\t\t<td class=\"subtitle1\">Class of recommendation (I, IIa, IIb, III)</td>\n\t\t\t\t\t<td class=\"subtitle1\">Level of evidence (A,B,C)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1</td>\n\t\t\t\t\t<td>New onset heart failure of <strong>less than 2 weeks</strong> duration associated with a normal size or dilated left ventricle and hemodynamic compromise</td>\n\t\t\t\t\t<td>I</td>\n\t\t\t\t\t<td>B</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2</td>\n\t\t\t\t\t<td>New onset heart failure of <strong>2 weeks to 3 months</strong> duration associated <strong>with</strong> a dilated left ventricle, and new ventricular arrhythmias, second or third degree heart block, or failure to respond to usual care within 1 to 2 weeks</td>\n\t\t\t\t\t<td>I</td>\n\t\t\t\t\t<td>B</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3</td>\n\t\t\t\t\t<td>Heart failure of <strong>greater than 3 months</strong> duration associated <strong>with</strong> a dilated left ventricle and new ventricular arrhythmias, second or third degree heart block, or failure to respond to usual care within 1 to 2 weeks</td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4</td>\n\t\t\t\t\t<td>Heart failure associated with a dilated cardiomyopathy of any duration associated with suspected allergic reaction and/or eosinophilia </td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5</td>\n\t\t\t\t\t<td>Heart failure associated with suspected anthracycline cardiomyopathy  </td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>6</td>\n\t\t\t\t\t<td>Heart failure associated with unexplained restrictive cardiomyopathy </td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>7</td>\n\t\t\t\t\t<td>Suspected cardiac tumors </td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>8</td>\n\t\t\t\t\t<td>Unexplained cardiomyopathy in children </td>\n\t\t\t\t\t<td>IIa</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>9</td>\n\t\t\t\t\t<td>New onset heart failure of <strong>2 weeks to 3 months</strong> duration associated with a dilated left ventricle, <strong>without</strong> new ventricular arrhythmias, or second or third degree heart block, and that responds to usual care within 1 to 2 weeks </td>\n\t\t\t\t\t<td>IIb</td>\n\t\t\t\t\t<td>B</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>10</td>\n\t\t\t\t\t<td>Heart failure of <strong>greater than 3 months</strong> duration associated with a dilated left ventricle, <strong>without</strong> new ventricular arrhythmias, or second or third degree heart block, and that responds to usual care within 1 to 2 weeks </td>\n\t\t\t\t\t<td>IIb</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>11</td>\n\t\t\t\t\t<td>Heart failure associated with unexplained hypertrophic cardiomyopathy</td>\n\t\t\t\t\t<td>IIb</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>12</td>\n\t\t\t\t\t<td>Suspected arrhythmogenic right ventricular dysplasia/cardiomyopathy</td>\n\t\t\t\t\t<td>IIb</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>13</td>\n\t\t\t\t\t<td>Unexplained ventricular arrhythmias </td>\n\t\t\t\t\t<td>IIb</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>14</td>\n\t\t\t\t\t<td>Unexplained atrial fibrillation</td>\n\t\t\t\t\t<td>III</td>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Cooper, LT, Baughman, KL, Feldman, AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216. Copyright &#169;2007 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 78022 Version 3.0</div></div></div>"},"78023":{"type":"graphic_table","displayName":"Survival appendix tumors SEER","title":"Prognosis of primary malignant neoplasms of the appendix from SEER data, 1973-1998","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis of primary malignant neoplasms of the appendix from SEER data, 1973-1998</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Five-year survival, percent</td> </tr> <tr> <td>Carcinoid</td> <td>90</td> </tr> <tr> <td>Goblet cell carcinoma (adenocarcinoid)</td> <td>78</td> </tr> <tr> <td>Colonic-type adenocarcinoma</td> <td>52</td> </tr> <tr> <td>Mucinous adenocarcinoma</td> <td>44</td> </tr> <tr> <td>Signet ring cell carcinoma</td> <td>20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology and End Results.</div><div class=\"graphic_reference\">Data from: McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: A population based study from the Surveillance, Epidemiology and End-Results program, 1973-1998. Cancer 2002; 94:3307.</div><div id=\"graphicVersion\">Graphic 78023 Version 3.0</div></div></div>"},"78024":{"type":"graphic_figure","displayName":"Surgical treatment of thenar space abscess","title":"Surgical treatment of thenar space abscess","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of thenar space abscess</div><div class=\"cntnt\"><img style=\"width:562px; height:382px;\" src=\"images/SURG/78024_Surg_tx_thenar_spac_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The combined palmar and dorsal surgical approach to a thenar space abscess is illustrated here.</div><div id=\"graphicVersion\">Graphic 78024 Version 1.0</div></div></div>"},"78027":{"type":"graphic_figure","displayName":"Weight loss and FBG in type 2 diabetes","title":"Initial fasting blood glucose concentration determines degree of weight loss required to achieve normoglycemia in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial fasting blood glucose concentration determines degree of weight loss required to achieve normoglycemia in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:444px; height:236px;\" src=\"images/ENDO/78027_Weight_loss_and_FBG_in_NIDD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glycemic response to weight reduction according to initial fasting blood glucose (in mmol/L) in type 2 diabetes. Patients who had mildly elevated fasting blood glucose concentrations of 6 to 8 mmol/L (108 to 144 mg/dL) initially had to lose 10 kg (16 percent of initial body weight) to achieve a value below 6 mmol/L (&lt;108 mg/dL). Greater degrees of weight loss were required in patients with higher initial values, rising to 26 kg and 41 percent, respectively, in patients with an initial value above 14 mmol/L (&gt;252 mg/dL).</div><div class=\"graphic_reference\">Data from: United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990; 39:905.</div><div id=\"graphicVersion\">Graphic 78027 Version 3.0</div></div></div>"},"78028":{"type":"graphic_picture","displayName":"Nod lymph predom HL CD20","title":"Nodular lymphocyte predominant Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphocyte predominant Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:255px; height:285px;\" src=\"images/HEME/78028_Nod_lymph_predom_HL_CD20.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The malignant (L&amp;H) cells stain positively for the B-cell marker CD20. In other sections, the small lymphocytes also stain for this marker (not shown).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 78028 Version 2.0</div></div></div>"},"78029":{"type":"graphic_figure","displayName":"Angina PI","title":"Angina","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Angina</div><div class=\"cntnt\"><img style=\"width:538px; height:444px;\" src=\"images/PI/78029_Angina_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78029 Version 1.0</div></div></div>"},"78030":{"type":"graphic_figure","displayName":"Homocysteine carotid stenosis","title":"Homocysteine and carotid stenosis","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Homocysteine and carotid stenosis</div><div class=\"cntnt\"><img style=\"width:457px; height:249px;\" src=\"images/CARD/78030_Homocysteine_carotid_stenos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-adjusted prevalence of extracranial carotid artery stenosis (&gt;25 percent) in 1041 elderly men and women in the Framingham Heart Study according to the plasma homocysteine concentration. The trends toward a higher frequency of carotid stenosis at increasing homocysteine levels was statistically significant. The individual data points represent the different quartiles for homocysteine.</div><div class=\"graphic_reference\">Data from: Selhub, J, Jacques, PF, Bostom, AG, et al, N Engl J Med 1995; 332:286.</div><div id=\"graphicVersion\">Graphic 78030 Version 1.0</div></div></div>"},"78032":{"type":"graphic_picture","displayName":"Amiodarone lung micrograph","title":"Amiodarone toxicity","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amiodarone toxicity</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/78032_Amiodarone_lung_micrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amiodarone lung biopsy photomicrograph shows diffuse alveolar damage in a patient with amiodarone toxicity. Alveolar spaces contain histiocytes with finely vacuolated cytoplasm (arrow). Chronic interstitial pneumonia with fibrosis and organizing pneumonia have also been described in patients with amiodarone toxicity.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 78032 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"78034":{"type":"graphic_picture","displayName":"Endocytoscopic image of esophageal squamous cell carcinoma","title":"Endocytoscopic image of esophageal squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endocytoscopic image of esophageal squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:284px; height:577px;\" src=\"images/GAST/78034_Endocytesophsqucellcarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endocytoscopic image of a squamous cell cancer of the esophagus (Panel A) and regular squamous epithelium (Panel B). Images were obtained after topical staining with methylene blue. Nuclei are clearly visible in both images. Whereas benign mucosa is characterized by regular nuclei, cancerous tissue shows irregularities with crowded nuclei and a clearly diminished nucleus to cell ratio.</div><div class=\"graphic_reference\">Courtesy of Alexander Meining, MD.</div><div id=\"graphicVersion\">Graphic 78034 Version 2.0</div></div></div>"},"78036":{"type":"graphic_waveform","displayName":"AV sequential pacing tutorial","title":"Dual chamber atrioventricular sequential pacing","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dual chamber atrioventricular sequential pacing</div><div class=\"cntnt\"><img style=\"width:344px; height:189px;\" src=\"images/CARD/78036_AV_sequential_pacing_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two pacemaker spikes are seen within each complex; there is an atrial spike (marked by red lines) and an associated P wave, followed by a ventricular spike (marked by green lines) and an associated paced QRS complex. The P wave morphology is variable, depending upon the location of the wire within the right atrium.</div><div id=\"graphicVersion\">Graphic 78036 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"78037":{"type":"graphic_movie","displayName":"Cardiac amyloidosis short axis echocardiogram","title":"Cardiac amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac amyloidosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78037_shaxcaamconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:266px; height:447px;\" src=\"images/CARD/78037_shaxcaam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view from a 2-D echocardiogram shows concentric left ventricular hypertrophy and thickened mitral valve leaflets.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 78037 Version 3.0</div></div></div>"},"78038":{"type":"graphic_figure","displayName":"NSAID lowers GFR in cirrhosis","title":"Graph showing reduction in creatinine clearance after NSAIDs in patients with hepatic cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing reduction in creatinine clearance after NSAIDs in patients with hepatic cirrhosis</div><div class=\"cntnt\"><img style=\"width:368px; height:234px;\" src=\"images/NEPH/78038_NSAID_lowers_GFR_in_cirrhos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction in GFR, as estimated from the creatinine clearance, from a mean of 73 mL/min down to 32 mL/min, after the administration of a nonsteroidal antiinflammatory drug (indomethacin or ibuprofen) to 12 patients with stable hepatic cirrhosis and ascites. Urinary prostaglandin E2 excretion was initially elevated and then fell markedly following therapy.</div><div class=\"graphic_reference\">Data from Zipser, RD, Hoefs JC, Speckhart PF, et al, J Clin Endocrinol Metab 1979; 48:895.</div><div id=\"graphicVersion\">Graphic 78038 Version 2.0</div></div></div>"},"78039":{"type":"graphic_table","displayName":"EEG predictors of epilepsy","title":"Spike location and probability of epilepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spike location and probability of epilepsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Probability:</td> <td class=\"subtitle1\">Most often associated with:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High probability of epilepsy (&#62;85 percent):</td> </tr> <tr> <td class=\"indent1\">Anterior-mid temporal spikes*</td> <td>Mesial temporal lobe epilepsy</td> </tr> <tr> <td class=\"indent1\">Midline spikes<sup>&#182;</sup></td> <td>Tonic-clonic seizures</td> </tr> <tr> <td class=\"indent1\">Hypsarrhythmia</td> <td>Infantile spasms (West syndrome)</td> </tr> <tr> <td class=\"indent1\">Slow spike-wave</td> <td>Lennox-Gastaut syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Generalized paroxysmal fast activity</td> <td>Lennox-Gastaut syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate probability of epilepsy (&#60;75 percent):</td> </tr> <tr> <td class=\"indent1\">Frontal spikes<sup>&#916;</sup></td> <td>Frontal lobe epilepsy</td> </tr> <tr> <td class=\"indent1\">Generalized spike-wave (&#8805;3 Hz)</td> <td>Absence epilepsy (3 Hz; CAE, JAE), juvenile myoclonic epilepsy (&#62;3 Hz), and other primary generalized epilepsies</td> </tr> <tr> <td class=\"indent1\">Centro-temporal spikes<sup>&#9674;</sup></td> <td>Benign rolandic epilepsy of childhoood (BREC)</td> </tr> <tr> <td class=\"indent1\">Occipital spikes<sup>&#167;</sup></td> <td>Benign focal epilepsy of childhood (Gastaut and Panayiotopolous syndromes: the 2 variants of CEOP)</td> </tr> <tr> <td class=\"indent1\">Photoparoxysmal response</td> <td>Primary generalized epilepsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; BECTS: benign focal epilepsy of childhood with centrotemporal spikes; BREC: benign rolandic epilepsy of childhood; CEOP: childhood epilepsy with occipital paroxysms.<br />* &gt;90 percent probability of seizures/epilepsy (adults)<SUP>[1]</SUP>.<br />Â¶ 76-91 percent probability of seizures/epilepsy (children)<SUP>[2]</SUP>.<br />Î ~75 percent probability of seizures/epilepsy (children)<SUP>[3]</SUP>.<br /><FONT class=lozenge>â</FONT> ~40 percent probability of seizures/epilepsy (children)<SUP>[3]</SUP>.<br />Â§ 50 percent probability of seizures/epilepsy (children)<SUP>[3]</SUP>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pedley TA, Mendiratta A, Walczak TS. Seizures and Epilepsy. In: Current Practice of Clinical Electroencephalography, Ebersole JS, Pedley TA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003 p.506.</li>&#xD;&#xA;    <li>Ehle A, Co S, Jones MG. Clinical correlates of midline spikes. An analysis of 21 patients. Arch Neurol 1981; 38:355.</li>&#xD;&#xA;    <li>Kellaway P. The incidence, significance and natural history of spike foci in children. In: Current clinical neurophysiology: update on EEG and evoked potentials, Henry C (Ed), Elsevier, Amsterdam 1981 p.151.</li>&#xD;&#xA;</ol>&#xD;&#xA;Table modified and expanded from: Pillai J, Sperling MR. Interictal EEG and the diagnosis of epilepsy. Epilepsia 2006; 47 Suppl 1:14.</div><div id=\"graphicVersion\">Graphic 78039 Version 4.0</div></div></div>"},"78040":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of umbilical arteries along the bladder","title":"Prenatal Doppler ultrasound showing umbilical arteries along the bladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal Doppler ultrasound showing umbilical arteries along the bladder</div><div class=\"cntnt\"><img style=\"width:396px; height:369px;\" src=\"images/OBGYN/78040_Umbilical_arteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral umbilical arteries seen lateral to the bladder in the center on color Doppler.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 78040 Version 2.0</div></div></div>"},"78042":{"type":"graphic_diagnosticimage","displayName":"Transverse acetabular fracture","title":"Transverse acetabular fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse acetabular fracture</div><div class=\"cntnt\"><img style=\"width:441px; height:511px;\" src=\"images/EM/78042_Acetab_fx_transv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anteroposterior pelvis view demonstrates disruption of four of the six radiograph landmarks of the acetabulum with the ilioischial line maintaining its normal relationship with the radiographic U (arrow), indicating that this is a transverse fracture below the level of the roof. Note the subluxation of the femoral head away from the intact portion of the acetabular roof.<br />(B) The obturator oblique view shows a break in the iliopectineal line (arrow) and subluxation of the femoral head with the displacement of the ischiopubic segment and verifies that the ischial ramus is not broken.<br />(C) The iliac oblique shows where the transverse fracture exits the greater sciatic notch (arrow) and again confirms the subluxation of the femoral head.<br />(D) This computed tomography section shows the orientation typical of a transverse fracture.</div><div class=\"graphic_reference\">Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.</div><div id=\"graphicVersion\">Graphic 78042 Version 2.0</div></div></div>"},"78043":{"type":"graphic_picture","displayName":"Air cast","title":"Air cast for ankle immobilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Air cast for ankle immobilization</div><div class=\"cntnt\"><img style=\"width:290px; height:575px;\" src=\"images/EM/78043_Air_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The air cast (figure A) is easy to apply (figure B) and is appropriate for the immobilization of nondisplaced Salter I fractures of the distal fibula and ankle sprains.</div><div class=\"graphic_reference\">Reproduced with permission from: DJO, LLC. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 78043 Version 1.0</div></div></div>"},"78045":{"type":"graphic_figure","displayName":"Cervical agenesis B","title":"Cervical agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical agenesis</div><div class=\"cntnt\"><img style=\"width:314px; height:325px;\" src=\"images/OBGYN/78045_Cervical_agenesis_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fundus of the uterus is present without the body of the cervix. Dotted lines represent missing cervix and upper vagina.</div><div id=\"graphicVersion\">Graphic 78045 Version 2.0</div></div></div>"},"78046":{"type":"graphic_table","displayName":"RBC antigens ethnic popul","title":"Genetic differences in RBC antigens in different ethnic populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic differences in RBC antigens in different ethnic populations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Antigen</td>\n\t\t\t\t\t<td class=\"subtitle1\">Present</td>\n\t\t\t\t\t<td class=\"subtitle1\">White, percent</td>\n\t\t\t\t\t<td class=\"subtitle1\">Black, percent</td>\n\t\t\t\t\t<td class=\"subtitle1\">Native American, percent</td>\n\t\t\t\t\t<td class=\"subtitle1\">Asian, percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"5\">Rh</td>\n\t\t\t\t\t<td>D</td>\n\t\t\t\t\t<td>85</td>\n\t\t\t\t\t<td>72</td>\n\t\t\t\t\t<td>79</td>\n\t\t\t\t\t<td>99</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>C</td>\n\t\t\t\t\t<td>70</td>\n\t\t\t\t\t<td>19</td>\n\t\t\t\t\t<td>46</td>\n\t\t\t\t\t<td>73</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>c</td>\n\t\t\t\t\t<td>80</td>\n\t\t\t\t\t<td>81</td>\n\t\t\t\t\t<td>53</td>\n\t\t\t\t\t<td>27</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>E</td>\n\t\t\t\t\t<td>30</td>\n\t\t\t\t\t<td>11</td>\n\t\t\t\t\t<td>40</td>\n\t\t\t\t\t<td>22</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>e</td>\n\t\t\t\t\t<td>98</td>\n\t\t\t\t\t<td>89</td>\n\t\t\t\t\t<td>59</td>\n\t\t\t\t\t<td>78</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Kell</td>\n\t\t\t\t\t<td>K</td>\n\t\t\t\t\t<td>9</td>\n\t\t\t\t\t<td>3.6</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>k</td>\n\t\t\t\t\t<td>99.8</td>\n\t\t\t\t\t<td>99.99</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Duffy</td>\n\t\t\t\t\t<td>Fy<sup>a</sup></td>\n\t\t\t\t\t<td>63</td>\n\t\t\t\t\t<td>10</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>99.7</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fy<sup>b</sup></td>\n\t\t\t\t\t<td>83</td>\n\t\t\t\t\t<td>23</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>9.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Kidd</td>\n\t\t\t\t\t<td>Jk<sup>a</sup></td>\n\t\t\t\t\t<td>77</td>\n\t\t\t\t\t<td>91</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>73</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Jk<sup>b</sup></td>\n\t\t\t\t\t<td>72</td>\n\t\t\t\t\t<td>43</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>77</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Lewis</td>\n\t\t\t\t\t<td>Le<sup>a</sup></td>\n\t\t\t\t\t<td>22</td>\n\t\t\t\t\t<td>23</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Le<sup>b</sup></td>\n\t\t\t\t\t<td>72</td>\n\t\t\t\t\t<td>55</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">MNSs</td>\n\t\t\t\t\t<td>M</td>\n\t\t\t\t\t<td>78</td>\n\t\t\t\t\t<td>70</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>N</td>\n\t\t\t\t\t<td>72</td>\n\t\t\t\t\t<td>74</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>S</td>\n\t\t\t\t\t<td>55</td>\n\t\t\t\t\t<td>31</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>s</td>\n\t\t\t\t\t<td>89</td>\n\t\t\t\t\t<td>97</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>P</td>\n\t\t\t\t\t<td>P1</td>\n\t\t\t\t\t<td>79</td>\n\t\t\t\t\t<td>94</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Lutheran</td>\n\t\t\t\t\t<td>Lu<sup>a</sup></td>\n\t\t\t\t\t<td>7.6</td>\n\t\t\t\t\t<td>5.3</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lu<sup>b</sup></td>\n\t\t\t\t\t<td>99.8</td>\n\t\t\t\t\t<td>99.9</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Anne Secord, MD, Qun Lu, MD, and Dennis Goldfinger, MD.</div><div id=\"graphicVersion\">Graphic 78046 Version 1.0</div></div></div>"},"78048":{"type":"graphic_table","displayName":"Injury prevention resources UK","title":"Injury prevention resources (UK)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Injury prevention resources (UK)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Child Accident Prevention Trust</td> </tr> <tr> <td><a href=\"http://www.capt.org.uk/\" target=\"_blank\">www.capt.org.uk</a>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Royal Society for the Prevention of Accidents</td> </tr> <tr> <td><a href=\"http://www.rospa.co.uk/\" target=\"_blank\">www.rospa.co.uk</a>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Injury Minimization Programme for Schools (IMPS)</td> </tr> <tr> <td><a href=\"http://www.impsweb.co.uk/\" target=\"_blank\">www.impsweb.co.uk</a>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Maconochie I. Accident prevention. Arch Dis Child 2003; 88:275.</div><div id=\"graphicVersion\">Graphic 78048 Version 5.0</div></div></div>"},"78049":{"type":"graphic_figure","displayName":"Analysis of thrombolysis tree","title":"Decision tree for thrombolysis in the elderly (example data for decision analysis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decision tree for thrombolysis in the elderly (example data for decision analysis)</div><div class=\"cntnt\"><img style=\"width:381px; height:400px;\" src=\"images/PC/78049_Analysis_of_thrombolysis_tr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each chance node is replaced by its expected value: the arithmetic average of the value of its branches. As an example, the expected value of the MI branch of No complication is 0.7506 [(0.7506 x 1) + (0.2494 x 0)].</div><div class=\"graphic_footnotes\">MI: myocardial infarction.</div><div class=\"graphic_reference\">Created with data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.</div><div id=\"graphicVersion\">Graphic 78049 Version 3.0</div></div></div>"},"78050":{"type":"graphic_table","displayName":"Patterns of inheritance","title":"Patterns of Mendelian and non-Mendelian inheritance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of Mendelian and non-Mendelian inheritance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mode of inheritance</td> <td class=\"subtitle1\">Gender preference</td> <td class=\"subtitle1\">Parental impact</td> <td class=\"subtitle1\">Probability sibling of affected individual will be affected </td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mendelian patterns of inheritance</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant</td> <td>None</td> <td>None</td> <td>50%</td> <td>If affected individuals are observed in all generations, the trait is 100% penetrant. Autosomal dominant mutations may arise de novo in an affected individual, in which case recurrence risks to siblings are very low.</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive</td> <td>None</td> <td>None</td> <td>25%</td> <td>Consanguinity is common in affected individuals.</td> </tr> <tr> <td class=\"indent1\">X-linked recessive</td> <td>Males</td> <td>No father-son transmission</td> <td> <p>Brothers: 50%</p> <p>Sisters: 0% (50% carriers)</p> </td> <td>Disease only rarely appears in females because manifestation in females would require skewed X inactivation or two X chromosome mutations (ie, one from each parent, including an affected father).</td> </tr> <tr> <td class=\"indent1\">X-linked dominant</td> <td>Males more severe</td> <td>No father-son transmission</td> <td>50%</td> <td>Affected rate similar between males and females, but disease is typically more severe in males.</td> </tr> <tr> <td class=\"indent1\">Y-linked dominant</td> <td>Males only</td> <td>Father-son</td> <td>Brothers: 100%</td> <td>No diseases manifest Y-dominant inheritance.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Deviations from strict Mendelian inheritance</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Incomplete penetrance</td> <td rowspan=\"5\">If expression is sex-limited</td> <td rowspan=\"5\">If imprinted</td> <td rowspan=\"5\"> <p>For AD: 50% x PF</p> <p>For AR: 25% x PF</p> </td> <td class=\"sublist1_start\">PF is the probability of disease given the risk genotype. PF can be influenced by multiple factors, including:</td> </tr> <tr> <td class=\"sublist1\">1) Environmental risk factors</td> </tr> <tr> <td class=\"sublist1\">2) Modifier genes</td> </tr> <tr> <td class=\"sublist1\">3) Gender</td> </tr> <tr> <td class=\"sublist1\">4) Parent of origin effects</td> </tr> <tr> <td class=\"indent1\">Sex-limited expression</td> <td>Yes</td> <td>None</td> <td>Gender-dependent</td> <td>Expression is either exclusive to one gender, or penetrance is substantially higher in one gender. </td> </tr> <tr> <td class=\"indent1\">Imprinting</td> <td>None</td> <td>Yes</td> <td>Similar to AD, AR traits</td> <td>Penetrance is dependent on parent of origin, but allele transmission is similar from both parents. </td> </tr> <tr> <td class=\"indent1\">Multigenic inheritance</td> <td>None</td> <td>None</td> <td>Variable</td> <td>Common diseases; mutations increase disease risk modestly.</td> </tr> <tr> <td class=\"indent1\">Anticipation</td> <td>None</td> <td>Disease more severe than in parents</td> <td>Variable</td> <td>Manifestations in parents and grandparents of affected offspring are typically diagnosed retrospectively.</td> </tr> <tr> <td class=\"indent1\">Mitochondrial inheritance</td> <td>None</td> <td>Exclusive maternal transmission</td> <td>Very high, can approach 100%</td> <td>Differs from X-linked dominant in that father-daughter transmission is not observed.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; PF: penetrance function.</div><div id=\"graphicVersion\">Graphic 78050 Version 7.0</div></div></div>"},"78051":{"type":"graphic_table","displayName":"Terminology used in back pain","title":"Terminology used in back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology used in back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Spondylosis:</strong> Arthritis of the spine. Seen radiographically as disc space narrowing and arthritic changes of the facet joint.</td> </tr> <tr> <td><strong>Anterolisthesis, spondylolisthesis, retrolisthesis:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Anterolisthesis is the anterior displacement of a vertebral body relative to the one below. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Spondylolisthesis is anterolisthesis secondary to spondylolysis but is also used to denote anterolisthesis from any cause. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Retrolisthesis is the posterior displacement of a vertebral body relative to the one below. </li> </ul> </td> </tr> <tr> <td>A radiologist determines the degree of slippage upon reviewing spinal radiographs. Slippage is graded I through IV:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Grade I - 1 to 25% slip </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Grade II - 26 to 50% slip </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Grade III - 51 to 75% slip </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Grade IV - 76 to 100% slip </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Generally, Grade I and Grade II slips do not require surgical treatment and are treated medically. However, Grade III and Grade IV slips, and some milder grade slips, may benefit from surgery if persistent and disabling symptoms are present.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Spondylolysis:</strong>A fracture in the pars interarticularis where the vertebral body and the posterior elements protecting the nerves are joined. In a small percent of the adult population, there is a developmental crack in one of the vertebrae, usually at L5.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Spinal stenosis:</strong> Local, segmental, or generalized narrowing of the vertebral canal by bone or soft tissue elements, usually bony hypertrophic changes in the facet joints and by thickening of the ligamentum flavum.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Radiculopathy:</strong> Impairment of a nerve root, usually causing radiating pain, numbness, tingling, or muscle weakness that corresponds to a specific nerve root.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sciatica:</strong> Pain, numbness, tingling in the distribution of the sciatic nerve, radiating down the posterior or lateral aspect of the leg, usually to the foot or ankle.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cauda equina syndrome:</strong> Loss of bowel and bladder control and numbness in the groin and saddle area of the perineum, associated with weakness of the lower extremities. This condition can be caused by abnormal pressure on the bottom-most portion of the spinal canal and spinal nerve roots, related to either bony stenosis or a large herniated disc.</td> </tr> <tr> <td><strong>Lordosis, kyphosis, scoliosis:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Kyphotic curves refer to the outward curve of the thoracic spine (at the level of the ribs). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lordotic curves refer to the inward curve of the lumbar spine (just above the buttocks). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Scoliotic curving is a sideways curvature of the spine and is always abnormal. </li> </ul> </td> </tr> <tr> <td>A small degree of both kyphotic and lordotic curvature is normal. Too much kyphotic curving causes round shoulders or hunched shoulders (Scheuermann's disease).</td> </tr> <tr> <td>Too much lordotic curving is called swayback (lordosis). Lordosis tends to make the buttocks appear more prominent.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78051 Version 7.0</div></div></div>"},"78052":{"type":"graphic_figure","displayName":"Dynamic hyperinflation","title":"Dynamic hyperinflation during controlled ventilation in obstructive lung disease","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Dynamic hyperinflation during controlled ventilation in obstructive lung disease</div><div class=\"cntnt\"><img style=\"width:473px; height:319px;\" src=\"images/PULM/78052_Dynamichyperinflation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During resting ventilation of normal lungs or controlled ventilation of lungs with decreased lung compliance (eg, ARDS), passive exhalation leads to a return to normal FRC at the end of each breath. However, in patients with airway obstruction, such as asthma or COPD, exhalation may not be complete at the time the next breath is initiated, leading to increasing amounts of trapped air at end-exhalation, a process known as dynamic hyperinflation. In this figure, the tidal volume curve in blue reflects ventilation of normal lungs and shows a return to the normal FRC at the end of each exhalation. The tidal volume curve in green shows the progressive increase in FRC in a patient with asthma or COPD when successive breaths are initiated before complete exhalation. Dynamic hyperinflation can occur in patients with airway obstruction during mechanical ventilation or with exercise.<br />Dynamic hyperinflation is associated with increased intrathoracic pressure and potentially decreased venous return to the heart. Dynamic hyperventilation is treated by decreasing minute ventilation (ie, reducing tidal volume and/or respiratory rate) and sometimes by shortening inspiratory time to enable adequate time for exhalation.</div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; FRC: functional residual capacity; I: inspiration; E: expiration.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Tuxen DV. Permissive hypercapnic ventilation. Am J Respir Crit Care Med 1994; 150:870.</div><div id=\"graphicVersion\">Graphic 78052 Version 6.0</div></div></div>"},"78053":{"type":"graphic_table","displayName":"Rx hyperlipidemia after OLT","title":"Pharmacotherapy for hyperlipidemia after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacotherapy for hyperlipidemia after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Usual starting dose*</td> <td class=\"subtitle1\">Metabolism<sup>&#182;</sup></td> <td class=\"subtitle1\">Selected drug interactions<sup>&#916;</sup></td> <td class=\"subtitle1\">Adverse effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">HMG CoA reductase inhibitors (\"statins\")</td> </tr> <tr> <td class=\"indent1\">Pravastatin</td> <td>10 or 20 mg once per day</td> <td>Approximately 50 percent is renally cleared as unchanged drug. Smaller amounts are cleared by biliary excretion or undergo non-CYP and CYP 3A4 hepatic transformation. Pravastatin is a substrate of P-gp.</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Cyclosporine: increased risk of myopathy due to additive toxicity and elevation of statin serum level by competitive inhibition of CYP 3A4 and/or P-gp. Pravastatin and fluvastatin are less likely than other statins to interact significantly with cyclosporine.</p> Sirolimus, everolimus: increased serum levels of sirolimus and everolimus in combination with atorvastatin due to inhibition of P-gp.</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Gastrointestinal intolerance, CK elevations, transaminase elevations, muscle toxicity, rhabdomyolysis (rare).</p> Close monitoring of transaminases may provide early evidence of elevated statin levels and toxicity.</td> </tr> <tr> <td class=\"indent1\">Fluvastatin</td> <td>10 or 20 mg once per day</td> <td>Approximately 75 percent undergoes hepatic transformation by CYP 2C9 and 20 percent by CYP 3A4. Fluvastatin inhibits, and can interact with other drugs metabolized by CYP 2C9.</td> </tr> <tr> <td class=\"indent1\">Rosuvastatin</td> <td>5 or 10 mg once per day. Maximum 5 mg per day with cyclosporine.</td> <td>Most clearance occurs as unchanged drug. Approximately 10 percent undergoes CYP 2C9 transformation to a partially active metabolite.</td> </tr> <tr> <td class=\"indent1\">Atorvastatin</td> <td>5 or 10 mg once per day. Maximum10 mg per day with cyclosporine.</td> <td>Undergoes extensive CYP 3A4 transformation to active metabolites. Atorvastatin is a substrate and inhibitor of P-gp.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Simvastatin</td> <td>5 or 10 mg once per day. Avoid use with cyclosporine.</td> <td>Undergoes extensive CYP 3A4 transformation to active and inactive metabolites.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cholesterol absorption inhibitor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ezetimibe</td> <td>10 mg once per day</td> <td>Undergoes glucuronide conjugation in small intestine and liver to form active metabolite. Most clearance occurs by enterohepatic recycling and fecal excretion.</td> <td> <p>Statins: useful for added LDL lowering in combination with a statin or as single agent if statin not tolerated.</p> <p>Fibrate: increased serum level of ezetimibe; theoretic increased risk of cholelithiasis.</p> Cyclosporine: increased serum level of ezetimibe and possible alteration of cyclosporine level. 5 mg ezetimibe daily may suffice for LDL lowering effect in combination with cyclosporine.</td> <td>Gastrointestinal intolerance, headache. In combination with statin, slightly higher incidence of serum transaminase elevations than statin monotherapy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Refractory severe hypertriglyceridemia (&#8805;500 mg/dL [5.6 mmol/L])</td> </tr> <tr> <td class=\"indent1\">Gemfibrozil</td> <td>600 mg twice per day</td> <td>Undergoes non CYP transformation by glucuronide conjugation with small amount of CYP 3A4 transformation. Gemfibrozil inhibits and can interact with other drugs metabolized by CYP 2C8, 2C9, 2C19 and OATP1B1.</td> <td> <p>Statins: increased risks of hepatotoxicity, myopathy, and rhabdomyolysis due to additive toxicity and elevation of statin serum level. Avoid combining gemfibrozil with statins.</p> Cyclosporine: additive risk of nephrotoxicity and altered serum concentration of cyclosporine.</td> <td rowspan=\"2\">Gastrointestinal intolerance, muscle toxicity, cholelithiasis, rhabdomyolysis (rare).</td> </tr> <tr> <td class=\"indent1\">Fenofibrate</td> <td>40 to 67 mg once per day depending on preparation</td> <td>Hydrolysed to active intermediary by plasma and tissue esterases. Undergoes non CYP metabolism by glucuronide conjugation.</td> <td> <p>Statins: increased risk of myopathy and rhabdomyolysis due to additive toxicity. If combination with a statin is unavoidable, fenofibrate with fluvastatin or pravastatin may be less likely to interact significantly than gemfibrozil with a statin.</p> Cyclosporine: additive risk of nephrotoxicity and altered serum concentration of cyclosporine.</td> </tr> <tr> <td class=\"indent1\">Omega-3-acid ethyl esters<sup>&#9674;</sup></td> <td>1 to 2 grams twice per day</td> <td>Inadequately defined.</td> <td>CYP mediated interactions with immunosuppressive agents, statins, fibrates or ezetimibe are not expected based on in vitro data.</td> <td>Dyspepsia, fishy taste, modest increase in LDL-C (5 percent). Modest increase in bleeding time that is insignificant for patients with functional hemostasis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450; OATP1B1: organic anion transporting polypeptide 1B1; P-gp: P-glycoprotein transporter.<br />* Adult doses, oral administration. Post liver transplant patients with compromised renal function are at elevated risk of adverse effects due to statins and other hypolipidemic drugs. Limited dose titration or dose reduction may be necessary.<br />&para; Shows metabolism and disposition of drug reaching systemic circulation. Statins undergo extensive pre-systemic clearance in gastric mucosa and/or liver. Patients with hepatic insufficiency may have increased systemic exposure.<br />&Delta; For additional information, see Lexi-Interact&trade; drug interactions application included with UpToDate.<br /><span class=\"lozenge\">&loz;</span> Potential option. Inadequate data and experience in patients with hepatic insufficiency and/or post liver transplant. If used, a licensed standardized preparation (eg, Lovaza&reg;) appears to be preferable.</div><div id=\"graphicVersion\">Graphic 78053 Version 5.0</div></div></div>"},"78054":{"type":"graphic_diagnosticimage","displayName":"Acute histoplasmosis chest CT","title":"Pulmonary histoplasmosis on chest CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary histoplasmosis on chest CT</div><div class=\"cntnt\"><img style=\"width:411px; height:360px;\" src=\"images/ID/78054_RML_obstruction_by_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of a patient with acute pulmonary histoplasmosis shows compression of the right middle lobe bronchus (arrow) by a lymph node (N), causing collapse and consolidation of the right middle lobe. The CT scan also shows central lucency in a subcarinal lymph node (L) and lucency within the right middle lobe infiltrate (L). These lucent areas are caused by caseous necrosis.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 78054 Version 4.0</div></div></div>"},"78058":{"type":"graphic_table","displayName":"Outcome pregnancy after MVA","title":"Pregnancy outcome after motor vehicle accidents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy outcome after motor vehicle accidents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Controls, no crash, percent (n = 17,274)</td> <td class=\"subtitle1\">Uninjured, ISS 0, percent (n = 189)</td> <td class=\"subtitle1\">Nonsevere injury, ISS 1 to 8, percent (n = 308)</td> <td class=\"subtitle1\">Severe injury, ISS 9 or more, percent (n = 84)</td> </tr> <tr> <td>Preterm labor</td> <td>6.6</td> <td>51.3*</td> <td>24.6*</td> <td>13.1</td> </tr> <tr> <td>Abruption</td> <td>1.4</td> <td>8.5*</td> <td>7.4*</td> <td>13.1*</td> </tr> <tr> <td>Preterm birth</td> <td>8.0</td> <td>13.9</td> <td>12.1</td> <td>5.0</td> </tr> <tr> <td>Fetal death</td> <td>0.3</td> <td>0</td> <td>1.6</td> <td>9.0*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROM: premature rupture of membranes.<br>* Significant compared to controls.</div><div class=\"graphic_reference\">Adapted from: Schiff MA, Holt VL. Am J Epidemiol 2005; 161:503.</div><div id=\"graphicVersion\">Graphic 78058 Version 2.0</div></div></div>"},"78061":{"type":"graphic_table","displayName":"Lymphocyte markers by cytometry","title":"Markers commonly used for assessment of lymphocyte subsets by flow cytometry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Markers commonly used for assessment of lymphocyte subsets by flow cytometry</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Marker name</td> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>CD3</td> <td>T cells</td> <td>Expressed on all T cells and no other cell type</td> </tr> <tr> <td>CD4</td> <td>T cell subset</td> <td>Predominantly helper/inducer T cells</td> </tr> <tr> <td>CD8</td> <td>T cell subset</td> <td>Predominantly cytotoxic T cells; expressed by up to one-third of NK cells</td> </tr> <tr> <td>CD19 or CD20</td> <td>B cells</td> <td>&nbsp;</td> </tr> <tr> <td>CD16</td> <td>NK cells</td> <td>Some NK cells may not express CD16</td> </tr> <tr> <td>CD56</td> <td>NK cells</td> <td>Expressed on the majority of NK cells</td> </tr> <tr> <td>CD57</td> <td>NK&nbsp;cells</td> <td>Expressed on the majority of NK cells; combinations of CD16, CD56, and CD57 will more reliably evaluate NK cell number than any marker alone</td> </tr> <tr> <td>CD45RA</td> <td>Na&#239;ve T cells</td> <td>&nbsp;</td> </tr> <tr> <td>CD45RO</td> <td>Memory T cells</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NK: natural killer.</div><div id=\"graphicVersion\">Graphic 78061 Version 4.0</div></div></div>"},"78062":{"type":"graphic_diagnosticimage","displayName":"Metaphyseal fracture of the proximal humerus","title":"Metaphyseal fracture of the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metaphyseal fracture of the proximal humerus</div><div class=\"cntnt\"><img style=\"width:280px; height:396px;\" src=\"images/EM/78062_Metaphysealfxhumerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Healing undisplaced fracture of the proximal humerus in a 5-year-old child. Note the absence of a physeal injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78062 Version 14.0</div></div></div>"},"78063":{"type":"graphic_algorithm","displayName":"Pediatric purpura algorithm","title":"Pediatric purpura algorithm*","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">Pediatric purpura algorithm*</div><div class=\"cntnt\"><img style=\"width:653px; height:882px;\" src=\"images/EM/78063_Pediatricpurpuraalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation; CBC: complete blood count; PT: prothrombin time; aPTT: activated partial thromboplastin time; HSP: Henoch Schoelein purpura; ITP: idiopathic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura.<br />* For more discussion of specific evaluation of children with purpura, please refer to UpToDate topics on purpura in children.<br />Â¶ Other vascular causes of purpura include vitamin C deficiency (scurvy), Ehlers-Danlos syndrome, and pigmented purpuric dermatoses (capillaritis).</div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 78063 Version 4.0</div></div></div>"},"78066":{"type":"graphic_waveform","displayName":"Post-PVC aortic stenosis hemodynamics","title":"Post-PVC aortic stenosis hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Post-PVC aortic stenosis hemodynamics</div><div class=\"cntnt\"><img style=\"width:464px; height:316px;\" src=\"images/CARD/78066_PostPVCaorticstenhemody.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-PVC hemodynamics in aortic stenosis (left) and HOCM (right) patients. In AS, post-PVC hemodynamics show aortic (Ao) pressure upstroke unchanged, larger pulse pressure and no change in aortic pressure wave form. These findings are different in the post-PVC HOCM tracings. Post-PVC of HOCM shows rapid aortic upstroke, narrow pulse pressure and spike and dome configuration of aortic pressure wave.</div><div class=\"graphic_footnotes\">PVC: premature ventricular contraction; HOCM: hypertrophic obstructive cardiomyopathy; AS: aortic stenosis.</div><div id=\"graphicVersion\">Graphic 78066 Version 3.0</div></div></div>"},"78067":{"type":"graphic_figure","displayName":"Frequency retained placenta by 3rd stage characteristics","title":"Frequency of retained placenta by length and management of third stage","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Frequency of retained placenta by length and management of third stage</div><div class=\"cntnt\"><img style=\"width:541px; height:351px;\" src=\"images/OBGYN/78067_Ret_placen_leng_mang_third.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Natural history of retained placentas with active and physiological management. Data on the natural history of the third stage are derived from the length of the third stage from the active versus control arms of trials of active management of labor, and the expectant management arms from trials of umbilical oxytocin as a treatment for retained placenta.</div><div class=\"graphic_reference\">Reproduced from: Weeks SD. The retained placenta. Best Pract Res Clin Obstet Gynaecol 2008; 22:1103. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78067 Version 2.0</div></div></div>"},"78069":{"type":"graphic_table","displayName":"Reporting elements for ER and PR immunohistochemistry assays","title":"Reporting elements for ER and PR immunohistochemistry assays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reporting elements for ER and PR immunohistochemistry assays</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #008000;\">Patient identification information</span></td> </tr> <tr> <td><span style=\"color: #008000;\">Physician identification</span></td> </tr> <tr> <td><span style=\"color: #008000;\">Date of service</span></td> </tr> <tr> <td><span style=\"color: #008000;\">Specimen site and type</span></td> </tr> <tr> <td><span style=\"color: #008000;\">Specimen identification (case and block number)</span></td> </tr> <tr> <td>Fixative</td> </tr> <tr> <td>Cold ischemia time (time between removal and fixation)</td> </tr> <tr> <td>Duration of fixation</td> </tr> <tr> <td class=\"sublist1_start\">Staining method utilized:</td> </tr> <tr> <td class=\"sublist1\">Primary antibody and vendor</td> </tr> <tr> <td class=\"sublist1\">Assay details and other reagents/vendors</td> </tr> <tr> <td class=\"sublist1\">References supporting validation of assay (note: most commonly, these will be published studies performed by others that the testing laboratory is emulating)</td> </tr> <tr> <td>Status of FDA approval</td> </tr> <tr> <td>Controls (high protein expression, low-level protein expression, negative protein expression, internal elements or from normal breast tissue included with sample)</td> </tr> <tr> <td>Adequacy of sample for evaluation</td> </tr> <tr> <td class=\"sublist1_start\"><span style=\"color: #008000;\">Results:</span></td> </tr> <tr> <td class=\"sublist1\"><span style=\"color: #008000;\">Percentage of invasive tumor cells exhibiting nuclear staining</span></td> </tr> <tr> <td class=\"sublist1\"><span style=\"color: #008000;\">Intensity of staining: Strong, medium, weak</span></td> </tr> <tr> <td class=\"sublist1\"><span style=\"color: #008000;\">Interpretation:</span></td> </tr> <tr> <td class=\"sublist2\">- <span style=\"color: #008000;\">Positive (for ER or PR receptor protein expression), negative (for ER or PR protein expression), uninterpretable</span></td> </tr> <tr> <td class=\"sublist2\">- <span style=\"color: #008000;\">Internal and external controls (positive, negative, not present)</span></td> </tr> <tr> <td class=\"sublist2\">- <span style=\"color: #008000;\">Standard assay conditions met/not met (including cold ischemic time and fixation parameters)</span></td> </tr> <tr> <td class=\"sublist2\">- <span style=\"color: #008000;\">Optional score and scoring system</span></td> </tr> <tr> </tr> <tr> <td class=\"sublist2\">- Comment: Should explain reason for uninterpretable result and or any other unusual conditions, if applicable. May report on status of any DCIS staining in the sample. Should also provide correlation with histologic type of the tumor. May provide information about laboratory accreditation status.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Report should contain the elements in <span style=\"color:#008000\"><strong>green</strong></span> as a minimum. Other information must be available in the laboratory for review or appear on the patient accession slip.</div><div class=\"graphic_footnotes\">ER: estrogen receptor; PR: progesterone receptor.</div><div id=\"graphicVersion\">Graphic 78069 Version 3.0</div></div></div>"},"78072":{"type":"graphic_figure","displayName":"Posterior tibial artery","title":"Posterior tibial artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tibial artery anatomy</div><div class=\"cntnt\"><img style=\"width:357px; height:399px;\" src=\"images/PEDS/78072_Posterior_tibial_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most accessible portion of the posterior tibial artery lies just posterior to the medial malleolus.</div><div class=\"graphic_reference\">Adapted from: King, C, Henretig, FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000. p.214.</div><div id=\"graphicVersion\">Graphic 78072 Version 1.0</div></div></div>"},"78073":{"type":"graphic_picture","displayName":"Tympanosclerosis 2","title":"Tympanosclerosis (also known as myringosclerosis)","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Tympanosclerosis (also known as myringosclerosis)</div><div class=\"cntnt\"><img style=\"width:460px; height:468px;\" src=\"images/PEDS/78073_Tympanosclerosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tympanosclerosis refers to asymptomatic whitish plaques of calcium and phosphate crystals, as depicted above. Notice areas of wispy, noncalcified changes as well as dense calcified regions.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 78073 Version 4.0</div></div></div>"},"78074":{"type":"graphic_table","displayName":"Low molecular weight heparins","title":"Low molecular weight heparins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low molecular weight heparins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Manufacturer</td> </tr> <tr> <td>Enoxaparin</td> <td>Lovenox</td> <td>Sanofi-Aventis</td> </tr> <tr> <td>Dalteparin</td> <td>Fragmin</td> <td>Pfizer</td> </tr> <tr> <td>Tinzaparin*</td> <td>Innohep</td> <td>Leo Pharma</td> </tr> <tr> <td>Nadroparin<sup>&#182;</sup></td> <td>Fraxiparine</td> <td>Glaxo Smith-Kline</td> </tr> <tr> <td>Certoparin</td> <td>Sandoparin</td> <td>Sandoz Pharmaceuticals</td> </tr> <tr> <td>Reviparin</td> <td>Clivarin</td> <td>Abbott</td> </tr> <tr> <td>Parnaparin</td> <td>Fluxum</td> <td>Opocrin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Prepared by heparinase digestion. All others prepared by chemical depolymerization.<br />Â¶ Ca salt. All others are sodium salt.</div><div id=\"graphicVersion\">Graphic 78074 Version 2.0</div></div></div>"},"78076":{"type":"graphic_diagnosticimage","displayName":"Small upper airway OSA MRI","title":"Reduced upper airway size in obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Reduced upper airway size in obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:452px; height:213px;\" src=\"images/PULM/78076_Small_upper_airway_OSA_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of a mid-sagittal image of a normal subject (left) and a patient with sleep apnea (right). Soft palate and tongue area are larger in the patient with sleep apnea, leading to a reduction in upper airway size.</div><div class=\"graphic_reference\">Courtesy of Richard J Schwab, MD.</div><div id=\"graphicVersion\">Graphic 78076 Version 2.0</div></div></div>"},"78078":{"type":"graphic_diagnosticimage","displayName":"Spina bifida","title":"Spina bifida","html":"<div class=\"graphic\"><div style=\"width: 930px\" class=\"figure\"><div class=\"ttl\">Spina bifida</div><div class=\"cntnt\"><img style=\"width:910px; height:442px;\" src=\"images/OBGYN/78078_Spina_bifida.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lumbosacral spina bifida at 22<SUP>2/7ths</SUP> weeks of gestation. Longitudinal view showing the large lumbo-sacral defect.<br />(B) Transverse view showing the U-shaped vertebral body (arrows) with the neural tissue protruding through.</div><div id=\"graphicVersion\">Graphic 78078 Version 3.0</div></div></div>"},"78079":{"type":"graphic_diagnosticimage","displayName":"TTTS8","title":"TTTS8","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS8</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/78079_TTTS8.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal cervical length indicating a short cervix of 1.15 cm due to extreme polyhydramnios&nbsp;at approximately 21.5&nbsp;weeks of gestation.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 78079 Version 3.0</div></div></div>"},"78080":{"type":"graphic_picture","displayName":"Intestinal sinonasal CA Light","title":"Intestinal-type sinonasal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intestinal-type sinonasal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/ONC/78080_Intestinal_sinonasal_CA_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph showing the anastamosing cords of columnar cells with interspersed goblet cells, resembling colonic carcinoma.</div><div class=\"graphic_reference\">Courtesy of D. Solt, DMD, PhD.</div><div id=\"graphicVersion\">Graphic 78080 Version 1.0</div></div></div>"},"78082":{"type":"graphic_picture","displayName":"Excision duplication cyst","title":"Transcervical excision of enteric duplication cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transcervical excision of enteric duplication cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/PEDS/78082_Excision_duplication_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 78082 Version 1.0</div></div></div>"},"78083":{"type":"graphic_table","displayName":"History joint pain child","title":"Key elements of the history when evaluating a child with joint pain or swelling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of the history when evaluating a child with joint pain or swelling</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Details </td> </tr> <tr> <td>Number of joints involved and their location</td> <td> <p>Single joint</p> <p>Multiple joints</p> </td> </tr> <tr> <td>Characteristics</td> <td> <p>Severity and quality of pain</p> <p>Frequency of pain</p> <p>Duration of the episode</p> <p>Presence of swelling, erythema, other discoloration</p> <p>Diurnal variation</p> <p>Interference with normal activities</p> <p>Inability to bear weight</p> <p>Progression over time</p> </td> </tr> <tr> <td>Precipitating factors</td> <td> <p>Trauma</p> <p>Antecedent illness</p> <p>Periods of inactivity</p> <p>Increased physical activity</p> </td> </tr> <tr> <td>Presence and pattern of associated symptoms</td> <td> <p>Fever</p> <p>Rash</p> <p>Weight loss</p> <p>Abdominal pain</p> <p>Diarrhea</p> <p>Eye symptoms</p> <p>Other</p> </td> </tr> <tr> <td>Pattern of symptoms</td> <td> <p>Acute versus chronic</p> <p>Morning stiffness</p> <p>Migratory pain</p> <p>Recurrent episodes of joint pain and swelling</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Yukiko Kimura, MD&nbsp;and Taunton R&nbsp;Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH.</div><div id=\"graphicVersion\">Graphic 78083 Version 3.0</div></div></div>"},"78089":{"type":"graphic_table","displayName":"Chemotherapy acral erythema","title":"Conventional cytotoxic chemotherapy agents causing acral erythema (hand-foot skin reaction)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conventional cytotoxic chemotherapy agents causing acral erythema (hand-foot skin reaction)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Bleomycin</td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Cytarabine*</td> </tr> <tr> <td>Daunorubicin</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Doxifluridine</td> </tr> <tr> <td>Doxorubicin (particularly pegylated liposomal doxorubicin)</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Fluorouracil (infusional regimens)</td> </tr> <tr> <td>Gemcitabine</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Idarubicin</td> </tr> <tr> <td>Ixabepilone</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Mitotane</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Tegafur</td> </tr> <tr> <td>Thiotepa</td> </tr> <tr> <td>Vinorelbine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Particularly in patients receiving cytarabine plus an anthracycline for treatment of acute leukemia.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</LI>&#xD;&#xA;<LI>Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.</LI>&#xD;&#xA;<LI>Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.</LI>&#xD;&#xA;<LI>Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82:965.</LI></OL></div><div id=\"graphicVersion\">Graphic 78089 Version 7.0</div></div></div>"},"78091":{"type":"graphic_figure","displayName":"Metabolic syndrome race","title":"Prevalence of NCEP ATP III metabolic syndrome among subjects in the NHANES III survey by race/ethnicity and sex","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Prevalence of NCEP ATP III metabolic syndrome among subjects in the NHANES III survey by race/ethnicity and sex</div><div class=\"cntnt\"><img style=\"width:460px; height:280px;\" src=\"images/ENDO/78091_Metabolic_syndrome_race.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.</div><div id=\"graphicVersion\">Graphic 78091 Version 2.0</div></div></div>"},"78092":{"type":"graphic_picture","displayName":"Endosc fundic gland polyp A","title":"Gastric fundic gland polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric fundic gland polyp</div><div class=\"cntnt\"><img style=\"width:360px; height:313px;\" src=\"images/GAST/78092_Endosc_fundic_gland_polyp_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the body of the stomach looking toward the antrum and pylorus showing numerous polypoid lesions, which on biopsy were proven to be fundic gland polyps.</div><div class=\"graphic_reference\">Courtesy of Akira Horiuchi, MD.</div><div id=\"graphicVersion\">Graphic 78092 Version 1.0</div></div></div>"},"78093":{"type":"graphic_diagnosticimage","displayName":"Pancreatic mucinous cystic neoplasm CT","title":"CT image of pancreatic mucinous cystic neoplasm","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">CT image of pancreatic mucinous cystic neoplasm</div><div class=\"cntnt\"><img style=\"width:500px; height:356px;\" src=\"images/GAST/78093_Muc_neoplasm_panc_CT_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of pancreatic mucinous cystic neoplasm (arrow). Note unilocular nature of cyst with enhancing region inside cyst.</div><div class=\"graphic_reference\">Courtesy of Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 78093 Version 5.0</div></div></div>"},"78094":{"type":"graphic_picture","displayName":"Imperforate hymen 2","title":"Imperforate hymen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Imperforate hymen</div><div class=\"cntnt\"><img style=\"width:287px; height:432px;\" src=\"images/OBGYN/78094_Imperforatehymen2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78094 Version 14.0</div></div></div>"},"78095":{"type":"graphic_figure","displayName":"Silicone band sterilization B","title":"Silicone bandÂ sterilization by laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Silicone band&nbsp;sterilization by laparoscopy</div><div class=\"cntnt\"><img style=\"width:456px; height:323px;\" src=\"images/OBGYN/78095_Tubal_ring_sterilization_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 78095 Version 2.0</div></div></div>"},"78096":{"type":"graphic_picture","displayName":"Scleromalacia perforans","title":"Scleromalacia perforans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scleromalacia perforans</div><div class=\"cntnt\"><img style=\"width:329px; height:216px;\" src=\"images/RHEUM/78096_Scleromalacia_perforans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scleromalacia perforans in a patient with rheumatoid arthritis. There are areas of significant collagen breakdown in the scleral wall with little to no associated redness or vascular engorgement.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 78096 Version 2.0</div></div></div>"},"78097":{"type":"graphic_table","displayName":"Normal respiratory rate and heart rate in children","title":"Pediatric respiratory rate and heart rate by age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric respiratory rate and heart rate by age*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group</td> <td class=\"subtitle1\">Respiratory rate</td> <td class=\"subtitle1\">Heart rate</td> </tr> <tr> <td class=\"subtitle2\">Median<br /> (1st-99th percentile)</td> <td class=\"subtitle2\">Median<br /> (1st-99th percentile)</td> </tr> <tr> <td>0 to 3 months</td> <td>43 (25-66)</td> <td>143 (107-181); term newborn at birth: 127 (90-164)</td> </tr> <tr> <td>3 to 6 months</td> <td>41 (24-64)</td> <td>140 (104-175)</td> </tr> <tr> <td>6 to 9 months</td> <td>39 (23-61)</td> <td>134 (98-168)</td> </tr> <tr> <td>9 to 12 months</td> <td>37 (22-58)</td> <td>128 (93-161)</td> </tr> <tr> <td>12 to 18 months</td> <td>35 (21-53)</td> <td>123 (88-156)</td> </tr> <tr> <td>18 to 24 months</td> <td>31 (19-46)</td> <td>116 (82-149)</td> </tr> <tr> <td>2 to 3 years</td> <td>28 (18-38)</td> <td>110 (76-142)</td> </tr> <tr> <td>3 to 4 years</td> <td>25 (17-33)</td> <td>104 (70-136)</td> </tr> <tr> <td>4 to 6 years</td> <td>23 (17-29)</td> <td>98 (65-131)</td> </tr> <tr> <td>6 to 8 years</td> <td>21 (16-27)</td> <td>91 (59-123)</td> </tr> <tr> <td>8 to 12 years</td> <td>19 (14-25)</td> <td>84 (52-115)</td> </tr> <tr> <td>12 to 15 years</td> <td>18 (12-23)</td> <td>78 (47-108)</td> </tr> <tr> <td>15 to 18 years</td> <td>16 (11-22)</td> <td>73 (43-104)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The respiratory and heart rates provided are based upon measurements in awake, healthy infants and children at rest. Many clinical findings besides the actual vital sign measurement must be taken into account when determining whether a specific vital sign is normal in an individual patient. Values for heart rate or respiratory rate that fall within normal limits for age may still represent abnormal findings that are caused by underlying disease in a particular infant or child.</div><div class=\"graphic_reference\">Data from: Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011; 377:1011.</div><div id=\"graphicVersion\">Graphic 78097 Version 7.0</div></div></div>"},"78098":{"type":"graphic_figure","displayName":"Microsporidia life cycle","title":"Microsporidia life cycle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microsporidia life cycle</div><div class=\"cntnt\"><img style=\"width:441px; height:694px;\" src=\"images/ID/78098_Microsporidia_life_cycle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infective form of Microsporidia is the resistant spore and it can survive for a long time in the environment <strong>(1)</strong>. The spore extrudes its polar tubule and infects the host cell <strong>(2)</strong>. The spore injects the infective sporoplasm into the eukaryotic host cell through the polar tubule <strong>(3)</strong>. Inside the cell, the sporoplasm undergoes extensive multiplication either by merogony (binary fission) or schizogony (multiple fission) <strong>(4)</strong>. This development can occur either in direct contact with the host cell cytoplasm (eg, <em>Enterocytozoon bieneusi</em>) or inside a vacuole termed parasitophorous vacuole (eg, <em>E. intestinalis</em>). Either free in the cytoplasm or inside a parasitophorous vacuole, microsporidia develop by sporogony to mature spores <strong>(5)</strong>. During sporogony, a thick wall is formed around the spore, which provides resistance to adverse environmental conditions. When the spores increase in number and completely fill the host cell cytoplasm, the cell membrane is disrupted and releases the spores to the surroundings <strong>(6)</strong>. These free mature spores can infect new cells, thus continuing the cycle.</div><div class=\"graphic_footnotes\">* Development inside parasitophorous vacuole also occurs in <em>E. hellum</em> and <em>E. cuniculi</em>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Microsporidiosis. Available at: <a href=\"http://www.cdc.gov/dpdx/microsporidiosis\" target=\"_blank\">http://www.cdc.gov/dpdx/microsporidiosis</a>.</div><div id=\"graphicVersion\">Graphic 78098 Version 6.0</div></div></div>"},"78099":{"type":"graphic_figure","displayName":"Organization of the human T cell receptor-gamma chain locus","title":"Organization of the human T cell receptor-gamma chain locus","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Organization of the human T cell receptor-gamma chain locus</div><div class=\"cntnt\"><img style=\"width:506px; height:134px;\" src=\"images/ALLRG/78099_Human_TCR_gamma_chain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are six functional V gamma genes, five pseudogenes (red boxes), and three unused genes with ORFs (boxes with Xs). There are three J gamma 1, and two J gamma 2 gene segments. There is one each of C gamma 1 and C gamma 2.</div><div class=\"graphic_footnotes\">ORFs: open reading frames.</div><div class=\"graphic_reference\">Adapted from: Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.</div><div id=\"graphicVersion\">Graphic 78099 Version 4.0</div></div></div>"},"78100":{"type":"graphic_picture","displayName":"Serum sickness-like reaction 2","title":"Serum sickness-like reaction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serum sickness-like reaction</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/DERM/78100_Serum_sickness_like_react2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple annular, edematous plaques are present.</div><div id=\"graphicVersion\">Graphic 78100 Version 1.0</div></div></div>"},"78102":{"type":"graphic_picture","displayName":"Retinal photoreceptor","title":"Retinal photoreceptors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal photoreceptors</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PC/78102_Retinal_photoreceptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The retina is a multilayer of neurons that line the back of the eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Jeffrey W Berger Retina Teaching Set. Copyrighted by the Scheie Eye Institute and the University of Pennsylvania.</div><div id=\"graphicVersion\">Graphic 78102 Version 1.0</div></div></div>"},"78104":{"type":"graphic_picture","displayName":"Morphologic features ARVC","title":"Morphologic features in arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Morphologic features in arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><img style=\"width:532px; height:191px;\" src=\"images/CARD/78104_MorphologicfeaturesARVD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Morphologic features in a 25-year-old man who died suddenly from arrhythmogenic right ventricular cardiomyopathy (ARVC). Panel A: Four chamber view cut of the heart specimen showing the transmural fatty replacement of the right ventricular free wall and the translucent infundibulum. Panel B: Panoramic histologic view of the same heart confirming that the replacement of the myocardium by fat is largely confined to the right ventricle (arrow) and substantially spares the interventricular septum as well as the left ventricular free wall (trichrome Heidenhain x 3).</div><div class=\"graphic_reference\">Reproduced with permission from: Basso C, Corrado D, Rossi L, et al. Morbid anatomy. In: Arrhythmogenic right ventricular cardiomyopathy - dysplasia, Nava A, Rossi L, Thiene G (Eds), Elsevier, Amsterdam 1997. p.71-86, Elsevier Science.</div><div id=\"graphicVersion\">Graphic 78104 Version 5.0</div></div></div>"},"78106":{"type":"graphic_figure","displayName":"Fick shunt calculation","title":"Calculation of systemic flow, pulmonary flow, and shunt fraction","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Calculation of systemic flow, pulmonary flow, and shunt fraction</div><div class=\"cntnt\"><img style=\"width:509px; height:277px;\" src=\"images/PULM/78106_Fick_shunt_calculation.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78106 Version 3.0</div></div></div>"},"78107":{"type":"graphic_table","displayName":"Primary graft dysfunction severity score","title":"Recommendations for grading of primary graft dysfunction (PGD) severity after lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for grading of primary graft dysfunction (PGD) severity after lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">PaO<sub>2</sub>/FiO<sub>2</sub></td> <td class=\"subtitle1\">Radiographic infiltrates consistent with pulmonary edema</td> </tr> <tr> <td>0</td> <td>&#62;300</td> <td>Absent</td> </tr> <tr> <td>1</td> <td>&#62;300</td> <td>Present</td> </tr> <tr> <td>2</td> <td>200-300</td> <td>Present</td> </tr> <tr> <td>3</td> <td>&#60;200</td> <td>Present</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454. Copyright Â© 2006 The International Society for Heart and Lung Transplantation.</div><div id=\"graphicVersion\">Graphic 78107 Version 2.0</div></div></div>"},"78108":{"type":"graphic_table","displayName":"Breast cancer specific survival according to stage at diagnosis ","title":"Breast cancer specific survival according to stage at diagnosis and lymph node status; SEER database, 1988-2000","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast cancer specific survival according to stage at diagnosis and lymph node status; SEER database, 1988-2000</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">&nbsp;</td>\n\n      <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">Cancer specific survival, percent</td>\n\n\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\" colspan=\"5\" rowspan=\"1\">Stage of disease</td>\n\n\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle3\">I</td>\n\n      <td class=\"subtitle3\">IIA</td>\n\n      <td class=\"subtitle3\">IIB</td>\n\n      <td class=\"subtitle3\">IIIA</td>\n\n      <td class=\"subtitle3\">IIIB</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" rowspan=\"1\" colspan=\"6\">Number of lymph nodes examined</td>\n\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0</td>\n\n      <td>92</td>\n\n      <td>82</td>\n\n      <td>71</td>\n\n      <td>58</td>\n\n      <td>49</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1 to 3</td>\n\n      <td>98</td>\n\n      <td>93</td>\n\n      <td>81</td>\n\n      <td>72</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">4 to 6</td>\n\n      <td>96</td>\n\n      <td>91</td>\n\n      <td>80</td>\n\n      <td>75</td>\n\n      <td>71</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">7 to 9</td>\n\n      <td>96</td>\n\n      <td>90</td>\n\n      <td>81</td>\n\n      <td>75</td>\n\n      <td>71</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">10 to 14</td>\n\n      <td>96</td>\n\n      <td>90</td>\n\n      <td>82</td>\n\n      <td>71</td>\n\n      <td>72</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">15 to 19</td>\n\n      <td>96</td>\n\n      <td>89</td>\n\n      <td>80</td>\n\n      <td>71</td>\n\n      <td>69</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">20+</td>\n\n      <td>95</td>\n\n      <td>88</td>\n\n      <td>78</td>\n\n      <td>68</td>\n\n      <td>67</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" rowspan=\"1\" colspan=\"6\">Ratio of positive to total number of lymph nodes</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0.01 to 0.25</td>\n\n      <td>-</td>\n\n      <td>92</td>\n\n      <td>85</td>\n\n      <td>81</td>\n\n      <td>78</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0.26 to 0.5</td>\n\n      <td>-</td>\n\n      <td>85</td>\n\n      <td>78</td>\n\n      <td>73</td>\n\n      <td>76</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0.51 to 0.75</td>\n\n      <td>-</td>\n\n      <td>77</td>\n\n      <td>71</td>\n\n      <td>67</td>\n\n      <td>63</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">0.76 to 1.00</td>\n\n      <td>-</td>\n\n      <td>72</td>\n\n      <td>61</td>\n\n      <td>55</td>\n\n      <td>50</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology, and End Results Database of the National Cancer Institute.</div><div class=\"graphic_reference\">Data from: Joslyn SA, et al. Breast Cancer Res Treat 2005; 91:11.</div><div id=\"graphicVersion\">Graphic 78108 Version 3.0</div></div></div>"},"78109":{"type":"graphic_picture","displayName":"Walk up wall stretch PI","title":"Walk-up-wall stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Walk-up-wall stretch</div><div class=\"cntnt\"><img style=\"width:264px; height:385px;\" src=\"images/PI/78109_Walk_up_wall_stretch_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Face a wall and stand about three-quarters of an arm's length away. Put your fingers on the wall. Then walk your fingers up the wall until your arm is at shoulder level. Use your shoulder muscles as little as possible and keep your shoulders level (do not shrug them). Repeat this stretch 10 to 20 times.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 78109 Version 4.0</div></div></div>"},"78111":{"type":"graphic_figure","displayName":"Midgut volvulus","title":"Midgut volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Midgut volvulus</div><div class=\"cntnt\"><img style=\"width:366px; height:483px;\" src=\"images/PEDS/78111_Midgut_volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Volvulus occurs because the narrow mesenteric base, which develops as a result of malrotation, allows the small bowel to twist around the superior mesenteric artery. This leads to vascular compromise of large portions of the midgut.</div><div id=\"graphicVersion\">Graphic 78111 Version 2.0</div></div></div>"},"78113":{"type":"graphic_table","displayName":"Criteria personality disorder","title":"General diagnostic criteria for personality disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General diagnostic criteria for personality disorder</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   DSM-IV requires that the following be present in order to diagnose a personality disorder:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   A. An enduring pattern of inner experience and behavior that deviates markedly from the expectations of the individual's culture. This pattern is manifested in two (or more) of the following areas:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   1. Cognition (ie, ways of perceiving and interpreting self, other people, and events)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   2. Affectivity (ie, the range, intensity, lability, and appropriateness of emotional response)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   3. Interpersonal functioning\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   4. Impulse control\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B. The enduring pattern is inflexible and pervasive across a broad range of personal and social situations.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>C. The enduring pattern leads to clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>D. The pattern is stable and of long duration and its onset can be traced back at least to adolescence or early adulthood</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>E. The enduring pattern is not better accounted for as a manifestation or consequence of another mental disorder</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>F. The enduring pattern is not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition (eg, head trauma)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58156&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Criteria_personality_disord.htm</title></head></div><div class=\"graphic_reference\">Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC 2000.</div><div id=\"graphicVersion\">Graphic 78113 Version 2.0</div></div></div>"},"78116":{"type":"graphic_picture","displayName":"Erythematous leg lesion","title":"Erythematous lesions of Kaposi sarcoma on the leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythematous lesions of Kaposi sarcoma on the leg</div><div class=\"cntnt\"><img style=\"width:287px; height:432px;\" src=\"images/ONC/78116_Erythematous_leg_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Bruce J Dezube, MD.</div><div id=\"graphicVersion\">Graphic 78116 Version 1.0</div></div></div>"},"78117":{"type":"graphic_picture","displayName":"Secondary extens metastasis","title":"Metastatic tumor and secondary extension","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Metastatic tumor and secondary extension</div><div class=\"cntnt\"><img style=\"width:504px; height:362px;\" src=\"images/ONC/78117_Secondary_extens_metastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moderately differentiated adenocarcinoma of the colon metastatic to urinary bladder in a patient with colon cancer.</div><div id=\"graphicVersion\">Graphic 78117 Version 1.0</div></div></div>"},"78118":{"type":"graphic_algorithm","displayName":"Acute diarrhea in children","title":"Acute diarrhea in children","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Acute diarrhea in children</div><div class=\"cntnt\"><img style=\"width:748px; height:712px;\" src=\"images/EM/78118_Diarrhea_acute_edit2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* More likely in older children and adolescents.<br />&para; More likely in infants and young children.</div><div id=\"graphicVersion\">Graphic 78118 Version 10.0</div></div></div>"},"78119":{"type":"graphic_picture","displayName":"Acne hyperpigmentation","title":"Postinflammatory hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:324px; height:279px;\" src=\"images/DERM/78119_Acne_hyperpigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient, healing acne was the cause of the postinflammatory hyperpigmented patch.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78119 Version 4.0</div></div></div>"},"78120":{"type":"graphic_algorithm","displayName":"Prehospital thrombolytic therapy flow sheet","title":"Example of prehospital thrombolytic therapy flow sheet","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Example of prehospital thrombolytic therapy flow sheet</div><div class=\"cntnt\"><img style=\"width:623px; height:842px;\" src=\"images/EM/78120_Prehos_throm_therapy_flow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is a sample flow sheet. A 12 lead ECG is performed by EMS and is evaluated for ST elevation or a new left bundle branch block. A thrombolytic screen is often performed while the patient is assessed and the ECG is obtained. Using a written protocol, a paramedic determines if the patient is a candidate for fibrinolytics. The patient and their suitability for prehospital fibrinolysis is discussed with the online medical control physician. Appropriate therapy is given and the patient is transported to a PCI-capable hospital.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; PCI: percutaneous coronary intervention.</div><div class=\"graphic_reference\">Courtesy of Henderson McGinnis, MD.</div><div id=\"graphicVersion\">Graphic 78120 Version 2.0</div></div></div>"},"78124":{"type":"graphic_picture","displayName":"Cartilage bone separation in HH","title":"Cartilage-bone separation in hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartilage-bone separation in hemochromatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/RHEUM/78124_Cartilage_bone_separation_i.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of the cartilage-bone interface of the femoral head from a patient with hereditary hemochromatosis shows separation of the cartilage (top) from the bone (bottom). Note the absence of a calcified zone of cartilage.</div><div class=\"graphic_reference\">Courtesy of John S Axford, BSc, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 78124 Version 1.0</div></div></div>"},"78125":{"type":"graphic_figure","displayName":"Submucosal rectal abscess","title":"Submucosal rectal abscess","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Submucosal rectal abscess</div><div class=\"cntnt\"><img style=\"width:465px; height:400px;\" src=\"images/SURG/78125_ARFdigitalexamination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the palpation of an abscess in the anal canal by digital examination. This procedure should be performed for every patient with an abscess and/or an anorectal fistula.</div><div id=\"graphicVersion\">Graphic 78125 Version 8.0</div></div></div>"},"78126":{"type":"graphic_waveform","displayName":"RA enlargement ECG tutorial","title":"Electrocardiogram showing right atrial enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram showing right atrial enlargement</div><div class=\"cntnt\"><img style=\"width:201px; height:173px;\" src=\"images/CARD/78126_RAenlargementtutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Delayed activation of an enlarged right atrium leads to simultaneous activation of the right and left atria; this results in a relatively narrow P wave which is of increased amplitude.</div><div id=\"graphicVersion\">Graphic 78126 Version 4.0</div></div></div>"},"78127":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound anal atresia with rectovesical fistula","title":"Prenatal ultrasound image of anal atresia with rectovesical fistula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of anal atresia with rectovesical fistula</div><div class=\"cntnt\"><img style=\"width:504px; height:402px;\" src=\"images/OBGYN/78127_Anal_atresia_wfist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of fetus with anal atresia and rectovesical fistula. Oblique view shows dilated fluid-filled rectum with intraluminal calcifications from urine mixing with meconium.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 78127 Version 5.0</div></div></div>"},"78128":{"type":"graphic_form","displayName":"Los Angeles Prehospital Stroke Screen","title":"Los Angeles Prehospital Stroke Screen","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Los Angeles Prehospital Stroke Screen</div><div class=\"cntnt\"><img style=\"width:609px; height:674px;\" src=\"images/NEURO/78128_LAPSS_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS). Stroke 2000; 31:71. Copyright Â© 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78128 Version 10.0</div></div></div>"},"78129":{"type":"graphic_figure","displayName":"Breech extraction2","title":"Delivery of the arms","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Delivery of the arms</div><div class=\"cntnt\"><img style=\"width:454px; height:326px;\" src=\"images/OBGYN/78129_Breech_extraction2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gentle traction on the pelvis. Note that traction is not applied above the pelvis. Continuation of traction, with rotation as the scapulae becomes visible, sweeping the posterior and then anterior arm free in the process.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78129 Version 1.0</div></div></div>"},"78130":{"type":"graphic_table","displayName":"Maternal opioid withdrawal symptoms","title":"Maternal opioid withdrawal symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal opioid withdrawal symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Opioid withdrawal signs and symptoms </td> </tr> <tr> <td class=\"subtitle2_single\">Mild withdrawal signs and symptoms include </td> </tr> <tr> <td class=\"indent1\">Generalized anxiety, irritability </td> </tr> <tr> <td class=\"indent1\">Opioid craving </td> </tr> <tr> <td class=\"indent1\">Restlessness </td> </tr> <tr> <td class=\"indent1\">Slight aching of muscles, joints, and bones </td> </tr> <tr> <td class=\"indent1\">Generalized pain</td> </tr> <tr> <td class=\"indent1\">Lower back pain </td> </tr> <tr> <td class=\"subtitle2_single\">Mild to moderate withdrawal signs and symptoms include </td> </tr> <tr> <td class=\"indent1\">Tension </td> </tr> <tr> <td class=\"indent1\">Restless sleep </td> </tr> <tr> <td class=\"indent1\">Mydriasis </td> </tr> <tr> <td class=\"indent1\">Lethargy </td> </tr> <tr> <td class=\"indent1\">Diaphoresis </td> </tr> <tr> <td class=\"subtitle2_single\">Moderate withdrawal signs and symptoms include </td> </tr> <tr> <td class=\"indent1\">Chills alternating with flushing and diaphoresis </td> </tr> <tr> <td class=\"indent1\">Nausea and/or stomach cramps </td> </tr> <tr> <td class=\"indent1\">Rhinorrhea </td> </tr> <tr> <td class=\"indent1\">Moderate aching of muscles, joints, and bones </td> </tr> <tr> <td class=\"indent1\">Anorexia </td> </tr> <tr> <td class=\"indent1\">Yawning </td> </tr> <tr> <td class=\"indent1\">Lacrimation </td> </tr> <tr> <td class=\"indent1\">Goose flesh (earlier if client is in a cold, drafty room) </td> </tr> <tr> <td class=\"indent1\">Elevated pulse and blood pressure </td> </tr> <tr> <td class=\"subtitle2_single\">Moderate to severe withdrawal signs and symptoms include </td> </tr> <tr> <td class=\"indent1\">Diarrhea </td> </tr> <tr> <td class=\"indent1\">Vomiting </td> </tr> <tr> <td class=\"indent1\">Tremors </td> </tr> <tr> <td class=\"indent1\">Tachycardia (pulse over 100 beats per minute) </td> </tr> <tr> <td class=\"indent1\">Increased respiratory rate and depth </td> </tr> <tr> <td class=\"subtitle2_single\">Severe withdrawal signs and symptoms include </td> </tr> <tr> <td class=\"indent1\">Doubling over with stomach cramps </td> </tr> <tr> <td class=\"indent1\">Kicking movements </td> </tr> <tr> <td class=\"indent1\">Elevated temperature (usually low grade, less than 100&#176;F) </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: Withdrawal signs and symptoms differ in their order of appearance from one individual to another. Some individuals may not exhibit certain withdrawal signs and symptoms. Signs may also include uterine irritability, increased fetal activity, or, rarely, hypotension.</div><div class=\"graphic_reference\">Reproduced from: Alcohol and other drug treatment guidelines for pregnant, substance-using women. In: Treatment Improvement Protocol Series 2: Pregnant, Substance-abusing Women, Mitchell JL (Ed), Center for Substance Abuse Treatment, Rockville, MD 1995.</div><div id=\"graphicVersion\">Graphic 78130 Version 9.0</div></div></div>"},"78132":{"type":"graphic_form","displayName":"Child asthma action plan PI","title":"Child asthma action plan","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Child asthma action plan</div><div class=\"cntnt\"><img style=\"width:608px; height:789px;\" src=\"images/PI/78132_Child_asthma_action_plan_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 78132 Version 3.0</div></div></div>"},"78133":{"type":"graphic_table","displayName":"Features of hypertonia in infants with colic","title":"Features of hypertonia in infants with colic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of hypertonia in infants with colic</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>The face of the baby is flushed, with occasional circumoral pallor</td>\n   </tr>\n   <tr>\n   <td>The abdomen is distended and tense</td>\n   </tr>\n   <tr>\n   <td>The legs are drawn up on the abdomen and the feet are often cold (the legs may extend periodically during forceful cries)</td>\n   </tr>\n   <tr>\n   <td>The fingers are clenched</td>\n   </tr>\n   <tr>\n   <td>The arms are stiff, tight, and extended (the elbows may also be flexed)</td>\n   </tr>\n   <tr>\n   <td>The back is arched</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=53067&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Hypertonia_in_colic.htm</title></head></div><div class=\"graphic_reference\">Adapted from Lester BM. Colic and Excessive Crying. Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus 1997. p.18.</div><div id=\"graphicVersion\">Graphic 78133 Version 3.0</div></div></div>"},"78134":{"type":"graphic_figure","displayName":"TIMI risk score predicts 30-day mortality after STEMI","title":"TIMI risk score predicts 30-day mortality after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">TIMI risk score predicts 30-day mortality after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:516px; height:451px;\" src=\"images/CARD/78134_TIMI_score_STEMI_30_days.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TIMI risk score, which is a arithmatic summation of eight clinical variables, has a continuous association with 30-day mortality in patients with an ST elevation (STE) myocardial infarction who are eligible for fibrinolytic therapy.</div><div class=\"graphic_footnotes\">bpm: beats per minute; LBBB: left bundle branch block; HTN: hypertension.</div><div class=\"graphic_reference\">Data from Morrow DA, Antman EM, Charlesworth A, et al. Circulation 2000; 102:2031.</div><div id=\"graphicVersion\">Graphic 78134 Version 3.0</div></div></div>"},"78135":{"type":"graphic_picture","displayName":"Stocking immersion","title":"Stocking immersion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stocking immersion</div><div class=\"cntnt\"><img style=\"width:432px; height:259px;\" src=\"images/EM/78135_Stocking_immersion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pattern of deep symmetrical burns in a stocking distribution is typical for inflicted immersion injury.</div><div class=\"graphic_reference\">Reproduced with permission from Stephen Ludwig, MD.</div><div id=\"graphicVersion\">Graphic 78135 Version 1.0</div></div></div>"},"78136":{"type":"graphic_table","displayName":"Estrogen products","title":"Some estrogen products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some estrogen products</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup width=\"35%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Drug and US brand name</td> <td class=\"subtitle1_left\">Available strengths</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Estrogen preparations and doses for the management of vasomotor symptoms</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral estradiol</strong>*</td> </tr> <tr> <td class=\"indent2\">Estrace<sup>&#182;</sup></td> <td>0.5, 1, 2 mg</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral esterified estrogen</strong>*</td> </tr> <tr> <td class=\"indent2\">Menest</td> <td>0.3, 0.625, 1.25 mg</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral estropipate</strong></td> </tr> <tr> <td class=\"indent2\">Generic (previously available as Ortho-Est<sup>)</sup></td> <td>0.75, 1.5, 3 mg estropipate (equivalent to 0.625, 1.25, 2.5 mg conjugated equine estrogen)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral conjugated equine estrogen (CEE)</strong>*</td> </tr> <tr> <td class=\"indent2\">Premarin</td> <td>0.3, 0.45, 0.625, 0.9, 1.25 mg</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral conjugated synthetic estrogens (A)</strong>*</td> </tr> <tr> <td class=\"indent2\">A: Cenestin</td> <td>0.3, 0.45, 0.625, 0.9 mg</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral estrogen-progestin combinations</strong></td> </tr> <tr> <td class=\"indent2\">Prempro<sup>&#916;</sup></td> <td>0.3 mg CEE/1.5 mg medroxyprogesterone, 0.45/1.5 mg, 0.625/2.5 mg, 0.625/5 mg</td> </tr> <tr> <td class=\"indent2\">Prefest</td> <td>1 mg estradiol/0.09 mg norgestimate (cyclic)</td> </tr> <tr> <td class=\"indent2\">Activella, Amabelz, Mimvey<sup>&#182;</sup></td> <td>0.5 mg estradiol/0.1 mg norethindrone acetate, 1 mg/0.5 mg</td> </tr> <tr> <td class=\"indent2\">FemHRT, Jevantique Lo</td> <td>2.5 mcg ethinyl estradiol/0.5 mg norethindrone acetate</td> </tr> <tr> <td class=\"indent2\">Jinteli</td> <td>5 mcg ethinyl estradiol/1 mg norethindrone acetate</td> </tr> <tr> <td class=\"indent2\">Angeliq</td> <td>0.5 mg estradiol/0.25 mg drospirenone, 1 mg/0.5 mg</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Oral conjugated equine estrogens and bazedoxifene</strong></td> </tr> <tr> <td class=\"indent2\">Duavee</td> <td>0.45 mg CEE/20 mg bazedoxifene</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup width=\"35%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Drug and US brand name</td> <td class=\"subtitle1_left\">Available strengths</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Estrogen preparations and doses for the management of vasomotor symptoms (continued)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Estradiol patches</strong>*</td> </tr> <tr> <td class=\"indent2\">Alora (twice weekly)</td> <td>0.025, 0.05, 0.075, 0.1 mg per day</td> </tr> <tr> <td class=\"indent2\">Generic (twice weekly)</td> <td>0.025, 0.0375, 0.05, 0.075, 0.1 mg per day</td> </tr> <tr> <td class=\"indent2\">Minivelle (twice weekly)</td> <td>0.025, 0.0375, 0.05, 0.075, 0.1 mg per day</td> </tr> <tr> <td class=\"indent2\">Vivelle-Dot (twice weekly)</td> <td>0.025, 0.0375, 0.05, 0.075, 0.1 mg per day</td> </tr> <tr> <td class=\"indent2\">Climara<sup>&#182;</sup> (weekly)</td> <td>0.025, 0.0375, 0.05, 0.06, 0.075, 0.1 mg per day</td> </tr> <tr> <td class=\"indent2\">Menostar (weekly)</td> <td>0.014 mg per day</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Estrogen-progestin patches</strong></td> </tr> <tr> <td class=\"indent2\">Combi-Patch (twice weekly)</td> <td>0.05 mg estradiol/0.14 mg norethindrone, 0.05 mg/0.25 mg per day</td> </tr> <tr> <td class=\"indent2\">Climara Pro (weekly)</td> <td>0.045 mg estradiol/0.015 mg levonorgestrel per day</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Topical gel</strong>*</td> </tr> <tr> <td class=\"indent2\">EstroGel 0.06%</td> <td>0.75 mg estradiol per pump</td> </tr> <tr> <td class=\"indent2\">Elestrin 0.06%</td> <td>0.52 mg estradiol per pump</td> </tr> <tr> <td class=\"indent2\">Divigel 0.1%</td> <td>0.25, 0.5, 1 mg estradiol per pouch</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Topical spray</strong>*</td> </tr> <tr> <td class=\"indent2\">EvaMist</td> <td>1.53 mg estradiol per spray</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Intravaginal rings</strong>*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Femring</td> <td>0.05 mg estradiol per day over three months, 0.1 mg estradiol per day over three months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vaginal estrogen preparations for treatment of genitourinary atrophy (inadequate dose to relieve vasomotor symptoms)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Vaginal ring</strong></td> </tr> <tr> <td class=\"indent2\">Estring</td> <td>7.5 mcg estradiol per day, released over three months</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Vaginal tablet</strong></td> </tr> <tr> <td class=\"indent2\">Vagifem</td> <td>10 mcg estradiol per vaginal tablet</td> </tr> <tr> <td class=\"indent2\">Yuvafem</td> <td>10 mcg estradiol per vaginal tablet</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Vaginal cream</strong></td> </tr> <tr> <td class=\"indent2\">Estrace 0.01%</td> <td>0.1 mg estradiol per gram cream</td> </tr> <tr> <td class=\"indent2\">Premarin vaginal</td> <td>0.625 mg CEE per gram cream</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Some esterified estrogen-methyl testosterone (EEMT) combinations remain available in US. These are considered unapproved products by US Food and Drug Administration (FDA) and are not recommended; refer to section on androgens in UpToDate topic review of treatment of menopausal symptoms with hormone therapy.</div><div class=\"graphic_footnotes\">CEE: conjugated equine estrogens.<br />* For women with an intact uterus, a progestin must be added to estrogen therapy.<br />&para; Also available as a generic product in United States (US) and some other countries.<br />&Delta; Also available as Premphase which contains both combination tablets and estrogen alone.</div><div class=\"graphic_reference\">Lexicomp online. Copyright Â© 1978-2018 by Lexicomp, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78136 Version 7.0</div></div></div>"},"78140":{"type":"graphic_table","displayName":"AJCC TNM stage cutaneous SCC","title":"American Joint Committee on Cancer TNM staging system for cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Joint Committee on Cancer TNM staging system for cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Primary tumor (T)<sup>*</sup></td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"3\">Carcinoma in situ</td> </tr> <tr> <td>T1</td> <td colspan=\"3\">Tumor 2 cm or less in greatest dimension with less than two high-risk features (see list of high-risk features below)</td> </tr> <tr> <td rowspan=\"2\">T2 </td> <td colspan=\"3\">Tumor greater than 2 cm in greatest dimension <strong>OR</strong></td> </tr> <tr> <td colspan=\"3\">Tumor any size with two or more high-risk features</td> </tr> <tr> <td>T3</td> <td colspan=\"3\">Tumor with invasion of maxilla, mandible, orbit, or temporal bone</td> </tr> <tr> <td>T4</td> <td colspan=\"3\">Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">High-risk features for the primary tumor (T) staging</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Depth/invasion</td> <td colspan=\"3\">&#62;2 mm thickness</td> </tr> <tr> <td colspan=\"3\">Clark level &#8805;IV</td> </tr> <tr> <td colspan=\"3\">Perineural invasion</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Anatomic location</td> <td colspan=\"3\">Primary site ear</td> </tr> <tr> <td colspan=\"3\">Primary site hair-bearing lip</td> </tr> <tr> <td class=\"indent1\">Differentiation</td> <td colspan=\"3\">Poorly differentiated or undifferentiated</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td>NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td>N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension</td> </tr> <tr> <td class=\"sublist1_start\">N2</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">N2a</td> <td class=\"sublist_other\" colspan=\"3\">Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">N2b</td> <td class=\"sublist_other\" colspan=\"3\">Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">N2c</td> <td class=\"sublist_other\" colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension</td> </tr> <tr> <td>N3</td> <td colspan=\"3\">Metastasis in a lymph node, more than 6 cm in greatest dimension</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastases</td> </tr> <tr> <td>MI</td> <td colspan=\"3\">Distant metastases</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Anatomic stage/prognostic groups<sup>&#182;</sup></td> </tr> <tr> <td>Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"4\">Stage III</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T1</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td rowspan=\"6\">Stage IV</td> <td>T1</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">cSCC: cutaneous squamous cell carcinoma.<br />* Excludes cSCC of the eyelid.<br />Â¶&nbsp;Patients with primary cSCC or other cutaneous carcinomas with no evidence (clinical, radiologic, or pathologic) of regional or distant metastases are divided into two stages: Stage I for tumors measuring â¤2 cm in size and Stage II for those that are greater than 2 cm in size. In instances where there is clinical concern for extension of tumor into bone and radiologic evaluation has been performed (and is negative), these data may be included to support the Stage I versus II designation. Tumors that are â¤2 cm in size can be upstaged to Stage II if they contain two or more high-risk features. Stage III patients are those with (1) clinical, histologic, or radiologic evidence of one solitary node measuring â¤3 cm in size or (2) tumor extension into bone: maxilla, mandible, orbit, or temporal bone. Stage IV patients are those with (1) tumor with direct or perineural invasion of skull base or axial skeleton, (2) â¥2 lymph nodes or (3) single or multiple lymph nodes measuring &gt;3 cm in size or (4) distant metastasis.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 78140 Version 17.0</div></div></div>"},"78141":{"type":"graphic_figure","displayName":"Ethanol ablation HCM","title":"Ethanol ablation in HCM","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Ethanol ablation in HCM</div><div class=\"cntnt\"><img style=\"width:542px; height:655px;\" src=\"images/CARD/78141_Ethanol-ablation-HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of alcohol (ethanol) septal ablation. Infarction of the proximal interventricular septum is caused by infusion of ethanol into the first septal perforating branch of the left anterior descending coronary artery through an angioplasty catheter. The inset demonstrates a balloon occluding the septal branch during the ethanol infusion.</div><div id=\"graphicVersion\">Graphic 78141 Version 5.0</div></div></div>"},"78142":{"type":"graphic_figure","displayName":"Inferior alveolar block","title":"Inferior alveolar nerve block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inferior alveolar nerve block</div><div class=\"cntnt\"><img style=\"width:296px; height:522px;\" src=\"images/PEDS/78142_Inferior_alveolar_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When administering the inferior alveolar block, the target area (*) lies on the medial surface of the mandibular ramus. The needle is inserted parallel to the mandibular occlusal plane (A), with the syringe overlying the first and second premolars on the opposite side of the mandible; the syringe is rotated approximately 30 degrees (in a horizontal plane) during the injection so that when the injection is complete, the syringe barrel rests on the anterior teeth.</div><div id=\"graphicVersion\">Graphic 78142 Version 1.0</div></div></div>"},"78143":{"type":"graphic_picture","displayName":"Meconium-stained infant with severe IUGR","title":"Meconium-stained infant with severe intrauterine growth restriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meconium-stained infant with severe intrauterine growth restriction</div><div class=\"cntnt\"><img style=\"width:256px; height:398px;\" src=\"images/PEDS/78143_SGA_meconium_stained.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infant has the characteristic appearance of an infant with intrauterine growth restriction. Note the loose, peeling skin, decreased subcutaneous tissue and muscle mass, and meconium staining.</div><div class=\"graphic_reference\">Courtesy of George T Mandy, MD.</div><div id=\"graphicVersion\">Graphic 78143 Version 3.0</div></div></div>"},"78144":{"type":"graphic_figure","displayName":"Example dose adjustments based on genetic variation","title":"Examples of dose adjustments based on PGDx","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Examples of dose adjustments based on PGDx</div><div class=\"cntnt\"><img style=\"width:575px; height:463px;\" src=\"images/PC/78144_Dose_adj_pharmacogenetics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The influence of genetic polymorphisms in cytochrome P450 enzymes CYP2D6, CYP2C19 and CYP2C9, thiopurine <EM>S</EM>-methyltransferase (TPMT), and <EM>N</EM>-acetyltransferase type 2 (NAT2) is expressed as subpopulation-specific dosages, according to the difference in pharmacokinetic parameters from clinical studies. The dose adjustments illustrated by the bars in this graph are based on differences in dose-related pharmacokinetic parameters (clearance, AUC, STEADY STATE CONCENTRATION) caused by particular genotypes and are calculated using the methods described earlier. Substantial adjustments need to be made to the drug dose to achieve the same level of drug exposure in individuals with different genotypes.</div><div class=\"graphic_footnotes\">UM: ultra-rapid metabolizer; RA: rapid acetylator; EM: extensive metabolizer; IA: intermediate acetylator; IM: intermediate metabolizer; SA: slow acetylator; PM: poor metabolizer; AUC: area under the curve; .</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers LTD: Kirchheiner J, Fuhr U, Borckmoller J. Pharmacogenetics-based therapeutic recommendations--ready for clinical practie? Nat Rev Drug Discov 2005; 4:639. Copyright Â© 2005.</div><div id=\"graphicVersion\">Graphic 78144 Version 3.0</div></div></div>"},"78145":{"type":"graphic_algorithm","displayName":"Pathogenesis DKA and HHS","title":"Pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state</div><div class=\"cntnt\"><img style=\"width:541px; height:479px;\" src=\"images/ENDO/78145_Pathogen_DKA_and_HHS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; HHS: hyperosmolar hyperglycemic state.<BR>++: Accelerated pathway.</div><div class=\"graphic_reference\">Copyright Â© 2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Reprinted with permission from The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 78145 Version 4.0</div></div></div>"},"78148":{"type":"graphic_table","displayName":"Ovarian cancer symptoms","title":"Frequency of symptom categories in women with ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of symptom categories in women with ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Type of symptom</td>\n\n\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal </td>\n\n\n\n      <td> 77</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gastrointestinal </td>\n\n\n\n      <td> 70</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain </td>\n\n\n\n      <td> 58</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Constitutional </td>\n\n\n\n      <td> 50</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary </td>\n\n\n\n      <td> 34</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pelvic </td>\n\n\n\n      <td> 26</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Goff BA, Mandel L, Muntz HG. Melancon CH. Cancer 2000; 89:2068.</div><div id=\"graphicVersion\">Graphic 78148 Version 2.0</div></div></div>"},"78149":{"type":"graphic_figure","displayName":"Neutrophil migration","title":"Determinants of neutrophil migration","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Determinants of neutrophil migration</div><div class=\"cntnt\"><img style=\"width:463px; height:317px;\" src=\"images/HEME/78149_Neutrophil_migration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates circulating neutrophil interactions with vascular endothelial cells during recruitment to sites of infection or inflammation. At left, neutrophils (PMNs) and endothelial cells are represented in their basal states prior to exposure of either cell type to inflammatory mediators. Constitutive ICAM-2 is expressed on endothelial cells and does not affect free-flowing PMN, which constitutively express L-selectin and its ligand SleX. The adjacent right section illustrates PMN rolling onto endothelial cells, which express E-selectin after activation by IL-1, TNF-alpha, or endotoxin. E-selectin induces attachment of PMN to endothelial cells, mediated by the L- selectin ligand SleX. Endothelial cells release IL-8, GM-CSF and PAF, while other chemoattractants may also be sensed by rolling PMN. One or more of these molecules induce PMN to express beta-2 integrin Mac 1 (and LFA-1, not shown) which mediates firm adherence of PMN to ICAM-1 expressed by activated endothelial cells. At right, PMN is illustrated crawling along endothelial cells and squeezing between them, aided by endothelial cell PECAN-1, which binds PMN Mac-1. The sub-endothelial basement membrane is eroded, presumably by secretion of PMN gelatinase B and elastase.</div><div class=\"graphic_reference\">Courtesy of Robert Baehner, MD.</div><div id=\"graphicVersion\">Graphic 78149 Version 1.0</div></div></div>"},"78150":{"type":"graphic_diagnosticimage","displayName":"Calcified pleural plaque CT I","title":"Malignant lung nodule and pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant lung nodule and pleural plaques</div><div class=\"cntnt\"><img style=\"width:288px; height:284px;\" src=\"images/PULM/78150_Calcified_pleural_plaq_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary pulmonary nodule with scalloped borders in a patient with known asbestos exposure and a visible parietal pleural plaques.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78150 Version 5.0</div></div></div>"},"78151":{"type":"graphic_table","displayName":"Lesions after exposure to RADS","title":"Time course of histologic lesions of RADS at different intervals after exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time course of histologic lesions of RADS at different intervals after exposure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">Interval After Exposure</td>\n\n      \n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Case 1</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3\">60 hours</td>\n\n      <td class=\"subtitle3\">15 days</td>\n\n      <td class=\"subtitle3\">60 days</td>\n\n      <td class=\"subtitle3\">150 days</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Superficial fibrinohemorrhagic layer replacing bronchial epithelium that has sloughed</td>\n\n      <td>Persistence of hemorrhage, bronchial epithelium sloughing; increased deposition of collagen</td>\n\n      <td>Regeneration\nof epithelial cells (basal); collagen deposition; spots of lymphocytes;\nfew PMNs; increase in thickness of basement membrane</td>\n\n      <td>Complete regeneration of the epithelium layer; numerous basal cells indicating regeneration.</td>\n\n    </tr>\n\n\n\n\n\n\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Case 2</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3\" colspan=\"2\" rowspan=\"1\">45 days</td>\n\n      \n\n      <td class=\"subtitle3\" colspan=\"2\" rowspan=\"1\">&nbsp;98 days</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Severe\ndamage of the epithelial layer with few remaining basal cells;\nsubepithelial edema with inflammatory cells underneath the basement\nmembrane.</td>\n\n      \n\n      <td colspan=\"2\" rowspan=\"1\"> Incomplete regeneration of the epithelial layer with few ciliated\ncells; inflammatory cells persisting in epithelium and connective\ntissue.</td>\n\n\n    </tr>\n\n\n\n\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78151 Version 1.0</div></div></div>"},"78152":{"type":"graphic_diagnosticimage","displayName":"RUL RML atelectasis-I","title":"Frontal chest radiograph reveals combined atelectasis of the right upper and right middle lobes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph reveals combined atelectasis of the right upper and right middle lobes</div><div class=\"cntnt\"><img style=\"width:432px; height:351px;\" src=\"images/PULM/78152_RUL_RML_atelectasis-I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A suprahilar opacity obscures the right upper mediastinal contour and fades laterally. A juxtaphrenic peak is present (arrow) as well as rightward shift of the mediastinum.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78152 Version 2.0</div></div></div>"},"78153":{"type":"graphic_table","displayName":"Histopathological classification of tendon disorders","title":"Histopathological classification of tendon disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathological classification of tendon disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathological diagnosis</td> <td class=\"subtitle1\">Macroscopic pathology</td> <td class=\"subtitle1\">Histopathological findings</td> </tr> <tr> <td>Tendinosis</td> <td>Intratendinous degeneration (commonly due to aging, microtrauma, vascular compromise)</td> <td>Collagen disorientation, disorganization and fiber separation by an increase in mucoid ground substance, increased preponderance of cells and vascular spaces with or without neovascularization and focal necrosis or calcification</td> </tr> <tr> <td>Tendinitis</td> <td>Symptomatic degeneration of the tendon with vascular disruption and inflammatory repair response</td> <td>Degenerative changes as noted above with superimposed evidence of tear, including fibroblastic and myofibroblastic proliferation, hemorrhage, and organizing granulation tissue</td> </tr> <tr> <td>Paratenonitis</td> <td>\"Inflammation\" of the outer layer of tendon (paratenon) alone, whether or not the paratenon is lined by synovium</td> <td>Mucoid degeneration if the areolar tissue is seen; a scattered mild mononuclear infiltrate with or without focal fibrin deposition and fibrinous exudate</td> </tr> <tr> <td>Paratenonitis with tendinosis</td> <td>Paratenonitis associated with intratendinous degeneration</td> <td>Degenerative changes as noted in tendinosis with mucoid degeneration with or without fibrous and scattered inflammatory cells in the paratenon alveolar tissue</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Khan KM, Cook JL, Bonar F, et al. Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med 1999; 27:393 with permission from Adis, a Wolters Kluwer business. Copyright &#169; Adis Data Information BV 1999. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78153 Version 2.0</div></div></div>"},"78154":{"type":"graphic_algorithm","displayName":"Approach to acute onset of weakness in children","title":"Approach to acute onset of weakness in children","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Approach to acute onset of weakness in children</div><div class=\"cntnt\"><img style=\"width:563px; height:674px;\" src=\"images/EM/78154_Acuteweaknessalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Hyponatremia, hypernatremia, hypokalemia, hypocalcemia, and hypophosphatemia may all be associated with muscle weakness.<br> Î Potassium may be high, low or normal in patients, and a family history is often present in patients with periodic paralysis.</div><div class=\"graphic_reference\">Adapted with permission from: Tsarouhas N, Decker JM. Weakness. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78154 Version 13.0</div></div></div>"},"78155":{"type":"graphic_diagnosticimage","displayName":"Salter-Harris I fracture proximal humerus","title":"Salter-Harris I fracture proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter-Harris I fracture proximal humerus</div><div class=\"cntnt\"><img style=\"width:303px; height:324px;\" src=\"images/EM/78155_Salterfxproxhumerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Salter-Harris I fracture of proximal humerus.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition Beaty JH, Kasser JR (Eds), Lippincottt Williams &amp; Wilkins 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78155 Version 13.0</div></div></div>"},"78159":{"type":"graphic_figure","displayName":"Inverted T episiotomy","title":"Diameter of the introitus","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Diameter of the introitus</div><div class=\"cntnt\"><img style=\"width:533px; height:384px;\" src=\"images/OBGYN/78159_Inverted_T_episiotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper figures show the introitus and perineum before and after making a traditional midline episiotomy. In the lower sequence of figures, the diameter of the introitus is significantly enlarged by an inverted T type episiotomy compared&nbsp;with the classical midline incision.</div><div class=\"graphic_reference\">Adapted from: Delancy J, Schaffer J, Brubaker L. Pelvic-floor injury. Is it inevitable? OBG Management 2001; 13:76. Copyright Â© 2001, Dowden Health media.</div><div id=\"graphicVersion\">Graphic 78159 Version 2.0</div></div></div>"},"78161":{"type":"graphic_waveform","displayName":"Sinus arrhythmia child","title":"Sinus arrhythmia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Sinus arrhythmia</div><div class=\"cntnt\"><img style=\"width:516px; height:74px;\" src=\"images/PEDS/78161_Sinus_arrhythmia_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This rhythm strip shows a variation in the heart rate with gradual slowing and speeding up of the rate, which correlated with changes in the respiratory rate. Also note that p wave axis is consistent with a sinus origin (upright in lead II).</div><div class=\"graphic_reference\">Courtesy of Andrew D Blaufox, MD</div><div id=\"graphicVersion\">Graphic 78161 Version 4.0</div></div></div>"},"78163":{"type":"graphic_picture","displayName":"Stasis dermatitis advanced 2","title":"Stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78163_Stasis_dermatitis_adv_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advanced stasis dermatitis with hyperpigmentation, lichenification, sclerosis, and ulceration.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78163 Version 4.0</div></div></div>"},"78164":{"type":"graphic_figure","displayName":"Pathogenesis of photoaging","title":"Pathogenesis of photoaging","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of photoaging</div><div class=\"cntnt\"><img style=\"width:598px; height:412px;\" src=\"images/DERM/78164_Pathogenesisphotoaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram demonstrates the effects of UV irradiation on the skin. UV radiations activate growth factor and cytokine receptors, which induce transcription factor AP-1, resulting in the upregulation of MMP genes. AP-1 also disturbs procollagen gene expression. The end results are dermal matrix breakdown and decreased collagen synthesis. The cumulative effect of repeated UV injury determines the clinical features seen in photoaged skin.</div><div class=\"graphic_footnotes\">UV: ultraviolet; FB: fibroblast; KC: keratinocyte; AP-1: activator protein 1; MMP: matrix metalloproteinase.</div><div class=\"graphic_reference\">Reproduced with permission from: Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002; 138:1462. Copyright Â© 2002 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78164 Version 12.0</div></div></div>"},"78165":{"type":"graphic_figure","displayName":"Scorpion anatomy","title":"Scorpion anatomy","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Scorpion anatomy</div><div class=\"cntnt\"><img style=\"width:506px; height:320px;\" src=\"images/EM/78165_Scorpion_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scorpion has a lobster-like body shape with seven sets of paired appendages: the chelicerae, the pedipalps (claws or pinchers), four sets of legs, and the pectines (comb-like structures on the ventral surface). The segmented tail curves up dorsally, ending in the terminal bulbous segment called the telson, which contains paired venom glands and the aculeus (stinger).</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78165 Version 1.0</div></div></div>"},"78167":{"type":"graphic_table","displayName":"Epidemiology of esophageal CA","title":"Epidemiology of esophageal cancer in the United States, 2012","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiology of esophageal cancer in the United States, 2012</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Squamous cell</td> <td class=\"subtitle1\">Adenocarcinoma</td> </tr> <tr> <td>Incidence rate, per 100,000 population</td> <td>1.2</td> <td>2.8</td> </tr> <tr> <td>Male-to-female ratio</td> <td>2.5:1</td> <td>6.5:1</td> </tr> <tr> <td>White-to-black&nbsp;ratio</td> <td>1:4</td> <td>4:1</td> </tr> <tr> <td>Most common locations</td> <td>Middle esophagus</td> <td>Distal esophagus</td> </tr> <tr> <td>Major risk factors</td> <td>Smoking, alcohol</td> <td>Barrett's esophagus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol 2016; 41:88.</div><div id=\"graphicVersion\">Graphic 78167 Version 3.0</div></div></div>"},"78169":{"type":"graphic_table","displayName":"Drug properties MAOIs","title":"Drug properties of monoamine oxidase inhibitor antidepressants and dosages in the elderly (see note)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug properties of monoamine oxidase inhibitor antidepressants and dosages in the elderly (see note)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Dose range for older adult</td> </tr> <tr> <td>Isocarboxazid</td> <td>10 mg every morning</td> <td>10 to 40 mg per day in divided doses</td> </tr> <tr> <td>Phenelzine</td> <td>7.5 mg every morning</td> <td>22.5 to 60 mg per day in three divided doses</td> </tr> <tr> <td>Tranylcypromine</td> <td>10 mg every morning</td> <td>10 to 40 mg per day in divided doses</td> </tr> <tr> <td>Selegiline (transdermal patch)</td> <td>6 mg/24 hours applied once daily</td> <td>6 to 12 mg/24 hours applied once daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IMPORTANT NOTE: MAOIs are <strong>NOT</strong> first line antidepressant medications due to the dietary restrictions, drug-drug interactions and potentially severe side-effects. MAOIs are rarely used in medically ill or older adults except when previously initiated and tolerated in the patient who is treatment resistant to all other antidepressants. For specific drug interactions see the Lexi-Interact program included with UpToDate. For additional information, refer to the separate topic on MAOIs for treating depressed adults.</div><div class=\"graphic_footnotes\">MAOI: monoamine oxidase inhibitors.</div><div id=\"graphicVersion\">Graphic 78169 Version 3.0</div></div></div>"},"78173":{"type":"graphic_picture","displayName":"Neonate with caudal regression","title":"Severe caudal regression in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe caudal regression in a neonate</div><div class=\"cntnt\"><img style=\"width:400px; height:474px;\" src=\"images/PEDS/78173_Severe_caudal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infant with caudal regression. Note the flattened, dimpled buttocks and hyperextended or subluxated knees.</div><div class=\"graphic_reference\">Reproduced with permission from: Boulas M. Recognition of caudal regression syndrome. Adv Neonatal Care 2009; 9:61. Copyright Â© 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78173 Version 9.0</div></div></div>"},"78174":{"type":"graphic_algorithm","displayName":"Blunt cerebrovascular injury algorithm","title":"Blunt cerebrovascular injury algorithm","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Blunt cerebrovascular injury algorithm</div><div class=\"cntnt\"><img style=\"width:618px; height:617px;\" src=\"images/SURG/78174_Blunt_cerebrovasc_inj_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BCVI: blunt cerebrovascular injury; OR: operating room; TIA: transient ischemic attack; GCS: Glasgow coma scale; CT: computed tomography; CTA: computed tomographic angiography; MRI: magnetic resonance imaging; PTT: partial thromboplastin time; CHI: closed head injury; DAI: diffuse axonal injury; MS: mental status.<br />* For positive arteriogram, follow treatment algorithm as per 16-slice CTA results (E and F).<br />Â¶ CT angiography with multidetector-row CT, 16-channel or higher. If fewer than 16 channels, interpret CTA with caution.<br />Î If signs/symptoms or high clinical suspicion and (-)CTA, consider arteriogram as the gold standard.<br /><FONT class=lozenge>â</FONT> If Grade II-V injury is surgically accessible and patient has not suffered completed stroke, pursue operative repair.<br />Â§ Heparin is preferred in the acute setting, as it is reversible and may be more efficacious than antiplatelet drugs. Anticoagulation may be contraindicated due to other injuries.<br />Â¥ Stenting should be performed with caution, and appropriate antithrombotic therapy administered concurrently.<br />â¡ Aspirin alone (75-150 mg daily) is adequate and should be considered lifelong as its risk profile is superior to coumadin.</div><div class=\"graphic_reference\">Reproduced with permission from: Biffl WL, Cothren CC, Moore EE, et al. Western Trauma Association critical decisions in trauma: screening for and treatment of blunt cerebrovascular injuries. J Trauma 2009; 67:1150. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78174 Version 11.0</div></div></div>"},"78175":{"type":"graphic_table","displayName":"Diagnosis of cysticercosis","title":"Diagnosis of cysticercosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of cysticercosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Revised diagnostic criteria for neurocysticercosis</td> </tr> <tr> <td class=\"subtitle2\">Categories of criteria</td> <td class=\"subtitle2\">Criteria</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Absolute</td> <td>Histologic demonstration of the parasite from biopsy of a brain or spinal cord lesion</td> </tr> <tr> <td>Cystic lesions showing the scolex on CT or MRI</td> </tr> <tr class=\"divider_bottom\"> <td>Direct visualization of subretinal parasites by funduscopic examination</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Major</td> <td>Lesions highly suggestive of neurocysticercosis on neuroimaging studies*</td> </tr> <tr> <td>Positive serum EITB<sup>&#182;</sup> for the detection of anticysticercal antibodies</td> </tr> <tr> <td>Resolution of intracranial cystic lesions after therapy with albendazole or praziquantel</td> </tr> <tr class=\"divider_bottom\"> <td>Spontaneous resolution of small single enhancing lesions<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Minor</td> <td>Lesions compatible with neurocysticercosis on neuroimaging studies<sup>&#9674;</sup></td> </tr> <tr> <td>Clinical manifestations suggestive of neurocysticercosis<sup>&#167;</sup></td> </tr> <tr> <td>Positive CSF ELISA for detection of anticysticercal antibodies or cysticercal antigens</td> </tr> <tr class=\"divider_bottom\"> <td>Cysticercosis outside the CNS<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Epidemiologic</td> <td>Evidence of a household contact with <em>Taenia solium</em> infection</td> </tr> <tr> <td>Individuals coming from or living in an area where cysticercosis is endemic</td> </tr> <tr> <td>History of frequent travel to disease-endemic areas</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Revised degrees of certainty for the diagnosis of neurocysticercosis</td> </tr> <tr> <td class=\"subtitle2\">Diagnostic certainty</td> <td class=\"subtitle2\">Criteria</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Definitive</td> <td>Presence of one absolute criterion</td> </tr> <tr class=\"divider_bottom\"> <td>Presence of two major plus one minor and one epidemiologic criterion</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Probable</td> <td>Presence of one major plus two minor criteria</td> </tr> <tr> <td>Presence of one major plus one minor and one epidemiologic criterion</td> </tr> <tr class=\"divider_bottom\"> <td>Presence of three minor plus one epidemiologic criterion</td> </tr> <tr> <td colspan=\"2\">The presence of two different lesions highly suggestive of neurocysticercosis on neuroimaging studies should be considered as two major diagnostic criteria. However, positive results in two separate types of antibody detection tests should be interpreted only on the basis of the test falling in the highest category of diagnostic criteria.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; EITB: enzyme-linked immunoelectrotransfer blot assay; CSF: cerebrospinal fluid;&nbsp;ELISA: enzyme-linked immunosorbent assay; CNS: central nervous system.<br />* CT or MRI showing cystic lesions without scolex, enhancing lesions, or typical parenchymal brain calcifications.<br />Â¶ EITB using purified extracts of <EM>Taenia solium</EM> antigens, as developed by the Centers for Disease Control and Prevention (Atlanta, GA).<br />Î Solitary ring-enhancing lesions measuring less than 20 mm in diameter in patients presenting with seizures, a normal neurologic examination, and no evidence of an active systemic disease.<br /><FONT class=lozenge>â</FONT> CT or MRI showing hydrocephalus or abnormal enhancement of the leptomeninges, and myelograms showing multiple filling defects in the column of contrast medium.<br />Â§ Seizures, focal neurologic signs, intracranial hypertension, and dementia.<br />Â¥ Histologically confirmed subcutaneous or muscular cysticercosis, plain radiograph films showing \"cigar-shaped\" soft-tissue calcifications, or direct visualization of cysticerci in the anterior chamber of the eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Del Brutto OH, Rajshekharm V, White AC, et al. Proposed diagnostic criteria for neurocysticerosis. Neurology 2001; 57:177. Copyright Â© 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78175 Version 14.0</div></div></div>"},"78176":{"type":"graphic_picture","displayName":"Plasmodium falciparum gametocyte","title":"Blood smear of <EM>Plasmodium falciparum </EM>malaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood smear of <EM>Plasmodium falciparum </EM>malaria</div><div class=\"cntnt\"><img style=\"width:368px; height:292px;\" src=\"images/ID/78176_Pfalciparumgametocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Giemsa-stained thin smear of blood showing the characteristic banana-shaped gametocyte of <EM>Plasmodium falciparum </EM>(arrow).</div><div class=\"graphic_reference\">Courtesy of Stephen B Calderwood, MD.</div><div id=\"graphicVersion\">Graphic 78176 Version 2.0</div></div></div>"},"78179":{"type":"graphic_picture","displayName":"Severe axillary intertrigo","title":"Candidal intertrigo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal intertrigo</div><div class=\"cntnt\"><img style=\"width:396px; height:527px;\" src=\"images/PC/78179_Severe_axillary_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe axillary intertrigo with erythema, skin breakdown, and satellite papules and pustules.</div><div class=\"graphic_reference\">Courtesy of Eva Rawlings Parker, MD.</div><div id=\"graphicVersion\">Graphic 78179 Version 4.0</div></div></div>"},"78180":{"type":"graphic_figure","displayName":"Longitudinal lie cephalic presentation","title":"Longitudinal lie, cephalic presentation","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Longitudinal lie, cephalic presentation</div><div class=\"cntnt\"><img style=\"width:497px; height:386px;\" src=\"images/OBGYN/78180_Longitudinal-lie-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences in attitude of the fetal body in (A) vertex, (B) brow,&nbsp;and (C) face presentations. A&nbsp;deflexed fetal&nbsp;neck&nbsp;results in&nbsp;a wider&nbsp;presenting cephalic diameter.</div><div id=\"graphicVersion\">Graphic 78180 Version 7.0</div></div></div>"},"78182":{"type":"graphic_picture","displayName":"Esophageal cast tethered","title":"Esophagitis dissecans superficialis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis dissecans superficialis</div><div class=\"cntnt\"><img style=\"width:396px; height:323px;\" src=\"images/GAST/78182_Esophageal_cast_tethered.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing an esophageal cast still tethered to gastroesophageal junction in a patient wth esophagitis dissecans superficialis.</div><div class=\"graphic_reference\">Courtesy of S. Ian Gan, MD, and Daniel Wild, MD.</div><div id=\"graphicVersion\">Graphic 78182 Version 2.0</div></div></div>"},"78183":{"type":"graphic_picture","displayName":"Congo red amyloid","title":"Congo red stain in amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congo red stain in amyloidosis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/78183_Congo_red_amyloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congo red stain viewed under polarized light of a renal biopsy from a patient with renal amyloidosis. Green birefringence (white arrows) of interstitial amyloid deposits can be seen.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78183 Version 1.0</div></div></div>"},"78184":{"type":"graphic_figure","displayName":"Events LQTS with beta blocker","title":"Outcome with beta blocker in the long QT syndrome is good in asymptomatic patients","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Outcome with beta blocker in the long QT syndrome is good in asymptomatic patients</div><div class=\"cntnt\"><img style=\"width:491px; height:358px;\" src=\"images/CARD/78184_Events_LQTS_with_beta_block.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a five year follow-up of 869 patients with a long QT syndrome, the estimated cumulative probability of experiencing aborted cardiac arrest or death on beta blocker therapy was significantly reduced in those who were asymptomatic (0.97 versus 0.31 events per year on therapy in probands and 0.26 versus 0.15 events per year in affected family members). Recurrent events despite beta blocker therapy were significantly higher in those with a history of syncope (hazard ratio 3.1) or aborted sudden death (hazard ratio 12.9).</div><div class=\"graphic_reference\">Data from Moss AJ, Zareba W, Hall WJ, et al, Circulation 2000; 101:616.</div><div id=\"graphicVersion\">Graphic 78184 Version 1.0</div></div></div>"},"78185":{"type":"graphic_table","displayName":"Clin features NB hypertension","title":"Clinical manifestations of neonatal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of neonatal hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Asymptomatic</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Cardiorespiratory</td>\n</tr>\n<tr>\n<td>Tachypnea</td>\n</tr>\n<tr>\n<td>Cyanosis</td>\n</tr>\n<tr>\n<td>Cardiomegaly</td>\n</tr>\n<tr>\n<td>Hepatomegaly</td>\n</tr>\n<tr>\n<td>Heart failure</td>\n</tr>\n<tr>\n<td>Mottling</td>\n</tr>\n<tr>\n<td>Decreased or unequal pulses</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Neurologic</td>\n</tr>\n<tr>\n<td>Lethargy</td>\n</tr>\n<tr>\n<td>Coma</td>\n</tr>\n<tr>\n<td>Tremors</td>\n</tr>\n<tr>\n<td>Seizures</td>\n</tr>\n<tr>\n<td>Hypertonicity</td>\n</tr>\n<tr>\n<td>Hypotonicity</td>\n</tr>\n<tr>\n<td>Apnea</td>\n</tr>\n<tr>\n<td>Opisthotonos</td>\n</tr>\n<tr>\n<td>Hemiparesis</td>\n</tr>\n<tr>\n<td>Intracranial hemorrhage</td>\n</tr>\n<tr>\n<td>Asymmetric reflexes</td>\n</tr>\n<tr>\n<td>Retinopathy</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Renal</td>\n</tr>\n<tr>\n<td>Renal enlargement</td>\n</tr>\n<tr>\n<td>Sodium wasting</td>\n</tr>\n<tr>\n<td>Oligoanuria</td>\n</tr>\n<tr>\n<td>Polyuria</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other</td>\n</tr>\n<tr>\n<td>Failure to thrive</td>\n</tr>\n<tr>\n<td>Abdominal distention</td>\n</tr>\n<tr>\n<td>Edema</td>\n</tr>\n<tr>\n<td>Adrenal mass</td>\n</tr>\n<tr>\n<td>Fever</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78185 Version 1.0</div></div></div>"},"78186":{"type":"graphic_diagnosticimage","displayName":"Malignant neuroendocrine tumor ileum CT","title":"Radiographic features associated with small bowel neuroendocrine tumors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic features associated with small bowel neuroendocrine tumors</div><div class=\"cntnt\"><img style=\"width:413px; height:288px;\" src=\"images/GAST/78186_MalignantcarcinoidileumC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan demonstrates a soft tissue mass containing coarse central calcifications (arrowhead) in the right lower quadrant. This neuroendocrine tumor is producing a characteristic desmoplastic response with spiculation of the adjacent mesenteric fat (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78186 Version 5.0</div></div></div>"},"78188":{"type":"graphic_picture","displayName":"Disseminated Candida tropicalis","title":"Disseminated <EM>Candida tropicalis </EM>infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated <EM>Candida tropicalis </EM>infection</div><div class=\"cntnt\"><img style=\"width:414px; height:246px;\" src=\"images/ID/78188_Disseminated_Candida_tropic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematogenous dissemination of <EM>C. tropicalis</EM> produced this hemorrhagic nodule on the arm of a patient with acute myelogenous leukemia and thrombocytopenia.</div><div class=\"graphic_reference\">Courtesy of Richard A Johnson, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Lippincott Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 78188 Version 10.0</div></div></div>"},"78189":{"type":"graphic_table","displayName":"Lab tests for pertussis","title":"Comparison of laboratory tests for the detection of <em>Bordetella pertussis</em>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of laboratory tests for the detection of <em>Bordetella pertussis</em></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory method</td> <td class=\"subtitle1\">Reported sensitivity*</td> <td class=\"subtitle1\">Reported specificity*</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Culture of nasopharyngeal secretions</td> <td>20 to 80 percent<br /> (decreases with increasing duration of cough)</td> <td>100 percent</td> <td> <ul> <li>Traditional reference standard for diagnosis </li> <li>Sensitivity depends on duration of symptoms and decreases after two weeks of illness; prior vaccination or antibiotic exposure also decrease sensitivity </li> <li>Permits antibiotic susceptibility testing and strain serotyping (helpful in outbreak setting) </li> <li>Results available in three to seven days </li> <li>Not available in all laboratories </li> <li>In an outbreak setting, confirmation is recommended for at least one case of suspected pertussis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Polymerase chain reaction of nasopharyngeal secretions<sup>&#182;</sup></td> <td>61 to 94 percent</td> <td>88 to 98 percent</td> <td> <ul> <li>Rapidly available results </li> <li>More sensitive than culture, but sensitivity decreases after three weeks of illness </li> <li>No standard methodology </li> <li>Subject to contamination, especially during outbreaks </li> <li>May also be positive in <em>B. holmesii</em> and <em>B. bronchiseptica</em> </li> <li>May detect non-viable <em>B. pertussis </em>organisms </li> </ul> </td> </tr> <tr> <td>Serology (ELISA) blood</td> <td>60 to 95 percent</td> <td>&#916;</td> <td> <ul> <li>A CDC/FDA-developed assay has been useful in outbreak settings; the accuracy of commercially available assays is not known. </li> <li>In general, serology is most useful for diagnosis two to eight weeks after cough onset. A single high antibody titer above a designated threshold may be sufficient and obviate the need for acute/convalescent titers; this cutoff is often laboratory-specific. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ELISA: enzyme-linked immunosorbent assay; CDC: Centers for Disease Control and Prevention; FDA: US Food and Drug Administration.<br />* Reported sensitivities and specificities taken from clinical or epidemiologic studies or vaccine trials.<br />Â¶ Compared with clinical case definitions + serology in most studies.<br />Î Not readily available from epidemiologic studies. An investigation in German adults found a specificity of 84 percent using a clinician's clinical diagnosis as a gold standard (Schmitt-GrohÃ© S, Cherry JD, Heininger U, et al. Pertussis in German adults. Clin Infect Dis 1995; 21:860).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Pertussis (whooping cough). Diagnosis confirmation. Available at: http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html (Accessed on October 8, 2014). </li>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Best practices for health care professionals on the use of polymerase chain reaction (PCR) for diagnosing pertussis. http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html (Accessed on October 17, 2014). </li>&#xD;&#xA;    <li>Cherry JD, Tan T, Wirsing von K&ouml;nig CH, et al. Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis 2012; 54:1756. </li>&#xD;&#xA;    <li>G&uuml;riÅ D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230. </li>&#xD;&#xA;    <li>Heininger U, Schmidt-Schl&auml;pfer G, Cherry JD, Stehr K. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 2000; 105:E31. </li>&#xD;&#xA;    <li>Kerr JR, Matthews RC. Bordetella pertussis infection: Pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Micribiol Infect Dis 2000; 19:77. </li>&#xD;&#xA;    <li>K&ouml;sters K, Riffelmann M, Dohrn B, von K&ouml;nig CH. Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagn Lab Immunol 2000;7:422. </li>&#xD;&#xA;    <li>Lind-Brandberg L, Welinder-Olsson C, Lagerg&aring;rd T, Taranger J, Trollfors B, Zackrisson G. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J Clin Microbiol 1998; 36:679. </li>&#xD;&#xA;    <li>Loeffelholz MJ, Thompson CJ, Long KS, Gilchrist MJ. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999; 37:2872.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 78189 Version 6.0</div></div></div>"},"78190":{"type":"graphic_figure","displayName":"Aggressive BP reduction in CRF","title":"Aggressive BP control preserves renal function in proteinuric patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aggressive BP control preserves renal function in proteinuric patients</div><div class=\"cntnt\"><img style=\"width:393px; height:238px;\" src=\"images/NEPH/78190_AggrssvBPredctnCRFedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean fall in glomerular filtration rate (GFR) according to the degree of proteinuria in patients treated with usual BP control (mean BP about 130/80 mmHg) or with more aggressive antihypertensive therapy in which the mean BP was 4.7 mmHg lower over a three-year period. The rate of fall in GFR varied directly with protein excretion, and the benefit of aggressive BP control was absent in the 420 patients excreting less than 1 g/day, modest in the 104 patients excreting between 1 and 3 g/day, and substantial (3.5 mL/min/year slower) and statistically significant in the 54 patients excreting at least 3 g/day.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Data from: Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.</div><div id=\"graphicVersion\">Graphic 78190 Version 6.0</div></div></div>"},"78191":{"type":"graphic_figure","displayName":"Cortical hyperemia associated with focal seizures","title":"Cortical hyperemia associated with increased flow-related enhancement in a patient in focal status epilepticus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cortical hyperemia associated with increased flow-related enhancement in a patient in focal status epilepticus</div><div class=\"cntnt\"><img style=\"width:435px; height:246px;\" src=\"images/NEURO/78191_Cortical_hyperemia_sz.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) MR angiogram showing dilatation of the right middle cerebral artery (MCA) branches presumably reflecting increased blood flow to the active cortex. B) Intra-operative photograph showing right motor strip exposed beneath the dura (right and panel).</div><div class=\"graphic_reference\">Reproduced with permission from: Doherty, CP, Cole, AJ, Grant, PE, et al. Multimodal longitudinal imaging of focal status epilepticus. Can J Neurol Sci 2004; 31:276. Copyright Â© Canadian Journal of Neurological Sciences.</div><div id=\"graphicVersion\">Graphic 78191 Version 2.0</div></div></div>"},"78192":{"type":"graphic_table","displayName":"Blood gases in pregnancy","title":"Arterial blood gas values in pregnant and nonpregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Arterial blood gas values in pregnant and nonpregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Parameter</td>\n<td class=\"subtitle1\">Pregnant, mmHg</td>\n<td class=\"subtitle1\">Nonpregnant, mmHg</td>\n</tr>\n<tr>\n<td>pCO2</td>\n<td>27 to 32</td>\n<td>39 to 40</td>\n</tr>\n<tr>\n<td>pO2</td>\n<td>100 to 108</td>\n<td>95 to 100</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>7.40 to 7.45</td>\n<td>7.40</td>\n</tr>\n<tr>\n<td>Bicarbonate</td>\n<td>18 to 21</td>\n<td>24 to 29</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78192 Version 1.0</div></div></div>"},"78193":{"type":"graphic_figure","displayName":"Cavoatrial tumor thrombus","title":"Cavoatrial tumor thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavoatrial tumor thrombus</div><div class=\"cntnt\"><img style=\"width:449px; height:256px;\" src=\"images/ONC/78193_Cavoatrial_tumor_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four stages of cavoatrial tumor extension are depicted. In type I and II disease, tumor excision can be safely achieved by means of simple proximal and distal control of the inferior vena cava, while for type III and IV disease, exposure and isolation of the inferior vena cava is more extensive, requiring liver mobilization with or without the use of cardiopulmonary bypass and, in some circumstances, deep hypothermic circulatory arrest.</div><div class=\"graphic_reference\">Reproduced with permission from: Chiappini B, Savini C, Marinelli G, et al. Cavoatrial tumor thrombus: Single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature. J Thor Cardiovasc Surg 2002; 124:684. Copyright Â© 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 78193 Version 2.0</div></div></div>"},"78194":{"type":"graphic_picture","displayName":"Immunofluorescence findings II","title":"Immunofluorescence findings in urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence findings in urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:468px; height:265px;\" src=\"images/ALLRG/78194_Immunofluorescence_findin1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence of a biopsy specimen from a patient with urticarial vasculitis, demonstrating IgM deposits along the dermal-epidermal junction as well as involving blood vessel walls in the dermis.</div><div id=\"graphicVersion\">Graphic 78194 Version 3.0</div></div></div>"},"78195":{"type":"graphic_picture","displayName":"Airway view of glottis and esophagus","title":"Airway view of the glottis and esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway view of the glottis and esophagus</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/EM/78195_Glottis_vs_esophagus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airway view during laryngoscopy. The glottis has a vertical orientation with vocal cords appearing as white structures superiorly and arytenoid cartilages posteriorily&nbsp;(black arrow). The esophagus has a horizontal orientation and appears slitlike inferiorly (white arrow).</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 78195 Version 3.0</div></div></div>"},"78199":{"type":"graphic_picture","displayName":"Mammary duct fistula","title":"Mammary duct fistula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mammary duct fistula</div><div class=\"cntnt\"><img style=\"width:504px; height:245px;\" src=\"images/PC/78199_Mammary_duct_fistula_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A mammary duct fistula is a communication between a subareolar duct and the skin, usually in the periareolar area. This patient has bilateral fistulae.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 78199 Version 4.0</div></div></div>"},"78200":{"type":"graphic_table","displayName":"Guidelines for family and couple therapy","title":"A practical guide for family and couples therapy for depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A practical guide for family and couples therapy for depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Principles and tasks</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Meet with the family</td> <td>Include as many family members as can come and are interested in helping.</td> </tr> <tr> <td>Elicit everyone's view</td> <td>All family members should discuss their perception of the family's problems, whether related to the depression or not. </td> </tr> <tr> <td>Assess couples/family functioning</td> <td>Evaluate how the family communicates, solves problems, connects emotionally with each other, assigns family responsibilities, and sets family rules.</td> </tr> <tr> <td>Focus on strengths</td> <td>Identify and reinforce family strengths.</td> </tr> <tr> <td>Evaluate motivation for change</td> <td>Ensure that families are committed to working together on their problems.</td> </tr> <tr> <td>Assess safety</td> <td>Ensure that the depressed patient is not suicidal and that there is no family violence.</td> </tr> <tr> <td>Psychoeducation</td> <td>Teach families about depression, including signs and symptoms, etiology, course of illness, and available treatments.</td> </tr> <tr> <td>Prioritize problems</td> <td>Determine with the family which of their problems they want to address. Prioritize problems related to safety.</td> </tr> <tr> <td>Negotiate expectations</td> <td>Establish clinician's expectations for the treatment process, eg, compliance with meetings and working on assigned tasks. Family members should negotiate expected changes with each other.</td> </tr> <tr> <td>Set realistic expectations</td> <td>Expectations about change and outcome should be realistic and achievable.</td> </tr> <tr> <td>Focus on behaviors and not feelings</td> <td>Feelings cannot be changed and are difficult to measure. Behaviors are more amenable to change and can be evaluated more objectively.</td> </tr> <tr> <td>Include some general goals</td> <td>Communicate directly and clearly, support and fulfill appropriate roles as spouse and parent, and reduce criticism, blame, and hostility.</td> </tr> <tr> <td>Support increased level of activity</td> <td>The depressed patient should gradually increase participation in activities first within the home and then outside of the home, including greater levels of physical activity.</td> </tr> <tr> <td>Provide feedback</td> <td>Inform the family when they are doing well and point out difficulties they are experiencing in making changes.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78200 Version 4.0</div></div></div>"},"78201":{"type":"graphic_table","displayName":"Weaning predictors","title":"Weaning predictors<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weaning predictors<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Measurements of oxygenation and gas exchange</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub>/FiO<sub>2</sub></td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub>/PAO<sub>2</sub></td> </tr> <tr> <td class=\"indent1\">Alveolar-arterial (A-a) oxygen gradient</td> </tr> <tr> <td class=\"indent1\">Dead space (V<sub>D</sub>/V<sub>T</sub>)</td> </tr> <tr> <td class=\"subtitle1_single\">Simple measurements of respiratory system load and respiratory muscle capacity</td> </tr> <tr> <td class=\"indent1\">Negative inspiratory force (NIF) or maximal inspiratory pressure (MIP)*</td> </tr> <tr> <td class=\"indent1\">Respiratory system compliance (dynamic, static)</td> </tr> <tr> <td class=\"indent1\">Respiratory system resistance</td> </tr> <tr> <td class=\"indent1\">Total minute ventilation*</td> </tr> <tr> <td class=\"indent1\">Vital capacity</td> </tr> <tr> <td class=\"indent1\">Respiratory frequency*</td> </tr> <tr> <td class=\"indent1\">Tidal volume*</td> </tr> <tr> <td class=\"subtitle1_single\">Integrative indices</td> </tr> <tr> <td class=\"indent1\">Frequency-tidal volume ratio, f/V<sub>T</sub>, or rapid shallow breathing index (RSBI)*</td> </tr> <tr> <td class=\"indent1\">CROP index (dynamic <strong>C</strong>ompliance, <strong>R</strong>espiratory rate, <strong>O</strong>xygenation, maximal inspiratory <strong>P</strong>ressure)*</td> </tr> <tr> <td class=\"indent1\">CORE index (<strong>C</strong>ompliance, <strong>O</strong>xygenation, <strong>R</strong>espiration, <strong>E</strong>ffort)</td> </tr> <tr> <td class=\"indent1\">Integrative Weaning Index (IWI)</td> </tr> <tr> <td class=\"indent1\">Inspiratory Effort Quotient (IEQ)</td> </tr> <tr> <td class=\"subtitle1_single\">Complex measurements (may require special equipment)</td> </tr> <tr> <td class=\"indent1\">Airway occlusion pressure measured at 100 msec (P0.1)</td> </tr> <tr> <td class=\"indent1\">P0.1/MIP*</td> </tr> <tr> <td class=\"indent1\">Esophageal pressure</td> </tr> <tr> <td class=\"indent1\">Oxygen cost of breathing (O<sub>2</sub>COB)</td> </tr> <tr> <td class=\"indent1\">Mechanical work of breathing</td> </tr> <tr> <td class=\"indent1\">Pdi/Pdimax</td> </tr> <tr> <td class=\"indent1\">Tension-time index</td> </tr> <tr> <td class=\"indent1\">Gastric intramucosal pH or P<sub>g</sub>CO<sub>2</sub></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PaO<sub>2</sub>: arterial oxygen tension; PAO<sub>2</sub>: alveolar oxygen; FiO<sub>2</sub>: fraction of inspired oxygen; Pdi: diaphragmatic pressure; P<sub>g</sub>CO<sub>2</sub>: gastric carbon dioxide tension.<br />* Predictors found to be most accurate in a systematic review.<sup>[2]</sup></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Adapted from: Epstein SK. Weaning from ventilatory support. In: Textbook of Pulmonary Diseases, 7th Edition, Crapo JD, Glassroth J, Karlinsky J, King TE (eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2003. p.1089.</li>&#xD;&#xA;    <li>Meade M, Guyatt G, Cook D, et al. Predicting success in weaning from mechanical ventilation. Chest 2001; 120:400S.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 78201 Version 3.0</div></div></div>"},"78202":{"type":"graphic_picture","displayName":"Subcutaneous sarcoidosis","title":"Subcutaneous sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcutaneous sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/78202_Subcutaneous_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcutaneous sarcoidosis. Multiple indurated nodules are present on the forearm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78202 Version 3.0</div></div></div>"},"78203":{"type":"graphic_figure","displayName":"Global distribution of plague","title":"Global distribution of plague","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Global distribution of plague</div><div class=\"cntnt\"><img style=\"width:594px; height:323px;\" src=\"images/ID/78203_Global_distribution_plague.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Data reported to World Health Organization (WHO).<br> Î Dot placed in center of reporting country.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, Division of Vector-Borne Diseases.</div><div id=\"graphicVersion\">Graphic 78203 Version 2.0</div></div></div>"},"78205":{"type":"graphic_table","displayName":"Components and administration of IXIARO","title":"Components and administration of IXIARO Japanese encephalitis vaccine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components and administration of IXIARO Japanese encephalitis vaccine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Inactivated Vero cell-derived vaccine</td> </tr> <tr> <td><strong>Trade name</strong></td> <td>IXIARO</td> </tr> <tr> <td><strong>JEV strain</strong></td> <td>SA<sub>14</sub>-14-2</td> </tr> <tr> <td><strong>Preparation</strong></td> <td>Liquid</td> </tr> <tr> <td><strong>Adjuvant</strong></td> <td>Aluminum hydroxide</td> </tr> <tr> <td><strong>Stabilizer</strong></td> <td>None</td> </tr> <tr> <td><strong>Preservative</strong></td> <td>None</td> </tr> <tr> <td><strong>Primary series</strong></td> <td>Two&nbsp;doses at 0 and 28 days</td> </tr> <tr> <td><strong>Booster</strong></td> <td>&#8805;17 years of age: &#8805;1 year after primary series<br /> 2 months&nbsp;to 16 years of age: No formal recommendation</td> </tr> <tr> <td><strong>Dose</strong></td> <td>&#8805;3 years of age: 0.5 mL<br /> 2 months&nbsp;to 2 years of age: 0.25 mL </td> </tr> <tr> <td><strong>Route</strong></td> <td>Intramuscular</td> </tr> <tr> <td><strong>Age indication</strong></td> <td>&#8805;2 months of age</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JEV: Japanese encephalitis virus.</div><div id=\"graphicVersion\">Graphic 78205 Version 5.0</div></div></div>"},"78206":{"type":"graphic_picture","displayName":"Acute ISN Light II","title":"Light micrograph of kidney biopsy of a patient with acute interstitial nephritis showing eosinophils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph of kidney biopsy of a patient with acute interstitial nephritis showing eosinophils</div><div class=\"cntnt\"><img style=\"width:378px; height:251px;\" src=\"images/NEPH/78206_Acute_ISN_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph with hematoxylin and eosin stain of acute interstitial nephritis showing diffuse interstitial infiltrate with many red-staining eosinophils. An uninvolved glomerulus is on the left.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78206 Version 2.0</div></div></div>"},"78207":{"type":"graphic_picture","displayName":"Bullous pemphigoid vulva","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/OBGYN/78207_Bullous_pemphigoid_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 78207 Version 2.0</div></div></div>"},"78209":{"type":"graphic_figure","displayName":"Neobladder PI","title":"Orthotopic neobladder (also called Studer neobladder or pouch)","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Orthotopic neobladder (also called Studer neobladder or pouch)</div><div class=\"cntnt\"><img style=\"width:464px; height:652px;\" src=\"images/PI/78209_Neobladder_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts one option for people who have a cystectomy (removal of bladder) due to bladder cancer. A new bladder may be created from a segment of bowel. The new bladder is connected to the urethra, allowing the person to urinate normally. This is called an orthotopic neobladder (commonly referred to as a Studer neobladder or pouch).</div><div id=\"graphicVersion\">Graphic 78209 Version 3.0</div></div></div>"},"78210":{"type":"graphic_diagnosticimage","displayName":"Convent AP and lat rt port","title":"Radiation therapy fields for cervical cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation therapy fields for cervical cancer</div><div class=\"cntnt\"><img style=\"width:348px; height:647px;\" src=\"images/OBGYN/78210_Convent_AP_and_lat_rt_port.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional anteroposterior, AP (A), and lateral (B) radiation portals for cervical cancer defined by a superior field border at the L4-L5 disk space, a inferior border extending 3 to 4 cm below the lowest extent of disease or the bottom of the obturator foramen, and a lateral edge 1.5 to 2 cm lateral to the pelvic brim.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 78210 Version 2.0</div></div></div>"},"78211":{"type":"graphic_picture","displayName":"Yolk sac tumor Low","title":"Mediastinal yolk sac tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal yolk sac tumor</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/PULM/78211_Yolk_sac_tumor_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows the characteristic reticular pattern of yolk sac tumors, with various-sized spaces lined by flattened cells (hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 78211 Version 2.0</div></div></div>"},"78212":{"type":"graphic_picture","displayName":"Linear scleroderma","title":"Linear scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear scleroderma</div><div class=\"cntnt\"><img style=\"width:209px; height:178px;\" src=\"images/RHEUM/78212_Linear_scleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The longitudinal bands of linear scleroderma resulting in atrophy of soft tissue and muscle.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 78212 Version 2.0</div></div></div>"},"78213":{"type":"graphic_figure","displayName":"Pregnancy birth and abortion rates in US teenagers","title":"Pregnancy, birth, and abortion rates among US teenagers 15 through 19 years of age, 1973 to 2011","html":"<div class=\"graphic\"><div style=\"width: 789px\" class=\"figure\"><div class=\"ttl\">Pregnancy, birth, and abortion rates among US teenagers 15 through 19 years of age, 1973 to 2011</div><div class=\"cntnt\"><img style=\"width:769px; height:444px;\" src=\"images/EM/78213_Preg_birth_ab_US_teens.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rates per 1000 women age 15 through 19 years.</div><div class=\"graphic_reference\">From: U.S. teen pregnancy, birth and abortion rates reached historic lows in 2011, Infographic, New York: Guttmacher Institute, 2016, <a href=\"https://www.guttmacher.org/infographic/2016/us-teen-pregnancy-birth-and-abortion-rates-reached-historic-lows-2011\" target=\"_blank\">https://www.guttmacher.org/infographic/2016/us-teen-pregnancy-birth-and-abortion-rates-reached-historic-lows-2011</a>. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 78213 Version 4.0</div></div></div>"},"78214":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of umbilical artery aneurysm","title":"Prenatal ultrasound image of umbilical artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of umbilical artery aneurysm</div><div class=\"cntnt\"><img style=\"width:511px; height:398px;\" src=\"images/OBGYN/78214_US_umbil_art_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Umbilical artery aneurysm.<br />Left upper and lower panels show an umbilical artery&nbsp;aneurysm at the base of the cord at 30 weeks of gestation&nbsp;on conventional and color Doppler ultrasound. Right upper and lower panels show increasing size of the aneurysm&nbsp;at 35 weeks of gestation. Newborn had trisomy 18.</div><div class=\"graphic_reference\">Reproduced from: Sepulveda W, Corral E, Kottmann C, et al. Umbilical cord aneurysm: prenatal identification in three fetuses with trisomy 18. Ultrasound Obstet Gynecol 2003; 21:292. Copyright Â© 2003. Reproduced with permission from: John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 78214 Version 5.0</div></div></div>"},"78215":{"type":"graphic_picture","displayName":"IPEX eczematous skin","title":"Eczematous skin lesions in IPEX","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczematous skin lesions in IPEX</div><div class=\"cntnt\"><img style=\"width:238px; height:304px;\" src=\"images/ALLRG/78215_IPEX_eczematous_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These eczematous skin lesions (with overlying ointment) were photographed on the back of a young child with IPEX.</div><div class=\"graphic_footnotes\">IPEX: immune dysregulation, polyendocrinopathy, enteropathy, X-linked.</div><div class=\"graphic_reference\">Courtesy of Talal Chatila, MD and Melinda Braskett, MD.</div><div id=\"graphicVersion\">Graphic 78215 Version 2.0</div></div></div>"},"78218":{"type":"graphic_figure","displayName":"Ectopic ureter male","title":"Location of ectopic ureteral orifices in boys","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Location of ectopic ureteral orifices in boys</div><div class=\"cntnt\"><img style=\"width:538px; height:586px;\" src=\"images/PEDS/78218_Ectopic_ureter_male.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Possible sites for ectopic ureter insertion are shown. The green dotted line demonstrates other potential sites for ectopic ureters in males, all of which are proximal to the external urethral sphincter.</div><div id=\"graphicVersion\">Graphic 78218 Version 3.0</div></div></div>"},"78219":{"type":"graphic_algorithm","displayName":"Obstruction post HS","title":"Algorithm for the diagnosis and management of the child with obstructive symptoms after a pull-through operation for Hirschsprung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis and management of the child with obstructive symptoms after a pull-through operation for Hirschsprung disease</div><div class=\"cntnt\"><img style=\"width:345px; height:498px;\" src=\"images/PEDS/78219_Obstruction_post_HS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Botox: Botulinum toxin injection in the anal sphincter</div><div class=\"graphic_reference\">Reproduced with permission from: Langer, JC. Persistent obstructive symptoms after surgery for Hirschsprung's Disease: Development of a diagnostic and therapeutic algorithm. J Pediatr Surg 2004; 39:1458. Copyright &#169;2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 78219 Version 2.0</div></div></div>"},"78221":{"type":"graphic_table","displayName":"Lower extremity neuropathies","title":"Lower extremity peripheral nerve syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lower extremity peripheral nerve syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nerve</td> <td class=\"subtitle1\">Site of injury</td> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Signs</td> </tr> <tr> <td>Common peroneal</td> <td>Fibular neck, just below the knee</td> <td>Prolonged lying, leg crossing, squatting, leg cast</td> <td>Foot drop, paresthesias and/or sensory loss over dorsum of foot and lateral shin</td> <td>Weakness on foot dorsiflexion and eversion; sensory loss on dorsum of foot; reflexes normal</td> </tr> <tr> <td>Deep peroneal</td> <td>Ankle</td> <td>Tight fitting shoe rim or strap</td> <td>Ankle pain, minimal weakness and sensory loss over web space between digits 1 and 2</td> <td>Minimal</td> </tr> <tr> <td>Posterior tibial</td> <td>Tarsal tunnel of ankle</td> <td>Fracture or dislocation of talus, calcaneus, medial malleolus, rheumatoid arthritis, tumor</td> <td>Aching, burning, numbness, tingling on sole of foot, distal foot, toes, and occasionally heel</td> <td>Positive Tinel's sign over nerve posterior to medial malleolus; sensory loss on sole of foot; atrophy of foot muscles if severe</td> </tr> <tr> <td rowspan=\"2\">Sciatic</td> <td>Sciatic notch/gluteal region</td> <td>Trauma (hip dislocation, fracture, or replacement), prolonged bed rest, deep-seated pelvic mass, piriformis syndrome</td> <td>Leg pain and weakness affecting most lower leg muscles</td> <td>Sensory loss in peroneal, tibial, and sural territories; may spare medial calf and arch of foot; normal knee jerk; absent ankle jerk</td> </tr> <tr> <td>Mid-thigh</td> <td>Femur fracture, mass, ischemic nerve infarction</td> <td>Similar to above but sparing hamstrings</td> <td>Similar to above</td> </tr> <tr> <td>Femoral</td> <td>Pelvis and anterior thigh</td> <td>Hip or pelvic fracture, hip replacement, lithotomy position, diabetes mellitus</td> <td>Quadriceps weakness and sensory loss</td> <td>Quadriceps weakness; sensory loss over anterior and medial thigh extending down medial shin to arch of foot; reduced or unobtainable knee jerk</td> </tr> <tr> <td>Lateral femoral cutaneous</td> <td>Inguinal ligament (meralgia paresthetica)</td> <td rowspan=\"2\">Obesity, tight fitting belts, idiopathic</td> <td rowspan=\"2\">Paresthesias and pain radiating down the lateral thigh to knee</td> <td rowspan=\"2\">Sensory loss on lateral thigh</td> </tr> <tr> <td>Lumbosacral radiculopathy</td> <td>See associated table</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78221 Version 2.0</div></div></div>"},"78222":{"type":"graphic_figure","displayName":"PEFR in esophageal infusion","title":"Peak expiratory flow rate during esophageal acid infusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak expiratory flow rate during esophageal acid infusion</div><div class=\"cntnt\"><img style=\"width:434px; height:257px;\" src=\"images/PULM/78222_PEFR_in_esophageal_infusion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peak expiratory flow rate data expressed as percent predicted during esophageal infusions of normal saline (NS) and acid.</div><div class=\"graphic_reference\">Redrawn from Schan CA, Harding SM, Haile JM, et al. Chest 1994; 106:731.</div><div id=\"graphicVersion\">Graphic 78222 Version 3.0</div></div></div>"},"78223":{"type":"graphic_algorithm","displayName":"Evaluation alkaline phosphatase","title":"Evaluation of elevated serum alkaline phosphatase","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Evaluation of elevated serum alkaline phosphatase</div><div class=\"cntnt\"><img style=\"width:460px; height:726px;\" src=\"images/GAST/78223_Eval_alkaline_phosph_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AMA: antimitochondrial antibodies; ERCP: endoscopic retrograde cholangiopancreatography; MRCP: magnetic resonance cholangiopancreatography; ULN: upper limit of normal.</div><div id=\"graphicVersion\">Graphic 78223 Version 7.0</div></div></div>"},"78224":{"type":"graphic_table","displayName":"IPV formulations","title":"Licensed vaccines containing inactivated poliovirus vaccine (IPV) - United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Licensed vaccines containing inactivated poliovirus vaccine (IPV) - United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine composition</td> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Approved use in ACIP routine schedule*</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>IPV</td> <td>Ipol (Poliovax<sup>&#916;</sup>)</td> <td>Sanofi Pasteur</td> <td>2, 4, 6 to 18 months, and 4 to 6 years<sup>&#182;</sup></td> <td>Approved for use in infants, children, and adults<sup>&#9674;</sup></td> </tr> <tr> <td>DTaP-HepB-IPV<sup>&#167;</sup></td> <td>Pediarix</td> <td>GlaxoSmithKline</td> <td>2, 4, and 6 months</td> <td>Approved for first 3 doses of IPV through age 6 years<sup>&#165;</sup></td> </tr> <tr> <td>DTaP-IPV/Hib<sup>&#135;</sup></td> <td>Pentacel</td> <td>Sanofi Pasteur</td> <td>2, 4, 6, and 15 to 18 months<sup>&#134;</sup></td> <td>Approved for 4 doses of IPV through age 4 years**</td> </tr> <tr> <td>DTaP-IPV<sup>&#182;&#182;</sup></td> <td>Kinrix</td> <td>GlaxoSmithKline</td> <td>4 to 6 years</td> <td>Approved for booster dose at age 4 to 6 years<sup>&#916;&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advisory Committee on Immunization Practices. Full schedule available at <A spellcheck=true href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5751a5.htm\" target=_blank>www.cdc.gov/mmwr/preview/mmwrhtml/mm5751a5.htm</A>.<br />Â¶ In the IPV series, the minimum age for dose 1 is six weeks. The minimum interval is four weeks between dose 1 and 2 and between dose 2 and 3. The minimum interval between dose 3 and 4 is six months. Dose 4 should be administered at age â¥4 years regardless of the number of previous doses. Shorter intervals and earlier start dates lead to lower seroconversion rates; therefore, the minimum age and minimum intervals in the first six months of life are recommended only if the recipient is at risk for imminent exposure to circulating poliovirus (eg, during an outbreak or because of travel to an endemic region).<br />Î Not currently distributed in the United States.<br /><FONT class=lozenge>â</FONT> Package insert available at <A spellcheck=true href=\"http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133479.pdf\" target=_blank>www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133479.pdf</A>.<br />Â§ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and inactivated poliovirus vaccine combined.<br />Â¥ Package insert available at <A href=\"https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136517.htm\">https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136517.htm</A>.<br />â¡ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and <EM>Haemophilus influenzae</EM>&nbsp;b conjugate (tetanus toxoid conjugate) vaccine.<br />â  When Pentacel is used to provide&nbsp;four doses at ages 2, 4, 6 and 15 to18 months, an additional booster dose of age-appropriate IPV-containing vaccine (Ipol or Kinrix) should be administered at age 4 to 6 years. This will results in a five-dose IPV series; Pentacel is not indicated for the booster dose at age 4 to 6 years. The minimum interval between dose 4 and dose 5 should be at least&nbsp;six months to optimize booster response.<br />** Package insert available at <A spellcheck=true href=\"http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109810.pdf\" target=_blank>www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109810.pdf</A>.<br />Â¶Â¶ Diphtheria and tetanus toxoids and acellular pertussis adsorbed, and inactivated poliovirus vaccine.<br />ÎÎ Package insert available at <A href=\"https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094027.htm\">https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094027.htm</A>.</div><div class=\"graphic_reference\">Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination. MMWR Morb Mortal Wkly Rep 2009; 58:829.</div><div id=\"graphicVersion\">Graphic 78224 Version 6.0</div></div></div>"},"78225":{"type":"graphic_picture","displayName":"Retinal examination showing severe hypertensive retinopathy I","title":"Retinal examination showing severe hypertensive retinopathy I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal examination showing severe hypertensive retinopathy I</div><div class=\"cntnt\"><img style=\"width:385px; height:307px;\" src=\"images/NEPH/78225_Grade_IV_HTN_retinopathy_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retinal examination in a patient with papilledema due to severe hypertension. There is blurring of the margins of the optic disc, distension of the retinal veins, two cotton wool spots inferior to the disc, and a flame-shaped hemorrhage at a venous bifurcation (arrow).</div><div class=\"graphic_reference\">Reproduced by permission from: Gallasch G, Ritz E. The fundus in malignant hypertension. Nephrol Dial Trans 1997; 12:1518.</div><div id=\"graphicVersion\">Graphic 78225 Version 7.0</div></div></div>"},"78227":{"type":"graphic_table","displayName":"Anomalies associated with oligohydramnios","title":"Type and frequency of congenital anomalies associated with oligohydramnios in a literature review","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type and frequency of congenital anomalies associated with oligohydramnios in a literature review</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n<tr>\r\n<td class=\"subtitle1\">Type</td>\r\n<td class=\"subtitle1\">Number of cases (percent)</td>\r\n</tr>\r\n<tr>\r\n<td>Renal</td>\r\n<td>94 (65)</td>\r\n</tr>\r\n<tr>\r\n<td>Multiple</td>\r\n<td>17 (12)</td>\r\n</tr>\r\n<tr>\r\n<td>Aneuploidy</td>\r\n<td>12 (8)</td>\r\n</tr>\r\n<tr>\r\n<td>Central nervous system</td>\r\n<td>7 (5)</td>\r\n</tr>\r\n<tr>\r\n<td>Skeletal system</td>\r\n<td>5 (4)</td>\r\n</tr>\r\n<tr>\r\n<td>Cardiovascular system</td>\r\n<td>4 (3)</td>\r\n</tr>\r\n<tr>\r\n<td>Other</td>\r\n<td>6 (4)</td>\r\n</tr>\r\n<tr>\r\n<td>Total</td>\r\n<td>145</td>\r\n</tr>\r\n</tbody>\r\n</table></div><div class=\"graphic_reference\">Adapted from: Hill, LM. Clin Obstet Gynecol 1997; 40:314.</div><div id=\"graphicVersion\">Graphic 78227 Version 2.0</div></div></div>"},"78228":{"type":"graphic_table","displayName":"Causes strabismus","title":"Causes of strabismus in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of strabismus in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Congenital\n   </td>\n   </tr>\n   <tr>\n   <td>Pseudostrabismus</td>\n   </tr>\n   <tr>\n   <td>Prenatal drug exposure</td>\n   </tr>\n   <tr>\n   <td>Duane syndrome</td>\n   </tr>\n   <tr>\n   <td>Mobius syndrome</td>\n   </tr>\n   <tr>\n   <td>Brown syndrome</td>\n   </tr>\n   <tr>\n   <td>Congenital familial external ophthalmoplegia</td>\n   </tr>\n   <tr>\n   <td>Congenital third nerve palsy</td>\n   </tr>\n   <tr>\n   <td>Congenital fourth nerve palsy</td>\n   </tr>\n   <tr>\n   <td>Central nervous system insults</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acquired\n   </td>\n   </tr>\n   <tr>\n   <td>Accommodative strabismus</td>\n   </tr>\n   <tr>\n   <td>Intermittent exotropia</td>\n   </tr>\n   <tr>\n   <td>Interference with foveal vision (eg, cataracts)</td>\n   </tr>\n   <tr>\n   <td>Tumors</td>\n   </tr>\n   <tr>\n   <td>Increase intracranial pressure</td>\n   </tr>\n   <tr>\n   <td>Orbital injury</td>\n   </tr>\n   <tr>\n   <td>Head trauma</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Vascular disorders\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Cerebral hemorrhage\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Ophthalmoplegic migraine\n   </td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acquired (continued)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Neuromuscular disorders\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Botulism\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Myasthenia gravis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Benign sixth nerve palsy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Guillain-Barre syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Ocular myopathy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Multiple sclerosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Infections\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Encephalitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Meningitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Orbital cellulitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Gradenigo's syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Measles\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Diphtheria\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Polio\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Drugs and toxins\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Lead\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Heavy metals\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Miscellaneous\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Orbital myositis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Thyrotoxicosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Diabetes mellitus\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Hypoglycemia\n   </td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from Strabismus. In: Signs and Symptoms in Pediatrics, 3rd ed, Tunnessen, WW Jr (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p. 248.</div><div id=\"graphicVersion\">Graphic 78228 Version 1.0</div></div></div>"},"78229":{"type":"graphic_table","displayName":"IDUS accuracy versus ERCP","title":"Intraductal ultrasound (IDUS) versus endoscopic retrograde cholangiopancreatography (ERCP) for evaluation of bile duct strictures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraductal ultrasound (IDUS) versus endoscopic retrograde cholangiopancreatography (ERCP) for evaluation of bile duct strictures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">ERCP (percent)</td> <td class=\"subtitle1\">IDUS (percent)</td> <td class=\"subtitle1\">p value</td> </tr> <tr> <td><strong>Sensitivity</strong></td> <td>54</td> <td>85</td> <td>0.10</td> </tr> <tr> <td><strong>Specificity</strong></td> <td>87</td> <td>87</td> <td>0.76</td> </tr> <tr> <td><strong>Accuracy</strong></td> <td>67</td> <td>86</td> <td>0.13</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002; 56:372.</div><div id=\"graphicVersion\">Graphic 78229 Version 3.0</div></div></div>"},"78231":{"type":"graphic_figure","displayName":"Age sex distribution ITP","title":"Incidence of immune thrombocytopenia (ITP) by age and sex","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Incidence of immune thrombocytopenia (ITP) by age and sex</div><div class=\"cntnt\"><img style=\"width:464px; height:373px;\" src=\"images/HEME/78231_Age_sex_distrib_ITP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data are presented for the incidence of ITP in females and males in different age groups. The incidence of ITP is highest in children, and may be greater in boys than in girls. In adults, the incidence increases with age. The incidence in women is greater than in men at younger ages, but in adults over age 60, the incidence of men and women is the same.</div><div class=\"graphic_reference\">Data from:<BR>1. Data for children from: Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatrica 2005; 94:178.<BR>2. Data for adults from: Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94:909.</div><div id=\"graphicVersion\">Graphic 78231 Version 4.0</div></div></div>"},"78232":{"type":"graphic_figure","displayName":"Pathogenesis MM","title":"The pathogenesis of multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">The pathogenesis of multiple myeloma</div><div class=\"cntnt\"><img style=\"width:605px; height:347px;\" src=\"images/HEME/78232_Pathogenesis_MM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pathogenesis of multiple myeloma (MM) is complex, but appears to follow a two-step model of progression. First, monoclonal gammopathy of undetermined significance (MGUS) develops as a result of genetic changes, some of which are thought to be the product of an abnormal response to antigenic stimulation. A second event, occurring at random rather than through cumulative damage, results in the accumulation of tumor cells and progression to MM. End organ damage is related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains.</div><div class=\"graphic_footnotes\">MGUS: monoclonal gammopathy of undetermined significance; MM: multiple myeloma.</div><div class=\"graphic_reference\">Modified with permission from: Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009; 15:5606. Copyright &#169; 2009 American Academy for Cancer Research.</div><div id=\"graphicVersion\">Graphic 78232 Version 3.0</div></div></div>"},"78234":{"type":"graphic_picture","displayName":"Tinea faciei","title":"Tinea faciei","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea faciei</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78234_Tinea_faciei.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, oval plaque and pustules on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78234 Version 6.0</div></div></div>"},"78237":{"type":"graphic_table","displayName":"Causes of flushing","title":"Causes of flushing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of flushing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type </td> <td class=\"subtitle1\">Causes </td> </tr> <tr> <td rowspan=\"4\">Physiologic </td> <td>Menopause</td> </tr> <tr> <td>Hot drinks</td> </tr> <tr> <td>Emotional distress</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td rowspan=\"7\">Drugs </td> <td>Alcohol </td> </tr> <tr> <td>Alcohol plus chlorpromazine or disulfuram</td> </tr> <tr> <td>Diltiazem</td> </tr> <tr> <td>Amyl nitrate</td> </tr> <tr> <td>Nicotinic acid (niacin)</td> </tr> <tr> <td>Levodopa</td> </tr> <tr> <td>Bromocriptine</td> </tr> <tr> <td rowspan=\"9\">Diseases </td> <td>Carcinoid syndrome</td> </tr> <tr> <td>Systemic mastocytosis</td> </tr> <tr> <td>Basophilic chronic granulocytic leukemia</td> </tr> <tr> <td>VIPoma</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Medullary carcinoma of the thyroid</td> </tr> <tr> <td>Renal cell carcinoma</td> </tr> <tr> <td>Diencephalic seizures</td> </tr> <tr> <td>Postural Orthostatic Tachycardia Syndrome (POTS)&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78237 Version 3.0</div></div></div>"},"78238":{"type":"graphic_picture","displayName":"Barretts squamous island","title":"Barrett's esophagus beneath squamous mucosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus beneath squamous mucosa</div><div class=\"cntnt\"><img style=\"width:404px; height:252px;\" src=\"images/GAST/78238_Barretts_squamous_island.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view demonstrates the glandular epithelium of Barrett's esophagus with an island of overlying squamous mucosa (arrows). Larger areas of squamous mucosa may render underlying Barrett's esophagus inapparent on endoscopy. This has been a concern in patients treated by some forms of ablative therapy in which replacement of columnar epithelium by squamous epithelium may not obviate the risk of malignant transformation from underlying Barrett's mucosa.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 78238 Version 3.0</div></div></div>"},"78239":{"type":"graphic_figure","displayName":"Normal voiding","title":"Normal voiding","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Normal voiding</div><div class=\"cntnt\"><img style=\"width:522px; height:393px;\" src=\"images/PEDS/78239_Normal_voiding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of urodynamics during normal voiding. Initially, the bladder neck is closed. After the command to void, the external sphincter opens, as shown by the&nbsp;relaxation of sphincter&nbsp;activity in the electromyogram (EMG). Meanwhile,&nbsp;the detrusor muscle of the bladder contracts,&nbsp;to cause&nbsp;urine flow. The process is reversed to stop urine flow.</div><div id=\"graphicVersion\">Graphic 78239 Version 2.0</div></div></div>"},"78242":{"type":"graphic_figure","displayName":"Persistence of beta agonist effect over time","title":"Persistence of beta agonist efficacy over time","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistence of beta agonist efficacy over time</div><div class=\"cntnt\"><img style=\"width:336px; height:489px;\" src=\"images/PULM/78242_Persistence_Beta_agonist_ef.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean FEV1 as a percentage of the predicted value on the first and last days of treatment in patients with asthma. Therapy consisted of salmeterol (40 &#181;g twice daily), albuterol (180 &#181;g four times a day), or placebo. Both beta agonists increased the FEV1, but the effect of a single dose lasted longer with salmeterol. The beneficial effect of both agents persisted at&nbsp;twelve weeks.</div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from Pearlman DS, Chervinsky P, LaForce C, et al, N Engl J Med 1992; 327:1420.</div><div id=\"graphicVersion\">Graphic 78242 Version 2.0</div></div></div>"},"78244":{"type":"graphic_figure","displayName":"Repair of iliac artery aneurysm with no landing zones","title":"Repair of iliac artery aneurysm with no landing zones","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Repair of iliac artery aneurysm with no landing zones</div><div class=\"cntnt\"><img style=\"width:465px; height:351px;\" src=\"images/SURG/78244_CIAA-no-landing-zone-.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A common iliac artery aneurysm without proximal or distal landing zones is managed with coil embolization of the internal iliac artery and placement of a bifurcated aortic endograft.</div><div id=\"graphicVersion\">Graphic 78244 Version 3.0</div></div></div>"},"78245":{"type":"graphic_algorithm","displayName":"Focal liver lesion algorithm","title":"Approach to a solitary focal liver lesion","html":"<div class=\"graphic\"><div style=\"width: 908px\" class=\"figure\"><div class=\"ttl\">Approach to a solitary focal liver lesion</div><div class=\"cntnt\"><img style=\"width:888px; height:1019px;\" src=\"images/GAST/78245_Focal_liver_lesion_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFP: alpha-fetoprotein; CA: carbohydrate antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; FNH: focal nodular hyperplasia; MDCT: multidector computed tomography; MRI: magnetic resonance imaging.<br />* Patients should be evaluated for HBV and cirrhosis if not already done.<br />Â¶ The management of patients with lesions &lt;1 cm in size varies among institutions. Guidelines from the American Association for the Study of Liver Diseases recommend ultrasound rather than MRI.<br />Î HCC is likely if any of the following are present: The mass is known to be new in a patient being screened for HCC; the AFP has been rising; the AFP is &gt;500 mcg/L; the mass is hypervascular on the arterial phase and radiolucent on the venous phase of a MDCT scan (arterial enhancement with washout); the mass has increased T2 signal intensity on MRI; the mass invades the portal vein.<br /><FONT class=lozenge>â</FONT> Other causes of an elevated AFP include pregnancy, tumors of gonadal origin, gastric cancer, and chronic liver disease without HCC.<br />Â§ Surveillance with MDCT or MRI is an alternative. If MDCT is being used, attention should be paid to the patient's cumulative radiation exposure.<br />Â¥ If the patient has a history of oral contraceptive use, a reasonable alternative is to stop the oral contraceptive and repeat the imaging in 3 to 4 months. If the lesion persists, it should be resected.</div><div id=\"graphicVersion\">Graphic 78245 Version 6.0</div></div></div>"},"78246":{"type":"graphic_table","displayName":"Testing in patients with transient visual loss","title":"Commonly used diagnostic tests for amaurosis fugax","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used diagnostic tests for amaurosis fugax</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Diagnostic test</td>\n\n      <td class=\"subtitle1\">Indictions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ophthalmologic consult</td>\n\n      <td>All patients with GCA, retinal vein disease, suspected ocular\ndisease, TMVL from suspected thromboembolic disease or uncertain cause</td>\n\n    </tr>\n\n    <tr>\n\n      <td>ESR and CRP</td>\n\n      <td>All patients &#62;50 years</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carotid imaging (carotid duplex ultrasound, MRA, CTA)</td>\n\n      <td>Patients with TMVL &#62;50 years or with risk factors, or suspected dissection, or uncertain cause</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac evaluation for embolic source</td>\n\n      <td>Patients with TMVL &#62;50 years or with risk factors, or with suspected VBI, or TMVL of unccertain cause</td>\n\n    </tr>\n\n    <tr>\n\n      <td>ECG</td>\n\n      <td>All patients with suspected ischemia (of brain or eye)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypercoaguable testing</td>\n\n      <td>Patients with history or family history of thrombosis or with probable ischemia and negative workup</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Brain MRI</td>\n\n      <td>Binocular symptoms atypical for migraine, possible optic neuropathy, seizure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>EEG</td>\n\n      <td>Suspected seizure</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">GCA: giant cell arteries; TMVL: transient monocular visual loss; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MRA: magnetic resonance angiography; CTA: computed tomography angiography; VBI: vertebrobasilar ischemia; ECG: electrocardiogram; MRI: magnetic resonance imaging; EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 78246 Version 2.0</div></div></div>"},"78251":{"type":"graphic_table","displayName":"AML induction regimens","title":"Chemotherapy induction regimens for acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy induction regimens for acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Cytarabine <strong>plus</strong> daunorubicin</td> <td><strong>Cytarabine</strong>: 100 to 200 mg/m<sup>2</sup> daily as a continuous infusion for 7 days; <strong>Daunorubicin</strong>: 60 to 90 mg/m<sup>2</sup> intravenous push on each of the first 3 days of treatment</td> <td>\"Standard 7+3\" induction regimen resulting in approximately 60 to 80% remission rate and acceptable toxicity in patients under 60 years old</td> </tr> <tr class=\"divider_top\"> <td>Cytarabine (HiDAC) <strong>plus</strong> daunorubicin</td> <td><strong>Cytarabine</strong>: 1 to 3 g/m<sup>2</sup> twice daily for a total of 12 doses; <strong>Daunorubicin</strong>: 45 mg/m<sup>2</sup> intravenous push for 3 days following cytarabine</td> <td>Yields a 90% remission rate; however, substantial toxicity precludes post-remission therapy in a high proportion of patients</td> </tr> <tr class=\"divider_top\"> <td>Cytarabine <strong>plus</strong> idarubicin</td> <td><strong>Cytarabine</strong>: 100 to 200 mg/m<sup>2</sup> daily as a continuous infusion for 7 days; <strong>Idarubicin</strong>: 12 to 13 mg/m<sup>2</sup> IV push on each of first 3 days of treatment</td> <td>Has produced a greater remission rate (88 versus 70%) than cytarabine/daunorubicin in younger patients; appears superior to daunorubicin in patients with hyperleukocytosis; overall survival not clearly superior to \"standard\" regimen</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Overview of common induction therapy regimens for acute myeloid leukemia in younger adults.</div><div class=\"graphic_footnotes\">HiDAC: high dose cytarabine.</div><div id=\"graphicVersion\">Graphic 78251 Version 5.0</div></div></div>"},"78252":{"type":"graphic_figure","displayName":"Optimal INR oral anticoag","title":"Optimal INR for minimizing bleeding and thromboembolism when using oral anticoagulation","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Optimal INR for minimizing bleeding and thromboembolism when using oral anticoagulation</div><div class=\"cntnt\"><img style=\"width:461px; height:491px;\" src=\"images/HEME/78252_Optimal_INR_oral_anticoag.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the relative risks and their 95 percent confidence intervals for the occurrence of thromboembolism (closed circles, confidence intervals in yellow) and hemorrhage (open circles, confidence intervals in blue) as a function of the INR range in patients prescribed oral anticoagulant therapy. The comparator for both end-points is the INR range of 2.0 to 3.0 (ie, relative risk of 1.0). Note that hemorrhagic risk becomes dominant at an INR &gt;3, while thromboembolic risk is dominant at an INR &lt;2.</div><div class=\"graphic_reference\">Data from: Oake N, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179:235.</div><div id=\"graphicVersion\">Graphic 78252 Version 3.0</div></div></div>"},"78253":{"type":"graphic_figure","displayName":"Perforation of the distal esophagus","title":"Perforation of the distal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforation of the distal esophagus</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/SURG/78253_Perf-distal-thorac-eso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the exposed esophagus with a perforation in the distal third.</div><div id=\"graphicVersion\">Graphic 78253 Version 1.0</div></div></div>"},"78254":{"type":"graphic_figure","displayName":"CKD-EPI and MDRD Study equations in estimating measured GFR","title":"Performance of the CKD-EPI and MDRD Study equations in estimating measured GFR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Performance of the CKD-EPI and MDRD Study equations in estimating measured GFR</div><div class=\"cntnt\"><img style=\"width:354px; height:630px;\" src=\"images/NEPH/78254_CKDEPIMDRDGFR.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604. Copyright Â© 2009 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 78254 Version 11.0</div></div></div>"},"78255":{"type":"graphic_diagnosticimage","displayName":"Tetralogy Fallot PA angio II","title":"Main pulmonary artery angiogram after stenting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Main pulmonary artery angiogram after stenting</div><div class=\"cntnt\"><img style=\"width:331px; height:317px;\" src=\"images/CARD/78255_Tetralogy_Fallot_PA_angio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following placement of a balloon expandable stent in the proximal left pulmonary artery (*) of a patient with tetralogy of Fallot there is significant improvement in size of the proximal left pulmonary artery (LPA).</div><div class=\"graphic_footnotes\">RPA: right pulmonary artery; RV: right ventricle; MPA: main pulmonary artery.</div><div class=\"graphic_reference\">Photo courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 78255 Version 2.0</div></div></div>"},"78256":{"type":"graphic_table","displayName":"Pediatric diet to prevent CVD","title":"Dietary recommendations for children to reduce the risk of cardiovascular disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary recommendations for children to reduce the risk of cardiovascular disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Dietary recommendations</td> </tr> <tr class=\"divider_bottom\"> <td>Birth to 6 months</td> <td>Infants should be exclusively breastfed (no supplemental formula or other foods) until age 6 months*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">6 to 12 months</td> <td>Continue breastfeeding* until at least age 12 months while gradually adding solids; transition to iron-fortified formula until 12 months if reducing breastfeeding</td> </tr> <tr> <td>Fat intake in infants less than 12 months of age should not be restricted without medical indication</td> </tr> <tr class=\"divider_bottom\"> <td>Limit 100 percent fruit juice &#60;4 oz/d; no sweetened beverages; encourage water</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">12 to 24 months</td> <td>Transition to reduced-fat<sup>&#182;</sup> (2 percent to fat-free) unflavored cow's milk<sup>&#916;</sup> (see <em>Supportive actions</em> bullet 1)</td> </tr> <tr> <td>Limit/avoid sugar-sweetened beverage intake; encourage water</td> </tr> <tr> <td>Transition to table food with:<br /> <ul> <li>Total fat 30 percent of daily kcal intake based on energy requirements </li> <li>Saturated fat 8 to 10 percent of daily intake based on energy requirements </li> <li>Avoid trans fat as much as possible </li> <li>Monounsaturated and polyunsaturated fat up to 20 percent of daily intake based on energy requirements </li> <li>Cholesterol &#60;300 mg/d </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>Supportive actions:</em><br /> <ul> <li>The fat content of cow's milk to introduce at age 12 to 24 months should be decided together by parents and health care providers based on the child's growth, appetite, intake of other nutrient dense foods, intake of other sources of fat, and potential risk for obesity and CVD </li> <li>100 percent fruit juice (from a cup) no more than 4 oz/d </li> <li>Limit sodium intake </li> <li>Consider DASH-type diet rich in fruits, vegetables, whole grains, low-fat/fat-free milk and milk products; lower in sugar (Table 5-3) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">2 to 10 years</td> <td>Primary beverage: Fat-free unflavored milk</td> </tr> <tr> <td>Limit/avoid sugar sweetened beverages; encourage water</td> </tr> <tr> <td>Fat content:<br /> <ul> <li>Total fat 25 to 30 percent of daily kcal intake based on energy requirement </li> <li>Limit saturated fat 8 to 10 percent of daily kcal intake based on energy requirements </li> <li>Avoid trans fats as much as possible </li> <li>Monounsaturated and polyunsaturated fat up to 20 percent of daily kcal intake based on energy requirements </li> <li>Cholesterol &#60;300 mg/d </li> </ul> </td> </tr> <tr> <td>Encourage high dietary fiber intake from foods<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><em>Supportive actions:</em><br /> <ul> <li>Teach portions based on energy requirements determined by activity level, age, and gender (Table 5-2) </li> <li>Encourage moderately increased energy intake during periods of rapid growth and/or regular moderate to vigorous physical activity </li> <li>Encourage dietary fiber from foods: Age plus 5 g/d<sup>&#9674;</sup> </li> <li>Limit naturally sweetened juice (no added sugar) to 4 oz/d </li> <li>Limit sodium intake </li> <li>Support DASH-style eating plan </li> </ul> </td> </tr> <tr> <td rowspan=\"5\">11 to 21 years</td> <td>Primary beverage: Fat-free unflavored milk</td> </tr> <tr> <td>Limit/avoid sugar sweetened beverages; encourage water</td> </tr> <tr> <td>Fat content:<br /> <ul> <li>Total fat 25 to 30 percent of daily kcal intake based on energy requirements </li> <li>Saturated fat 8 to 10 percent of daily caloric intake based on energy requirements for activity level/age/gender </li> <li>Avoid trans fat as much as possible </li> <li>Monounsaturated and polyunsaturated fat up to 20 percent Grade D of daily caloric intake based on energy requirements for activity level/age/gender </li> <li>Cholesterol &#60;300 mg/d </li> </ul> </td> </tr> <tr> <td>Encourage high dietary fiber intake from foods<sup>&#9674;</sup></td> </tr> <tr> <td><em>Supportive actions:</em><br /> <ul> <li>Teach portions based on energy requirements determined by activity level, age, and gender </li> <li>Encourage moderately increased energy intake during periods of rapid growth and/or regular moderate to vigorous physical activity </li> <li>Advocate dietary fiber: Goal of 14 g/1000 kcal<sup>&#9674;</sup> </li> <li>Limit naturally sweetened juice (no added sugar) to 4 to 6 oz/d </li> <li>Limit sodium intake </li> <li>Encourage healthy eating habits: Breakfast every day, eating meals as a family, limiting fast food meals </li> <li>Support DASH-style eating plan </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Infants that cannot be fed directly at the breast should be fed expressed milk. Infants for whom expressed milk is not available should be fed iron-fortified infant formula.<br />&para; Toddlers 12 to 24 months of age with a family history of obesity, heart disease, or high cholesterol, should discuss transition to reduced-fat milk with pediatric care provider after 12 months of age.<br />&Delta; Continued breastfeeding is still appropriate and nutritionally superior to cow's milk. Milk reduced in fat should be used only in the context of an overall diet that supplies 30 percent of calories from fat.<br /><span class=\"lozenge\">&loz;</span> Naturally fiber-rich foods are recommended (fruits, vegetables, and whole grains); fiber supplements are not advised. Limit refined carbohydrates (sugars, white rice, and white bread).</div><div class=\"graphic_reference\">Modified from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Available at:&nbsp;<A href=\"https://www.nhlbi.nih.gov/node/80139\">https://www.nhlbi.nih.gov/node/80139</A> (Accessed January 3, 2012).</div><div id=\"graphicVersion\">Graphic 78256 Version 6.0</div></div></div>"},"78257":{"type":"graphic_diagnosticimage","displayName":"Anterior acetabular wall fracture","title":"Anterior acetabular wall fracture","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Anterior acetabular wall fracture</div><div class=\"cntnt\"><img style=\"width:516px; height:414px;\" src=\"images/EM/78257_Acetabularfxantwall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) On the anteroposterior (AP) view, the disruption of the iliopectineal line is seen in two locations.<br> (B) The obturator oblique view confirms this disruption, but shows that the femoral head remains congruent against the anterior wall.<br> (C) The iliac oblique view shows that the posterior border of the acetabulum is intact, and that the ilioischial line disruption seen on the AP view is due to a fragment from the quadrilateral surface. (Courtesy of Michael Stover, MD.)</div><div class=\"graphic_reference\">Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78257 Version 15.0</div></div></div>"},"78258":{"type":"graphic_picture","displayName":"Handprint","title":"Handprint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Handprint</div><div class=\"cntnt\"><img style=\"width:360px; height:361px;\" src=\"images/EM/78258_Handprint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Stephen Ludwig, MD.</div><div id=\"graphicVersion\">Graphic 78258 Version 1.0</div></div></div>"},"78259":{"type":"graphic_figure","displayName":"Effect of neck flexion","title":"Effect of neck movement with variable thoracic inlet obstruction","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Effect of neck movement with variable thoracic inlet obstruction</div><div class=\"cntnt\"><img style=\"width:586px; height:366px;\" src=\"images/PULM/78259_Effect_of_neck_flexion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume loops in variable thoracic inlet obstruction with the neck flexed (top) and with the neck extended (bottom). The loops show an intrathoracic and then an extrathoracic location, as the lesion moves within the chest with neck flexion and outside the thoracic inlet with neck extension.</div><div id=\"graphicVersion\">Graphic 78259 Version 1.0</div></div></div>"},"78260":{"type":"graphic_diagnosticimage","displayName":"LLL atelectasis CT","title":"CT scan of left lower lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of left lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:308px; height:253px;\" src=\"images/PULM/78260_LLL_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic complete lobar atelectasis of the left lower lobe. Triangular opacity in left paraspinal location (arrow) obscures the lateral contour of the descending aorta. Cylindrical bronchiectasis is seen in the affected lobe and accounts for the multiple small lucencies permeating the atelectatic left lower lobe. These findings are the result of necrotizing pneumonia in the patient's distant past.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78260 Version 3.0</div></div></div>"},"78262":{"type":"graphic_figure","displayName":"Virtual bronch central","title":"Virtual bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Virtual bronchoscopy</div><div class=\"cntnt\"><img style=\"width:404px; height:272px;\" src=\"images/PULM/78262_Virtual_bronch_central_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Left mainstem bronchus, (B) carina, (C) bronchus intermedius and segmental orifices, and (D) right upper lobe bronchus. An external shaded surface display (CT bronchography) and a&nbsp;coronal multiplanar reconstruction are provided to the right of the virtual bronchoscopy image.</div><div id=\"graphicVersion\">Graphic 78262 Version 5.0</div></div></div>"},"78263":{"type":"graphic_diagnosticimage","displayName":"MRI of a hip fracture","title":"MRI of a hip fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of a hip fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:330px;\" src=\"images/RADIOL/78263_Intertrochanteric_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traumatic hip fracture. Coronal T1-weighted (A) and coronal STIR images (B) of the left hip show the incomplete intertrochanteric fracture line (arrow) which was not seen on the plain radiograph in this patient with hip pain following a recent fall.</div><div class=\"graphic_footnotes\">STIR: short tau inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 78263 Version 4.0</div></div></div>"},"78264":{"type":"graphic_figure","displayName":"Laparoscopic appendectomy","title":"Laparoscopic appendectomy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Laparoscopic appendectomy</div><div class=\"cntnt\"><img style=\"width:502px; height:686px;\" src=\"images/SURG/78264_Appendectomy_laparoscopic.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Illustration by&nbsp;Jenny Wang.</div><div id=\"graphicVersion\">Graphic 78264 Version 5.0</div></div></div>"},"78269":{"type":"graphic_picture","displayName":"Normal eyelid position","title":"Normal eyelid position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal eyelid position</div><div class=\"cntnt\"><img style=\"width:324px; height:212px;\" src=\"images/NEURO/78269_External_eyelid_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper lid covers 1 to 2 mm of the upper limbus. The lower lid covers the lower limbus minimally. The central light reflex can be seen within the pupil. The margin reflex distance is measured from this reflex to the upper eyelid margin.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 78269 Version 3.0</div></div></div>"},"78270":{"type":"graphic_picture","displayName":"Irritant contact derm PI","title":"Irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:341px; height:216px;\" src=\"images/PI/78270_Irritant_contact_derm_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irritant contact dermatitis usually affects the hands. It causes the skin to turn red and dry, and to chap and crack.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 78270 Version 4.0</div></div></div>"},"78272":{"type":"graphic_picture","displayName":"Incontinentia pigmenti 2","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78272_Incontpigmenti2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crops of erythematous papules and vesicles distributed in linear streaks along the Blaschko lines in a female neonate with incontinentia pigmenti.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78272 Version 5.0</div></div></div>"},"78274":{"type":"graphic_table","displayName":"DRI selected nutrients children","title":"Estimated energy requirements (low activity) and recommended dietary allowance (RDA) of selected nutrients for infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated energy requirements (low activity) and recommended dietary allowance (RDA) of selected nutrients for infants, children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Energy<br /> (kcal/day)</td> <td class=\"subtitle1\">Protein<br /> (g/day)</td> <td class=\"subtitle1\">Total fat<br /> (g/day)</td> <td class=\"subtitle1\">Iron<br /> (mg/day)</td> <td class=\"subtitle1\">Calcium<br /> (mg/day)</td> <td class=\"subtitle1\">Zinc<br /> (mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">1 to 3 years</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>850 to 1300</td> <td>13</td> <td>30 to 40</td> <td>7</td> <td>700</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>750 to 1250</td> <td>13</td> <td>30 to 40</td> <td>7</td> <td>700</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">4 to 8 years</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>1400 to 1700</td> <td>19</td> <td>25 to 35</td> <td>10</td> <td>1000</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>1300 to 1600</td> <td>19</td> <td>25 to 35</td> <td>10</td> <td>1000</td> <td>5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">9 to 13 years</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>1800 to 2300</td> <td>34</td> <td>25 to 35</td> <td>8</td> <td>1300</td> <td>8</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>1700 to 2000</td> <td>34</td> <td>25 to 35</td> <td>8</td> <td>1300</td> <td>8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">14 to 18 years</td> </tr> <tr> <td class=\"indent1\">Boys</td> <td>2500 to 2800</td> <td>52</td> <td>25 to 35</td> <td>11</td> <td>1300</td> <td>11</td> </tr> <tr> <td class=\"indent1\">Girls</td> <td>2000</td> <td>46</td> <td>25 to 35</td> <td>15</td> <td>1300</td> <td>9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>The Dietary Reference Intakes, National Academy of Sciences, Washington, DC, 2002. </LI>&#xD;&#xA;<LI>National Academies Press. Dietary Reference Intakes for Calcium and Vitamin D (2010). Available at <A href=\"http://books.nap.edu/openbook.php?record_id=13050&amp;page=291\" target=_blank>books.nap.edu/openbook.php?record_id=13050&amp;page=291</A>. Accessed on December 13, 2010. </LI></OL></div><div id=\"graphicVersion\">Graphic 78274 Version 13.0</div></div></div>"},"78275":{"type":"graphic_waveform","displayName":"Doppler LA appendage flow during atrial fib and atrial flutter","title":"Doppler interrogation of LA appendage flow during atrial fibrillation and atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler interrogation of LA appendage flow during atrial fibrillation and atrial flutter</div><div class=\"cntnt\"><img style=\"width:432px; height:415px;\" src=\"images/CARD/78275_LAA_flow_AF_atrial_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulsed-Doppler tracing of LAA flow in atrial fibrillation is seen in panel A. Note the rapid fibrillatory flow waves, which are of higher velocity during ventricular diastole than systole (arrows). Pulsed-Doppler tracing of LAA flow in atrial flutter (with a 2:1 ventricular response) is seen in panel B. Flutter flow waves are, in general, slower and of higher velocity than fibrillatory flow waves.</div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology. Agmon, Y, Khandheria, BK, Gentile, F, Seward, JB. J Am Coll Cardio, 1999; 34:1867.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 78275 Version 3.0</div></div></div>"},"78276":{"type":"graphic_diagnosticimage","displayName":"Anterior shoulder dislocation","title":"Anterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Anterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:500px; height:421px;\" src=\"images/RHEUM/78276_Anterior_shoulder_dislocati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior view of the right shoulder demonstrates medial displacement of the humeral head in relation to the glenoid fossa, with the humeral head lying inferior to the coracoid process.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 78276 Version 2.0</div></div></div>"},"78277":{"type":"graphic_table","displayName":"Caloric needs for children with burns Curreri Junior formula","title":"Caloric needs for children with burns Curreri Junior formula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caloric needs for children with burns Curreri Junior formula</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Calories (kcal/day)</td> </tr> <tr> <td>&#60;1</td> <td>RDA + 15 kcal/TBSA</td> </tr> <tr> <td>1 to 3</td> <td>RDA + 25 kcal/TBSA</td> </tr> <tr> <td>4 to 15</td> <td>RDA + 40 kcal/TBSA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RDA: recommended daily allowance; TBSA: total body surface area burned.</div><div class=\"graphic_reference\">Data from: Saffle JR, Graves C, Cochran A. Nutritional Support of the Burned Patient. In: Total Burn Care, 4th ed, Herndon DN (Ed), Saunders Elsevier, Philadelphia 2012. p.335.</div><div id=\"graphicVersion\">Graphic 78277 Version 8.0</div></div></div>"},"78278":{"type":"graphic_picture","displayName":"Nevus central hypopigmentation","title":"Dermoscopic image of a nevus with a peripheral reticular and central hypopigmented pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a peripheral reticular and central hypopigmented pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78278_Nevus_central_hypopigment.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 78278 Version 3.0</div></div></div>"},"78279":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid stage 2","title":"Stage 2 ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Stage 2 ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:540px; height:362px;\" src=\"images/DERM/78279_Ocular_cicatricial_stage_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the foreshortening of the inferior fornix of the conjunctiva.</div><div id=\"graphicVersion\">Graphic 78279 Version 1.0</div></div></div>"},"78281":{"type":"graphic_figure","displayName":"Epidemiology of trachoma","title":"Epidemiology of trachoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidemiology of trachoma</div><div class=\"cntnt\"><img style=\"width:447px; height:312px;\" src=\"images/ID/78281_Epidemiology_of_trachoma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active infection with <EM>Chlamydia trachomatis </EM>is mostly seen in young children with a peak incidence before age 10, while subsequent scarring and blindness is seen in adults.</div><div id=\"graphicVersion\">Graphic 78281 Version 2.0</div></div></div>"},"78283":{"type":"graphic_table","displayName":"Body weight in PD adequacy","title":"Table showing the effect of body weight on Kt/V and creatinine clearance among peritoneal dialysis patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Table showing the effect of body weight on Kt/V and creatinine clearance among peritoneal dialysis patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Body weight ratio, actual to desired</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&#60;0.9</td> <td class=\"subtitle2\">0.9 to 1.1</td> <td class=\"subtitle2\">&#62;1.1</td> </tr> <tr> <td>Percent of patients</td> <td class=\"centered\">19</td> <td class=\"centered\">33</td> <td class=\"centered\">48</td> </tr> <tr> <td>BWa/BWd</td> <td class=\"centered\">0.82</td> <td class=\"centered\">1.01</td> <td class=\"centered\">1.37</td> </tr> <tr> <td>Kt/Va</td> <td class=\"centered\">1.95</td> <td class=\"centered\">2.08</td> <td class=\"centered\">1.94</td> </tr> <tr> <td>Kt/Vd</td> <td class=\"centered\">1.74</td> <td class=\"centered\">2.08</td> <td class=\"centered\">2.25</td> </tr> <tr> <td>CCra, L/week</td> <td class=\"centered\">68.1</td> <td class=\"centered\">71.5</td> <td class=\"centered\">64.1</td> </tr> <tr> <td>CCrd, L/week</td> <td class=\"centered\">62.6</td> <td class=\"centered\">71.7</td> <td class=\"centered\">72.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Effect of body weight, using actual (a) and desired (d) values, on Kt/V and weekly creatinine clearance (CCr). If the actual weight is used, patients well below the desired weight (ratio between actual and desired weight below 0.9) will overestimate solute clearance, while those well above the desired weight (ratio above 1.1) will underestimate solute clearance.</div><div id=\"graphicVersion\">Graphic 78283 Version 4.0</div></div></div>"},"78284":{"type":"graphic_picture","displayName":"Amnion nodosum","title":"Amnion nodosum","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Amnion nodosum</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/78284_Amnion_nodosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to amnion nodosum on the membranes in a case of bilateral renal agenesis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 78284 Version 2.0</div></div></div>"},"78285":{"type":"graphic_diagnosticimage","displayName":"Severe fetal scoliosis","title":"Severe fetal scoliosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe fetal scoliosis</div><div class=\"cntnt\"><img style=\"width:432px; height:383px;\" src=\"images/OBGYN/78285_Severe_fetal_scoliosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prenatal ultrasound showing severe fetal scoliosis</div><div class=\"graphic_footnotes\">A: abdomen; LSP: lower spine showing curvature.</div><div class=\"graphic_reference\">Courtesy of SM Jenkins, MD.</div><div id=\"graphicVersion\">Graphic 78285 Version 3.0</div></div></div>"},"78286":{"type":"graphic_picture","displayName":"Clutton joints","title":"Congenital syphilis: Clutton joints","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Clutton joints</div><div class=\"cntnt\"><img style=\"width:432px; height:404px;\" src=\"images/PEDS/78286_Clutton_joints.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with congenital syphilis shows &quot;Clutton joints,&quot; or symmetrical hydrarthrosis of the knee joint. This is a painless condition that often occurs during the late stages of congenital syphilis.</div><div class=\"graphic_reference\">Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.</div><div id=\"graphicVersion\">Graphic 78286 Version 2.0</div></div></div>"},"78287":{"type":"graphic_diagnosticimage","displayName":"Severe influenza pneumonia CT","title":"Influenza pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Influenza pneumonia</div><div class=\"cntnt\"><img style=\"width:420px; height:363px;\" src=\"images/ID/78287_Influenzapneumonia4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography (1 mm collimation) scan at the level of the aortic arch demonstrates extensive bilateral ground-glass opacities, patchy areas of consolidation, and several centrilobular nodules (arrows). The patient was a 61-year-old woman with influenza pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Muller NL, Franquet T, Lee KS, Silva CIS. Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78287 Version 12.0</div></div></div>"},"78288":{"type":"graphic_picture","displayName":"Burkholderia pseudomallei Gram stain","title":"Gram stain showing scant gram-negative bacilli of Burkholderia pseudomallei","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Gram stain showing scant gram-negative bacilli of Burkholderia pseudomallei</div><div class=\"cntnt\"><img style=\"width:480px; height:344px;\" src=\"images/ID/78288_Burkholderia_gramstain_arrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Bart Currie, Microbiology Department, Royal Darwin Hospital.</div><div id=\"graphicVersion\">Graphic 78288 Version 2.0</div></div></div>"},"78289":{"type":"graphic_figure","displayName":"Development internal genitalia","title":"Phenotypic differentiation of the female and male urogenital tracts","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Phenotypic differentiation of the female and male urogenital tracts</div><div class=\"cntnt\"><img style=\"width:546px; height:577px;\" src=\"images/ENDO/78289_Development_internal_genita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In females, the mÃ¼llerian ducts give rise to the fallopian tubes, uterus, and upper vagina, and the Wolffian ducts persist in vestigial form. In males, the Wolffian ducts give rise to the epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts, and the mÃ¼llerian ducts regress.</div><div id=\"graphicVersion\">Graphic 78289 Version 5.0</div></div></div>"},"78291":{"type":"graphic_picture","displayName":"Myeloblasts with Auer rod","title":"Myeloblasts with Auer rod in acute myeloid leukemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myeloblasts with Auer rod in acute myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:366px; height:251px;\" src=\"images/HEME/78291_Myeloblasts_with_Auer_rod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with acute myeloid leukemia. There are two myeloblasts, which are large cells with high nuclear-to-cytoplasmic ratio and nucleoli. Each myeloblast has a pink/red rod-like structure (Auer rod) in the cytoplasm (arrows).</div><div class=\"graphic_reference\">From Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 78291 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"78294":{"type":"graphic_table","displayName":"Monoamine oxidase inhibitor","title":"Monoamine oxidase inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monoamine oxidase inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Trade name*</td> <td class=\"subtitle1\">Class</td> </tr> <tr> <td>Furazolidone</td> <td>Furoxone<sup>&#182;</sup></td> <td>Antimicrobial</td> </tr> <tr> <td>Isocarboxazid<sup>&#916;</sup></td> <td>Marplan</td> <td>Antidepressant</td> </tr> <tr> <td>Linezolid</td> <td>Zyvox</td> <td>Antimicrobial</td> </tr> <tr> <td>Moclobemide</td> <td>Manerix<sup>&#182;</sup></td> <td>Antidepressant</td> </tr> <tr> <td>Pargyline<sup>&#916;</sup></td> <td>Eutonyl<sup>&#182;</sup></td> <td>Antidepressant</td> </tr> <tr> <td>Phenelzine<sup>&#916;</sup></td> <td>Nardil</td> <td>Antidepressant</td> </tr> <tr> <td>Procarbazine</td> <td>Matulane</td> <td>Antineoplastic</td> </tr> <tr> <td>Rasagiline</td> <td>Azilect</td> <td>Parkinson disease</td> </tr> <tr> <td>Safinamide</td> <td>Xadago</td> <td>Parkinson disease</td> </tr> <tr> <td>Selegiline</td> <td>Eldepryl</td> <td>Parkinson disease</td> </tr> <tr> <td>Selegiline transdermal patch</td> <td>Emsam</td> <td>Parkinson disease</td> </tr> <tr> <td>Tranylcypromine<sup>&#916;</sup></td> <td>Parnate</td> <td>Antidepressant</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Trade name in&nbsp;the United States&nbsp;and some other countries.<br />Â¶ Not available in the United States.<br />Î Potent non-selective monoamine oxidase inhibitor requiring vigilant food and drug interaction monitoring or preferably discontinuation two to three weeks preoperatively.</div><div id=\"graphicVersion\">Graphic 78294 Version 7.0</div></div></div>"},"78295":{"type":"graphic_table","displayName":"Vesicles and bullae","title":"Differential diagnosis of vesicles and bullae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of vesicles and bullae</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Bullous disease in diabetes</td> </tr> <tr> <td>Bullous pemphigoid</td> </tr> <tr> <td>Burn</td> </tr> <tr> <td>Cellulitis</td> </tr> <tr> <td>Congenital syphilis</td> </tr> <tr> <td>Contact dermatitis</td> </tr> <tr> <td>Dermatitis herpetiformis</td> </tr> <tr> <td>Eczema (especially hand/foot)</td> </tr> <tr> <td>Epidermolysis bullosa</td> </tr> <tr> <td>Erythema multiforme</td> </tr> <tr> <td>Fixed drug eruption</td> </tr> <tr> <td>Fungal infections (especially tinea pedis)</td> </tr> <tr> <td>Hand, foot, and mouth disease</td> </tr> <tr> <td>Herpes gestationis</td> </tr> <tr> <td>Herpes simplex</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Id reaction</td> </tr> <tr> <td>Impetigo</td> </tr> <tr> <td>Insect bite reaction</td> </tr> <tr> <td>Lichen planus</td> </tr> <tr> <td>Lupus erythematosus (bullous)</td> </tr> <tr> <td>Pemphigus vulgaris/foliaceus</td> </tr> <tr> <td>Porphyria cutanea tarda</td> </tr> <tr> <td>Scabies</td> </tr> <tr> <td>Staphylococcal scalded skin</td> </tr> <tr> <td>Streptococcal toxic shock</td> </tr> <tr> <td>Toxic epidermal necrolysis</td> </tr> <tr> <td>Varicella</td> </tr> <tr> <td>Vasculitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78295 Version 2.0</div></div></div>"},"78298":{"type":"graphic_table","displayName":"Causes of cardiomyopathy I","title":"Etiologic classification of cardiomyopathy-I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of cardiomyopathy-I</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Diptheria*</td> </tr> <tr> <td class=\"indent1\">Tuberculosis*</td> </tr> <tr> <td class=\"indent1\">Typhoid fever*</td> </tr> <tr> <td class=\"indent1\">Rheumatic fever*</td> </tr> <tr> <td class=\"indent1\">Scarlet fever*</td> </tr> <tr> <td class=\"indent1\">Meningococcal*</td> </tr> <tr> <td class=\"indent1\">Pneumococcal</td> </tr> <tr> <td class=\"indent1\">Gonococcal</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Tetanus</td> </tr> <tr> <td class=\"indent1\">Meliodosis</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pertussis</td> </tr> <tr> <td class=\"subtitle2_single\">Spirochetal</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Leptospirosis*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lyme disease*</td> </tr> <tr> <td class=\"subtitle2_single\">Rickettsial</td> </tr> <tr> <td class=\"indent1\">Typhus</td> </tr> <tr> <td class=\"indent1\">Rocky mountain spotted fever*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Q fever</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Parvovirus B19*</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6*</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis*</td> </tr> <tr> <td class=\"indent1\">Influenza*</td> </tr> <tr> <td class=\"indent1\">Mumps*</td> </tr> <tr> <td class=\"indent1\">Rubella*</td> </tr> <tr> <td class=\"indent1\">Rubeola*</td> </tr> <tr> <td class=\"indent1\">Variola*</td> </tr> <tr> <td class=\"indent1\">Varicella*</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr*</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle2_single\">Viral (cont'd)</td> </tr> <tr> <td class=\"indent1\">Coxsackievirus*</td> </tr> <tr> <td class=\"indent1\">Echovirus*</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus*</td> </tr> <tr> <td class=\"indent1\">Hepatitis*</td> </tr> <tr> <td class=\"indent1\">Rabies*</td> </tr> <tr> <td class=\"indent1\">Mycoplasma*</td> </tr> <tr> <td class=\"indent1\">Psittacosis*</td> </tr> <tr> <td class=\"indent1\">Herpes</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arboviruses*</td> </tr> <tr> <td class=\"subtitle2_single\">Mycotic</td> </tr> <tr> <td class=\"indent1\">Actinomycosis</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> </tr> <tr> <td class=\"indent1\">Moniliasis</td> </tr> <tr> <td class=\"indent1\">Aspergiliosis</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis*</td> </tr> <tr> <td class=\"indent1\">Coccidiomycosis</td> </tr> <tr> <td class=\"indent1\">Cryptococcosis*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Candidiasis</td> </tr> <tr> <td class=\"subtitle2_single\">Protozoal</td> </tr> <tr> <td class=\"indent1\">South American</td> </tr> <tr> <td class=\"indent1\">trypanosomiasis*</td> </tr> <tr> <td class=\"indent1\">African trypanosomiasis*</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis*</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Amebiasis</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Balantidiasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sarcosporidiosis</td> </tr> <tr> <td class=\"subtitle2_single\">Helminthic</td> </tr> <tr> <td class=\"indent1\">Trichiniasis*</td> </tr> <tr> <td class=\"indent1\">Echinococcosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle2_single\">Helminthic (cont'd)</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis*</td> </tr> <tr> <td class=\"indent1\">Ascariasis</td> </tr> <tr> <td class=\"indent1\">Heterophydiasis</td> </tr> <tr> <td class=\"indent1\">Filariasis</td> </tr> <tr> <td class=\"indent1\">Paragonimiasis</td> </tr> <tr> <td class=\"indent1\">Strongyloidiasis</td> </tr> <tr> <td class=\"indent1\">Cysticercosis</td> </tr> <tr> <td class=\"indent1\">Visceral larva migrans</td> </tr> <tr> <td class=\"subtitle1_single\">Toxins and drugs</td> </tr> <tr> <td class=\"indent1\">Adriamycin*</td> </tr> <tr> <td class=\"indent1\">Amphetamine*</td> </tr> <tr> <td class=\"indent1\">Antimony</td> </tr> <tr> <td class=\"indent1\">Arsenic*</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Carbon tetrachloride</td> </tr> <tr> <td class=\"indent1\">Catecholamines*</td> </tr> <tr> <td class=\"indent1\">Cobalt*</td> </tr> <tr> <td class=\"indent1\">Cocaine*</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Emetine</td> </tr> <tr> <td class=\"indent1\">Ethyl alcohol*</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Lead</td> </tr> <tr> <td class=\"indent1\">Methysergide</td> </tr> <tr> <td class=\"indent1\">Phenothiazine drugs</td> </tr> <tr> <td class=\"indent1\">Phosphorus*</td> </tr> <tr> <td class=\"indent1\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"indent1\">Zidovudine*</td> </tr> <tr> <td class=\"indent1\">Radiation*<sup>&#182;</sup></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Conditions that may manifest clinically as dilated cardiomyopathy.<br />Â¶ Conditions that may manifest clinically as restrictive cardiomyopathy.</div><div class=\"graphic_reference\">Adapted with permission from: Abelmann, WH. Introduction to Atlas of Heart Diseases, Vol. II: Cardiomyopathies, Myocarditis and Pericardial disease, Abelmann, WH (Ed), Current Medicine, Philadelphia, 1995, p. 1.</div><div id=\"graphicVersion\">Graphic 78298 Version 6.0</div></div></div>"},"78301":{"type":"graphic_picture","displayName":"Mod diff squamous CA Light","title":"Focally keratinizing (moderately differentiated) squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focally keratinizing (moderately differentiated) squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:396px; height:256px;\" src=\"images/ONC/78301_Mod_diff_squamous_CA_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nests of basaloid tumor cells with peripheral palisading at the stromal interface. Intercellular bridges may be present, but keratinization is focal (arrow).</div><div class=\"graphic_reference\">Courtesy of Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 78301 Version 4.0</div></div></div>"},"78302":{"type":"graphic_diagnosticimage","displayName":"Adrenal neuroblastoma","title":"Neuroblastoma arising from the adrenal gland","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Neuroblastoma arising from the adrenal gland</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/PEDS/78302_Adrenal_neuroblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tumor is heterogeneous in appearance and contains calcifications. Note how it surrounds and displaces the aorta.</div><div class=\"graphic_reference\">Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.</div><div id=\"graphicVersion\">Graphic 78302 Version 2.0</div></div></div>"},"78303":{"type":"graphic_table","displayName":"Risk factors for calcium stones","title":"Major risk factors for calcium stones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major risk factors for calcium stones</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Urinary</td> </tr> <tr> <td class=\"sublist1\">Lower volume</td> </tr> <tr> <td class=\"sublist1\">Higher calcium</td> </tr> <tr> <td class=\"sublist1\">Higher oxalate (CaOx stones)</td> </tr> <tr> <td class=\"sublist1\">Lower citrate</td> </tr> <tr> <td class=\"sublist1\">Higher pH (CaP stones)</td> </tr> <tr> <td class=\"sublist1_start\">Anatomic</td> </tr> <tr> <td class=\"sublist1\">Medullary sponge kidney</td> </tr> <tr> <td class=\"sublist1\">Horseshoe kidney</td> </tr> <tr> <td class=\"sublist1_start\">Diet</td> </tr> <tr> <td class=\"sublist1\">Lower fluid intake</td> </tr> <tr> <td class=\"sublist1\">Lower dietary calcium</td> </tr> <tr> <td class=\"sublist1\">Higher oxalate</td> </tr> <tr> <td class=\"sublist1\">Lower potassium</td> </tr> <tr> <td class=\"sublist1\">Higher sodium</td> </tr> <tr> <td class=\"sublist1\">Higher sucrose</td> </tr> <tr> <td class=\"sublist1\">Higher fructose</td> </tr> <tr> <td class=\"sublist1\">Lower phytate</td> </tr> <tr> <td class=\"sublist1\">Higher vitamin C</td> </tr> <tr> <td class=\"sublist1_start\">Other medical conditions</td> </tr> <tr> <td class=\"sublist1\">Primary hyperparathyroidism</td> </tr> <tr> <td class=\"sublist1\">Gout</td> </tr> <tr> <td class=\"sublist1\">Obesity</td> </tr> <tr> <td class=\"sublist1\">Diabetes mellitus</td> </tr> <tr> <td class=\"sublist1\">Distal renal tubular acidosis</td> </tr> <tr> <td class=\"sublist1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"sublist1\">Malabsorptive bariatric surgery</td> </tr> <tr> <td class=\"sublist1\">Short bowel syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78303 Version 4.0</div></div></div>"},"78304":{"type":"graphic_figure","displayName":"Mitral annular dynamics","title":"Mitral annular dynamics and corresponding tissue Doppler echocardiogram spectral display","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Mitral annular dynamics and corresponding tissue Doppler echocardiogram spectral display</div><div class=\"cntnt\"><img style=\"width:487px; height:287px;\" src=\"images/CARD/78304_Mitral_annular_dynamics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B show the movement of the mitral annulus during systole and diastole; panel C shows the corresponding pulsed-tissue Doppler echocardiogram spectral display.</div><div class=\"graphic_footnotes\">S: peak systolic velocity; E: peak early diastolic velocity; A: peak atrial velocity.</div><div id=\"graphicVersion\">Graphic 78304 Version 3.0</div></div></div>"},"78306":{"type":"graphic_diagnosticimage","displayName":"US of Bakers cyst with needle","title":"Ultrasound of needle entry into popliteal cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of needle entry into popliteal cyst</div><div class=\"cntnt\"><img style=\"width:288px; height:389px;\" src=\"images/RHEUM/78306_US_Bakers_cyst_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal US scan showing needle moved down to the center of the Baker's cyst.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div class=\"graphic_reference\">Courtesy of Juhani Koski, MD.</div><div id=\"graphicVersion\">Graphic 78306 Version 2.0</div></div></div>"},"78310":{"type":"graphic_table","displayName":"Clin manif RT fibrosis","title":"Common clinical manifestations of radiation-induced fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common clinical manifestations of radiation-induced fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Tissues</td>\n<td class=\"subtitle1\">Manifestations and symptoms</td>\n</tr>\n\n<tr>\n<td>Skin, subcutaneous tissue</td>\n<td>Induration, thickening, impaired cosmesis, loss of elasticity, shrinkage, limited joint mobility, lymphedema</td>\n</tr>\n\n<tr>\n<td>Lung</td>\n<td>Restrictive pulmonary symptoms, dyspnea, impaired lung function, oxygen dependency</td>\n</tr>\n\n<tr>\n<td>Head and neck</td>\n<td>Trismus, mucosal fibrosis, ulcerations, fistula</td>\n</tr>\n\n<tr>\n<td>Gastrointestinal tract</td>\n<td>Obstruction, dysphagia, ulceration, fistula, diarrhea, pain</td>\n</tr>\n\n<tr>\n<td>Urinary tract</td>\n<td>Ureteral and urethral stenosis, bladder shrinkage, urgency, increased voiding frequency</td>\n</tr>\n\n<tr>\n<td>Female genital tract</td>\n<td>Loss of reproductive function, pain, rigidness, shortness and narrowness of vagina, dyspareunia</td>\n</tr>\n\n<tr>\n<td>Muscles</td>\n<td>Muscle atrophy, muscle shortening, reduced mobility, decreased strength</td>\n</tr>\n\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78310 Version 1.0</div></div></div>"},"78311":{"type":"graphic_table","displayName":"Causes of clitoromegaly","title":"Causes of clitoromegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of clitoromegaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" colspan=\"2\">Can present</td> <td class=\"subtitle1\" rowspan=\"2\">Comments and reference</td> </tr> <tr> <td class=\"subtitle2\">At birth</td> <td class=\"subtitle2\">After birth</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Virilized XX</td> </tr> <tr> <td class=\"indent2\">Congenital adrenal hyperplasia (CAH)</td> <td>Yes</td> <td>Yes</td> <td>21 alpha hydroxylase deficiency and 11 beta hydroxylase deficiency are the most common. Late presentation does occur<sup>[1,2]</sup>. Refer to UpToDate topics on congenital adrenal hyperplasia.</td> </tr> <tr> <td class=\"indent2\">Maternal androgens or synthetic progestational agents</td> <td>Yes</td> <td>No</td> <td> <p>Refer to UpToDate topic on causes of gestational hyperandrogenism.</p> </td> </tr> <tr> <td class=\"indent2\">Placental aromatase enzyme deficiency</td> <td>Yes</td> <td>No</td> <td>Maternal virilization during pregnancy can be a clue to the diagnosis. Refer to UpToDate topic on causes of gestational hyperandrogenism. </td> </tr> <tr> <td class=\"indent2\">Androgen-secreting tumors</td> <td>No</td> <td>Yes</td> <td>Ovarian<sup>[3]</sup> and adrenal<sup>[4]</sup></td> </tr> <tr> <td class=\"indent2\">Hepatic dysfunction</td> <td>No</td> <td>Yes</td> <td>Report of 10-year-old girl with portal hypertension and impaired hepatic steroid metabolism<sup>[5]</sup></td> </tr> <tr> <td class=\"indent2\">Exogenous androgens</td> <td>Yes</td> <td>Yes</td> <td>(Akcam 2003)<sup>[6]</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Feminized XY (not true clitoromegaly, but small penis can appear as large clitoris)</td> </tr> <tr> <td class=\"indent2\">Congenital adrenal hyperplasia (CAH)</td> <td>Yes</td> <td>Yes</td> <td>Examples include 17 hydroxylase deficiency, 3 beta hydroxysteroid deficiency. Refer to UpToDate topics on uncommon causes of congenital adrenal hyperplasia.</td> </tr> <tr> <td class=\"indent2\">Androgen insensitivity syndrome (aka testicular feminization syndrome)</td> <td>Yes</td> <td>Yes</td> <td>Complete insensitivity usually presents at birth, whereas partial insensitivity can present at birth or later<sup>[7,8]</sup>.&nbsp;Refer to UpToDate topic on disorders of the androgen receptor.</td> </tr> <tr> <td class=\"indent2\">5-alpha reductase deficiency (5aRD)</td> <td>Yes</td> <td>No</td> <td>5aR converts testosterone to DHT.&nbsp;Refer to UpToDate topic on steroid 5-alpha-reductase 2 deficiency.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Other</td> </tr> <tr> <td class=\"indent2\">True hermaphroditism</td> <td>Yes</td> <td>Yes</td> <td>Patients can be XX or XY. Genitalia can vary from ambiguous to isolated clitoromegaly<sup>[9]</sup>.</td> </tr> <tr> <td class=\"indent2\">Mixed gonadal dysgenesis</td> <td>Yes</td> <td>No</td> <td>Most patients are mosaics 45,XO/46,XY. Refer to UpToDate topic on evaluation of the infant with ambiguous genitalia.</td> </tr> <tr> <td class=\"indent2\">Neurofibromatosis</td> <td>Yes</td> <td>Yes</td> <td>Has been reported both with type 1 and type 2<sup>[10]</sup></td> </tr> <tr> <td class=\"indent2\">Vascular malformation</td> <td>TP</td> <td>Yes</td> <td>Report of 5-year-old girl<sup>[11]</sup></td> </tr> <tr> <td class=\"indent2\">Sebaceous cyst</td> <td>TP</td> <td>Yes</td> <td>Case report in adolescent girl<sup>[12]</sup></td> </tr> <tr> <td class=\"indent2\">Idiopathic</td> <td>Yes</td> <td>Yes</td> <td>Report of two adults with acquired isolated clitoromegaly<sup>[13]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TP: theoretically possible but no case report found.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Silverman K, Couey SM, Murmam D. Non-classic 21-hydroxylase deficiency in an 18-year-old female athlete. J Pediatr Adolesc gynecol. 2000; 13:96-7. </li> <li>Pang S. Congenital adrenal hyperplasia. Baillieres Clin Obstet Gynecol. 1997; 11:281-306. </li> <li>Sayer RA, Deutsch A, Hoffman MS. Clitoroplasty. Obstet Gynecol. 2007; 110:523-5. </li> <li>Wolthers OD, Cameron FJ, Scheimberg J, Honour JW, Hindmarsh PC, Savage MO, Stanhope RG, Brook CG. Androgen secreting adrenocortical tumors. Arch Dis Child, 1999; 80:46-50. </li> <li>Speiser PW, Susin M, Sassano H, Bohrer S, Markowitz J. Ovarian hyperthecosis in the setting of portal hypertension. J Clini Endocrinol Metab. 2000; 85:873-7. </li> <li>Akcam M, Topaloglu A. Extremely immature infant who developed clitoromegaly during the second month of her postnatal life probably due to frequent whole blood transfusion from an adult male. Pediatr Int. 2003; 45:347-8. </li> <li>Sultan C, Lumbroso S, Paris F, Jeandel C, Terouanne B, et al. Disorders of androgen action. Semin Reprod Med. 2002; 20:217-27. </li> <li>Chipashvili MK, Kristesashvili DI, Kopaliani NSh. Georgian Med News. 2006; 131:21-4. </li> <li>Yordam N, Alikasifoglu A, Kandemir N, Caglar M, Balci S. True hermaphroditism: clinical features, genetic variants and gonadal histology. J Pediatr Endocrinol Metab. 2001; 4:421-7. </li> <li>Yuksel H, Odabasi AR, Kafkas S, Onur E, Turgut M. Clitoromegaly in type 2 neurofibromatosis: a case report and review of the literature. Eur J Gynaecol Oncol. 2003; 24:447-51. </li> <li>Haritharan T, Islah M, Zulfiqar A, Thambi Dorai CR. Solitary vascular malformation of the clitoris. Med J Malaysia. 2006; 61:258-9. </li> <li>Guelinckx PJ, Sinsel NK. An unusual case of clitoral enlargement. Acta Chir Belg. 2002; 102:192-5. </li> <li>Copcu E, Aktas A, Sivrioglu N, Copcu O, Oztan Y. Idiopathic isolated clitoromegaly: a report of two cases. Reprod Health. 2004; 1:4. </li> </ol></div><div id=\"graphicVersion\">Graphic 78311 Version 6.0</div></div></div>"},"78313":{"type":"graphic_picture","displayName":"Congenital muscular torticollis","title":"Congenital muscular torticollis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital muscular torticollis</div><div class=\"cntnt\"><img style=\"width:379px; height:401px;\" src=\"images/PEDS/78313_Congen_muscular_tortico_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) There is a fibrous mass in the right sternocleidomastoid muscle (arrow).<br> (B) Rotation toward the right is limited by the tightness in the right sternocleidomastoid muscle.<br> (C) Rotation toward the left is normal.</div><div class=\"graphic_reference\">Reproduced with permission from: MacDonald MG, Seshia MM, et al. Avery's Neonatology Pathophysiology and Management of the Newborn, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78313 Version 2.0</div></div></div>"},"78314":{"type":"graphic_picture","displayName":"Retinal hamartoma","title":"Retinal hamartoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal hamartoma</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/NEURO/78314_Retinal_hamartoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smaller, multinodular, calcified astrocytic hamartoma of the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore, Lippincott Williams &amp; Wilkins, 2001. Copyright Â© 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78314 Version 2.0</div></div></div>"},"78315":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis elbows","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78315_Dermatitis_herpetiformis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles, bullae, erosions, and crusts on elbow skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78315 Version 4.0</div></div></div>"},"78316":{"type":"graphic_figure","displayName":"Transducer position long axis","title":"Transducer position for imaging parasternal long axis view","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Transducer position for imaging parasternal long axis view</div><div class=\"cntnt\"><img style=\"width:453px; height:371px;\" src=\"images/CARD/78316_Transducer_position_long_ax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transducer is positioned at the third or fourth intercostal space immediately adjacent to the sternum; as the plane of the ultrasound beam is directed from left hip to right shoulder, the heart is sectioned along its long axis. This is usually the first view obtained in a standard ultrasound cardiac examination. The left ventricular chamber is shown with the septum and posterior/inferior walls forming the perimeter.</div><div class=\"graphic_footnotes\">Ao: aorta; LA: left atrium; LV: left ventricle; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 78316 Version 3.0</div></div></div>"},"78317":{"type":"graphic_table","displayName":"ASGE guideline anesthesiologist","title":"Guideline for anesthesiology assistance during gastrointestinal endoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guideline for anesthesiology assistance during gastrointestinal endoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Anesthesiologist assistance may be considered in the following situations:</td> </tr> <tr> <td class=\"sublist1\">Prolonged or therapeutic endoscopic procedure requiring deep sedation</td> </tr> <tr> <td class=\"sublist1\">Anticipated intolerance to standard sedatives</td> </tr> <tr> <td class=\"sublist1\">Increased risk for complication because of severe comorbidity (ASA class III or greater)</td> </tr> <tr> <td class=\"sublist1\">Increased risk for airway obstruction</td> </tr> <tr> <td>The routine assistance of an anesthesiologist for average-risk patients undergoing standard upper and lower endoscopic procedures is not warranted and is cost prohibitive.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASA: American Society of Anesthesiologists.</div><div class=\"graphic_reference\">Modified with permission from: Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56:613. Copyright Â© 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 78317 Version 3.0</div></div></div>"},"78320":{"type":"graphic_picture","displayName":"One-legged hyperextension","title":"One-legged hyperextension test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">One-legged hyperextension test</div><div class=\"cntnt\"><img style=\"width:449px; height:330px;\" src=\"images/PEDS/78320_One-legged_hyperextension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The test is performed by having the patient hyperextend his or her lumbar spine while standing on a single leg. This test is used in the evaluation of a suspected spondylolytic defect at the pars interarticularis. The test is positive if the patient's pain is reproduced. A positive test may indicate an active spondylolysis and/or irritation of the facet structures.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169;2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78320 Version 2.0</div></div></div>"},"78321":{"type":"graphic_table","displayName":"Stages of opiate withdrawal","title":"Stages of opiate withdrawal syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of opiate withdrawal syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td>Stage I: Up to 8 hours</td> <td>Fear of withdrawal, anxiety, drug craving</td> </tr> <tr> <td>Stage II: 8-24 hours</td> <td>Insomnia, restlessness, anxiety, yawning, stomach cramps, lacrimation, rhinorrhea, diaphoresis, mydriasis</td> </tr> <tr> <td>Stage III: Up to 3 days</td> <td>Vomiting, diarrhea, fever, chills, muscle spasms, tremor, tachycardia, piloerection, hypertension, seizures*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Only seen in neonates.</div><div id=\"graphicVersion\">Graphic 78321 Version 3.0</div></div></div>"},"78322":{"type":"graphic_table","displayName":"Adjusting Rx 0 to 4 years","title":"Assessing asthma control and adjusting therapy in children 0 to 4 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessing asthma control and adjusting therapy in children 0 to 4 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Components of control</td> <td class=\"subtitle1\" colspan=\"3\">Classification of asthma control (0 to 4 years of age)</td> </tr> <tr> <td class=\"subtitle2\">Well controlled</td> <td class=\"subtitle2\">Not well controlled</td> <td class=\"subtitle2\">Very poorly controlled</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;1 time/month</td> <td>&#62;1 time/month</td> <td>&#62;1 time/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr class=\"divider_bottom\"> <td>Short-acting beta<sub>2 </sub>agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Risk</td> <td><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td><strong>2 to 3/year</strong></td> <td><strong>&#62;3/year</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Treatment-related adverse effects</td> <td colspan=\"3\">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> <tr> <td colspan=\"2\">Recommended action for treatment</td> <td> <ul> <li>Maintain current treatment. </li> <li>Regular follow-ups every one to six months. </li> <li>Consider step down if well controlled for at least three months. </li> </ul> </td> <td> <ul> <li>Step up (one step) and </li> <li>Reevaluate in two to six weeks. </li> <li>If no clear benefit in four to six weeks, consider alternative diagnoses or adjusting therapy. </li> <li>For side effects, consider alternative treatment options. </li> </ul> </td> <td> <ul> <li>Consider short course of oral systemic glucocorticoids, </li> <li>Step up (one to two steps) and </li> <li>Reevaluate in two weeks. </li> <li>If no clear benefit in four to six weeks, consider alternative diagnoses or adjusting therapy. </li> <li>For side effects, consider alternative treatment options. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous two to four weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have not well-controlled asthma, even in the absence of impairment levels consistent with not well-controlled asthma.<br /><strong>Before step up in therapy:</strong><br />- Review adherence to medication, inhaler technique, and environmental control.<br />- If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 78322 Version 7.0</div></div></div>"},"78323":{"type":"graphic_figure","displayName":"Insertion of needle","title":"Insertion of the TBNA needle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of the TBNA needle</div><div class=\"cntnt\"><img style=\"width:248px; height:269px;\" src=\"images/PULM/78323_Insertion_of_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TBNA needle should be inserted to its fullest extent into the airway wall in order to improve diagnostic yield.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN eds. Progress in Respiratory Research- Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 78323 Version 1.0</div></div></div>"},"78325":{"type":"graphic_picture","displayName":"Lupus arthritis swan neck","title":"Lupus arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/RHEUM/78325_Lupus_arthritis_swan_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with longstanding lupus has developed subluxation at the MCP joints and swan neck deformities of her fingers. These deformities are reducible (probably being due to lax tendons) and radiographs reveal no erosions or cysts, both of which differentiate these findings from those in rheumatoid arthritis.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 78325 Version 2.0</div></div></div>"},"78326":{"type":"graphic_table","displayName":"Efficacy pancreatic drainage","title":"Incidence of pancreatitis according to the type of pancreatic drainage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of pancreatitis according to the type of pancreatic drainage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Nasopancreatic drainage </td> <td>0 of 98 (0 percent)</td> </tr> <tr> <td class=\"subtitle1_left\">Pancreatic stenting </td> <td>1 of 50 (2 percent)</td> </tr> <tr> <td class=\"subtitle1_left\">Any drainage</td> <td>1 of 148 (0.7 percent)*</td> </tr> <tr> <td class=\"subtitle1_left\">No drainage </td> <td>2 of 16 (12.5 percent)*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* p&lt;0.003 for pancreatic duct drainage versus no drainage</div><div class=\"graphic_reference\">Data from: Elton E, et al. Gastrointest Endosc 1998; 47:240.</div><div id=\"graphicVersion\">Graphic 78326 Version 2.0</div></div></div>"},"78328":{"type":"graphic_picture","displayName":"Gram stain bacterial vaginosis","title":"Bacterial vaginosis: Gram stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial vaginosis: Gram stain</div><div class=\"cntnt\"><img style=\"width:364px; height:240px;\" src=\"images/ID/78328_Gramstainvagina2withan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of vaginal discharge (x1000) from a patient with bacterial vaginosis shows the borders of an epithelial cell obscured by small gram-variable coccobacilli.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 78328 Version 6.0</div></div></div>"},"78330":{"type":"graphic_picture","displayName":"HUS Vascular III","title":"Light microscopy showing thrombotic microangiopathy with onion-skin thickening of a muscular renal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing thrombotic microangiopathy with onion-skin thickening of a muscular renal artery</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/NEPH/78330_HUS_vascular_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentric onion-skin thickening of a muscular renal artery, leading to complete obliteration of the vascular lumen, during the later healing phase of previous fibrinoid injury in any of the forms of the hemolytic uremic syndrome, including scleroderma and acute hypertensive nephrosclerosis (formerly called \"malignant nephrosclerosis\").</div><div class=\"graphic_reference\">Courtesy of Carol Black, MD.</div><div id=\"graphicVersion\">Graphic 78330 Version 6.0</div></div></div>"},"78331":{"type":"graphic_table","displayName":"Clinical etiologic classification of myoclonus","title":"Classification of myoclonus by clinical syndrome and etiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of myoclonus by clinical syndrome and etiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Physiologic myoclonus (normal subjects)</td> </tr> <tr> <td class=\"sublist2_start\">A. Sleep jerks (eg, hypnic jerks)</td> </tr> <tr> <td class=\"sublist2_start\">B. Anxiety-induced</td> </tr> <tr> <td class=\"sublist2_start\">C. Exercise-induced</td> </tr> <tr> <td class=\"sublist2_start\">D. Hiccough (singultus)</td> </tr> <tr> <td class=\"sublist2_start\">E. Benign infantile myoclonus with feeding</td> </tr> <tr> <td class=\"subtitle1_single\">II. Essential myoclonus (primary symptom, nonprogressive history)</td> </tr> <tr> <td class=\"sublist2_start\">A. Hereditary (autosomal dominant)</td> </tr> <tr> <td class=\"sublist2_start\">B. Sporadic</td> </tr> <tr> <td class=\"subtitle1_single\">III. Epileptic myoclonus (associated with a chronic seizure disorder or syndrome)</td> </tr> <tr> <td class=\"sublist2_start\">A. Fragments of epilepsy</td> </tr> <tr> <td class=\"sublist2\">1. Isolated epileptic myoclonic jerks</td> </tr> <tr> <td class=\"sublist2\">2. Epilepsia partialis continua</td> </tr> <tr> <td class=\"sublist2\">3. Idiopathic stimulus-sensitive myoclonus</td> </tr> <tr> <td class=\"sublist2\">4. Photosensitive myoclonus</td> </tr> <tr> <td class=\"sublist2\">5. Absences with a minor myoclonic component</td> </tr> <tr> <td class=\"sublist2\">6. Epilepsy with myoclonic absences</td> </tr> <tr> <td class=\"sublist2_start\">B. Childhood myoclonic epilepsy</td> </tr> <tr> <td class=\"sublist2\">1. Infantile spasms (West syndrome)</td> </tr> <tr> <td class=\"sublist2\">2. Severe myoclonic epilepsy of infancy (Dravet syndrome)</td> </tr> <tr> <td class=\"sublist2\">3. Benign myoclonic epilepsy of infancy</td> </tr> <tr> <td class=\"sublist2\">4. Lennox-Gastaut syndrome</td> </tr> <tr> <td class=\"sublist2\">5. Myoclonic astatic epilepsy (Doose syndrome)</td> </tr> <tr> <td class=\"sublist2\">6. Cryptogenic myoclonus epilepsy (Aicardi)</td> </tr> <tr> <td class=\"sublist2\">7. Juvenile myoclonic epilepsy (Janz syndrome)</td> </tr> <tr> <td class=\"sublist2_start\">C. Familial cortical myoclonic tremor with epilepsy</td> </tr> <tr> <td class=\"sublist2\">1. Autosomal dominant cortical myoclonus and epilepsy</td> </tr> <tr> <td class=\"sublist2\">2. Benign adult familial myoclonic epilepsy</td> </tr> <tr> <td class=\"sublist2\">3. Cortical tremor</td> </tr> <tr> <td class=\"sublist2\">4. Familial adult myoclonic epilepsy</td> </tr> <tr> <td class=\"sublist2\">5. Familial cortical myoclonic tremor</td> </tr> <tr> <td class=\"sublist2\">6. Familial cortical tremor with epilepsy</td> </tr> <tr> <td class=\"sublist2\">7. Familial essential myoclonus and epilepsy</td> </tr> <tr> <td class=\"sublist2\">8. Familial rhythmic cortical myoclonus (tremor) with epilepsy</td> </tr> <tr> <td class=\"sublist2\">9. Familial benign myoclonus epilepsy of adult onset</td> </tr> <tr> <td class=\"sublist2\">10. Heredofamilial tremor and epilepsy</td> </tr> <tr> <td class=\"subtitle1_single\">IV. Symptomatic (secondary) myoclonus (not defined by occurrence of seizures)</td> </tr> <tr> <td class=\"sublist2_start\">A. Progressive myoclonic epilepsy: Unverricht-Lundborg disease (Baltic myoclonus)</td> </tr> <tr> <td class=\"sublist2_start\">B. Storage disease</td> </tr> <tr> <td class=\"sublist2\">1. Lafora body disease</td> </tr> <tr> <td class=\"sublist2\">2. GM2 gangliosidosis (late infantile, juvenile)</td> </tr> <tr> <td class=\"sublist2\">3. Tay-Sachs disease</td> </tr> <tr> <td class=\"sublist2\">4. Gaucher disease (noninfantile neuronopathic form)</td> </tr> <tr> <td class=\"sublist2\">5. Krabbe leukodystrophy</td> </tr> <tr> <td class=\"sublist2\">6. Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"sublist2\">7. Sialidosis (types 1 and 2)</td> </tr> <tr> <td class=\"sublist2_start\">C. Spinocerebellar degenerations</td> </tr> <tr> <td class=\"sublist2\">1. Progressive myoclonus ataxia (Ramsay-Hunt cerebellar syndrome)</td> </tr> <tr> <td class=\"sublist2\">2. Friedreich ataxia</td> </tr> <tr> <td class=\"sublist2\">3. Ataxia-telangiectasia</td> </tr> <tr> <td class=\"sublist2\">4. Other spinocerebellar degenerations</td> </tr> <tr> <td class=\"sublist2_start\">D. Basal ganglia degenerations</td> </tr> <tr> <td class=\"sublist2\">1. Wilson disease</td> </tr> <tr> <td class=\"sublist2\">2. Torsion dystonia</td> </tr> <tr> <td class=\"sublist2\">3. Pantothenate kinase-associated neurodegeneration</td> </tr> <tr> <td class=\"sublist2\">4. Progressive supranuclear palsy</td> </tr> <tr> <td class=\"sublist2\">5. Huntington disease</td> </tr> <tr> <td class=\"sublist2\">6. Parkinson disease</td> </tr> <tr> <td class=\"sublist2\">7. Multiple system atrophy</td> </tr> <tr> <td class=\"sublist2\">8. Corticobasal degeneration</td> </tr> <tr> <td class=\"sublist2\">9. Dentatorubral pallidoluysian atrophy</td> </tr> <tr> <td class=\"sublist2_start\">E. Dementias</td> </tr> <tr> <td class=\"sublist2\">1. Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"sublist2\">2. Alzheimer disease</td> </tr> <tr> <td class=\"sublist2\">3. Dementia with Lewy bodies</td> </tr> <tr> <td class=\"sublist2\">4. Frontotemporal dementia</td> </tr> <tr> <td class=\"sublist2\">5. Rett syndrome</td> </tr> <tr> <td class=\"sublist2_start\">F. Diffuse infectious/postinfectious/inflammatory disorders</td> </tr> <tr> <td class=\"sublist2\">1. Subacute sclerosing panencephalitis</td> </tr> <tr> <td class=\"sublist2\">2. Encephalitis lethargica</td> </tr> <tr> <td class=\"sublist2\">3. Arbovirus encephalitis</td> </tr> <tr> <td class=\"sublist2\">4. Herpes simplex encephalitis</td> </tr> <tr> <td class=\"sublist2\">5. Human T-lymphotropic virus I</td> </tr> <tr> <td class=\"sublist2\">6. Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"sublist2\">7. Postinfectious encephalitis</td> </tr> <tr> <td class=\"sublist2\">8. Miscellaneous bacteria (Streptococcus, Clostridium, other)</td> </tr> <tr> <td class=\"sublist2\">9. Malaria</td> </tr> <tr> <td class=\"sublist2\">10. Syphilis</td> </tr> <tr> <td class=\"sublist2\">11. Cryptococcus</td> </tr> <tr> <td class=\"sublist2\">12. Lyme disease</td> </tr> <tr> <td class=\"sublist2\">13. Paraneoplastic</td> </tr> <tr> <td class=\"sublist2\">14. Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"sublist2_start\">G. Metabolic</td> </tr> <tr> <td class=\"sublist2\">1. Hyperthyroidism</td> </tr> <tr> <td class=\"sublist2\">2. Hepatic failure</td> </tr> <tr> <td class=\"sublist2\">3. Renal failure</td> </tr> <tr> <td class=\"sublist2\">4. Dialysis syndrome</td> </tr> <tr> <td class=\"sublist2\">5. Hyponatremia</td> </tr> <tr> <td class=\"sublist2\">6. Hypoglycemia</td> </tr> <tr> <td class=\"sublist2\">7. Nonketotic hyperglycemia</td> </tr> <tr> <td class=\"sublist2\">8. Multiple carboxylase deficiency</td> </tr> <tr> <td class=\"sublist2\">9. Biotin deficiency</td> </tr> <tr> <td class=\"sublist2\">10. Hypoxia</td> </tr> <tr> <td class=\"sublist2\">11. Metabolic alkalosis</td> </tr> <tr> <td class=\"sublist2\">12. Vitamin E deficiency</td> </tr> <tr> <td class=\"sublist2_start\">H. Toxic and drug-induced syndromes</td> </tr> <tr> <td class=\"sublist2\">1. Drugs</td> </tr> <tr> <td class=\"sublist3\">&#8226; Levodopa</td> </tr> <tr> <td class=\"sublist3\">&#8226; Psychiatric medications (eg, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, lithium)</td> </tr> <tr> <td class=\"sublist3\">&#8226; Antibiotics (eg, penicillins, cephalosporins, quinolones)</td> </tr> <tr> <td class=\"sublist3\">&#8226; Narcotics</td> </tr> <tr> <td class=\"sublist3\">&#8226; Anticonvulsants</td> </tr> <tr> <td class=\"sublist3\">&#8226; Anesthetics</td> </tr> <tr> <td class=\"sublist3\">&#8226; Contrast media</td> </tr> <tr> <td class=\"sublist3\">&#8226; Cardiac medications (eg, calcium channel blockers, antiarrhythmic agents)</td> </tr> <tr> <td class=\"sublist3\">&#8226; Drug withdrawal from certain agents (eg, sedatives)</td> </tr> <tr> <td class=\"sublist2\">2. Toxins</td> </tr> <tr> <td class=\"sublist3\">&#8226; Bismuth</td> </tr> <tr> <td class=\"sublist3\">&#8226; Heavy metals</td> </tr> <tr> <td class=\"sublist3\">&#8226; Methyl bromide</td> </tr> <tr> <td class=\"sublist3\">&#8226; Dichlorodiphenyltrichloroethane (DDT)</td> </tr> <tr> <td class=\"sublist2_start\">I. Physical encephalopathies (usually static)</td> </tr> <tr> <td class=\"sublist2\">1. Posthypoxic (Lance-Adams)</td> </tr> <tr> <td class=\"sublist2\">2. Post-traumatic</td> </tr> <tr> <td class=\"sublist2\">3. Heat stroke</td> </tr> <tr> <td class=\"sublist2\">4. Electric shock</td> </tr> <tr> <td class=\"sublist2\">5. Decompression injury</td> </tr> <tr> <td class=\"sublist2_start\">J. Focal nervous system damage</td> </tr> <tr> <td class=\"sublist2\">1. Central nervous system</td> </tr> <tr> <td class=\"sublist3\">a. Post-stroke</td> </tr> <tr> <td class=\"sublist3\">b. Post-thalamotomy</td> </tr> <tr> <td class=\"sublist3\">c. Tumor</td> </tr> <tr> <td class=\"sublist3\">d. Trauma</td> </tr> <tr> <td class=\"sublist3\">e. Infection</td> </tr> <tr> <td class=\"sublist3\">f. Inflammation (eg, multiple sclerosis)</td> </tr> <tr> <td class=\"sublist3\">g. Mobius syndrome</td> </tr> <tr> <td class=\"sublist3\">h. Developmental</td> </tr> <tr> <td class=\"sublist3\">i. Idiopathic</td> </tr> <tr> <td class=\"sublist2\">2. Peripheral nervous system</td> </tr> <tr> <td class=\"sublist3\">a. Trauma</td> </tr> <tr> <td class=\"sublist3\">b. Hematoma</td> </tr> <tr> <td class=\"sublist2_start\">K. Malabsorption</td> </tr> <tr> <td class=\"sublist2\">1. Celiac disease</td> </tr> <tr> <td class=\"sublist2\">2. Whipple disease</td> </tr> <tr> <td class=\"sublist2_start\">L. Eosinophilia-myalgia syndrome</td> </tr> <tr> <td class=\"sublist2_start\">M. Opsoclonus-myoclonus syndrome</td> </tr> <tr> <td class=\"sublist2\">1. Idiopathic</td> </tr> <tr> <td class=\"sublist2\">2. Paraneoplastic</td> </tr> <tr> <td class=\"sublist2\">3. Infectious</td> </tr> <tr> <td class=\"sublist2\">4. Other</td> </tr> <tr> <td class=\"sublist2_start\">N. Exaggerated startle syndrome</td> </tr> <tr> <td class=\"sublist2\">1. Hereditary</td> </tr> <tr> <td class=\"sublist2\">2. Sporadic</td> </tr> <tr> <td class=\"sublist2_start\">O. Hashimoto's encephalopathy</td> </tr> <tr> <td class=\"sublist2_start\">P. Other multiple system degenerations</td> </tr> <tr> <td class=\"sublist2\">1. Action myoclonus-renal failure syndrome</td> </tr> <tr> <td class=\"sublist2\">2. Mitochondrial disorders</td> </tr> <tr> <td class=\"sublist2\">3. Allgrove syndrome</td> </tr> <tr> <td class=\"sublist2\">4. DiGeorge syndrome</td> </tr> <tr> <td class=\"sublist2\">5. Membranous lipodystrophy</td> </tr> <tr> <td class=\"sublist2_start\">Q. Primary progressive myoclonus of aging</td> </tr> <tr> <td class=\"sublist2_start\">R. Unknown</td> </tr> <tr> <td class=\"sublist2\">1. Familial</td> </tr> <tr> <td class=\"sublist2\">2. Sporadic</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Movement Disorders, Marsden CD, Fahn S (Eds), Butterworths, London 1982. p.196.</div><div id=\"graphicVersion\">Graphic 78331 Version 7.0</div></div></div>"},"78333":{"type":"graphic_picture","displayName":"Subcorneal pustular dermatosis - axilla","title":"Subcorneal pustular dermatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcorneal pustular dermatosis</div><div class=\"cntnt\"><img style=\"width:266px; height:164px;\" src=\"images/DERM/78333_Subcorn_pust_derm_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous plaques with superficial pustules are present in the axilla.</div><div id=\"graphicVersion\">Graphic 78333 Version 1.0</div></div></div>"},"78334":{"type":"graphic_waveform","displayName":"Normal RA and PCW and LV pressures","title":"Normal RA, PCW, and LV pressures","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Normal RA, PCW, and LV pressures</div><div class=\"cntnt\"><img style=\"width:602px; height:400px;\" src=\"images/CARD/78334_Norm_RA_PCW_LV_pressures.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Morton Kern.</div><div id=\"graphicVersion\">Graphic 78334 Version 2.0</div></div></div>"},"78335":{"type":"graphic_picture","displayName":"Pigmented melanocytic lesions II","title":"Dermoscopic structures seen in melanocytic lesions","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures seen in melanocytic lesions</div><div class=\"cntnt\"><img style=\"width:548px; height:413px;\" src=\"images/DERM/78335_Pigment_melanocy_lesions_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Aggregated globules (solid square) and pigment network (solid arrow) in a melanocytic nevus.<br> (B) Homogeneous blue pigmentation seen in a blue nevus.<br> (C, D) Streaks: Pseudopods in a Spitz nevus (C) and radial streaming in a melanoma (D).</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 78335 Version 4.0</div></div></div>"},"78336":{"type":"graphic_algorithm","displayName":"Management of suspected preterm labor","title":"Suggested approach to management of suspected preterm labor","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Suggested approach to management of suspected preterm labor</div><div class=\"cntnt\"><img style=\"width:758px; height:592px;\" src=\"images/OBGYN/78336_Manag_suspect_preterm_labor.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GBS: group B streptococcus.</div><div id=\"graphicVersion\">Graphic 78336 Version 3.0</div></div></div>"},"78338":{"type":"graphic_picture","displayName":"Fracture padding","title":"Fracture padding in different sizes","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Fracture padding in different sizes</div><div class=\"cntnt\"><img style=\"width:468px; height:355px;\" src=\"images/EM/78338_Fracture_padding.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 78338 Version 1.0</div></div></div>"},"78339":{"type":"graphic_figure","displayName":"Population stratification","title":"Population stratification","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Population stratification</div><div class=\"cntnt\"><img style=\"width:579px; height:536px;\" src=\"images/PC/78339_Population_stratification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Population stratification is a form of confounding in genetic association studies that occurs when disease and non-disease populations include a different racial or ethnic mix. In this example, 60 percent of the light-skinned people have the red variant (regardless of eye color), and 80 percent of the dark-skinned people have the red variant (regardless of eye color). Hence, there is an association&nbsp;between skin color and the red variant but not between eye color and the red variant. However,&nbsp;there appears to be an association between eye color and the red variant because people who are light-skinned are more likely to have blue eyes&nbsp;and people with dark skin are more likely to have black eyes. Correction for this type of confounding is done by adjusting or stratifying the analysis. </div><div id=\"graphicVersion\">Graphic 78339 Version 2.0</div></div></div>"},"78340":{"type":"graphic_diagnosticimage","displayName":"Value spot compression","title":"Value of spot compression","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Value of spot compression</div><div class=\"cntnt\"><img style=\"width:495px; height:388px;\" src=\"images/PC/78340_Spot_compression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is suggestion of a nodule (arrows) in the medial aspect of the breast on the CC view (Panel A). The borders, shape and size of the nodule are better evaluated with spot compression (Panel B).</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 78340 Version 2.0</div></div></div>"},"78341":{"type":"graphic_picture","displayName":"Endobronchial Kaposi sarcoma","title":"Endobronchial Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:402px; height:266px;\" src=\"images/PULM/78341_Endobronchial_Kaposis_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power light micrograph of endobronchial Kaposi sarcoma showing spindle cells surrounding thin vascular channels.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 78341 Version 2.0</div></div></div>"},"78343":{"type":"graphic_table","displayName":"Undifferentiated overlap synd","title":"Undifferentiated rheumatic diseases and overlap syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Undifferentiated rheumatic diseases and overlap syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Synonyms</td> </tr> <tr> <td class=\"subtitle2_left\">Mixed connective tissue disease</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lupus-scleroderma-polymyositis-rheumatoid arthritis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Undifferentiated systemic rheumatic disease</td> <td>(Early) undifferentiated connective tissue, collagen vascular, or autoimmune disease</td> </tr> <tr> <td class=\"subtitle2_left\">Nonclassic systemic lupus erythematosus</td> <td>Lupus-like, lupus variant, or near, borderline, latent, incipient, incomplete, possible, or probable lupus</td> </tr> <tr> <td class=\"subtitle2_left\">Overlap syndromes</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis-lupus</td> <td>Rhupus</td> </tr> <tr> <td class=\"indent1\">Scleroderma-polymyositis/dermatomyositis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Scleroderma-lupus</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Scleroderma-rheumatoid arthritis</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Other scleroderma overlaps</td> </tr> <tr> <td class=\"indent1\">Polymyositis overlaps</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis-lupus</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome overlaps</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Other</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Undifferentiated polyarthritis syndrome</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Undifferentiated spondyloarthritis</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78343 Version 4.0</div></div></div>"},"78344":{"type":"graphic_table","displayName":"Risk stratification of myeloma","title":"Risk stratification of myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk stratification of myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">High risk</td> <td class=\"subtitle1\">Intermediate risk</td> <td class=\"subtitle1\">Standard risk</td> </tr> <tr> <td> <p>17p13 deletion</p> <p>t (14;16)</p> <p>t (14;20)</p> <p>LDH <span style=\"font-size: 10pt; font-family: verdana,sans-serif;\">&#8805;</span>2 times institutional upper limit of normal</p> <p>Features of primary plasma cell leukemia*</p> <p>High risk gene expression profiling signature</p> </td> <td> <p>t (4;14)</p> <p>Deletion 13 or hypodiploidy by conventional karyotyping</p> Gain 1q</td> <td> <p>Trisomies (hyperdiploidy)</p> <p>t (11;14)</p> <p>t (6;14)</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Myeloma patients are risk-stratified at initial diagnosis based on fluorescence in situ hybridization (FISH) studies on the bone marrow for t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, 1q+, and trisomies of odd numbered chromosomes. If FISH is unavailable, conventional cytogenetics can be used as an alternative, but is much less sensitive.</div><div class=\"graphic_footnotes\">LDH: lactate dehydrogenase.<br />* Defined by either â¥2000 plasma cells/microL of peripheral blood, or â¥20 percent on a manual differential count.</div><div class=\"graphic_reference\">Adapted from: Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.</div><div id=\"graphicVersion\">Graphic 78344 Version 10.0</div></div></div>"},"78345":{"type":"graphic_figure","displayName":"Transabdominal CVS","title":"Technique for transabdominal chorionic villus sampling (CVS)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Technique for transabdominal chorionic villus sampling (CVS)</div><div class=\"cntnt\"><img style=\"width:534px; height:548px;\" src=\"images/OBGYN/78345_Transabdominal_CVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the transabdominal CVS technique, the physician guides a needle from the patient's abdomen into the placenta under ultrasound guidance.</div><div id=\"graphicVersion\">Graphic 78345 Version 3.0</div></div></div>"},"78348":{"type":"graphic_picture","displayName":"Petroleum gauze PI","title":"Petroleum gauze","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Petroleum gauze</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/PI/78348_Petroleum_gauze_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 78348 Version 1.0</div></div></div>"},"78349":{"type":"graphic_table","displayName":"Rx serious MRSA child","title":"Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious methicillin-resistant* <EM>Staphylococcus aureus </EM>infection in children older than 30 days when antimicrobial susceptibilities are known","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious methicillin-resistant* <EM>Staphylococcus aureus </EM>infection in children older than 30 days when antimicrobial susceptibilities are known</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antimicrobial regimen</td> <td class=\"subtitle1\">Doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Life-threatening infection (eg, endocarditis, CNS infection, septic shock)</td> </tr> <tr> <td class=\"indent1\">Regimen of choice</td> <td> <p>Vancomycin &#177;</p> <p>Rifampin<sup>&#182;</sup></p> </td> <td> <p>Vancomycin: 60 mg/kg per day in 4 doses; maximum daily dose 4 g</p> <p>Rifampin: 20 mg/kg per day in 2 doses; maximum daily dose 600 mg</p> </td> </tr> <tr> <td class=\"indent1\">Alternative regimen, excluding CNS infections and pneumonia (also may be used for patients with persistent bacteremia despite adequate therapy)</td> <td>Daptomycin<sup>&#916;&#9674;</sup></td> <td> <p>1 through 6 years: 12 mg/kg per day in 1 dose</p> <p>7 through 11 years: 9 mg/kg per day in 1 dose</p> <p>12 through 17 years: 7 mg/kg per day in 1 dose</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nonlife-threatening, nonendovascular infection (eg, pneumonia, septic arthritis, osteomyelitis)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Regimens of choice</td> <td> <p>Clindamycin<sup>&#167;</sup> (if strain susceptible and D-test<sup>&#165;</sup> negative), <strong>or</strong></p> </td> <td> <p>40 mg/kg per day in 3 to 4 doses; maximum daily dose 2.7 g</p> </td> </tr> <tr> <td>Vancomycin</td> <td>60 mg/kg per day in 4 doses; maximum daily dose 4 g</td> </tr> <tr> <td class=\"indent1\">Alternative regimens for pneumonia</td> <td>Linezolid<sup>&#916;</sup><br /> </td> <td> <p>&#60;12 years: 30 mg/kg per day in 3 doses</p> <p>&#8805;12 years: 600 mg twice per day</p> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Alternative regimens for septic arthritis, osteomyelitis</td> <td>Daptomycin<sup>&#916;&#9674;</sup></td> <td> <p>1 through 6 years: 12 mg/kg per day in 1 dose</p> <p>7 through 11 years: 9 mg/kg per day in 1 dose</p> <p>12 through 17 years: 7 mg/kg per day in 1 dose</p> </td> </tr> <tr> <td>Linezolid<sup>&#916;</sup></td> <td> <p>&#60;12 years: 30 mg/kg per day in 3 doses</p> <p>&#8805;12 years: 600 mg twice per day</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Complicated skin and soft-tissue infection</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Regimens of choice</td> <td>Clindamycin<sup>&#167;</sup> (if strain susceptible and D-test<sup>&#165;</sup> negative), <strong>or</strong></td> <td>30 to 40 mg/kg per day in 3 to 4 doses; maximum daily dose&nbsp;1.8 g</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> <td>8 to 12 mg/kg trimethoprim/40 to 60 mg/kg sulfamethoxazole per day in 4 doses</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Alternative regimens</td> <td>Vancomycin</td> <td>40 to 60 mg/kg per day in 4 doses; maximum daily dose 4 g</td> </tr> <tr> <td>Linezolid<sup>&#916;</sup></td> <td> <p>&#60;12 years: 30 mg/kg per day in 3 doses</p> <p>&#8805;12 years: 600 mg twice per day</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Oxacillin minimum inhibitory concentration (MIC) â¥4 mcg/mL.<br />Â¶ Rifampin may be added for life-threatening infections such as endocarditis or CNS infection, although there are no data from controlled trials to indicate that combination therapy is beneficial. Rifampin may be added for any methicillin-resistant <EM>S. aureus</EM> (MRSA) infection of prosthetic material. Gentamicin (3 mg/kg per day for&nbsp;two weeks) is added to vancomycin and rifampin as recommended treatment of MRSA prosthetic valve endocarditis. Consultation with an expert in infectious diseases may be warranted to determine which agent to use and duration of use.<br />Î Consultation with an expert in infectious diseases is suggested before use.<br /><FONT class=lozenge>â</FONT> Daptomycin is active in vitro against multidrug-resistant gram-positive organisms, including <EM>S. aureus</EM>, but is not well studied in children. It is approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections in patients â¥1 year of age, the treatment of <EM>S. aureus</EM> bacteremia in children age 1 through 17 years of age, and the treatment of <EM>S. aureus</EM> bacteremia (including right-sided endocarditis) in patients â¥18 years of age. Dosing for other indications is not well established.&nbsp;Daptomycin should not be used alone if pulmonary infection is present. There is no experience with daptomycin in the treatment of <FONT color=black>central nervous system infections.<br />Â§&nbsp;Once bacteremia is cleared.<br />Â¥</FONT><FONT color=red><FONT color=black>&nbsp;The \"D test\" assesses for&nbsp;inducible clindamycin resistance in MRSA isolates.&nbsp;The D test is the gold standard for detection of inducible clindamycin resistance; automated tests are also available.&nbsp;Organisms that appear susceptible to clindamycin and resistant to erythromycin by standard techniques may have induction of clindamycin resistance when exposed to the drug. Refer to separate UpToDate content on antibacterial susceptibility testing for additional details</FONT>.</FONT></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.715. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881. </LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</LI>&#xD;&#xA;<LI>Cubicin (daptomycin for injection). United States Prescribing Information. Revised September, 2017. US Food&nbsp;and Drug Administration. Available online: <A spellcheck=true id=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm \" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm </A>(Accessed on September 7, 2017). </LI></OL></div><div id=\"graphicVersion\">Graphic 78349 Version 11.0</div></div></div>"},"78350":{"type":"graphic_figure","displayName":"Age nomogram","title":"Age nomogram","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Age nomogram</div><div class=\"cntnt\"><img style=\"width:514px; height:482px;\" src=\"images/DRUG/78350_Sotalol.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78350 Version 3.0</div></div></div>"},"78353":{"type":"graphic_table","displayName":"Cardiovascular parameters for grading TTTS severity","title":"Cardiovascular parameters assessed in grading severity of twin-twin transfusion syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular parameters assessed in grading severity of twin-twin transfusion syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Donor twin</td> </tr> <tr> <td>Umbilical artery blood flow</td> </tr> <tr> <td class=\"subtitle1_single\">Recipient twin</td> </tr> <tr> <td>Ventricular hypertrophy or wall thickness</td> </tr> <tr> <td>Cardiac dilation</td> </tr> <tr> <td>Ventricular dysfunction</td> </tr> <tr> <td>Tricuspid valve regurgitation</td> </tr> <tr> <td>Mitral valve regurgitation</td> </tr> <tr> <td>Tricuspid valve inflow</td> </tr> <tr> <td>Mitral valve inflow</td> </tr> <tr> <td>Ductus venosus flow</td> </tr> <tr> <td>Umbilical vein flow</td> </tr> <tr> <td>Right-sided outflow tract obstruction</td> </tr> <tr> <td>Pulmonary regurgitation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Rychik J, Tian Z, Bebbington M, et al. The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. Am J Obstet Gynecol 2007; 197:392.</div><div id=\"graphicVersion\">Graphic 78353 Version 3.0</div></div></div>"},"78354":{"type":"graphic_figure","displayName":"ECG and action potential","title":"Ventricular action potential and QRS-T cycle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular action potential and QRS-T cycle</div><div class=\"cntnt\"><img style=\"width:262px; height:270px;\" src=\"images/CARD/78354_ECG_and_action_potential.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS-T cycle on the electrocardiogram corresponds to different phases of the ventricular action potential.</div><div id=\"graphicVersion\">Graphic 78354 Version 1.0</div></div></div>"},"78355":{"type":"graphic_table","displayName":"BTS guidelines rx empyema child","title":"British thoracic guidelines for management of pleural infection in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">British thoracic guidelines for management of pleural infection in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Supportive care\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Antipyretics should be given.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Analgesia is important to keep the child comfortable, particularly if he or she has a chest drain.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chest physiotherapy is not beneficial.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Early mobilization is recommended.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Antibiotics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>All cases should be treated with intravenous antibiotics.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Coverage for Streptococcus pneumoniae should be included. Broader spectrum coverage is necessary for children with hospital acquired infections, and effusions secondary to surgery, trauma, or aspiration.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Antibiotic therapy should be tailored to microbiology results.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Oral antibiotics should be continued at discharge for one to four weeks or longer if there is residual disease.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Chest drains\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chest drains should be inserted by adequately trained personnel.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ultrasonography should be used to guide thoracentesis or drain placement.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adequate analgesia and/or sedation, with appropriate monitoring, should be used during the procedure.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Small drains (including pigtail catheters) should be used whenever possible to minimize discomfort; there is no evidence that large bore chest drains confer any advantage over small drains.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A chest radiograph should be performed after insertion of the chest drain.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A bubbling chest drain should never be clamped.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A clamped chest drain should be immediately unclamped if the patient complains of chest pain or breathlessness.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>The drain should be removed once there is clinical resolution.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A drain that cannot be unblocked should be removed and replaced if significant pleural fluid remains.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Intrapleural fibrinolytics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intrapleural fibrinolytics may shorten hospital stay and are recommended for any complicated parapneumonic effusion or empyema.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Surgery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Failure of chest tube drainage, antibiotics, and fibrinolysis should prompt early discussion with a thoracic surgeon.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Patients should be considered for surgical treatment if they have persisting sepsis in association with persistent pleural fluid, despite chest tube drainage and antibiotics.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Organized empyema in a symptomatic child may require formal thoracotomy and decortication.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Follow-up\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Children should be followed until they have recovered completely and their chest radiograph has returned to near normal.</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Balfour-Lynn, IM, Abrahamson, E, Cohen, G, et al. BTS guidelines for the management of pleural infection in children. Thorax 2005; 60 Suppl 1:i1.</div><div id=\"graphicVersion\">Graphic 78355 Version 1.0</div></div></div>"},"78356":{"type":"graphic_algorithm","displayName":"Dysuria adolescent female","title":"Diagnostic approach to the adolescent female with dysuria","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the adolescent female with dysuria</div><div class=\"cntnt\"><img style=\"width:754px; height:833px;\" src=\"images/EM/78356_Dysuriaadolescentfemedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">UTI may coexist with noninfectious etiologies. Unless the cause of dysuria is obvious on physical examination (eg, vulvar ulcers, obvious local trauma, or viral exanthem) a urine specimen for rapid dipstick should be obtained in all patients. Urinalysis and urine culture should also be obtained if the urine dipstick suggests a UTI (refer to UpToDate topics on diagnosis of UTI in children).</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; UTI: urinary tract infection.<br />* In addition to Stevens-Johnson, varicella infection, Beh&ccedil;et syndrome, and reactive arthritis with urethritis and conjunctivitis, potential causes include inflammatory bowel disease. Refer to UpToDate topics on vulvar vesicles and bullae.<br />&para; Testing for <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> is warranted. Refer to UpToDate topics on vaginitis, cervicitis, and pelvic inflammatory disease.<br />&Delta; For menstruating females, the urinalysis and culture will be more reliable if obtained by bladder catheterization or by clean catch after placing a tampon. However, a clean catch specimen without tampon placement may have to suffice in some patients who decline.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topics and algorithms on symptomatic microscopic hematuria in children.</div><div id=\"graphicVersion\">Graphic 78356 Version 9.0</div></div></div>"},"78357":{"type":"graphic_figure","displayName":"Ileocolic stapled anastomosis - end to side","title":"Ileocolic stapled anastomosis - end to side","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Ileocolic stapled anastomosis - end to side</div><div class=\"cntnt\"><img style=\"width:456px; height:410px;\" src=\"images/SURG/78357_End-to-side-anastomosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78357 Version 1.0</div></div></div>"},"78359":{"type":"graphic_figure","displayName":"Anatomy of the dorsal aspect of the wrist","title":"Anatomy of the dorsal aspect of the wrist","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Anatomy of the dorsal aspect of the wrist</div><div class=\"cntnt\"><img style=\"width:477px; height:580px;\" src=\"images/EM/78359_Anatomy_wrist_dorsal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One useful landmark for dorsal palpation is Lister's tubercle which lies in approximately the middle of the distal radius, aligned with the middle metacarpal (blue arrow). Between these bony landmarks lie the lunate and capitate.</div><div id=\"graphicVersion\">Graphic 78359 Version 3.0</div></div></div>"},"78360":{"type":"graphic_figure","displayName":"Circumvaginal incision","title":"Total vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Total vulvectomy</div><div class=\"cntnt\"><img style=\"width:216px; height:429px;\" src=\"images/OBGYN/78360_Circumvaginal_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutting around the vagina to the level of the urethra.</div><div id=\"graphicVersion\">Graphic 78360 Version 1.0</div></div></div>"},"78361":{"type":"graphic_table","displayName":"Breast cancer risk Hodgkin lymphoma","title":"Cumulative absolute risk for developing breast cancer in young women treated for Hodgkin lymphoma after 30 years of follow-up","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cumulative absolute risk for developing breast cancer in young women treated for Hodgkin lymphoma after 30 years of follow-up</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age at Dx</td>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Mediastinal RT (Gy)</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Absolute risk of breast CA after 30 years of follow-up</td>\n\n\n    </tr>\n\n    <tr>\n      \n      \n      <td class=\"subtitle2\">Alk agents used</td>\n      <td class=\"subtitle2\">Alk agents not used</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">15</td>\n\n      <td>0</td>\n\n      <td>0.8</td>\n\n      <td>1.7</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>20 - &#60;40</td>\n      <td>4.1</td>\n      <td>8.5</td>\n    </tr>\n    <tr>\n      \n      <td>&#8805;40</td>\n      <td>5.0</td>\n      <td>10.3</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">20</td>\n\n      <td>0</td>\n\n      <td>1.6</td>\n\n      <td>3.4</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>20 -&#60;40</td>\n      <td>7.9</td>\n      <td>16.0</td>\n    </tr>\n    <tr>\n      \n      <td> &#8805;40</td>\n      <td>9.5</td>\n      <td>19.1</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">25</td>\n\n      <td>0</td>\n\n      <td>2.6</td>\n\n      <td>5.5</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>20 -&#60;40</td>\n      <td>12.5</td>\n      <td>24.6</td>\n    </tr>\n    <tr>\n      \n      <td> &#8805;40</td>\n      <td>15.0</td>\n      <td>29.0</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">30</td>\n\n      <td>0</td>\n\n      <td>4.0</td>\n\n      <td>8.2</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>20 -&#60;40</td>\n\n      <td>18.1</td>\n\n      <td>34.1</td>\n\n    </tr>\n    <tr>\n      \n      <td>&#8805;40</td>\n      <td>21.6</td>\n      <td>39.6</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">This table shows the estimated absolute risk of developing breast cancer (percent) after 30 years of follow-up in young women treated for Hodgkin lymphoma as a function of age at diagnosis (dx), amount of mediastinal irradiation (Gy), and whether or not alkylating (alk) agents were employed in the treatment program.</div><div class=\"graphic_reference\">Data from: Travis LB, Hill D, Dores GM, et al.&nbsp;Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:1428.</div><div id=\"graphicVersion\">Graphic 78361 Version 3.0</div></div></div>"},"78362":{"type":"graphic_table","displayName":"Actions of immunosuppressives","title":"Mechanisms of action of immunosuppressive drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of action of immunosuppressive drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" rowspan=\"6\">Glucocorticoids</td> <td>Inhibits phospholipase A2, cyclooxygenase (COX)-2, and nitric oxide synthetase</td> </tr> <tr> <td>Inhibits production of pro-inflammatory prostaglandins, leukotrienes, and thromboxanes</td> </tr> <tr> <td>Inhibits production of interleukin (IL)-1, IL-2, and tumor necrosis factor-alpha</td> </tr> <tr> <td>Inhibits neutrophil adhesion to endothelium and chemotaxis</td> </tr> <tr> <td>Inhibits monocyte/macrophage activation, chemotaxis, and ability to recognize antigen</td> </tr> <tr> <td>Inhibits T lymphocyte proliferative response to antigen</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"8\">Methotrexate</td> <td>Stimulates adenosine release from fibroblasts and endothelial cells</td> </tr> <tr> <td>Reduces neutrophil adhesion</td> </tr> <tr> <td>Antiproliferative effect on synovial fibroblasts and endothelial cells</td> </tr> <tr> <td>Inhibits leukotriene B4 synthesis by neutrophils</td> </tr> <tr> <td>Inhibits local IL-1 production</td> </tr> <tr> <td>Reduces levels of IL-6 and IL-8</td> </tr> <tr> <td>Suppresses cell-mediated immunity</td> </tr> <tr> <td>Inhibits synovial collagenase gene expression</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"4\">Hydroxychloroquine</td> <td>Interferes with normal antigen processing</td> </tr> <tr> <td>Inhibits lysosomal enzymes</td> </tr> <tr> <td>Inhibits IL-1 release</td> </tr> <tr> <td>Inhibits polymorphonuclear and lymphocyte responses</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"3\">Sulfasalazine</td> <td>Inhibits polymorphonuclear cell migration</td> </tr> <tr> <td>Reduces lymphocyte responses</td> </tr> <tr> <td>Inhibits angiogenesis</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"4\">Azathioprine</td> <td>Purine analogue; inhibts purine metabolism</td> </tr> <tr> <td>Inhibits B- and T-cell lymphocyte functions</td> </tr> <tr> <td>Inhibits B-cell proliferation and antibody synthesis</td> </tr> <tr> <td>Inhibits natural killer cell activity</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"4\">Cyclophosphamide and chlorambucil</td> <td>Alkylating agents</td> </tr> <tr> <td>Crosslinks DNA leading to cell death</td> </tr> <tr> <td>Produces B- and T-cell lymphocytopenia</td> </tr> <tr> <td>Inhibits immunoglobulin synthesis</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"4\">Cyclosporine and tacrolimus (FK506)</td> <td>Blocks transcription of IL-2</td> </tr> <tr> <td>Suppresses T-cell activation</td> </tr> <tr> <td>Preferential effect on CD4+ T-lymphocyte</td> </tr> <tr> <td>Blocks synthesis and release of IL-1 from monocytes</td> </tr> <tr> <td class=\"subtitle1_left\">Etanercept</td> <td>Neutralizes soluble tumor necrosis factor (TNF)-alpha, preventing it from binding to cell bound</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"3\">Infliximab and adalimumab</td> <td>Combine with TNF</td> </tr> <tr> <td>Down-regulate endothelial cell adhesion molecules</td> </tr> <tr> <td>Decreases leukocyte migration</td> </tr> <tr> <td class=\"subtitle1_left\">Leflunomide</td> <td>Inhibits dihydro-orate dehydrogenase which leads to depletion of intracellular pyrimidine and reduces RNA synthesis</td> </tr> <tr> <td class=\"subtitle1_left\">Anakinra</td> <td>IL-1 receptor antagonist</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78362 Version 2.0</div></div></div>"},"78363":{"type":"graphic_waveform","displayName":"EP study tracings post RF ablation WPW","title":"Intracardiac and surface ECG recordings during electrophysiologic study post-radiofrequency ablation of accessory pathway in Wolff-Parkinson-White","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG recordings during electrophysiologic study post-radiofrequency ablation of accessory pathway in Wolff-Parkinson-White</div><div class=\"cntnt\"><img style=\"width:592px; height:422px;\" src=\"images/CARD/78363_PostRFablationWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are five surface leads (I, AVF, V1, V3, and V6) and intracardiac recording from the high right atrium (HRA), lateral mitral annulus (HBE1-2 and HBE3-4), coronary sinus proximal to distal (CS9-10, 7-8, 5-6, 3-4, 1-2), and right ventricular apex (RVA3-4). The tip of the mapping catheter is positioned at the site along the mitral annulus recording the earliest ventricular activity (HBE1-2) (ie, the location of the accessory pathway). Within a few beats after the application of radiofrequency energy (RF on), the delta wave on the ECG disappeared (arrow) and the PR interval normalized. Prior to ablation, the recordings from the CS catheter show continuous atrial (A) and ventricular (V) electrograms; after ablation, there is a normal interval between A and V.</div><div id=\"graphicVersion\">Graphic 78363 Version 5.0</div></div></div>"},"78364":{"type":"graphic_diagnosticimage","displayName":"Multiple metatarsal fractures after crush injury","title":"Multiple metatarsal fractures after crush injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple metatarsal fractures after crush injury</div><div class=\"cntnt\"><img style=\"width:290px; height:468px;\" src=\"images/RHEUM/78364_Mlt_mttr_frct_crsh_injry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple distal metatarsal shaft fractures are evident in this patient who suffered a severe crush injury (arrows). There is widening of the space between the first and second metatarsal. This is usually caused by a tarsometatarsal fracture dislocation (Lisfranc injury), but in this case, it is due to fracture of the cuneiform (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL, Calmbach W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 78364 Version 5.0</div></div></div>"},"78365":{"type":"graphic_diagnosticimage","displayName":"Hummingbird sign in PSP","title":"\"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">\"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy</div><div class=\"cntnt\"><img style=\"width:361px; height:355px;\" src=\"images/NEURO/78365_Hummingbird_sign_PSP_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midsagittal MRI of the brain demonstrates prominent midbrain atrophy without pontine atrophy (divided by white line), forming the silhouette of the \"penguin\" or \"hummingbird\" sign.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Graber JJ, Staudinger R. Teaching NeuroImages: \"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009; 72:e81. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78365 Version 6.0</div></div></div>"},"78369":{"type":"graphic_table","displayName":"Long term outcomes in infantile spasms","title":"Key outcome parameters in West syndrome/Infantile spasms (irrespective of cause)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key outcome parameters in West syndrome/Infantile spasms (irrespective of cause)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Suppression of spasms (in response to treatment)</td> <td>50 to 90 percent</td> </tr> <tr> <td>Development of other seizure types</td> <td>50 to 70 percent (intractable in 40 to 50 percent)</td> </tr> <tr> <td>Evolution into the Lennox-Gastaut syndrome</td> <td>20 to 50 percent</td> </tr> <tr> <td>Learning difficulties (usually moderate or severe)</td> <td>70 to 90 percent*</td> </tr> <tr> <td>Psychiatric (including autistic) dysfunction</td> <td>20 to 40 percent*</td> </tr> <tr> <td>Mortality</td> <td>5 to 30 percent (of which 50 percent are disease, and 50 percent treatment-related)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Appleton RE. West syndrome: long-term prognosis and social aspects. Brain and Development 2001; 23:688. Copyright Â© 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 78369 Version 4.0</div></div></div>"},"78370":{"type":"graphic_figure","displayName":"Sling and swathe splint","title":"Sling and swathe splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sling and swathe splint</div><div class=\"cntnt\"><img style=\"width:432px; height:276px;\" src=\"images/PEDS/78370_Sling_and_swathe_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A powdered pad is placed in the axilla prior to application of the swathe to prevent maceration. <br />(B) The swathe component is essential to minimize motion of the shoulder region.</div><div id=\"graphicVersion\">Graphic 78370 Version 2.0</div></div></div>"},"78372":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor CT","title":"Pancoast tumor on CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancoast tumor on CT</div><div class=\"cntnt\"><img style=\"width:360px; height:215px;\" src=\"images/PULM/78372_Pancoast_tumor_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT section shows brachial plexus invasion of lung cancer with a soft tissue mass in the left lung apex (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78372 Version 3.0</div></div></div>"},"78373":{"type":"graphic_table","displayName":"Secretion clearance methods","title":"Secretion clearance/bronchial hygiene","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secretion clearance/bronchial hygiene</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique </td> <td class=\"subtitle1\">Advantages </td> <td class=\"subtitle1\">Comment/disadvantage </td> </tr> <tr> <td>Directed cough</td> <td>Inexpensive, simple</td> <td>Chest pain may limit</td> </tr> <tr> <td>Regular exercise</td> <td>Inexpensive, strengthens respiratory and peripheral muscles</td> <td>&nbsp;</td> </tr> <tr> <td>Autogenic breathing</td> <td>Controls breathing</td> <td>Requires patient cooperation</td> </tr> <tr> <td>Forced expiration</td> <td>Helps control breathing</td> <td>Requires patient learning</td> </tr> <tr> <td>Chest physical therapy (CPT) (postural drainage, hand, or mechanical chest clapping)</td> <td>Most tested in cystic fibrosis</td> <td>Needs assistant, hard to position, hypoxemia, sometimes worsens gastroesophageal reflux</td> </tr> <tr> <td>Positive expiratory pressure (PEP)</td> <td>Easy, inexpensive</td> <td>Device needs cleaning</td> </tr> <tr> <td>Oscillatory PEP (eg, flutter valve acapella device)</td> <td>Easy, inexpensive, adds vibration to airways</td> <td>Device needs cleaning</td> </tr> <tr> <td>High frequency chest wall compression</td> <td>Better tolerated than chest PT</td> <td>Very expensive, pain may limit</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78373 Version 3.0</div></div></div>"},"78374":{"type":"graphic_table","displayName":"Contraindications to percutaneous liver biopsy","title":"Contraindications to a percutaneous liver biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to a percutaneous liver biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Absolute</td> <td class=\"subtitle1\">Relative</td> </tr> <tr> <td>Inability of patient to cooperate with procedure</td> <td>Morbid obesity</td> </tr> <tr> <td rowspan=\"2\">Significant coagulopathy or thrombocytopenia (unless corrected prior to the liver biopsy)</td> <td>Ascites</td> </tr> <tr> <td>Hemophilia</td> </tr> <tr> <td>NSAID use (including aspirin) within last 7 to 10 days</td> <td>Infection within the right pleural cavity</td> </tr> <tr> <td>Patient refusal to accept blood transfusion or inability to provide blood transfusion support</td> <td>Infection below right hemidiaphragm</td> </tr> <tr> <td>Suspected hemangioma, vascular tumor, or echinococcal cyst</td> <td>Amyloidosis</td> </tr> <tr> <td>Inability to identify an adequate biopsy site by percussion and/or ultrasound</td> <td>&nbsp;</td> </tr> <tr> <td>Extrahepatic biliary obstruction</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.</div><div id=\"graphicVersion\">Graphic 78374 Version 9.0</div></div></div>"},"78378":{"type":"graphic_table","displayName":"Causes of INO","title":"Possible etiologies of internuclear ophthalmoplegia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible etiologies of internuclear ophthalmoplegia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Multiple sclerosis (commonly bilateral)</td> </tr> <tr> <td>Brainstem infarction (commonly unilateral)</td> </tr> <tr> <td>Brainstem and fourth ventricle tumors</td> </tr> <tr> <td>Arnold-Chiari malformation</td> </tr> <tr> <td>Infection: bacterial, viral, and other forms of meningoencephalitis</td> </tr> <tr> <td>Hydrocephalus, subdural hematoma, supratentorial arteriovenous malformation</td> </tr> <tr> <td>Nutritional disorders: Wernicke encephalopathy and pernicious anemia</td> </tr> <tr> <td>Metabolic disorders: hepatic encephalopathy, maple syrup urine disease, abetalipoproteinemia, Fabry disease</td> </tr> <tr> <td>Drug intoxications: tricyclic antidepressants, phenothiazines, narcotics, lithium, barbiturates, propranolol</td> </tr> <tr> <td>Cancer</td> </tr> <tr> <td>Head trauma</td> </tr> <tr> <td>Degenerative conditions: progressive supranuclear palsy</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Pseudointernuclear ophthalmoplegia of myasthenia gravis and Miller Fisher syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78378 Version 2.0</div></div></div>"},"78379":{"type":"graphic_waveform","displayName":"EEG Wicket spikes","title":"Wicket spikes","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Wicket spikes</div><div class=\"cntnt\"><img style=\"width:544px; height:283px;\" src=\"images/NEURO/78379_Wicket_spikes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These may appear in clusters or singly in the temporal regions.</div><div class=\"graphic_reference\">Courtesy of Drs. Lawrence Hirsch and Hiba Arif.</div><div id=\"graphicVersion\">Graphic 78379 Version 3.0</div></div></div>"},"78380":{"type":"graphic_figure","displayName":"PTH alone or with alendronate","title":"Trabecular volumetric BMD with PTH 1-84, alendronate, or both","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Trabecular volumetric BMD with PTH 1-84, alendronate, or both</div><div class=\"cntnt\"><img style=\"width:508px; height:347px;\" src=\"images/ENDO/78380_PTH_aln_wth_alendronat_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in trabecular volumetric BMD in the lumbar spine and total hip by QCT (g/cm<SUP>3</SUP>) after 12 months of treatment with PTH 1-84 (100 mcg; red bar), PTH and alendronate (10 mg/day; diagonal-lined blue bar), or alendronate (10 mg/day alone; checkered green bar).</div><div class=\"graphic_footnotes\">BMD: bone mineral density; PTH: parathyroid hormone;&nbsp;ALN:&nbsp;alendronate;&nbsp;QCT: quantitative computed tomography.</div><div class=\"graphic_reference\">Data from: Black DM, Greenspan SL, Ensrud KE,&nbsp;et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207.</div><div id=\"graphicVersion\">Graphic 78380 Version 3.0</div></div></div>"},"78381":{"type":"graphic_figure","displayName":"Mechanism for anemia of chronic disease","title":"Mechanism for the anemia of chronic disease","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Mechanism for the anemia of chronic disease</div><div class=\"cntnt\"><img style=\"width:534px; height:510px;\" src=\"images/HEME/78381_Mechanism_anemia_chron_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A proposed mechanism for the anemia of chronic disease (ACD) is shown here. In the presence of infection, inflammation, or malignancy, the macrophage is stimulated to produce interleukin-6 (IL-6) and interleukin-1 beta (IL-1Î²), which induce the production of hepcidin by the liver. Hepcidin, in turn, through its interaction with the iron export protein ferroportin, inhibits iron absorption from the gastrointestinal tract and decreases release of iron from macrophages. Both effects lead to the reduced plasma iron levels (hypoferremia) characteristic of ACD. Inflammatory cytokines such as IL-1Î² and TNF-Î±&nbsp; reduce erythropoietin production and the efficiency of erythropoiesis, which are also components of ACD.</div><div id=\"graphicVersion\">Graphic 78381 Version 3.0</div></div></div>"},"78382":{"type":"graphic_diagnosticimage","displayName":"Fetal hydrocephaly","title":"Fetal hydrocephaly at 21 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal hydrocephaly at 21 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:442px; height:298px;\" src=\"images/OBGYN/78382_Hydrocephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All four images were obtained using transvaginal sonography.<br />(A) Posterior coronal section showing the very large posterior horns of the lateral ventricles. In the posterior fossa a relatively normal appearing cerebellum (between arrows) and the cisterna magna are seen.<br />(B) A more anterior section than A and also showing dilation of the lateral ventricles (Lv).<br />(C) An axial section showing the large ventricles, the dangling choroid plexus, and the very thin cortical mantle.<br />(D) Oblique section showing the hydrocephaly.</div><div class=\"graphic_footnotes\">T: thalamus; CP: choroid plexus.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 78382 Version 3.0</div></div></div>"},"78383":{"type":"graphic_picture","displayName":"Pemphigoid gestationis umbilicus","title":"Pemphigoid gestationis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis</div><div class=\"cntnt\"><img style=\"width:432px; height:330px;\" src=\"images/DERM/78383_Pemphigoid_gestationis_umb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periumbilical erythematous papules, vesicles, erosions, and crusts are present in this patient with pemphigoid gestationis. </div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78383 Version 6.0</div></div></div>"},"78384":{"type":"graphic_figure","displayName":"Positions for administering sinus medications","title":"Positions for administering sinus medications","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Positions for administering sinus medications</div><div class=\"cntnt\"><img style=\"width:541px; height:579px;\" src=\"images/ALLRG/78384_Medication_positions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These positions allow medications put into the nostrils to move up into the sinuses (highlighted in green in the right-hand column). To start, get into the head down forward position (top panel), and&nbsp;put the medication into the right nostril. Stay in this position for the amount of time specified by your health care provider. This will&nbsp;treat the right frontal&nbsp;and ethmoid sinuses.&nbsp;Next, slowly roll onto your right side to treat the right maxillary sinus, and remain in this position for the same amount of time. Then, if your provider suggests that you do the third position, slowly roll onto your back (bottom panel), and stay there for the same amount of time. This will&nbsp;treat the right sphenoid sinus. Once the right side is completed, sit up and allow the remaining nasal solution to drain from the nose. The entire procedure should then be repeated on the left side (not illustrated),&nbsp;starting in the head down forward position, then rolling onto your left side, and finally (optional), rolling onto your back.&nbsp;Note that lying on your back is optional and should not be done if it feels like the medicine gets into your inner ear when you do this.</div><div class=\"graphic_reference\">Courtesy of Daniel Hamilos, MD.</div><div id=\"graphicVersion\">Graphic 78384 Version 7.0</div></div></div>"},"78385":{"type":"graphic_figure","displayName":"Femoral anatomy child","title":"Anatomy of the femur in the child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the femur in the child</div><div class=\"cntnt\"><img style=\"width:437px; height:518px;\" src=\"images/EM/78385_Femoral_anatomy_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration depicts the anatomy of the femur in the child. The epiphyses appear as blue shaded regions and the physes as salmon shaded areas.</div><div id=\"graphicVersion\">Graphic 78385 Version 1.0</div></div></div>"},"78386":{"type":"graphic_algorithm","displayName":"Algorithm for management of rotator cuff tear","title":"Algorithm for management of rotator cuff tear","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of rotator cuff tear</div><div class=\"cntnt\"><img style=\"width:615px; height:738px;\" src=\"images/EM/78386_RC_tear_tx_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; NSAID: nonsteroidal antiinflammatory drug; PT: physical therapy; RC: rotator cuff; US: ultrasound.<br />* Regular reevaluation is appropriate for those patients who would be surgical candidates were significant pain or shoulder dysfunction to develop. Refer to text for details.<br />&Delta; Age below 50 is a general guideline and not mandatory to be considered a surgical candidate.</div><div id=\"graphicVersion\">Graphic 78386 Version 5.0</div></div></div>"},"78388":{"type":"graphic_figure","displayName":"Bilirubin circulation summary","title":"Enterohepatic and systemic circulation of bilirubin and its metabolites in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enterohepatic and systemic circulation of bilirubin and its metabolites in adults</div><div class=\"cntnt\"><img style=\"width:350px; height:460px;\" src=\"images/GAST/78388_Bilirubin_circulation_summa.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78388 Version 1.0</div></div></div>"},"78389":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis in heel","title":"Osteomyelitis in the heel","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis in the heel</div><div class=\"cntnt\"><img style=\"width:516px; height:273px;\" src=\"images/ID/78389_Osteomyelitis_in_heel_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal&nbsp;computed tomography&nbsp;image demonstrates cortical fragmentation of the plantar aspect of the calcaneus (arrows) and adjacent air and soft tissue ulceration.<br />(B) Corresponding fluid-sensitive short inversion time inversion recovery (STIR) image&nbsp;demonstrates extensive high-signal edema in the calcaneus (asterisk) and again demonstrates posterior plantar ulcer overlying the calcaneus (arrow).</div><div class=\"graphic_reference\">Courtesy of Perry Horwich, MD.</div><div id=\"graphicVersion\">Graphic 78389 Version 7.0</div></div></div>"},"78390":{"type":"graphic_figure","displayName":"Ventricular pacing with 100 percent capture","title":"Ventricular pacing with 100 percent capture","html":"<div class=\"graphic normal\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Ventricular pacing with 100 percent capture</div><div class=\"cntnt\"><img style=\"width:460px; height:186px;\" src=\"images/CARD/78390_Complete_ventric_pacer_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Every QRS complex is preceded by a pacemaker stimulus (marked by red lines). The QRS complex is abnormal, wide, and bizarre, resembling a ventricular beat. The QRS complexes usually have a left bundle branch block configuration since the ventricular lead is most commonly located in the right ventricle.</div><div id=\"graphicVersion\">Graphic 78390 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"78391":{"type":"graphic_diagnosticimage","displayName":"3-D ultrasound of club foot","title":"Three-dimensional ultrasound picture of a club foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-dimensional ultrasound picture of a club foot</div><div class=\"cntnt\"><img style=\"width:345px; height:438px;\" src=\"images/OBGYN/78391_U-S_club_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rendered three-dimensional image of a second trimester fetus. the lower legs are demonstrated. Both feet are abnormally positioned with the plane of the lower legs parallel to that of the sole of the foot. A fetus with the feet persistently in this position has bilateral talipes equinovarus, or bilateral clubfoot.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 78391 Version 3.0</div></div></div>"},"78392":{"type":"graphic_table","displayName":"Outcome surveil IA dysgerminoma","title":"Outcomes of surveillance for stage IA ovarian dysgerminoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of surveillance for stage IA ovarian dysgerminoma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Author, year\n   </td>\n   <td  class=\"subtitle1\">\n   Progression free survival/total (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   Overall survival/total (percent)\n   </td>\n   </tr>\n   <tr>\n   <td>Asadourian, LA; 1969</td>\n   <td>46/57 (80)</td>\n   <td>52/57 (91)</td>\n   </tr>\n   <tr>\n   <td>Krepart, G; 1978</td>\n   <td>5/5 (100)</td>\n   <td>5/5 (100)</td>\n   </tr>\n   <tr>\n   <td>Gordon, A; 1981</td>\n   <td>58/72 (80)</td>\n   <td>68/72 (95) (5-year)</td>\n   </tr>\n   <tr>\n   <td>Buskirk, SJ; 1987</td>\n   <td>12/16 (75)</td>\n   <td>16/16 (100) (5-year)</td>\n   </tr>\n   <tr>\n   <td>LaPolla, JP; 1987</td>\n   <td>7/7 (100)</td>\n   <td>7/7 (100)</td>\n   </tr>\n   <tr>\n   <td>Dark, GG; 1997</td>\n   <td>6/9 (66)</td>\n   <td>9/9 (100)</td>\n   </tr>\n   <tr>\n   <td>Vicus, D; 2010</td>\n   <td>18/23 (78)</td>\n   <td>23/23 (100)</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 78392 Version 1.0</div></div></div>"},"78394":{"type":"graphic_picture","displayName":"Vulvar incision drainage","title":"Vulvar incision and drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar incision and drainage</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/78394_Vulvar_incision_drainage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A generous incision overlying the left vulvar abscess has been made and drainage effected. The surgical site is now packed with gauze.</div><div class=\"graphic_reference\">Courtesy of Andrea R Thurman, MD.</div><div id=\"graphicVersion\">Graphic 78394 Version 2.0</div></div></div>"},"78396":{"type":"graphic_picture","displayName":"Type II hyperplasia in IPH","title":"Pathology of idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><img style=\"width:413px; height:277px;\" src=\"images/PULM/78396_Type_II_hyperplasia_in_IPH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunoperoxidase staining for cytokeratin number 7 (brown), performed on a transbronchial lung biopsy, demonstrates hyperplasia of type II pneumocytes.</div><div class=\"graphic_reference\">Courtesy of Per Praetorius Clausen, MD.</div><div id=\"graphicVersion\">Graphic 78396 Version 2.0</div></div></div>"},"78397":{"type":"graphic_table","displayName":"Risk stratification for syncope","title":"Risk stratification for syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk stratification for syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>SHORT-TERM HIGH RISK CRITERIA WHICH REQUIRE PROMPT HOSPITALIZATION OR INTENSIVE EVALUATION</strong></td> </tr> <tr> <td><strong>Severe structural or coronary artery disease</strong> (heart failure, low LVEF, or previous myocardial infarction)</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Clinical or ECG features suggesting arrhythmic syncope</strong></td> </tr> <tr> <td class=\"sublist1\">- Syncope during exertion or supine</td> </tr> <tr> <td class=\"sublist1\">- Palpitations at the time of syncope</td> </tr> <tr> <td class=\"sublist1\">- Family history of SCD</td> </tr> <tr> <td class=\"sublist1\">- Non-sustained VT</td> </tr> <tr> <td class=\"sublist1\">- Bifascicular-block (LBBB or RBBB combined with left anterior or left posterior fascicular block) or other intraventricular conduction abnormalities with QRS duration &#8805;120 ms</td> </tr> <tr> <td class=\"sublist1\">- Inadequate sinus bradycardia (&#60;50 bpm) or sinoartrial block in absence of negative chronotropic medications or physical training</td> </tr> <tr> <td class=\"sublist1\">- Pre-excited QRS complex</td> </tr> <tr> <td class=\"sublist1\">- Prolonged or short QT interval</td> </tr> <tr> <td class=\"sublist1\">- RBBB pattern with ST-elevation in leads V1-V3 (Brugada pattern)</td> </tr> <tr> <td class=\"sublist1\">- Negative T waves in right precordial leads, epsilon waves, and ventricular late potentials suggestive of ARVC</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Important co-morbidities</strong></td> </tr> <tr> <td class=\"sublist1\">- Severe anaemia</td> </tr> <tr> <td class=\"sublist1\">- Electrolyte disturbance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARVC: arrhythmogenic right ventricular cardiomyopathy; bpm: beats per minute; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; RBBB: right bundle branch block; SCD: sudden cardiac death; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 78397 Version 9.0</div></div></div>"},"78399":{"type":"graphic_figure","displayName":"Nonsense mutation","title":"Nonsense mutation","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Nonsense mutation</div><div class=\"cntnt\"><img style=\"width:478px; height:281px;\" src=\"images/ALLRG/78399_Nonsense_mutation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: United States National Library of Medicine. Available online at: http://ghr.nlm.nih.gov/handbook/illustrations/nonsense (Accessed on 1/12/2009).</div><div id=\"graphicVersion\">Graphic 78399 Version 1.0</div></div></div>"},"78401":{"type":"graphic_table","displayName":"Child-Pugh classification","title":"Child-Pugh classification of severity of cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Child-Pugh classification of severity of cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parameter</td> <td class=\"subtitle1\" colspan=\"3\">Points assigned</td> </tr> <tr> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> </tr> <tr> <td>Ascites</td> <td>Absent</td> <td>Slight</td> <td>Moderate</td> </tr> <tr> <td>Bilirubin</td> <td>&#60;2 mg/dL (&#60;34.2 micromol/L)</td> <td>2 to 3 mg/dL (34.2 to 51.3 micromol/L)</td> <td>&#62;3 mg/dL (&#62;51.3 micromol/L)</td> </tr> <tr> <td>Albumin</td> <td>&#62;3.5 g/dL (35 g/L)</td> <td>2.8 to 3.5 g/dL (28 to 35 g/L)</td> <td>&#60;2.8 g/dL (&#60;28 g/L)</td> </tr> <tr> <td colspan=\"4\">Prothrombin time</td> </tr> <tr> <td class=\"indent1\">Seconds over control</td> <td>&#60;4</td> <td>4 to 6</td> <td>&#62;6</td> </tr> <tr> <td class=\"indent1\">INR</td> <td>&#60;1.7</td> <td>1.7 to 2.3</td> <td>&#62;2.3</td> </tr> <tr> <td>Encephalopathy</td> <td>None</td> <td>Grade 1 to 2</td> <td>Grade 3 to 4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Modified Child-Pugh classification of the severity of liver disease according to the degree of ascites, the serum concentrations of bilirubin and albumin, the prothrombin time, and the degree of encephalopathy. A total Child-Turcotte-Pugh score of 5 to 6 is considered Child-Pugh class A (well-compensated disease); 7 to 9 is class B (significant functional compromise); and 10 to 15 is class C (decompensated disease). These classes correlate with one- and two-year patient survival: class A: 100 and 85%; class B: 80 and 60%; and class C: 45 and 35%.</div><div class=\"graphic_footnotes\">INR: international normalized ratio.</div><div id=\"graphicVersion\">Graphic 78401 Version 13.0</div></div></div>"},"78402":{"type":"graphic_movie","displayName":"MR due to mitral valve prolapse four chamber color Doppler echo","title":"Mitral valve prolapse with mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse with mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78402_4chcdmvpconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:249px; height:224px;\" src=\"images/CARD/78402_4chcdmvp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram with color flow Doppler shows significant mitral regurgitation due to a prolapse of the posterior leaflet of the mitral valve. As a result, the mitral regurgitation &quot;jet&quot; is directed anteriorly, toward the interatrial septum and aortic root.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 78402 Version 2.0</div></div></div>"},"78403":{"type":"graphic_figure","displayName":"Contraction relaxation cycle","title":"Role of adenosine triphosphate and calcium in the cross-bridge cycle","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Role of adenosine triphosphate and calcium in the cross-bridge cycle</div><div class=\"cntnt\"><img style=\"width:524px; height:273px;\" src=\"images/CARD/78403_Contraction_relaxation_cycl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cross-bridge cycle (eg, contraction and relaxation) begins when adenosine triphospate (ATP) binds to myosin, causing dissociation of the thick myosin and thin actin filaments and muscle relaxation. At step 1, hydrolysis of myosin bound ATP transfers the energy of the ATP molecule to the cross-bridge which remains in a relaxed, unattached, but energized state. Step 2 involves an interaction of the energized myosin cross-bridge with actin in the thin filament, leading to the formation of the actomyosin active complex in which the energy derived from ATP is still associated with the cross-bridge, which has yet to move. This step is regulated by the binding of troponin-C to calcium; such binding is controlled by the cytosolic calcium concentration. When the cytosolic calcium concentration is low, as in normal diastole, troponin-C has minimal or no calcium bound to it, the troponin-tropomyosin complex inhibits the formation of the actomyosin complex, and the myofilaments remain in a relaxed, but energized state. Systolic contraction is initiated by the release of calcium from the sarcoplasmic reticulum (SR); calcium binds to troponin C, the configuration of the troponin-tropomyosin complex changes, inhibition of the actin-myosin interaction is removed, and the active complex of actiomyosin is formed. At step 3, ATP is hypdrolyzed to adenosine diphosphate (ADP) and phosphate (P) and the energy produced results in motion of the cross bridges and mechanical work. For relaxation to occur (step 4), the actomyosin complex must be dissociated into actin and myosin by ATP which binds to the myosin head. Diastolic dysfunction and impaired relaxation can therefore result from ATP depletion or an inadequate lowering of cytosolic calcium during diastole.</div><div id=\"graphicVersion\">Graphic 78403 Version 1.0</div></div></div>"},"78404":{"type":"graphic_figure","displayName":"Spectrum of anorectal anatomy in the female","title":"Spectrum of anorectal anatomy in the female","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Spectrum of anorectal anatomy in the female</div><div class=\"cntnt\"><img style=\"width:491px; height:392px;\" src=\"images/PEDS/78404_Anterior_anus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Normal anatomy with anus in normal location and perineal body between anus and vagina. B) Severe anomaly with rectum ending high in the vagina. Arrowheads mark normal anal location. C) Low anomaly with rectoperineal fistula (fourchette ectopic anus), anterior to normal anal location. D) Intermediate position of anal opening in the perineum.</div><div class=\"graphic_reference\">Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright &#169;1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 78404 Version 2.0</div></div></div>"},"78405":{"type":"graphic_table","displayName":"Venous catheters according to age and weight","title":"Venous catheters according to age and weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Venous catheters according to age and weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age (Weight)</td> <td class=\"subtitle1\" colspan=\"5\">Venous catheters</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">French size</td> <td class=\"subtitle2\" rowspan=\"2\">Length</td> <td class=\"subtitle2\" colspan=\"2\">Wire diameter</td> <td class=\"subtitle2\" rowspan=\"2\">Needle gauge</td> </tr> <tr> <td class=\"subtitle3\">mm</td> <td class=\"subtitle3\">inches</td> </tr> <tr> <td>Newborn (4-8 kg)</td> <td>3.0</td> <td>5-12 cm</td> <td>0.46</td> <td>0.018</td> <td>21</td> </tr> <tr> <td>Infant [&#60;12 months] (5-15 kg)</td> <td>3.0-4.0</td> <td>5-12 cm</td> <td>0.46 to 0.53</td> <td>0.018 to 0.021</td> <td>21, 20, 18</td> </tr> <tr> <td>1 to &#60;8 years (10-30 kg)</td> <td>4.0-5.0</td> <td>5-25 cm</td> <td>0.53 to 0.89</td> <td>0.021 to 0.035</td> <td>20, 18</td> </tr> <tr> <td>&#8805;8 years (25-70 kg)</td> <td>5.0-8.0</td> <td>5-30 cm</td> <td>0.89</td> <td>0.035</td> <td>18, 16</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Chameides, L, Hazinski, MF (Eds). Pediatric Advanced Life Support, 3rd ed, American Heart Association, Dallas 1997.</div><div id=\"graphicVersion\">Graphic 78405 Version 2.0</div></div></div>"},"78406":{"type":"graphic_diagnosticimage","displayName":"M mode amyloid cardiomyopathy","title":"M-mode echocardiogram of amyloid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of amyloid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:279px; height:229px;\" src=\"images/CARD/78406_M_mode_amyloid_cardiomyopat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram in a patient with amyloid cardiomyopathy shows a small left ventricular (LV) cavity, brightly reflective myocardium, and markedly reduced systolic function.</div><div class=\"graphic_footnotes\">IVS: interventricular septum; PWLV: posterior wall of the LV.</div><div id=\"graphicVersion\">Graphic 78406 Version 2.0</div></div></div>"},"78408":{"type":"graphic_figure","displayName":"EtCO2 wave interpretation a","title":"Capnographic airway assessment for procedural sedation and analgesia","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Capnographic airway assessment for procedural sedation and analgesia</div><div class=\"cntnt\"><img style=\"width:601px; height:654px;\" src=\"images/EM/78408_EtCO2_wave_interpretation_a.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Krauss, B, Hess, DR. Capnography for Procedural Sedation and Analgesia in the Emergency Department. Annals of Emergency Medicine 2007; 50:172. Copyright &#169; 2007 The American College of Emergency Physicians.</div><div id=\"graphicVersion\">Graphic 78408 Version 2.0</div></div></div>"},"78409":{"type":"graphic_table","displayName":"Bisphos AI bone loss","title":"Use of bisphosphonates in women treated with AIs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of bisphosphonates in women treated with AIs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Trial</td> <td class=\"subtitle1\" rowspan=\"2\">N</td> <td class=\"subtitle1\" rowspan=\"2\">F/U (mo)</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment</td> <td class=\"subtitle1\" colspan=\"2\">Mean percentage difference in BMD between groups</td> <td class=\"subtitle1\" rowspan=\"2\">Fractures (percent)</td> </tr> <tr> <td class=\"subtitle2\">LS</td> <td class=\"subtitle2\">Hip</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Z-FAST</td> <td class=\"divider_bottom centered\" rowspan=\"3\">602</td> <td class=\"centered\">12</td> <td class=\"divider_bottom\" rowspan=\"3\">LET + ZA/D-ZA</td> <td>4.4 [p&#60;0.0001]</td> <td>3.3 [p&#60;0.0001]</td> <td>1.0 versus 0.7</td> </tr> <tr> <td class=\"centered\">36</td> <td>6.7 [p&#60;0.001]</td> <td>5.2 [p&#60;0.001]</td> <td>5.6 versus 6.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">61</td> <td>8.9 [p&#60;0.001]</td> <td>6.7 [p&#60;0.001]</td> <td>9.3 versus 11.0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">ZO-FAST</td> <td class=\"divider_bottom centered\" rowspan=\"2\">1065</td> <td class=\"centered\">12</td> <td class=\"divider_bottom\" rowspan=\"2\">LET + ZA/D-ZA</td> <td>5.7 [p&#60;0.0001]</td> <td>3.6 [p&#60;0.0001]</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">36</td> <td>9.3 [p&#60;0.0001]</td> <td>5.4 [p&#60;0.0001]</td> <td>5.0 versus 6.0</td> </tr> <tr> <td>SABRE</td> <td class=\"centered\">234</td> <td class=\"centered\">24</td> <td>ANA + R/Placebo</td> <td>4.0 [p&#60;0.0001]</td> <td>2.9 [p&#60;0.0001]</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LET: letrozole; F/U: follow-up; BMD: bone mineral density; ZA: zoledronic acid; D: delayed; ANA: anastrazole; R: risedronate.</div><div class=\"graphic_reference\">Modified with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28:967.</li>&#xD;&#xA;    <li>Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvent letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188.</li>&#xD;&#xA;    <li>Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright &copy; 2008 Adis Data Information BV.</div><div id=\"graphicVersion\">Graphic 78409 Version 7.0</div></div></div>"},"78410":{"type":"graphic_table","displayName":"Differential diagnosis of anaphylaxis in pregnancy","title":"Disorders that may mimic features of anaphylaxis during or after labor and delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that may mimic features of anaphylaxis during or after labor and delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Hypotension due to anesthesia</td> </tr> <tr> <td>Hypotension due to hemorrhage (eg, placenta previa, abruption, postpartum hemorrhage)</td> </tr> <tr> <td>Seizure or laryngeal edema associated with preeclampsia/eclampsia</td> </tr> <tr> <td>Acute pulmonary edema</td> </tr> <tr> <td>Amniotic fluid embolism</td> </tr> <tr> <td>Decompensation of underlying cardiovascular disorder (eg, cardiomyopathy, myocarditis, acute coronary syndrome, valvular disease [eg, mitral stenosis], tetralogy of Fallot, primary pulmonary hypertension, aortic dissection, Eisenmenger syndrome, Marfan syndrome, coarctation of the aorta)</td> </tr> <tr> <td>Stroke</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> <tr> <td>Septic shock</td> </tr> <tr> <td>Laryngopathia gravidarum</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597.</div><div id=\"graphicVersion\">Graphic 78410 Version 9.0</div></div></div>"},"78412":{"type":"graphic_table","displayName":"Fever and rash ddx by sign 1","title":"Differential diagnosis of fever and rash based upon accompanying signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fever and rash based upon accompanying signs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Arthritis or arthralgia</td> </tr> <tr> <td>Acute meningococcemia</td> </tr> <tr> <td>Allergic purpura</td> </tr> <tr> <td>Disseminated gonococcal infection</td> </tr> <tr> <td>Erythema marginatum (acute rheumatic fever)</td> </tr> <tr> <td>Hepatitis B virus, prodromal phase</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Parvovirus B19</td> </tr> <tr> <td>Reiter's syndrome</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Roseola (especially in adults)</td> </tr> <tr> <td>Rubella</td> </tr> <tr> <td>Serum sickness</td> </tr> <tr> <td>Still's disease</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Desquamation</td> </tr> <tr> <td><em>Arcanobacterium haemolyticum</em> infection</td> </tr> <tr> <td>Drug hypersensitivity</td> </tr> <tr> <td>Graft-versus-host reaction</td> </tr> <tr> <td>Kawasaki syndrome</td> </tr> <tr> <td>Measles</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Scarlet fever</td> </tr> <tr> <td>Staphylococcal scalded-skin syndrome</td> </tr> <tr> <td>Stevens-Johnson syndrome</td> </tr> <tr> <td>Toxic epidermal necrolysis</td> </tr> <tr> <td>Toxic shock syndrome</td> </tr> <tr> <td>von Zumbusch pustular psoriasis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lymphadenopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Cervical</td> </tr> <tr> <td class=\"indent1\">Kawasaki syndrome</td> </tr> <tr> <td class=\"indent1\">Rubella</td> </tr> <tr> <td class=\"indent1\">Scarlet fever</td> </tr> <tr> <td class=\"subtitle2_single\">Generalized</td> </tr> <tr> <td class=\"indent1\">Infectious mononucleosis</td> </tr> <tr> <td class=\"indent1\">Secondary syphilis</td> </tr> <tr> <td class=\"indent1\">Serum sickness</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"subtitle2_single\">Hilar</td> </tr> <tr> <td class=\"indent1\">Atypical measles</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Local</td> </tr> <tr> <td class=\"indent1\">Cat-scratch disease</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Meningitis</td> </tr> <tr> <td>Acute meningococcemia</td> </tr> <tr> <td>Cryptococcosis</td> </tr> <tr> <td>Enterovirus (Coxsackieviruses, echoviruses)</td> </tr> <tr> <td>Leptospirosis</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Secondary syphilis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Adapted with permission from Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Hurst JW (Ed). Medicine for the Practicing Physician., 3rd ed, Butterworth-Heinemann, Boston, 1992, p. 273.</div><div id=\"graphicVersion\">Graphic 78412 Version 2.0</div></div></div>"},"78415":{"type":"graphic_table","displayName":"Imatinib Rx advanced GIST","title":"Results of imatinib therapy for metastatic gastrointestinal stromal tumor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of imatinib therapy for metastatic gastrointestinal stromal tumor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Trial </td> <td class=\"subtitle1\" rowspan=\"2\">Phase </td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients </td> <td class=\"subtitle1\" rowspan=\"2\">Dose in, mg/day </td> <td class=\"subtitle1\" rowspan=\"2\">Follow-up, months </td> <td class=\"subtitle1\" colspan=\"4\">Best response, percent </td> </tr> <tr> <td class=\"subtitle2\">CR </td> <td class=\"subtitle2\">PR </td> <td class=\"subtitle2\">SD </td> <td class=\"subtitle2\">PFS, months </td> </tr> <tr> <td rowspan=\"2\">US Multicenter Blanke, C; 2008 </td> <td rowspan=\"2\">II </td> <td>73</td> <td>400</td> <td rowspan=\"2\">63 </td> <td>-</td> <td>61</td> <td rowspan=\"2\">16 </td> <td>20*</td> </tr> <tr> <td>74</td> <td>600</td> <td>3</td> <td>65</td> <td>26*</td> </tr> <tr> <td rowspan=\"2\">EORTC Verweij, J; 2004 </td> <td rowspan=\"2\">III </td> <td>470</td> <td>400</td> <td rowspan=\"2\">25 </td> <td rowspan=\"2\">5 </td> <td rowspan=\"2\">45 </td> <td rowspan=\"2\">32 </td> <td>2-year PFS 50%</td> </tr> <tr> <td>472</td> <td>800</td> <td>2-year PFS 56%</td> </tr> <tr> <td rowspan=\"2\">US Intergroup Blanke, C; 2008 </td> <td rowspan=\"2\">III </td> <td>361</td> <td>400</td> <td rowspan=\"2\">54 </td> <td rowspan=\"2\">- </td> <td rowspan=\"2\">43 </td> <td rowspan=\"2\">32 </td> <td>18</td> </tr> <tr> <td>360</td> <td>800</td> <td>20</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Median time to tumor progression (TTP) in months.</div><div class=\"graphic_footnotes\">CR: complete response; PR: partial response; SD: stable disease; PFS: progression-free survival; EORTC: European Organization for the Research and Treatment of Cancer.</div><div id=\"graphicVersion\">Graphic 78415 Version 2.0</div></div></div>"},"78417":{"type":"graphic_figure","displayName":"Effects n3 PUFA consumption","title":"Schema of potential dose responses and time courses for altering clinical events of physiologic effects of fish or fish oil intake","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Schema of potential dose responses and time courses for altering clinical events of physiologic effects of fish or fish oil intake</div><div class=\"cntnt\"><img style=\"width:600px; height:333px;\" src=\"images/PC/78417_Effects_n3_PUFA_consumption.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schema of physiologic effects of n-3 PUFA consumption. The relative strength of effect denotes the relative impact of n-3 PUFA consumption on the physiologic effect (eg, triglyceride-lowering). The time course to alter clinical events denotes the expected duration of consumption for the physiologic effect to alter disease outcomes. For example, the dose-response for antiarrhythmic effects appears to be initially steep with a subsequent plateau, and effects on disease outcomes may occur within weeks, whereas the dose-response for triglyceride-lowering is more gradual and monotonic, and effects on disease outcomes may require months or years of intake. Potentially important effects of n-3 PUFA on endothelial, autonomic, and antiinflammatory responses are not shown because the dose- and time-responses of these effects are not well-established. Physiologic effects are not necessarily exclusive: eg, antiarrhythmic effects may be partly mediated by effects on blood pressure (BP) or heart rate.</div><div class=\"graphic_reference\">Reproduced with permission from: Mozaffarian D, Rimm EB. Fish Intake, Contaminants, and Human Health. Evaluating the Risks and the Benefits. JAMA 2006; 296:1885. Copyright Â© 2006 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78417 Version 5.0</div></div></div>"},"78418":{"type":"graphic_figure","displayName":"Posterior dissection vulvectomy","title":"Posterior dissection for vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior dissection for vulvectomy</div><div class=\"cntnt\"><img style=\"width:253px; height:360px;\" src=\"images/OBGYN/78418_Posterior_dissection_vulvec.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78418 Version 2.0</div></div></div>"},"78420":{"type":"graphic_diagnosticimage","displayName":"Plastic deformation","title":"Plastic deformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plastic deformation</div><div class=\"cntnt\"><img style=\"width:285px; height:428px;\" src=\"images/EM/78420_Plastic_deformation_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plastic deformation (bowing deformity) of the right radius (arrow) and an oblique mid-diaphyseal ulnar fracture with posterior displacement of the distal fragment which is one shaft-width (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 78420 Version 3.0</div></div></div>"},"78421":{"type":"graphic_figure","displayName":"Slit lamp ocular lens","title":"Slit lamp ocular lens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slit lamp ocular lens</div><div class=\"cntnt\"><img style=\"width:432px; height:268px;\" src=\"images/EM/78421_Slit_lamp_ocular_lens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Set each ocular lens to &quot;0&quot; as shown here.</div><div id=\"graphicVersion\">Graphic 78421 Version 1.0</div></div></div>"},"78422":{"type":"graphic_table","displayName":"Differential diagnosis of nausea and vomiting","title":"Differential diagnosis of nausea and vomiting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of nausea and vomiting</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications and toxic etiologies</td> </tr> <tr> <td class=\"sublist1_start\">Cancer chemotherapy</td> </tr> <tr> <td class=\"sublist1\">Severe - cisplatinum, dacarbazine, nitrogen mustard</td> </tr> <tr> <td class=\"sublist1\">Moderate - etoposide, methotrexate, cytarabine</td> </tr> <tr> <td class=\"sublist1\">Mild -f luorouracil, vinblastine, tamoxifen</td> </tr> <tr> <td class=\"sublist1_start\">Analgesics</td> </tr> <tr> <td class=\"sublist1\">Aspirin</td> </tr> <tr> <td class=\"sublist1\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist1\">Auranofin</td> </tr> <tr> <td class=\"sublist1\">Antigout drugs</td> </tr> <tr> <td class=\"sublist1_start\">Cardiovascular medications</td> </tr> <tr> <td class=\"sublist1\">Digoxin</td> </tr> <tr> <td class=\"sublist1\">Antiarrhythmics</td> </tr> <tr> <td class=\"sublist1\">Antihypertensives</td> </tr> <tr> <td class=\"sublist1\">Beta blockers</td> </tr> <tr> <td class=\"sublist1\">Calcium channel antagonists</td> </tr> <tr> <td>Diuretics</td> </tr> <tr> <td class=\"sublist1_start\">Hormonal preparations/therapies</td> </tr> <tr> <td class=\"sublist1\">Oral antidiabetics</td> </tr> <tr> <td class=\"sublist1\">Oral contraceptives</td> </tr> <tr> <td class=\"sublist1_start\">Antibiotics/antivirals</td> </tr> <tr> <td class=\"sublist1\">Erythromycin</td> </tr> <tr> <td class=\"sublist1\">Tetracycline</td> </tr> <tr> <td class=\"sublist1\">Sulfonamides</td> </tr> <tr> <td class=\"sublist1\">Antituberculous drugs</td> </tr> <tr> <td class=\"sublist1\">Acyclovir</td> </tr> <tr> <td class=\"sublist1_start\">Gastrointestinal medications</td> </tr> <tr> <td class=\"sublist1\">Sulfasalazine</td> </tr> <tr> <td class=\"sublist1\">Azathioprine</td> </tr> <tr> <td class=\"sublist1_start\">Nicotine</td> </tr> <tr> <td class=\"sublist1_start\">CNS active drugs</td> </tr> <tr> <td class=\"sublist1\">Narcotics</td> </tr> <tr> <td class=\"sublist1\">Antiparkinsonian drugs</td> </tr> <tr> <td class=\"sublist1\">Anticonvulsants</td> </tr> <tr> <td class=\"sublist1_start\">Antiasthmatics</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1_start\">Radiation therapy</td> </tr> <tr> <td class=\"sublist1\">Ethanol abuse</td> </tr> <tr> <td class=\"sublist1\">Jamaican vomiting sickness</td> </tr> <tr> <td class=\"sublist1\">Hypervitaminosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious causes</td> </tr> <tr> <td class=\"sublist1_start\">Gastroenteritis</td> </tr> <tr> <td class=\"sublist1\">Viral</td> </tr> <tr> <td class=\"sublist1\">Bacterial</td> </tr> <tr> <td>Nongastrointestinal infections</td> </tr> <tr> <td class=\"sublist1\">Otitis media</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of the gut and peritoneum</td> </tr> <tr> <td class=\"sublist1_start\">Mechanical obstruction</td> </tr> <tr> <td class=\"sublist1\">Gastric outlet obstruction</td> </tr> <tr> <td class=\"sublist1\">Small bowel obstruction</td> </tr> <tr> <td>Functional gastrointestinal disorders</td> </tr> <tr> <td>Gastroparesis</td> </tr> <tr> <td>Chronic intestinal pseudo-obstruction</td> </tr> <tr> <td>Nonulcer dyspepsia</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Organic gastrointestinal disorders</td> </tr> <tr> <td class=\"sublist1\">Pancreatic adenocarcinoma</td> </tr> <tr> <td class=\"sublist1\">Inflammatory intraperitoneal disease</td> </tr> <tr> <td class=\"sublist1\">Peptic ulcer disease</td> </tr> <tr> <td class=\"sublist1\">Cholecystitis</td> </tr> <tr> <td class=\"sublist1\">Pancreatitis</td> </tr> <tr> <td class=\"sublist1\">Hepatitis</td> </tr> <tr> <td class=\"sublist1\">Crohn disease</td> </tr> <tr> <td class=\"sublist1\">Mesenteric ischemia</td> </tr> <tr> <td class=\"sublist1\">Retroperitoneal fibrosis</td> </tr> <tr> <td class=\"sublist1\">Mucosal metastases</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CNS causes</td> </tr> <tr> <td>Migraine</td> </tr> <tr> <td class=\"sublist1_start\">Increased intracranial pressure</td> </tr> <tr> <td class=\"sublist1\">Malignancy</td> </tr> <tr> <td class=\"sublist1\">Hemorrhage</td> </tr> <tr> <td class=\"sublist1\">Infarction</td> </tr> <tr> <td class=\"sublist1\">Abscess</td> </tr> <tr> <td class=\"sublist1\">Meningitis</td> </tr> <tr> <td class=\"sublist1\">Congenital malformation</td> </tr> <tr> <td class=\"sublist1\">Hydrocephalus</td> </tr> <tr> <td class=\"sublist1\">Pseudotumor cerebri</td> </tr> <tr> <td>Seizure disorders</td> </tr> <tr> <td>Demyelinating disorders</td> </tr> <tr> <td>Cranial radiation</td> </tr> <tr> <td>Emotional responses</td> </tr> <tr> <td class=\"sublist1_start\">Psychiatric disease</td> </tr> <tr> <td class=\"sublist1\">Psychogenic vomiting</td> </tr> <tr> <td class=\"sublist1\">Anxiety disorders</td> </tr> <tr> <td class=\"sublist1\">Depression</td> </tr> <tr> <td class=\"sublist1\">Pain</td> </tr> <tr> <td class=\"sublist1\">Anorexia nervosa</td> </tr> <tr> <td class=\"sublist1\">Bulimia nervosa</td> </tr> <tr> <td class=\"sublist1_start\">Labyrinthine disorders</td> </tr> <tr> <td class=\"sublist1\">Motion sickness</td> </tr> <tr> <td class=\"sublist1\">Labyrinthitis</td> </tr> <tr> <td class=\"sublist1\">Tumors</td> </tr> <tr> <td class=\"sublist1\">M&#233;ni&#232;re disease</td> </tr> <tr> <td class=\"sublist1\">Iatrogenic</td> </tr> <tr> <td class=\"sublist1\">Fluorescein angiography</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrinologic and metabolic causes</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td class=\"sublist1_start\">Other endocrine and metabolic</td> </tr> <tr> <td class=\"sublist1\">Uremia</td> </tr> <tr> <td class=\"sublist1\">Diabetic ketoacidosis</td> </tr> <tr> <td class=\"sublist1\">Hyperparathyroidism</td> </tr> <tr> <td class=\"sublist1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"sublist1\">Hyperthyroidism</td> </tr> <tr> <td class=\"sublist1\">Addison's disease</td> </tr> <tr> <td class=\"sublist1\">Acute intermittent porphyria</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td>Postoperative nausea and vomiting</td> </tr> <tr> <td>Cyclic vomiting syndrome&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac disease</td> </tr> <tr> <td class=\"sublist1\">Myocardial infarction</td> </tr> <tr> <td class=\"sublist1\">Heart failure</td> </tr> <tr> <td class=\"sublist1\">Radiofrequency ablation of the liver</td> </tr> <tr> <td>Starvation</td> </tr> <tr> <td>Radiation therapy to the upper abdomen and lower chest</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2001; 120:263.</div><div id=\"graphicVersion\">Graphic 78422 Version 8.0</div></div></div>"},"78423":{"type":"graphic_table","displayName":"Etiology of acute pancreatitis","title":"Etiology of acute pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of acute pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Mechanical</td> <td>Gallstones, biliary sludge, ascariasis, periampullary diverticulum, pancreatic or periampullary cancer, ampullary stenosis, duodenal stricture or obstruction</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Toxic</td> <td>Ethanol, methanol, scorpion venom, organophosphate poisoning</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Metabolic</td> <td>Hyperlipidemia (types I, IV, V), hypercalcemia</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Drugs</td> <td>Didanosine, pentamidine, metronidazole, stibogluconate, tetracycline furosemide, thiazides, sulphasalazine, 5-ASA, L-asparaginase, azathioprine, valproic acid, sulindac, salicylates, calcium, estrogen</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" rowspan=\"4\">Infection</td> <td>Viruses-mumps, coxsackie, hepatitis B, CMV, varicella-zoster, HSV, HIV</td> </tr> <tr> <td>Bacteria-mycoplasma, Legionella, Leptospira, salmonella</td> </tr> <tr> <td>Fungi-aspergillus</td> </tr> <tr> <td>Parasites-toxoplasma, cryptosporidium, Ascaris</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Trauma</td> <td>Blunt or penetrating abdominal injury, iatrogenic injury during surgery or ERCP (sphincterotomy)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Congenital</td> <td>Cholodochocele type V, ? pancreas divisum</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Vascular</td> <td>Ischemia, atheroembolism, vasculitis (polyarteritis nodosa, SLE)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Miscellaneous</td> <td>Post ERCP, pregnancy, renal transplantation, alpha-1-antitrypsin deficiency</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Genetic</td> <td>CFTR and other genetic mutations</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">5-ASA: 5-aminosalicylic acid; CMV: cytomegalovirus; HSV: herpes simplex virus; HIV: human immunodeficiency virus; ERCP: endoscopic retrograde cholangiopancreatography; SLE: systemic lupus erythematosus; CFTR: cystic fibrosis transmembrane conductance regulator.</div><div id=\"graphicVersion\">Graphic 78423 Version 3.0</div></div></div>"},"78424":{"type":"graphic_table","displayName":"ACC AHA ESC drugs maintain NSR","title":"ACC/AHA/ESC guideline summary: Maintenance of sinus rhythm in atrial fibrillation (AF)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/ESC guideline summary: Maintenance of sinus rhythm in atrial fibrillation (AF)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class I - There is evidence and/or\ngeneral agreement that the following approach is effective for the\nmaintenance of sinus rhythm in patients with AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Treatment of precipitating or reversible causes of AF before initiating therapy with antiarrhythmic drugs.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class IIa - The weight of evidence\nor opinion is in favor of the usefulness of the following approaches\nfor the maintenance of sinus rhythm in patients with AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Antiarrhythmic drug therapy to maintain sinus rhythm and prevent tachycardia-induced cardiomyopathy.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Infrequent, well tolerated recurrent episodes of recurrent AF is reasonable as a successful outcome of antiarrhythmic drug therapy.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Outpatient initiation of therapy in patients with no associated heart disease when the antiarrhythmic drug is well tolerated.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; In patients with lone AF and no structural heart disease, outpatient initiation of propafenone or flecainide therapy in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Sotalol in outpatients in sinus rhythm who have little or no heart disease, are prone to paroxysmal AF, a baseline uncorrected QT interval less than 460 msec, normal serum electrolytes, and no risk factors for class III drug-related proarrhythmia.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Catheter ablation as an alternative to antiarrhythmic drug therapy to prevent recurrent AF in symptomatic patients with little or no left atrial enlargement.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class III - There is evidence and/or\ngeneral agreement that the following approaches are not useful or may\nbe harmful for the maintenance of sinus rhythm in patients with AF</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Use of a particular antiarrhythmic drug is not recommended in patients with well-defined risk factors for proarrhythmia with that drug.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; Antiarrhythmic drug therapy is not recommended in patients with advanced sinus node disease or atrioventricular node dysfunction unless they have a functioning electronic cardiac pacemaker.</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.</div><div id=\"graphicVersion\">Graphic 78424 Version 2.0</div></div></div>"},"78425":{"type":"graphic_figure","displayName":"Blood lactate during exercise","title":"Lactate threshold during exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lactate threshold during exercise</div><div class=\"cntnt\"><img style=\"width:413px; height:324px;\" src=\"images/PULM/78425_Blood_lactate_during_exerci.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the normal blood lactate - oxygen uptake (VO<sub>2</sub>) relationship during incremental exercise. The lactate threshold (LT) denotes the onset of a sustained rise in blood lactate.</div><div id=\"graphicVersion\">Graphic 78425 Version 2.0</div></div></div>"},"78426":{"type":"graphic_table","displayName":"Signs of nutritional deficiency","title":"Physical signs of selected nutritional deficiency states","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical signs of selected nutritional deficiency states</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Signs </td> <td class=\"subtitle1\">Deficiencies </td> </tr> <tr> <td rowspan=\"5\">Hair </td> <td>Alopecia</td> <td>Severe undernutrition, zinc deficiency</td> </tr> <tr> <td>Brittle</td> <td>Biotin, severe undernutrition</td> </tr> <tr> <td>Color change</td> <td>Severe undernutrition</td> </tr> <tr> <td>Dryness</td> <td>Vitamins E and A</td> </tr> <tr> <td>Easy pluckability</td> <td>Severe undernutrition</td> </tr> <tr> <td rowspan=\"10\">Skin </td> <td>Acneiform lesions</td> <td>Vitamin A</td> </tr> <tr> <td>Follicular keratosis</td> <td>Vitamin A</td> </tr> <tr> <td>Xerosis (dry skin)</td> <td>Vitamin A</td> </tr> <tr> <td>Perioral and perianal bullous dermatitis (wet, flaming red plaques)</td> <td>Zinc</td> </tr> <tr> <td>Ecchymosis</td> <td>Vitamin C or K</td> </tr> <tr> <td>Intradermal petechiae</td> <td>Vitamin C or K</td> </tr> <tr> <td>Erythema (especially where exposed to sunlight)</td> <td>Niacin</td> </tr> <tr> <td>Hyperpigmentation</td> <td>Niacin</td> </tr> <tr> <td>Seborrheic dermatitis (nose, eyebrows, eyes)</td> <td>Vitamin B2, Vitamin B6, Niacin</td> </tr> <tr> <td>Scrotal dermatitis</td> <td>Niacin, Vitamin B2, Vitamin B6</td> </tr> <tr> <td rowspan=\"4\">Eyes </td> <td>Angular palpebritis</td> <td>Vitamin B2</td> </tr> <tr> <td>Corneal revascularization</td> <td>Vitamin B2</td> </tr> <tr> <td>Bitot's spots</td> <td>Vitamin A</td> </tr> <tr> <td>Conjunctival xerosis, keratomalacia</td> <td>Vitamin A</td> </tr> <tr> <td rowspan=\"6\">Mouth </td> <td>Angular stomatitis</td> <td>Vitamin B2, Vitamin B6, Vitamin B12</td> </tr> <tr> <td>Atrophic papillae</td> <td>Niacin</td> </tr> <tr> <td>Bleeding gums</td> <td>Vitamin C</td> </tr> <tr> <td>Cheilosis</td> <td>Vitamin B2, Vitamin B6</td> </tr> <tr> <td>Glossitis</td> <td>Niacin, Folate, Vitamin B1 (thiamine), Vitamin B2, Vitamin B6, Vitamin B12</td> </tr> <tr> <td>Magenta tongue</td> <td>Vitamin B2</td> </tr> <tr> <td rowspan=\"2\">Extremities </td> <td>Genu valgum or varum, metaphyseal widening</td> <td>Vitamin D</td> </tr> <tr> <td>Loss of deep tendon reflexes of the lower extremities</td> <td>Vitamins B1 and B12</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Vitamin B1: thiamine; Vitamin B2: riboflavin; Vitamin B3: niacin; Vitamin B6: pyridoxine; Vitamin B12: cyanocobalamin.</div><div class=\"graphic_reference\">Adapted from: Bernard MA, Jacobs DO, Rombeau JL. Nutrition and Metabolic Support of Hospitalized Patients. WB Saunders, Philadelphia 1986.</div><div id=\"graphicVersion\">Graphic 78426 Version 7.0</div></div></div>"},"78428":{"type":"graphic_table","displayName":"Resource use in children with liver or spleen injury","title":"Guidelines for resource utilization in children with isolated liver or spleen injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for resource utilization in children with isolated liver or spleen injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">CT grade</td> </tr> <tr> <td class=\"subtitle2\">I</td> <td class=\"subtitle2\">II</td> <td class=\"subtitle2\">III</td> <td class=\"subtitle2\">IV</td> </tr> <tr> <td>ICU stay (d)</td> <td>None</td> <td>None</td> <td>None</td> <td>1</td> </tr> <tr> <td>Hospital stay (d)</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> </tr> <tr> <td>Predischarge imaging</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td>Postdischarge imaging</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td>Activity restriction (wk)*</td> <td>3</td> <td>4</td> <td>5</td> <td>6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; ICU: intensive care unit.<br> * Return to normal age-appropriate activity; return to competitive contact sports should be individualized.</div><div class=\"graphic_reference\">Reproduced from: Stylianos S. Evidence-based guidelines for resource utilization in children with isolated spleen or liver injury. J Pediatr Surg 2000; 35:164. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78428 Version 2.0</div></div></div>"},"78429":{"type":"graphic_table","displayName":"NCEP: Adult treatment panel III risk factors","title":"National Cholesterol Education Program (NCEP): Adult treatment panel III risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Cholesterol Education Program (NCEP): Adult treatment panel III risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Positive risk factors</td> </tr> <tr> <td class=\"indent1\">Age: Male &#8805;45, female &#8805;55 or premature menopause without estrogen replacement therapy</td> </tr> <tr> <td class=\"indent1\">Family history of premature coronary heart disease: Definite myocardial infarction or sudden death before age 55 years in male first-degree relative and before age 65 in female first-degree relative</td> </tr> <tr> <td class=\"indent1\">Current cigarette smoking</td> </tr> <tr> <td class=\"indent1\">Hypertension: Blood pressure &#62;140/90 mmHg or an antihypertensive medication</td> </tr> <tr> <td class=\"indent1\">HDL cholesterol &#60;40 mg/dL (1.03 mmol/L)*</td> </tr> <tr> <td class=\"subtitle1_single\">Negative risk factors<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">HDL cholesterol &#8805;60 mg/dL (1.55 mmol/L)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Status based on presence of risk factors other than LDL cholesterol.</div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; LDL: low-density lipoprotein.<br />* Confirmed by measurements on several occasions.<br />Â¶ If the HDL cholesterol level is &gt;60 mg/dL, subtract one risk factor.</div><div class=\"graphic_reference\">Data from: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.</div><div id=\"graphicVersion\">Graphic 78429 Version 5.0</div></div></div>"},"78430":{"type":"graphic_figure","displayName":"Foot amputations","title":"Foot amputations","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Foot amputations</div><div class=\"cntnt\"><img style=\"width:528px; height:309px;\" src=\"images/SURG/78430_Foot-amputations.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78430 Version 3.0</div></div></div>"},"78432":{"type":"graphic_figure","displayName":"Tonic pupil right eye","title":"Tonic pupil in right eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tonic pupil in right eye</div><div class=\"cntnt\"><img style=\"width:400px; height:485px;\" src=\"images/NEURO/78432_Tonic_pupil_right_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical features of a tonic pupil are seen in the right eye. The photos were made with a prism to bring the eyes closer together. Pupil size asymmetry (anisocoria) is greater in light, particularly in bright light. The tonic right pupil constricts poorly to light and better to near (light-near dissociation). The tonic pupil also demonstrates denervation supersensitivity to low-dose pilocarpine by constricting better than the fellow left pupil.</div><div class=\"graphic_reference\">Courtesy of Andrew G Lee, MD and Paul W Brazis, MD.</div><div id=\"graphicVersion\">Graphic 78432 Version 1.0</div></div></div>"},"78433":{"type":"graphic_table","displayName":"ACOG two step approach for screening and diagnosis of GDM","title":"ACOG two-step approach for screening and diagnosis of gestational diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACOG two-step approach for screening and diagnosis of gestational diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Step one</td> </tr> <tr> <td class=\"indent1\">1. Give 50-gram oral glucose load without regard to time of day</td> </tr> <tr> <td class=\"indent1\">2. Measure plasma or serum glucose</td> </tr> <tr> <td class=\"indent1\">3. Glucose &#8805;135 mg/dL (7.5 mmol/L) or &#8805;140 mg/dL (7.8 mmol/L) is elevated and requires administration of a 100-gram oral glucose tolerance test*. The lower threshold provides greater sensitivity, but would result in more false positives and would require administering the full glucose tolerance test to more patients than the 140 mg/dL threshold. The lower threshold should be considered in populations with higher prevalence of gestational diabetes. </td> </tr> <tr> <td class=\"subtitle1_single\">Step two</td> </tr> <tr> <td class=\"indent1\">1. Measure fasting serum or plasma glucose concentration</td> </tr> <tr> <td class=\"indent1\">2. Give 100-gram oral glucose load</td> </tr> <tr> <td class=\"indent1\">3. Measure plasma or serum glucose at one, two, and three hours after glucose load</td> </tr> <tr> <td class=\"indent1\">4. A positive test is generally defined by elevated glucose concentrations at two or more time points (either Carpenter and Coustan thresholds or National Diabetes Data Group thresholds can be used). In 2017, ACOG stated that even one abnormal value may be used for the diagnosis of GDM.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACOG: American College of Obstetricians and Gynecologists.<br />*Some experts use a threshold of 130 mg/dL (7.2 mmol/L)</div><div class=\"graphic_reference\">Data from: American College of Obstetricians and Gynecologists. Practice&nbsp;Bulletin&nbsp;No. 180:&nbsp;Gestational diabetes&nbsp;mellitus. Committee on&nbsp;Practice&nbsp;BulletinsâObstetrics. Obstet Gynecol&nbsp;2017;1 30:e17.</div><div id=\"graphicVersion\">Graphic 78433 Version 15.0</div></div></div>"},"78434":{"type":"graphic_figure","displayName":"Tumor spread into leptomeningeal space","title":"Pathophysiology of tumor spread into the leptomeningeal space","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of tumor spread into the leptomeningeal space</div><div class=\"cntnt\"><img style=\"width:541px; height:586px;\" src=\"images/ONC/78434_Tumor_spread_leptomenin_spa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure at the left illustrates a metastasis to the skull (A), with cells infiltrating through the dura into the subarachnoid space (B), and subsequently down the virchow-Robin spaces into the brain (C). Cells may also be found circulating in the blood as seen in the sagittal sinus (D). The figure at the right illustrates tumor cells entering the subarachnoid space from the vertebral body through connecting blood vessels (E) or from the paravertebral space along nerve sheaths (F).</div><div class=\"graphic_reference\">Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.</div><div id=\"graphicVersion\">Graphic 78434 Version 2.0</div></div></div>"},"78436":{"type":"graphic_table","displayName":"Comparison of ventilation","title":"Volume cycled versus pressure controlled ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Volume cycled versus pressure controlled ventilation</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Volume cycled</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Advantages</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Guaranteed tidal volume and VE</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Clinician familiarity</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Disadvantages</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Airway pressures not controlled</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Worse patient tolerance</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Pressure controlled</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Advantages</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Airway pressures controlled</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Better patient tolerance</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Disadvantages</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Less clinician familiarity</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">VT and VE not guaranteed</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78436 Version 1.0</div></div></div>"},"78437":{"type":"graphic_diagnosticimage","displayName":"Endoscopic ultrasound image of a gallstone in the gallbladder","title":"Endoscopic ultrasound image of a gallstone in the gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound image of a gallstone in the gallbladder</div><div class=\"cntnt\"><img style=\"width:324px; height:316px;\" src=\"images/GAST/78437_EUS_gallstone_in_gallbladde.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 78437 Version 3.0</div></div></div>"},"78439":{"type":"graphic_waveform","displayName":"Advanced case 13","title":"Advanced case 13","html":"<div class=\"graphic normal\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Advanced case 13</div><div class=\"cntnt\"><img style=\"width:505px; height:127px;\" src=\"images/CARD/78439_Advanced_case_13.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78439 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"78440":{"type":"graphic_table","displayName":"Lung cancer risk Hodgkin lymphoma","title":"Relative risk of developing lung cancer in Hodgkin lymphoma by treatment modality and smoking status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk of developing lung cancer in Hodgkin lymphoma by treatment modality and smoking status</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Radiation</td> <td class=\"subtitle1\">Alkylating agent</td> <td class=\"subtitle1\">Smoking</td> <td class=\"subtitle1\">Relative risk*</td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>1<sup>&#182;</sup></td> </tr> <tr> <td>&ndash;</td> <td>+</td> <td>&ndash;</td> <td>4.3 (2 to 12)</td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td>+</td> <td>6 (2 to 20)</td> </tr> <tr> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> <td>7.2 (3 to 21)</td> </tr> <tr> <td>+</td> <td>+</td> <td>&ndash;</td> <td>7.2 (3 to 22)</td> </tr> <tr> <td>&ndash;</td> <td>+</td> <td>+</td> <td>16.8 (6 to 53)</td> </tr> <tr> <td>+</td> <td>&ndash;</td> <td>+</td> <td>20.2 (7 to 68)</td> </tr> <tr> <td>+</td> <td>+</td> <td>+</td> <td>49.1 (15 to 187)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Radiation: radiation &ge;5 Gy to specific location in the lung where cancer was diagnosed. Smoking: estimated smoking habit five years before diagnosis date of lung cancer. Smokers include those smoking one or more packs of cigarettes per day. Those smoking less than this amount, former cigarette smokers, and smokers of pipes or cigars were considered to be non-smokers in this analysis.</div><div class=\"graphic_footnotes\">* Relative risk of developing lung cancer is shown with 95 percent confidence interval in parentheses.<br />&para; Reference group.</div><div class=\"graphic_reference\">Data from: Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.</div><div id=\"graphicVersion\">Graphic 78440 Version 5.0</div></div></div>"},"78443":{"type":"graphic_picture","displayName":"Postoperative nipple inversion","title":"Postoperative nipple inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative nipple inversion</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/78443_Post_surg_nipple_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative inversion of the nipple can occur with reduction mammoplasty. The breast may pull on the nipple-areola complex leading to inversion, particularly if the nipple was inverted or flat initially.</div><div id=\"graphicVersion\">Graphic 78443 Version 2.0</div></div></div>"},"78444":{"type":"graphic_picture","displayName":"Hamstring strength testing with IR","title":"Hamstring strength testing with internal rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hamstring strength testing with internal rotation</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/EM/78444_Hamstr_strength_test_IR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Testing hamstring strength with the leg internally rotated accentuates the stress placed upon the semitendinosus and semimembranosus muscles.</div><div class=\"graphic_reference\">Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.</div><div id=\"graphicVersion\">Graphic 78444 Version 1.0</div></div></div>"},"78445":{"type":"graphic_figure","displayName":"Construction of a loop colostomy- defunctionalized distal limb","title":"Construction of a loop colostomy- defunctionalized distal limb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a loop colostomy- defunctionalized distal limb</div><div class=\"cntnt\"><img style=\"width:361px; height:355px;\" src=\"images/SURG/78445_Loop-colostomy-.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the matured loop colostomy with an everted proximal limb and defunctionalized distal limb. Full-thickness distal bowel is sutured to the dermis of the skin. The proximal functioning limb is constructed by suturing the end of the full-thickness bowel wall to the seromuscular layer 3 cm proximal to the colotomy, then suturing to the dermis of the skin.</div><div id=\"graphicVersion\">Graphic 78445 Version 1.0</div></div></div>"},"78446":{"type":"graphic_picture","displayName":"Prominent occiput with pediatric airway obstruction","title":"Prominent occiput with pediatric airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Prominent occiput with pediatric airway obstruction</div><div class=\"cntnt\"><img style=\"width:514px; height:211px;\" src=\"images/EM/78446_Prominent_occiput.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Without support under the shoulders, the prominent occiput causes the head to flex forward and obstruct the airway in this sedated&nbsp;infant&nbsp;(A). With a shoulder roll in place, the airway is now in neutral position and&nbsp;clear (B).</div><div class=\"graphic_reference\">Reproduced from: Santillanes, G, Gausche-Hill, M. Pediatric airway management. Emerg Med Clin North Am 2008; 26:961. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78446 Version 2.0</div></div></div>"},"78452":{"type":"graphic_figure","displayName":"Reduced dialysis delivery","title":"Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output, recirculation, and low mass transfer coefficient for urea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output, recirculation, and low mass transfer coefficient for urea</div><div class=\"cntnt\"><img style=\"width:442px; height:258px;\" src=\"images/NEPH/78452_Reduced_dialysis_delivery.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of increasing dialyzer blood flow (Qb) on total body urea clearance (K<SUB>tb</SUB>) during hemodialysis. The top curve (Kd) represents the ideal curve in which all of the dialysis prescription is delivered. The lower curves reflect the progressive decrease in K<SUB>tb</SUB> induced by the sequential addition of a low cardiac output (Q<SUB>co</SUB> = 5 L/min); plus a high access blood flow (Q<SUB>ac</SUB> = 50% Q<SUB>co</SUB>); plus 15% access recirculation; plus a low rate of urea equilibration from the tissues (low MTC<SUB>urea</SUB>).</div><div class=\"graphic_footnotes\">K<SUB innerHtml>tb</SUB>: total body urea clearance; Qb: blood flow; Kd: dialyzer clearance; Q<SUB innerHtml>co</SUB>: cardiac output; Q<SUB innerHtml>ac: </SUB>access blood flow; AR: access recirculation; MTC<SUB innerHtml>urea</SUB>: mass transfer coefficient for urea.</div><div id=\"graphicVersion\">Graphic 78452 Version 4.0</div></div></div>"},"78453":{"type":"graphic_waveform","displayName":"Acute anterior MI tutorial","title":"Acute transmural anterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Acute transmural anterior wall myocardial infarction</div><div class=\"cntnt\"><img style=\"width:511px; height:146px;\" src=\"images/CARD/78453_Acute_anterior_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST elevation in some or all of the precordial leads is characteristic of an acute anterior wall infarct.</div><div id=\"graphicVersion\">Graphic 78453 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"78455":{"type":"graphic_table","displayName":"Lab diagnosis fibrinolysis","title":"Laboratory diagnosis of abnormal fibrinolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory diagnosis of abnormal fibrinolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Primary hyperfibrinolysis</td> <td class=\"subtitle1\">DIC</td> <td class=\"subtitle1\">TTP</td> </tr> <tr> <td>Platelet count</td> <td>Normal</td> <td>Decreased</td> <td>Decreased</td> </tr> <tr> <td>Fibrinogen</td> <td>Decreased</td> <td>Decreased</td> <td>Normal</td> </tr> <tr> <td>FDP</td> <td>Increased</td> <td>Increased</td> <td>Normal</td> </tr> <tr> <td>D-dimer</td> <td>Increased</td> <td>Increased</td> <td>Normal</td> </tr> <tr> <td>Antithrombin</td> <td>Normal</td> <td>Decreased</td> <td>Normal</td> </tr> <tr> <td>Schistocytes</td> <td>Absent</td> <td>Present</td> <td>Present</td> </tr> <tr> <td>Plasma clotting times*</td> <td>Normal or prolonged</td> <td>Prolonged</td> <td>Normal</td> </tr> <tr> <td>Euglobulin lysis time</td> <td>Shortened</td> <td>Shortened</td> <td>Normal</td> </tr> <tr> <td>ADAMTS13 level</td> <td>Normal</td> <td>Normal<sup>&#182;</sup></td> <td>Low (usually &#60;10 percent)<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on disorders of fibrinolysis, DIC, and TTP for additional details.</div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation; TTP: thrombotic thrombocytopenic purpura; FDP: fibrinogen degradation products; ADAMTS13: von Willebrand factor-cleaving protease (A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).<br />* Clotting times include the prothrombin time with international normalized ratio (PT/INR) and the activated partial thromboplastin time (aPTT).<br />Â¶ May be reduced when bacterial sepsis is present.<br />Î A normal plasma ADAMTS13 level does not exclude the diagnosis of TTP.</div><div class=\"graphic_reference\">Modified with permission from: Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica 1998; 83:1024. Copyright &copy; 1998 Ferrata Storti Foundation.</div><div id=\"graphicVersion\">Graphic 78455 Version 7.0</div></div></div>"},"78456":{"type":"graphic_algorithm","displayName":"Emergent ear pain in children","title":"Emergent diagnoses associated with ear pain in children","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Emergent diagnoses associated with ear pain in children</div><div class=\"cntnt\"><img style=\"width:542px; height:421px;\" src=\"images/EM/78456_Emergent_dx_ear_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TM: tympanic membrane.</div><div id=\"graphicVersion\">Graphic 78456 Version 5.0</div></div></div>"},"78459":{"type":"graphic_table","displayName":"Nasoenteric tube complications","title":"Potential nasoenteric tube complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential nasoenteric tube complications</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Arrhythmia</td>\n\n\n</tr>\n<tr>\n<td>Empyema</td>\n\n\n</tr>\n<tr>\n<td>Gastric perforation</td>\n\n\n</tr>\n<tr>\n<td>Myocardial infarction</td>\n\n\n</tr>\n<tr>\n<td>Otitis media</td>\n\n\n</tr>\n<tr>\n<td>Pulmonary intubation</td>\n\n\n</tr>\n<tr>\n<td>Rupture and leakage of mercury weight</td>\n\n\n</tr>\n<tr>\n<td>Tube feeding into pulmonary tree</td>\n\n\n</tr><tr><td>Clogging</td></tr><tr><td>Epistaxsis</td></tr><tr><td>Gastrointestinal bleeding</td></tr><tr><td>Nasal mucosal ulceration</td></tr><tr><td>Pneumothorax</td></tr><tr><td>Pyriform sinus perforation</td></tr><tr><td>Tracheobronchial trauma</td></tr><tr><td>Tube dislodgment</td></tr><tr><td>Duodenal perforation</td></tr><tr><td>Esophageal perforation</td></tr><tr><td>Knotted tubes</td></tr><tr><td>Nasal trauma</td></tr><tr><td>Pulmonary aspiration</td></tr><tr><td>Reflux esophagitis, ulceration, or stricture</td></tr><tr><td>Tracheoesophageal fistula</td></tr><tr><td>Tube obstruction</td></tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Kahrilas PJ, Clouse RE, Hogan WG. American Gastroenterological Association technical review on the clinical use of esophageal manometry. Gastroenterology 1994; 107:1865.</div><div id=\"graphicVersion\">Graphic 78459 Version 2.0</div></div></div>"},"78460":{"type":"graphic_picture","displayName":"Perianal fistula Crohn disease","title":"Perianal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal fistula</div><div class=\"cntnt\"><img style=\"width:373px; height:274px;\" src=\"images/GAST/78460_Perianal_fistula_Crohns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal fistula in a patient with Crohn disease. Scarring and deformity from previous fistulas is also apparent.</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 78460 Version 2.0</div></div></div>"},"78462":{"type":"graphic_table","displayName":"Beighton Score for joint hypermobility","title":"Beighton score for joint hypermobility*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Beighton score for joint hypermobility*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Ability to:</td> <td class=\"subtitle1\">Left</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Right</td> </tr> <tr> <td>Passively dorsiflex the fifth metacarpophalangeal joint by at least 90 degrees</td> <td>1</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td>Oppose the thumb to the volar aspect of the ipsilateral forearm</td> <td>1</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td>Hyperextend the elbow&nbsp;by at least 10 degress</td> <td>1</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td>Hyperextend the knee by at least 10 degrees</td> <td>1</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td>Place the hands flat on the floor without bending the knees</td> <td>&nbsp;</td> <td>1</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One point is scored for each of the maneuvers above. A total of nine points is achievable, and four or more points is considered an indication of generalized joint hypermobility.</div><div id=\"graphicVersion\">Graphic 78462 Version 3.0</div></div></div>"},"78463":{"type":"graphic_table","displayName":"Foods that make UC worse PI","title":"List of foods that can make ulcerative colitis symptoms worse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">List of foods that can make ulcerative colitis symptoms worse</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Milk, yogurt, cheese and other dairy products</td> </tr> <tr> <td>Coffee, tea, soda, and other foods that have caffeine</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Fruit and juice</td> </tr> <tr> <td>Fried, fatty, and spicy foods</td> </tr> <tr> <td>Whole-grain and multigrain breads</td> </tr> <tr> <td>Condiments (such as ketchup or mustard) and salad dressings</td> </tr> <tr> <td>Some vegetables, including cabbage, broccoli and cauliflower</td> </tr> <tr> <td>Red meat</td> </tr> <tr> <td>Beans</td> </tr> <tr> <td>Artificial colors, flavors and sweeteners</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78463 Version 1.0</div></div></div>"},"78464":{"type":"graphic_algorithm","displayName":"Algorithm treatment HBV children","title":"Algorithm for selection of children for HBV antiviral treatment","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Algorithm for selection of children for HBV antiviral treatment</div><div class=\"cntnt\"><img style=\"width:606px; height:434px;\" src=\"images/PEDS/78464_Algo_tx_HBV_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; HBsAg: hepatitis B s antigen; ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; HBeAb: hepatitis B e antibody; DNA: deoxyribonucleic acid; IU: international unit; ULN: upper limit of normal; HCC: hepatocellular carcinoma; AST: aspartate aminotransferase&nbsp;.<br />* The upper limit of normal (ULN) for ALT in children is not well-established; it varies with the testing laboratory and the age of the child. For the purposes of HBV monitoring, we suggest that a child's ALT be considered elevated if it is greater than the ULN established by the testing laboratory, or &gt;40 IU/L, whichever is lower. For older adolescents, we suggest using 30 IU/L for males and 19 IU/L for females (the same ULN used for adults).<br />Â¶ For patients in the immune tolerant and inactive chronic HBV phases, we suggest monitoring liver biochemical tests (ALT and AST) every 6 to 12 months, and HBeAg and HBeAb every 12 months. If the ALT becomes elevated, HBV DNA should be measured.<br />Î Because of limited options with current drugs, it may be appropriate to treat older adolescents with immune active HBV with one of these newer agents using adult protocols, or to enroll children in clinical trials of newer agents, or even withhold treatment until the patient is old enough to be treated as adults (if liver fibrosis is only mild).</div><div class=\"graphic_reference\">Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology 2010. Copyright &copy; 2010 American Association for the Study of Liver Diseases. Reproduced with permission from John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 78464 Version 7.0</div></div></div>"},"78465":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of normal three-vessel cord","title":"Ultrasound image of a normal three-vessel umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of a normal three-vessel umbilical cord</div><div class=\"cntnt\"><img style=\"width:383px; height:576px;\" src=\"images/OBGYN/78465_US_normal_3v_cord_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-sectional image of the umbilical cord at 18 weeks of gestation shows two arteries (arrows) and one vein (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 78465 Version 6.0</div></div></div>"},"78466":{"type":"graphic_picture","displayName":"Serum sickness-like reaction","title":"Serum sickness-like reaction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serum sickness-like reaction</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78466_Serum_sickness_like_react.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous plaques are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78466 Version 3.0</div></div></div>"},"78468":{"type":"graphic_table","displayName":"Street names phencyclidine","title":"Street names for phencyclidine (PCP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Street names for phencyclidine (PCP)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pill or powder form</td> </tr> <tr> <td>Angel dust</td> </tr> <tr> <td>Boat</td> </tr> <tr> <td>Crystal</td> </tr> <tr> <td>Dust</td> </tr> <tr> <td>Dusting</td> </tr> <tr> <td>Elephant tranquilizer</td> </tr> <tr> <td>Hog</td> </tr> <tr> <td>Horse tranquilizer</td> </tr> <tr> <td>Little ones</td> </tr> <tr> <td>Live ones</td> </tr> <tr> <td>Love boat</td> </tr> <tr> <td>Ozone</td> </tr> <tr> <td>PCE</td> </tr> <tr> <td>Peace pill</td> </tr> <tr> <td>Porker</td> </tr> <tr> <td>Purple rain</td> </tr> <tr> <td>Rocket fuel</td> </tr> <tr> <td>Sherms</td> </tr> <tr> <td>TCP</td> </tr> <tr> <td>Tic tac</td> </tr> <tr> <td>Whack</td> </tr> <tr> <td>Wickey</td> </tr> <tr> <td>Worm</td> </tr> <tr> <td>Zombie</td> </tr> <tr> <td>Zoot</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Combined with Marijuana</td> </tr> <tr> <td>Crystal super grass</td> </tr> <tr> <td>Embalming fluid</td> </tr> <tr> <td>Fry</td> </tr> <tr> <td>Green leaves</td> </tr> <tr> <td>Killer joints</td> </tr> <tr> <td>Killer weed</td> </tr> <tr> <td>KJ</td> </tr> <tr> <td>Super weed</td> </tr> <tr> <td>Wets</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78468 Version 4.0</div></div></div>"},"78470":{"type":"graphic_figure","displayName":"Normal hair cycle","title":"Hair-growth cycle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hair-growth cycle</div><div class=\"cntnt\"><img style=\"width:504px; height:271px;\" src=\"images/PC/78470_Normal_hair_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal human hair cycle.</div><div class=\"graphic_reference\">Reproduced with permission from: Sinclair RD, Thai KE. Chapter 18: Male androgenetic alopecia. In: Endocrinology of the Male Reproductive System, McLachlan R (Ed). Copyright Â© 2004 www.endotext.org.</div><div id=\"graphicVersion\">Graphic 78470 Version 3.0</div></div></div>"},"78476":{"type":"graphic_table","displayName":"Risk ben ESA RBC","title":"Comparison of risks and benefits of erythropoiesis-stimulating agents (ESAs) versus red blood cell (RBC) transfusion for chemotherapy-related anemia in patients with solid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of risks and benefits of erythropoiesis-stimulating agents (ESAs) versus red blood cell (RBC) transfusion for chemotherapy-related anemia in patients with solid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">ESAs</td> <td class=\"subtitle1\">RBC transfusion</td> </tr> <tr> <td>Risks</td> <td> <p>Thrombotic events<sup>*</sup></p> Potentially decreased survival<sup>*</sup></td> <td> <p>Transfusion reactions<sup>&#182;</sup></p> <p>Circulatory overload</p> <p>Viral infection<sup>&#916;</sup></p> <p>Iron overload</p> Development of multiple alloantibodies</td> </tr> <tr> <td>Benefits</td> <td> <p>Gradual improvement in hemoglobin/hematocrit</p> <p>Gradual clinical improvement</p> <p>Avoidance of RBC transfusions in some patients</p> Net reduction in transfusion requirements<sup>&#9674;</sup></td> <td> <p>Rapid improvement in hemoglobin/hematocrit</p> Rapid clinical improvement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In trials where target hemoglobin was &gt;12 g/dL.<br />Â¶ Febrile nonhemolytic reactions (1:100); hemolytic reactions (1:19,000); transfusion-related acute lung injury (1:1000-1:5000).<br />Î Hepatitis B, Hepatitis C, HIV.<br /><FONT class=lozenge>â</FONT> Average 1 unit per person.</div><div id=\"graphicVersion\">Graphic 78476 Version 4.0</div></div></div>"},"78478":{"type":"graphic_figure","displayName":"Color Doppler HCM with MR and LVOT obstruction","title":"Color Doppler echocardiography showing left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR) in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color Doppler echocardiography showing left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR) in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:299px; height:266px;\" src=\"images/CARD/78478_HCMcolorflowDoppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical view from a two-dimensional echocardiogram with color flow Doppler in a patient with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction shows turbulence in the outflow tract caused by contact between the anterior mitral valve leaflet and the interventricular septum. As a consenquence of the systolic anterior motion of the mitral valve, there is abnormal coaptation of the mitral leaflets, resulting in a posteriorly directed jet of mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Perry Elliot, MD.</div><div id=\"graphicVersion\">Graphic 78478 Version 3.0</div></div></div>"},"78479":{"type":"graphic_picture","displayName":"Intrauterine sucking lesion","title":"Intrauterine sucking lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intrauterine sucking lesions</div><div class=\"cntnt\"><img style=\"width:324px; height:397px;\" src=\"images/PEDS/78479_Intrauterinesuckinglesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intrauterine sucking lesions can be seen in the dorsum of the fingers, hand, or radial aspect of the wrist of newborn infants. The lesions may appear as ruptured (pictured above) or intact vesicles. They can be multiple, unilateral, or bilateral. Rarely, they may have a hemorrhagic component.</div><div class=\"graphic_reference\">Courtesy of Gerardo A Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 78479 Version 3.0</div></div></div>"},"78481":{"type":"graphic_picture","displayName":"Eyelid lesion in blastomycosis","title":"Disseminated blastomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated blastomycosis</div><div class=\"cntnt\"><img style=\"width:242px; height:360px;\" src=\"images/ID/78481_Eyelid_lesion_in_blastomyco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular lesion of the left upper eyelid with a granular surface due to disseminated blastomycosis.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 78481 Version 6.0</div></div></div>"},"78486":{"type":"graphic_figure","displayName":"Modified Martius fat pad graft5","title":"Modified Martius fat pad graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Martius fat pad graft</div><div class=\"cntnt\"><img style=\"width:405px; height:405px;\" src=\"images/OBGYN/78486_Modified_Martius_fat_pad_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The labial incision is closed in two layers.</div><div id=\"graphicVersion\">Graphic 78486 Version 1.0</div></div></div>"},"78487":{"type":"graphic_picture","displayName":"Ingrown toenail PI","title":"Ingrown toenail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ingrown toenail</div><div class=\"cntnt\"><img style=\"width:396px; height:338px;\" src=\"images/PI/78487_Ingrown_toenail_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You can get an&nbsp;ingrown toenail if the side or corner of your toenail grows into the flesh of that toe.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78487 Version 3.0</div></div></div>"},"78490":{"type":"graphic_table","displayName":"Signs of adrenal crisis","title":"Clinical and laboratory findings suggesting adrenal crisis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory findings suggesting adrenal crisis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Dehydration, hypotension, or shock out of proportion to severity of\ncurrent illness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nausea and vomiting with a history of weight loss and anorexia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal pain, so-called \"acute abdomen\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unexplained hypoglycemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unexplained fever</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyponatremia, hyperkalemia, azotemia, hypercalcemia, or eosinophilia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperpigmentation or vitiligo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other autoimmune endocrine deficiencies, such as hypothyroidism or gonadal failure</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985; 14:947.</div><div id=\"graphicVersion\">Graphic 78490 Version 3.0</div></div></div>"},"78492":{"type":"graphic_picture","displayName":"Bivalving of torsed ovary 3","title":"The same ovary seen later in situ with a normal appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The same ovary seen later in situ with a normal appearance</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/OBGYN/78492_Bivalvingoftorsedovary3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78492 Version 12.0</div></div></div>"},"78493":{"type":"graphic_table","displayName":"AC regimen for breast cancer","title":"Doxorubicin and cyclophosphamide (AC) chemotherapy for breast cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin and cyclophosphamide (AC) chemotherapy for breast cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 4 cycles (in the adjuvant setting).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5% dextrose in water (D5W). If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclophosphamide</td> <td>600 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Not applicable. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment is not necessary for doxorubicin in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin and cyclophosphamide may be needed. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>A baseline assessment of LVEF is recommended, with periodic reassessment of during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin.<sup>[2]</sup> Further information on anthracycline-associated cardiotoxicity, including discussion about prevention and treatment, is available. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cumulative doxorubicin dose should be monitored. As appropriate, assess cardiac function prior to initiation of AC then periodically during treatment. For patients receiving AC for metastatic disease, consider the addition of dexrazoxane after 300 mg/m<sup>2</sup> total dose. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/microL and platelet count greater than 100,000/microL. If there is more than a three week delay in treatment, a dose reduction of 25% is recommended.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for hepatic or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin and cyclophosphamide in patients who have changes in kidney or liver function during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fisher B, et al. J Clin Oncol 1990; 8:1483. </LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011). </LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011). </LI></OL></div><div id=\"graphicVersion\">Graphic 78493 Version 24.0</div></div></div>"},"78494":{"type":"graphic_figure","displayName":"Balloon tamponade to manage liver injury","title":"Balloon tamponade to manage liver injury","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Balloon tamponade to manage liver injury</div><div class=\"cntnt\"><img style=\"width:461px; height:500px;\" src=\"images/SURG/78494_Balloon-tamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A tamponade device is passed through the parenchymal tract and inflated. The end of the device is brought through the abdominal wall via a separate stab wound. Prior to deflation of the balloon, hepatic arteriography with embolization can be performed, if needed.</div><div id=\"graphicVersion\">Graphic 78494 Version 3.0</div></div></div>"},"78495":{"type":"graphic_figure","displayName":"Reduction of proteinuria on renal survival in IgA nephropathy","title":"Effect of reduction of proteinuria on renal survival in IgA nephropathy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Effect of reduction of proteinuria on renal survival in IgA nephropathy</div><div class=\"cntnt\"><img style=\"width:468px; height:431px;\" src=\"images/NEPH/78495_Reduction_proteinuria.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impact of reduction of proteinuria on renal survival. Patients attaining partial remission (&lt;1 g/d), regardless of peak proteinuria, had a similar favorable outcome (NS). Group 1, 1 to 2 g/d peak proteinuria; group 2, 2 to 3 g/d peak proteinuria; group 3, &gt;3 g/d peak proteinuria. p = NS.</div><div class=\"graphic_reference\">Reproduced with permission from: Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18:3177. Copyright &#169; 2007 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 78495 Version 3.0</div></div></div>"},"78496":{"type":"graphic_figure","displayName":"Microsporidiosis spores","title":"Microsporidiosis spores","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microsporidiosis spores</div><div class=\"cntnt\"><img style=\"width:339px; height:381px;\" src=\"images/ID/78496_Microsporidiosis_spores.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microsporidia spores on stool swabs stained with modified Weber's trichrome.</div><div class=\"graphic_reference\">Reproduced from: Anane S, Attouchi H. Microsporidiosis: epidemiology, clinical data and therapy. Gastroenterologie Clinique et Biologique 2010; 34:450. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78496 Version 2.0</div></div></div>"},"78497":{"type":"graphic_picture","displayName":"Bacillary angiomatosis","title":"Cutaneous lesion of bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous lesion of bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/78497_Bacillary_angiomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bacillary angiomatosis presenting as a purplish-black vascular nodule.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78497 Version 5.0</div></div></div>"},"78498":{"type":"graphic_figure","displayName":"Abdominal perineal resection","title":"Abdominal perineal resection - Anatomic outline for resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal perineal resection - Anatomic outline for resection</div><div class=\"cntnt\"><img style=\"width:435px; height:545px;\" src=\"images/SURG/78498_APR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the segments of the colon and rectum resected for an abdominal perineal resection (APR). An APR is most commonly performed for low lying rectal cancer, anal cancer, Crohn's proctitis, or ulcerative colitis.</div><div id=\"graphicVersion\">Graphic 78498 Version 1.0</div></div></div>"},"78500":{"type":"graphic_table","displayName":"B cell surface markers I","title":"Surface markers during B cell development-I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surface markers during B cell development-I</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Antigen-independent phase</td> <td class=\"subtitle1\" colspan=\"4\">Antigen-dependent phase</td> </tr> <tr> <td class=\"subtitle2\">Pre-pro B cell</td> <td class=\"subtitle2\">Pro-B cell</td> <td class=\"subtitle2\">Pre B cell</td> <td class=\"subtitle2\">Immature B cell</td> <td class=\"subtitle2\">Mature B cell</td> <td class=\"subtitle2\">Activated B cell</td> <td class=\"subtitle2\">Blast B cell</td> <td class=\"subtitle2\">Memory B cell</td> <td class=\"subtitle2\">Plasma B cell</td> </tr> <tr> <td>MHC Class II</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD10</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>CD19</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD20</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD21</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>CD23</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>CD25, IL-2R alpha</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>CD32, Fc gamma RII</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD34</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>CD35, CR1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD40</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>CD80/86, B7-1/2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IL: interleukin; R: receptor; alpha: alpha chain.</div><div class=\"graphic_reference\">Data from Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102 (no table number).</div><div id=\"graphicVersion\">Graphic 78500 Version 2.0</div></div></div>"},"78501":{"type":"graphic_figure","displayName":"Identification of the thoracodorsal bundle","title":"Identification of the thoracodorsal bundle","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Identification of the thoracodorsal bundle</div><div class=\"cntnt\"><img style=\"width:485px; height:557px;\" src=\"images/SURG/78501_ID_thoracodorsal_bundle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axillary vein has been exposed on its anterior surface, and dissection is carried out approximately 5 mm below the vein to expose the thoracodorsal bundle.</div><div class=\"graphic_reference\">Modified with permission from: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78501 Version 3.0</div></div></div>"},"78502":{"type":"graphic_picture","displayName":"Beau line on the toe","title":"Beau line","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beau line</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/78502_Beaulineonthetoe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transverse groove on the nail plate is a Beau line.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78502 Version 7.0</div></div></div>"},"78503":{"type":"graphic_table","displayName":"Recommended dosing with United States standardized extracts","title":"Recommended dosing with United States standardized extracts<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dosing with United States standardized extracts<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergen</td> <td class=\"subtitle1\">Extracts available</td> <td class=\"subtitle1\">Dosing by average major allergen content</td> <td class=\"subtitle1\">Dosing recommended in practice parameters</td> </tr> <tr> <td>Short ragweed</td> <td>1:10 w/v (100,000 AU/mL)</td> <td>2500 AU</td> <td>1000 to 4000 AU</td> </tr> <tr> <td><em>Dermatophagoides pteronyssinus</em></td> <td>3000, 5000, 10,000, and 30,000 AU/mL</td> <td>1000 AU</td> <td>500 to 2000 AU</td> </tr> <tr> <td><em>Dermatophagoides farinae</em></td> <td>3000, 5000, 10,000, and 30,000 AU/mL</td> <td>1500 AU</td> <td>500 to 2000 AU</td> </tr> <tr> <td>Cat hair or pelt</td> <td>5000 and 10,000 BAU/mL</td> <td>3750 BAU</td> <td>1000 to 4000 BAU</td> </tr> <tr> <td>Timothy grass</td> <td>100,000 BAU/mL</td> <td>3000 BAU</td> <td>1000 to 4000 BAU</td> </tr> <tr> <td>Bermuda grass</td> <td>10,000 BAU/mL</td> <td>1000 BAU</td> <td>300 to 1500 BAU</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">w/v: weight/volume; AU: allergy unit; BAU: bioequivalent allergy unit.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-55.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 78503 Version 9.0</div></div></div>"},"78504":{"type":"graphic_table","displayName":"Classification of stem cells","title":"Classification of stem cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of stem cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of cell</td> <td class=\"subtitle1\">Capable of producing</td> <td class=\"subtitle1\">Example</td> </tr> <tr> <td>Totipotent</td> <td>Embryonic and extraembryonic tissues</td> <td>Within the first few cell divisions of the zygote</td> </tr> <tr> <td>Pluripotent</td> <td>Any cell in the body including germ cells</td> <td>Inner cell mass of the blastocyst, embryonic stem cells, embryonic germ cells, induced pluripotent cells</td> </tr> <tr> <td>Multipotent</td> <td>Restricted to a given germ layer or tissue cell type</td> <td>Hematopoietic stem cells</td> </tr> <tr> <td>Unipotent</td> <td>Restricted to a specific cell lineage</td> <td>Germ cell stem cells</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78504 Version 1.0</div></div></div>"},"78508":{"type":"graphic_table","displayName":"Objectives of mechanical vent","title":"Objectives of mechanical ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Objectives of mechanical ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Physiologic objectives</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Support pulmonary gas exchange based on alveolar ventilation and arterial oxygenation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduce the metabolic cost of breathing by unloading the ventilatory muscles</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Minimize ventilator-induced lung injury</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Clinical objectives</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reverse hypoxemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reverse acute respiratory acidosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Relieve respiratory distress</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prevent or reverse atelectasis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reverse ventilatory muscle fatigue</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Permit sedation and/or neuromuscular blockade</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decrease systemic or myocardial oxygen consumption</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stabilize the chest wall</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Slutsky, AS, Chest 1993; 104:1833.</div><div id=\"graphicVersion\">Graphic 78508 Version 1.0</div></div></div>"},"78511":{"type":"graphic_figure","displayName":"Intermediate case 4 with answer","title":"Wolff-Parkinson-White pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wolff-Parkinson-White pattern</div><div class=\"cntnt\"><img style=\"width:352px; height:295px;\" src=\"images/CARD/78511_Intermediate_case_4_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Precordial leads in a patient with preexcitation due to the WPW syndrome. The three characteristic findings are the short PR interval (0.09 sec in this case), the wide QRS, and the delta wave (slurring of the QRS upstroke) that is best seen in leads V5 and V6 (arrows).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 78511 Version 1.0</div></div></div>"},"78513":{"type":"graphic_table","displayName":"Diagnostic criteria for obsessive-compulsive disorder","title":"Diagnostic criteria for obsessive-compulsive disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for obsessive-compulsive disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">1. Either obsessions or compulsions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Obsessions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Recurrent thoughts, impulses or images that cause\nmarked anxiety or distress, are experienced as intrusive, go beyond\nexcessive worry about real-life problems, and are not related to\nanother mental disorder (eg, are not limited to thoughts about food in a person\nwith anorexia nervosa).</td>\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n      <td class=\"sublist1\">Compulsions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Ritualistic behaviors or mental acts that are performed\nin response to an obsession or need to be rigidly carried out. These\nbehaviors are excessive and performed to decrease anxiety or distress\nor avoid some dreaded event, but they are not realistically connected\nto those dreaded events.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. The obsessions or compulsions are time-consuming\n(more than one hour per day), cause clinically significant distress, or\ninterfere with a person's daily routine and occupational or social\nfunctioning.</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58552&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Dx_obsessive_compulsive_dis.htm</title></head></div><div class=\"graphic_reference\">Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.</div><div id=\"graphicVersion\">Graphic 78513 Version 2.0</div></div></div>"},"78514":{"type":"graphic_picture","displayName":"Nikolsky sign","title":"Nikolsky sign","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nikolsky sign</div><div class=\"cntnt\"><img style=\"width:540px; height:400px;\" src=\"images/PC/78514_Nikolsky_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B show the Nikolsky sign elicited by rubbing the skin at the periphery of an existing lesion. Panels C and D show the Nikolsky sign elicited by rubbing the normal-appearing skin distant from the lesions. These two methods appear to have different sensitivity and specificity for pemphigus.</div><div class=\"graphic_reference\">Reproduced with permission from: Uzun S, Durdu M. The specificity and sensitivity of Nikolsky sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411. Copyright Â© 2006 The American Academy of Dermatology.</div><div id=\"graphicVersion\">Graphic 78514 Version 3.0</div></div></div>"},"78516":{"type":"graphic_table","displayName":"Sudden sensorineural loss","title":"Main causes of sudden sensorineural hearing loss (SSNHL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Main causes of sudden sensorineural hearing loss (SSNHL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Viral cochleitis associated with herpesviruses, parainfluenza virus, influenza, mumps, measles, rubella, or HIV; bacterial meningitis; <em>Mycoplasma pneumoniae</em> infection; Lyme disease; tuberculosis, syphilis, or fungal infection</td> </tr> <tr> <td class=\"subtitle1_single\">Ototoxic drugs</td> </tr> <tr> <td>Aminoglycosides, vancomycin, erythromycin, loop diuretics, antimalarials, cisplatin, sildenafil, cocaine</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasms</td> </tr> <tr> <td>Acoustic neurinoma; meningeal carcinomatosis; lymphoma, leukemia, or plasma cell dyscrasia</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td>Head injury, barotraumas; noise exposure</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disease</td> </tr> <tr> <td>Autoimmune inner ear disease; Cogan's syndrome; Susac syndrome; systemic lupus erythematosus; antiphospholipid antibody sydrome; rheumatoid arthritis; Sj&#246;gren's syndrome; relapsing polychondritis; vasculitides (polyarteritis nodosa, Beh&#231;et's syndrome, Kawasaki disease, granulomatosis with polyangiitis [Wegener's], temporal arteritis, or primary central nervous system vasculititis)</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular disorder</td> </tr> <tr> <td>Vertebrobasilar cerebrovascular accident or transient ischemic attack; cerebellar infarction; inner ear hemorrhage</td> </tr> <tr> <td class=\"subtitle1_single\">Varied causes</td> </tr> <tr> <td>Meniere disease, otosclerosis; Paget disease; multiple sclerosis; sarcoidosis; hypothroidism; idiopathic SSNHL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In many of the conditions listed, SSNHL can be the presenting manifestation of the disease. Sometimes, both ears may be affected simultaneously.</div><div class=\"graphic_reference\">Reproduced with permission from: Schattner A, Halperin D, Wolf D, Zimhony O. Enteroviruses and sudden deafness. CMAJ 2003; 168:1421. Copyright Â© 2003 Canadian Medical Association.</div><div id=\"graphicVersion\">Graphic 78516 Version 10.0</div></div></div>"},"78517":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 8","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:443px; height:294px;\" src=\"images/OBGYN/78517_Tx_post_vaginal_wall_def_8.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a transverse defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 78517 Version 2.0</div></div></div>"},"78518":{"type":"graphic_table","displayName":"Ewing tumor immunohistochemistry","title":"Immunohistochemical staining in the differential diagnosis of Ewing sarcoma family of tumors and other small round blue cell tumors of childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical staining in the differential diagnosis of Ewing sarcoma family of tumors and other small round blue cell tumors of childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Marker</td> <td class=\"subtitle1\" colspan=\"2\">Ewing's sarcoma</td> <td class=\"subtitle1\" rowspan=\"2\">PNET</td> <td class=\"subtitle1\" rowspan=\"2\">Neuro-blastoma</td> <td class=\"subtitle1\" rowspan=\"2\">Rhabdomyo-sarcoma</td> <td class=\"subtitle1\" rowspan=\"2\">Lymphoma*</td> </tr> <tr> <td class=\"subtitle2\">Typical</td> <td class=\"subtitle2\">Atypical</td> </tr> <tr> <td>NSE</td> <td>&ndash;</td> <td>+/&ndash;</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>S-100</td> <td>_</td> <td>+/&ndash;</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>NFTP</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;/+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Desmin</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;/+</td> <td>+</td> <td>+</td> <td>&ndash;</td> </tr> <tr> <td>Actin</td> <td>&ndash;</td> <td>&ndash;</td> <td>+/&ndash;</td> <td>&ndash;</td> <td>+</td> <td>&ndash;</td> </tr> <tr> <td>Vimentin</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Cytokeratin</td> <td>+/&ndash;</td> <td>+/&ndash;</td> <td>+/&ndash;</td> <td>&ndash;</td> <td>+/&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>LCA</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;/+</td> <td>&ndash;</td> <td>&ndash;</td> <td>+</td> </tr> <tr> <td>HNK&ndash;1</td> <td>+/&ndash;</td> <td>+/&ndash;</td> <td>+</td> <td>+</td> <td>+</td> <td>&ndash;</td> </tr> <tr> <td>&#946;2-microglobulin</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;<sup>&#182;</sup></td> <td>+/&ndash;</td> <td>+</td> </tr> <tr> <td>HBA71</td> <td>+</td> <td>+</td> <td>+/&ndash;</td> <td>&ndash;</td> <td>+<sup>&#916;</sup></td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PNET: primitive neuroectodermal tumor; â: negative; +/â: positive in greater than 10 percent of cases; â/+: positive in less than 10 percent of cases; +: positive; NSE: neuron specific enolase; LCA: leucocyte common antigen.<br />* Nonhistiocytic.<br />Â¶ Only in ganglion cells, Schwann cells, and stage IVS.<br />Î Only well-differentiated rhabdomyoblasts.</div><div class=\"graphic_reference\">Reproduced with permission from: Ginsberg JP, Woo SY, Johnson ME, et al. Ewing's sarcoma familiy of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 78518 Version 12.0</div></div></div>"},"78521":{"type":"graphic_diagnosticimage","displayName":"Pilocytic astrocytoma","title":"Magnetic resonance image (MRI) of pilocytic astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image (MRI) of pilocytic astrocytoma</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PEDS/78521_Juv_pilocytic_astrocytoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1 post-contrast MRI of a pilocytic astrocytoma (large cystic mass with a mural nodule, arrow) in the posterior fossa.</div><div id=\"graphicVersion\">Graphic 78521 Version 6.0</div></div></div>"},"78522":{"type":"graphic_figure","displayName":"Pectus severity index","title":"Measurement of the pectus severity index","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measurement of the pectus severity index</div><div class=\"cntnt\"><img style=\"width:313px; height:497px;\" src=\"images/PEDS/78522_Pectusseverityindex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pectus severity index (PSI), also known as Haller index,&nbsp;in a normal chest (PSI&nbsp;â¤2.5) and in a patient with severe pectus excavatum (PSI = 3.5). The PSI is the&nbsp;ratio of the lateral diameter of the chest&nbsp;to the distance between the sternum and spine at the point of maximal depression (or A/B in the figure above). </div><div class=\"graphic_reference\">Courtesy of Dr. Oscar H Mayer.</div><div id=\"graphicVersion\">Graphic 78522 Version 3.0</div></div></div>"},"78524":{"type":"graphic_picture","displayName":"Acrochordon thigh","title":"Acrochordon  (skin tag or soft fibroma) of the thigh","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrochordon  (skin tag or soft fibroma) of the thigh</div><div class=\"cntnt\"><img style=\"width:328px; height:347px;\" src=\"images/OBGYN/78524_acrochordon_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission fromÂ Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 78524 Version 4.0</div></div></div>"},"78525":{"type":"graphic_table","displayName":"Healthy weight parent tips","title":"Tips for maintaining a healthy weight: tips for parents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: tips for parents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Be a good role model.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Children learn by example. Eat a variety of healthful foods and be physically active every day so that your children will learn healthful habits.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Offer structured meals and snacks.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Most children need food every 4 - 5 hours. Three meals and one snack time is appropriate for most school-aged children. Discourage between meal \"grazing.\" Plan meals and snacks ahead of time.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Disband the \"clean plate\" club.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Children are born with an innate sense of when they have had enough to eat. Encouraging them to eat past the point of fullness will result in weight gain.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Never use food as a reward or punishment.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Food is for nourishing and fueling bodies. Instead, use non-food rewards such as special time spent together.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Remember the rules.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Parents should be responsible for offering healthy foods and structured meals and snacks. Children should decide how much they eat. Be consistent.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Choosing a weight maintenance program.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">The program should:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Be staffed with a variety of health professionals. The best\nprograms include pediatric dietitians, exercise physiologists,\nphysicians, and psychiatrists or psychologists.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Perform in depth medical assessment and medical monitoring.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Focus on the whole family, and not just the overweight child.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Be adapted to the specific age and capabilities of the child.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Focus on behavior changes including appropriate diet and physical activity.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Include a maintenance program or other support and referral\nresources to deal with underlying issues that contributed to being\noverweight.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 78525 Version 1.0</div></div></div>"},"78529":{"type":"graphic_picture","displayName":"Papular urticaria 1","title":"Papular urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular urticaria</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/78529_Papular_urticaria_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy adolescent returned from a hike in the woods with itchy bumps on her legs the day before she was evaluated. Note the central crusts where she had been scratching. Linear collections of insect bite like this are referred to as \"breakfast, lunch, and dinner.\"</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 78529 Version 7.0</div></div></div>"},"78530":{"type":"graphic_picture","displayName":"Balanitis xerotica obliterans","title":"Balanitis xerotica obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balanitis xerotica obliterans</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/78530_Balanit_xerotica_obliterans.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78530 Version 3.0</div></div></div>"},"78531":{"type":"graphic_picture","displayName":"Inverse psoriasis chest","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:278px;\" src=\"images/DERM/78531_Inverse_psoriasis_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-defined, erythematous plaque in the inframammary area.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78531 Version 4.0</div></div></div>"},"78533":{"type":"graphic_figure","displayName":"Transverse loops examples","title":"Magnetic 3-D imaging colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Magnetic 3-D imaging colonoscopy</div><div class=\"cntnt\"><img style=\"width:472px; height:215px;\" src=\"images/GAST/78533_Transverse_loops_examples.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of common and atypical transverse loops seen during routine colonoscopy (AP views). (A) Intubation to the mid-transverse colon with a deep transverse loop. (B) Gamma loop with endoscope inserted to the cecal pole. (C) Reverse splenic flexure loop with endoscope inserted to the hepatic flexure.</div><div class=\"graphic_reference\">Courtesy of Christopher B Williams, BM, FRCP, FRCS.</div><div id=\"graphicVersion\">Graphic 78533 Version 1.0</div></div></div>"},"78534":{"type":"graphic_table","displayName":"Food allergy school guidelines","title":"School guidelines for managing students with food allergies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">School guidelines for managing students with food allergies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Food allergies can be life threatening. The risk of accidental exposure to foods can be reduced in the school setting if schools work with students, parents, and physicians to minimize risks and provide a safe educational environment for food-allergic students.</td> </tr> <tr> <td class=\"subtitle1_single\">Family's responsibility</td> </tr> <tr> <td>Notify the school of the child's allergies.</td> </tr> <tr> <td>Work with the school team to develop a plan that accommodates the child's needs throughout the school including in the classroom, in the cafeteria, in after-care programs, during school-sponsored activities, and on the school bus, as well as a Food Allergy Action Plan.</td> </tr> <tr> <td>Provide written medical documentation, instructions, and medications as directed by a physician, using the Food Allergy Action Plan as a guide. Include a photo of the child on written form.</td> </tr> <tr> <td>Provide properly labeled medications and replace medications after use or upon expiration.</td> </tr> <tr> <td class=\"sublist1_start\">Educate the child in the self-management of their food allergy including:</td> </tr> <tr> <td class=\"sublist1\">- Safe and unsafe foods</td> </tr> <tr> <td class=\"sublist1\">- Strategies for avoiding exposure to unsafe foods</td> </tr> <tr> <td class=\"sublist1\">- Symptoms of allergic reactions</td> </tr> <tr> <td class=\"sublist1\">- How and when to tell an adult they may be having an allergy-related problem</td> </tr> <tr> <td class=\"sublist1\">- How to read food labels (age appropriate)</td> </tr> <tr> <td>Review policies/procedures with the school staff, the child's physician, and the child (if age appropriate) after a reaction has occurred.</td> </tr> <tr> <td>Provide emergency contact information.</td> </tr> <tr> <td class=\"subtitle1_single\">School's responsibility</td> </tr> <tr> <td>Be knowledgeable about and follow applicable federal laws including ADA, IDEA, Section 504, and FERPA and any state laws or district policies that apply.</td> </tr> <tr> <td>Review the health records submitted by parents and physicians.</td> </tr> <tr> <td>Include food-allergic students in school activities. Students should not be excluded from school activities solely based on their food allergy.</td> </tr> <tr> <td>Identify a core team of, but not limited to, school nurse, teacher, principal, school food service and nutrition manager/director, and counselor (if available) to work with parents and the student (age appropriate) to establish a prevention plan. Changes to the prevention plan to promote food allergy management should be made with core team participation.</td> </tr> <tr> <td>Assure that all staff who interact with the student on a regular basis understand food allergy, can recognize symptoms, know what to do in an emergency, and work with other school staff to eliminate the use of food allergens in the allergic student's meals, educational tools, arts and crafts projects, or incentives.</td> </tr> <tr> <td>Practice the Food Allergy Action Plans before an allergic reaction occurs to assure the efficiency/effectiveness of the plans.</td> </tr> <tr> <td>Coordinate with the school nurse to be sure medications are appropriately stored, and be sure that an emergency kit is available that contains a physician's standing order for epinephrine. In states were regulations permit, medications are kept in a easily accessible secure location central to designated school personnel, not in locked cupboards or drawers. Students should be allowed to carry their own epinephrine, if age appropriate after approval from the students physician/clinic, parent and school nurse, and allowed by state or local regulations.</td> </tr> <tr> <td>Designate school personnel who are properly trained to administer medications in accordance with the State Nursing and Good Samaritan Laws governing the administration of emergency medications.</td> </tr> <tr> <td>Be prepared to handle a reaction and ensure that there is a staff member available who is properly trained to administer medications during the school day regardless of time or location.</td> </tr> <tr> <td>Review policies/prevention plan with the core team members, parents/guardians, student (age appropriate), and physician after a reaction has occurred.</td> </tr> <tr> <td>Work with the district transportation administrator to assure that school bus driver training includes symptom awareness and what to do if a reaction occurs.</td> </tr> <tr> <td>Recommend that all buses have communication devices in case of an emergency.</td> </tr> <tr> <td>Enforce a \"no eating\" policy on school buses with exceptions made only to accommodate special needs under federal or similar laws, or school district policy. Discuss appropriate management of food allergy with family.</td> </tr> <tr> <td>Discuss field trips with the family of the food-allergic child to decide appropriate strategies for managing the food allergy.</td> </tr> <tr> <td>Follow federal/state/district laws and regulations regarding sharing medical information about the student.</td> </tr> <tr> <td>Take threats or harassment against an allergic child seriously.</td> </tr> <tr> <td class=\"subtitle1_single\">Student's responsibility</td> </tr> <tr> <td>Should not trade food with others.</td> </tr> <tr> <td>Should not eat anything with unknown ingredients or known to contain any allergen.</td> </tr> <tr> <td>Should be proactive in the care and management of their food allergies and reactions based on their developmental level.</td> </tr> <tr> <td>Should notify an adult immediately if they eat something they believe may contain the food to which they are allergic.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">10/18/2006 perm requested afurlong@foodallergymail.org 10/19/2006 granted</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=639&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">ADA: Americans With Disabilities; IDEA: Individuals With Disabilities Education Act; FERPA: Family Educational Rights and Privacy Act.</div><div class=\"graphic_reference\">The following organizations participated in the development of this document: American School Food Service Association; National Association of Elementary School Principals; National Association of School Nurses; National School Boards Association; The Food Allergy &amp; Anaphylaxis Network.<br> Reproduced with permission from: the Food Allergy and Anaphylaxis Network. Copyright Â© Food Allergy and Anaphylaxis Network.</div><div id=\"graphicVersion\">Graphic 78534 Version 4.0</div></div></div>"},"78535":{"type":"graphic_table","displayName":"Severity of aortic stenosis","title":"Hemodynamic definitions of severity of aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic definitions of severity of aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Aortic jet velocity, m/sec</td> <td class=\"subtitle1\">Mean gradient, mmHg</td> <td class=\"subtitle1\">Valve area, cm<sup>2</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Normal</td> <td>1.0</td> <td>&#60;5</td> <td>3.0-4.0</td> </tr> <tr> <td class=\"subtitle2_left\">Mild</td> <td>2.5-2.9</td> <td>&#60;20</td> <td>&#62;1.5</td> </tr> <tr> <td class=\"subtitle2_left\">Moderate</td> <td>3.0-4.0</td> <td>20-40</td> <td>1.0-1.5</td> </tr> <tr> <td class=\"subtitle2_left\">Severe</td> <td>&#62;4.0</td> <td>&#62;40</td> <td>&#60;1.0</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78535 Version 2.0</div></div></div>"},"78536":{"type":"graphic_algorithm","displayName":"Pediatric palpitations algorithm","title":"Pediatric palpitations algorithm","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Pediatric palpitations algorithm</div><div class=\"cntnt\"><img style=\"width:622px; height:968px;\" src=\"images/EM/78536_Peds_palpitations_algo_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachycardia; VT: ventricular tachycardia; WPW: Wolff-Parkinson-White syndrome; SA: sinoatrial; PVC: premature ventricular contraction; PAC: premature atrial contraction; ARF: acute rheumatic fever.</div><div id=\"graphicVersion\">Graphic 78536 Version 5.0</div></div></div>"},"78537":{"type":"graphic_diagnosticimage","displayName":"Melanoma small bowel SBFT","title":"Melanoma of the small bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanoma of the small bowel</div><div class=\"cntnt\"><img style=\"width:316px; height:288px;\" src=\"images/GAST/78537_Melanoma_small_bowel_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through study shows multiple rounded, nodular filling defects in the wall of the small bowel (arrows). Multiple small bowel tumors may be seen in metastatic disease or in polyposis syndromes; the most common cause of small bowel metastases is melanoma.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78537 Version 2.0</div></div></div>"},"78538":{"type":"graphic_table","displayName":"Differential dx hyperamylasemia","title":"Differential diagnosis of hyperamylasemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hyperamylasemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Disease</td>\n\n      <td class=\"subtitle1\">Predominant amylase isoform</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Pancreatic disease</td>\n\n      <td colspan=\"1\" rowspan=\"5\">Pancreatic</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Acute or chronic pancreatitis</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Post-ERCP</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Pseudocyst</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Pancreatic ascites</td>\n      \n    </tr>\n    <tr>\n\n      <td>Acute cholecystitis</td>\n\n      <td>Pancreatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Intestinal diseases</td>\n\n      <td colspan=\"1\" rowspan=\"8\">Pancreatic</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Parotitis</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Trauma</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Surgery</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Radiation</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Calculi</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Obstruction</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Infarction</td>\n      \n    </tr>\n    <tr>\n\n      <td>Malignancy with ectopic amylase production</td>\n\n      <td>Salivary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acidosis or ketoacidosis</td>\n\n      <td>Salivary or pancreatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Renal failure</td>\n\n      <td>Salivary and pancreatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Macroamylasemia</td>\n\n      <td>Macroamylase</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Fallopian tube diseases</td>\n\n      <td colspan=\"1\" rowspan=\"3\">Salivary</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Ruptured ectopic pregnancy</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist1\">Salpingitis</td>\n      \n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Miscellaneous</td>\n\n      <td colspan=\"1\" rowspan=\"4\">Salivary and/or pancreatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Alcoholism</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Anorexia nervosa/bulimia</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Cirrhosis</td>\n\n      \n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78538 Version 1.0</div></div></div>"},"78543":{"type":"graphic_figure","displayName":"Asymmetric leg folds","title":"Asymmetric leg folds","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Asymmetric leg folds</div><div class=\"cntnt\"><img style=\"width:484px; height:655px;\" src=\"images/PEDS/78543_Asymmetric_leg_folds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetry of the thigh or popliteal creases is suggestive of developmental dysplasia of the hip (DDH), with the abnormality on the side where the crease is most proximal. Asymmetry of the thigh folds or popliteal creases is not helpful in cases of bilateral DDH.</div><div id=\"graphicVersion\">Graphic 78543 Version 2.0</div></div></div>"},"78544":{"type":"graphic_picture","displayName":"Acute urticaria on the trunk","title":"Acute urticaria on the trunk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute urticaria on the trunk</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/ALLRG/78544_New_onset_urt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78544 Version 2.0</div></div></div>"},"78545":{"type":"graphic_picture","displayName":"Atypical leiomyoma","title":"Histology of atypical uterine leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of atypical uterine leiomyoma</div><div class=\"cntnt\"><img style=\"width:443px; height:294px;\" src=\"images/OBGYN/78545_Atypicalleiomyomaedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This atypical leiomyoma was biphasic.<br />(A) Microscopic features of an atypical leiomyoma.<br />(B) Focus of severe nuclear atypia, comprised of pleomorphism, hyperchromasia, and multinucleation. Other features of malignancy are also present (ie, mitotic activity, geographic tumor necrosis).</div><div id=\"graphicVersion\">Graphic 78545 Version 4.0</div></div></div>"},"78546":{"type":"graphic_figure","displayName":"Criteria for seborrheic keratosis","title":"Dermoscopic criteria for seborrheic keratosis: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup>","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic criteria for seborrheic keratosis: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup></div><div class=\"cntnt\"><img style=\"width:596px; height:498px;\" src=\"images/DERM/78546_Cri_seborrheic_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679. </li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109. </li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556. </li>&#xD;&#xA;    <li>Scope A, Benvenuto-Andraden C, Agero AL, Marghoob AA. Nonmelanocytic lesions defying the two-step dermoscopy algorithm. Dermatol Surg 2006; 32:1398. </li>&#xD;&#xA;    <li>Stricklin SM, Stoecker WV, Oliviero MD, et al. Cloudy and starry milia-like cysts: how well do they distinguish seborrheic keratoses from malignant melanomas? J Eur Acad Dermatol Venereol 2011; 25:1222. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 78546 Version 4.0</div></div></div>"},"78547":{"type":"graphic_picture","displayName":"Porphyria cutanea tarda 2","title":"Porphyria cutanea tarda","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porphyria cutanea tarda</div><div class=\"cntnt\"><img style=\"width:380px; height:336px;\" src=\"images/DERM/78547_Porphyriacutaneatarda2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macular erythema, erosions, crusts, and scars are present on the hands of this patient with porphyria cutanea tarda.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78547 Version 2.0</div></div></div>"},"78548":{"type":"graphic_figure","displayName":"Algorithm for reoperation for primary hyperparathyroidism","title":"Evaluation paradigm for patient undergoing reoperation for primary hyperparathyroidism when no abnormal parathyroid tissue had been previously excised","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Evaluation paradigm for patient undergoing reoperation for primary hyperparathyroidism when no abnormal parathyroid tissue had been previously excised</div><div class=\"cntnt\"><img style=\"width:552px; height:541px;\" src=\"images/ENDO/78548_Reop_prim_hyperparathy_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Alexander, HR Jr, Chen, Shawker, T, et al. Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N133. Copyright &#169; 2002 American Society for Bone and Mineral Research.</div><div id=\"graphicVersion\">Graphic 78548 Version 4.0</div></div></div>"},"78549":{"type":"graphic_picture","displayName":"Zollinger Ellison Light","title":"Zollinger-Ellison syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zollinger-Ellison syndrome</div><div class=\"cntnt\"><img style=\"width:330px; height:468px;\" src=\"images/GAST/78549_Zollinger_Ellison_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light micrograph of a gastric body biopsy from a patient with Zollinger-Ellison syndrome. The mucosa has an abnormally thick pit compartment and an expanded glandular compartment with much of the expansion due to an excess of parietal cells.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 78549 Version 3.0</div></div></div>"},"78550":{"type":"graphic_picture","displayName":"RTT after 10 years of age","title":"Rett syndrome, wasting of lower extremities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, wasting of lower extremities</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/78550_RS_stage_IVB_late_deteriora.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After 10 years of age, quadriparesis, scoliosis, and staring may be features of RTT. In contrast to figure 3, this child now shows wasting of lower extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: Meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright Â© 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 78550 Version 4.0</div></div></div>"},"78552":{"type":"graphic_diagnosticimage","displayName":"Lymphangioleiomyomatosis CT II","title":"Advanced lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:325px; height:187px;\" src=\"images/PULM/78552_Lymphangioleiomyomatosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advanced lymphangioleiomyomatosis characterized by severe destruction of the lung parenchyma with replacement by cysts.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78552 Version 2.0</div></div></div>"},"78557":{"type":"graphic_figure","displayName":"Felodipine in HF V HeFT","title":"Felodipine does not affect mortality in heart failure","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Felodipine does not affect mortality in heart failure</div><div class=\"cntnt\"><img style=\"width:482px; height:176px;\" src=\"images/CARD/78557_Felodipine_in_HF_V_HeFT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In V-HeFT III, felodipine SR or placebo was randomly administered to 450 patients with chronic heart failure receiving optimal therapy with enalapril and diuretics. Mortality (13.8 versus 12.8 percent) did not differ significantly between the two groups.</div><div class=\"graphic_reference\">Data from: Cohen JN, Ziesche S, Smith R, et al, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Circulation 1997; 96:856.</div><div id=\"graphicVersion\">Graphic 78557 Version 2.0</div></div></div>"},"78559":{"type":"graphic_figure","displayName":"Dinner fork deformity","title":"Colles' fracture","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Colles' fracture</div><div class=\"cntnt\"><img style=\"width:542px; height:366px;\" src=\"images/EM/78559_Dinner_fork_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Due to the dorsal displacement of the distal fragment, Colles' type fractures are often said to have a &quot;dinner fork&quot; appearance.</div><div id=\"graphicVersion\">Graphic 78559 Version 2.0</div></div></div>"},"78560":{"type":"graphic_figure","displayName":"Nighttime serum melatonin","title":"Nighttime peak serum melatonin levels in subjects of different ages, years","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Nighttime peak serum melatonin levels in subjects of different ages, years</div><div class=\"cntnt\"><img style=\"width:516px; height:393px;\" src=\"images/ENDO/78560_Nighttime_serum_melatonin.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Zhdanova, IV, Wurtman, RJ. In: Endocrinology: Basic and Clinical Principles, PM, Conn, S, Melmed (Eds), Humana Press, Inc, Totowa, NJ, 1997. p. 281. Copyright &#169; 1997 Humana Press.</div><div id=\"graphicVersion\">Graphic 78560 Version 1.0</div></div></div>"},"78561":{"type":"graphic_picture","displayName":"Endoscopic image of aphthous lesions in Crohn disease","title":"Aphthous lesions in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aphthous lesions in Crohn disease</div><div class=\"cntnt\"><img style=\"width:230px; height:221px;\" src=\"images/GAST/78561_Aphthous_ulcers_Crohns_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy demonstrates small discreet aphthous lesions (superficial ulcerations) that are characteristic of early lesions in Crohn disease.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 78561 Version 9.0</div></div></div>"},"78562":{"type":"graphic_table","displayName":"Supportive abortive Rx CVS","title":"Supportive and abortive treatment approaches in CVS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supportive and abortive treatment approaches in CVS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Supportive care</td> </tr> <tr> <td class=\"subtitle2_single\">Fluid, electrolyte and nutritional management</td> </tr> <tr> <td class=\"indent1\">Infuse 10% dextrose, 0.45% (half normal) saline solution and potassium chloride as appropriate at 1.5 times maintenance fluid rates OR through a Y-connector 10% dextrose infusion at one times maintenance and normal saline at 0.5 times maintenance</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If no enteral intake for 3 to 5 days, initiate peripheral parenteral nutrition with 1.5 g of amino acids/kg/day and energy units above the catabolic threshold of 55 to 70 kcal/kg/day</td> </tr> <tr> <td class=\"subtitle2_single\">Antiemetic (5HT<sub>3</sub> antagonist) agents</td> </tr> <tr> <td class=\"indent1\">Ondansetron 0.3 to 0.4 mg/kg/dose intravenously every 4 to 6 hours (maximum 16 mg per dose if younger than 75 years old, 8 mg per dose if 75 years old or older)</td> </tr> <tr> <td class=\"indent1\">Side effects: Constipation, prolonged QT interval</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternatives: Granisetron</td> </tr> <tr> <td class=\"subtitle2_single\">Sedatives</td> </tr> <tr> <td class=\"indent1\">Diphenhydramine 1 to 1.25 mg/kg/dose intravenously every 6 hours (maximum 50 mg per dose)</td> </tr> <tr> <td class=\"indent1\">Lorazepam 0.05 to 0.1 mg/kg/dose intravenously every 6 hours (maximum 2 mg per dose)</td> </tr> <tr> <td class=\"indent1\">Side effects: Respiratory depression, hallucinations</td> </tr> <tr> <td class=\"sublist2_start\">Chlorpromazine 0.5 to 1 mg/kg/dose intravenously every 6 hours + diphenhydramine (refer to above) intravenously:</td> </tr> <tr> <td class=\"sublist2\">&#60;5 years or &#60;23 kg maximum 10 mg per dose, 40 mg per 24 hours chlorpromazine</td> </tr> <tr> <td class=\"sublist2\">&#62;5 years or &#8805;23 kg maximum 18 mg per dose, 75 mg per 24 hours chlorpromazine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Side effects: Dystonic reactions with chlorpromazine alone</td> </tr> <tr> <td class=\"subtitle2_single\">Analgesics (nonsteroidal and narcotic) agents</td> </tr> <tr> <td class=\"indent1\">Ketorolac 0.4 to 1 mg/kg intravenously every 6 hours &times; 48 hours (maximum 30 mg per dose, maximum 120 mg per 24 hours); avoid in renal insufficiency or dehydration</td> </tr> <tr> <td class=\"indent1\">Side effects: Gastrointestinal hemorrhage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternatives: Narcotics, intravenous morphine or fentanyl by bolus or by patient-control infusion</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment of specific signs and symptoms: Epigastric pain, diarrhea, and hypertension</td> </tr> <tr> <td class=\"indent1\">Epigastric pain: Acid suppression by H<sub>2</sub>RAs or PPIs, (eg, intravenous ranitidine, pantoprazole)</td> </tr> <tr> <td class=\"indent1\">Diarrhea: Antidiarrheals (eg, loperamide)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypertension: Short-acting ACE inhibitors (eg, captopril)</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment of specific complications</td> </tr> <tr> <td class=\"indent1\">Dehydration and electrolyte deficit: Replace calculated deficits</td> </tr> <tr> <td class=\"indent1\">Metabolic acidosis: Determine cause and treat accordingly</td> </tr> <tr> <td class=\"indent1\">SIADH: Restrict free water intake</td> </tr> <tr> <td class=\"indent1\">Hematemesis: Intravenous H<sub>2</sub>RAs or PPIs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Weight loss: Nasogastric or parenteral nutrition</td> </tr> <tr> <td class=\"subtitle1_single\">Abortive care</td> </tr> <tr> <td class=\"subtitle2_single\">Antimigraine (triptan) agents</td> </tr> <tr> <td class=\"indent1\">Sumatriptan: 20 mg once intranasally as early as possible at episode onset for children 12 years and older (maximum 40 mg/24 hours)</td> </tr> <tr> <td class=\"indent1\">Side effects: Neck pain/burning, coronary vasospasm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Contraindications: Basilar artery migraine</td> </tr> <tr> <td class=\"subtitle1_single\">Recovery and refeeding</td> </tr> <tr> <td class=\"subtitle2_single\">Feed ad libitum when child declares episode is over</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">H<SUB>2</SUB>RAs: histamine-2 receptor antagonists; PPIs: proton pump inhibitors; ACE: angiotensive converting enzyme; SIADH: syndrome of inappropriate antidiuretic hormone.</div><div class=\"graphic_reference\">Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78562 Version 13.0</div></div></div>"},"78565":{"type":"graphic_movie","displayName":"Mitral stenosis apical long axis echocardiogram 2","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78565_aplaxms2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:255px; height:439px;\" src=\"images/CARD/78565_aplaxms2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical long axis view from a 2-D echocardiogram shows mitral stenosis. The mitral leaflets are thickened and have limited mobility and doming, with failure to open normally during diastole. There is also marked thickening and shortening of the chordae tendineae.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 78565 Version 2.0</div></div></div>"},"78567":{"type":"graphic_table","displayName":"Characteristic serious headache","title":"Characteristics of headache with serious underlying pathology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of headache with serious underlying pathology</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   History\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Explosive onset and severe at onset</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No similar headaches in the past</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Concomitant infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Altered mental status</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Headache with exertion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Age over 50</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Immunosuppression</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Physical examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neurologic abnormalities</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased level of consciousness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meningismus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Toxic appearance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Papilledema</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 78567 Version 1.0</div></div></div>"},"78569":{"type":"graphic_diagnosticimage","displayName":"MM lytic lesions","title":"Multiple myeloma lytic lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple myeloma lytic lesions</div><div class=\"cntnt\"><img style=\"width:418px; height:451px;\" src=\"images/HEME/78569_mm_lytic_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this radiograph of the skull in multiple myeloma, the &quot;punched out&quot; radiolucent lesions are the result of destruction by nodules of plasma cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E. Pathology. 4th ed. Philadelphia. Lippincott Williams and Wilkins, 2005. Copyright Â©2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78569 Version 3.0</div></div></div>"},"78570":{"type":"graphic_figure","displayName":"Finger trap fixture","title":"Finger trap fixture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Finger trap fixture</div><div class=\"cntnt\"><img style=\"width:343px; height:529px;\" src=\"images/EM/78570_Finger_trap_fixture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regardless of whether they are used in reduction, finger traps are a useful adjunct before the procedure. Traction is applied by attaching the finger traps to the thumb, index, and middle fingers, while keeping the elbow flexed at 90 degrees and the forearm in neutral rotation. Downward traction, using weights, is placed on the distal humerus for at least five minutes before any reduction attempt. This enables muscular relaxation and helps distract the fracture fragments, bringing the radius closer to normal length.</div><div id=\"graphicVersion\">Graphic 78570 Version 2.0</div></div></div>"},"78571":{"type":"graphic_picture","displayName":"Cutaneous lichen amyloid 2","title":"Cutaneous lichen amyloidosis in a patient with MEN2","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen amyloidosis in a patient with MEN2</div><div class=\"cntnt\"><img style=\"width:468px; height:311px;\" src=\"images/ENDO/78571_Cutaneous_lichen_amyloid2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.</div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD.</div><div id=\"graphicVersion\">Graphic 78571 Version 2.0</div></div></div>"},"78572":{"type":"graphic_figure","displayName":"Causes of nonulcer dyspepsia","title":"Causes of nonulcer dyspepsia","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Causes of nonulcer dyspepsia</div><div class=\"cntnt\"><img style=\"width:455px; height:440px;\" src=\"images/GAST/78572_Causes_nonulcer_dyspepsia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A number of motor and sensory disorders may contribute to nonulcer dyspepsia.</div><div class=\"graphic_reference\">Reproduced with permission from: Camilleri M, Prather CM. Gastric motor physiology and motor disorders. In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia, PA 1998.</div><div id=\"graphicVersion\">Graphic 78572 Version 4.0</div></div></div>"},"78573":{"type":"graphic_diagnosticimage","displayName":"Pancreatic fistula ERCP","title":"Pancreatic fistula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic fistula</div><div class=\"cntnt\"><img style=\"width:504px; height:387px;\" src=\"images/GAST/78573_Pancreatic_fistula_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) showing balloon dilation of a pancreatic duct stricture and transpapillary stenting that led to closure of a pancreatic duct leak and healing of a pancreaticocutaneous fistula.</div><div class=\"graphic_reference\">Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.</div><div id=\"graphicVersion\">Graphic 78573 Version 3.0</div></div></div>"},"78574":{"type":"graphic_picture","displayName":"Lichen sclerosus vulva","title":"Vulvar lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:257px; height:397px;\" src=\"images/OBGYN/78574_Lichen_sclerosus_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright Â© 1999 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 78574 Version 3.0</div></div></div>"},"78575":{"type":"graphic_figure","displayName":"Effect of heart failure severity on workload at altitude","title":"Maximum workload progressively decreases at higher altitudes","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Maximum workload progressively decreases at higher altitudes</div><div class=\"cntnt\"><img style=\"width:692px; height:258px;\" src=\"images/PC/78575_Altitude_workload_HF_Edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mean reduction in maximal workload, expressed as percentage decreases from baseline, is shown at various simulated altitudes. The reduction in workload at altitude in those with stable heart failure is generally in proportion to the limitation in workload of healthy people at altitude, but greater in those who have severely impaired capacity due to heart failure.</div><div class=\"graphic_reference\">Data from Agostoni, P, Cattadori, G, Guazzi, M, et al. Effects of Simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med 2000; 109:450.</div><div id=\"graphicVersion\">Graphic 78575 Version 5.0</div></div></div>"},"78576":{"type":"graphic_diagnosticimage","displayName":"Irreducible middle phalanx neck fracture","title":"Irreducible middle phalanx neck fracture as a result of volar plate interposition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irreducible middle phalanx neck fracture as a result of volar plate interposition</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/SURG/78576_Irreducible_fx_mid_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some phalangeal fractures are irreducible, which is usually due to soft tissue interposition, most commonly the volar plate in juxta-articular fractures as shown here. Irreducible fractures require operative intervention.</div><div id=\"graphicVersion\">Graphic 78576 Version 7.0</div></div></div>"},"78577":{"type":"graphic_picture","displayName":"Erythema toxicum trunk","title":"Erythema toxicum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema toxicum</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/78577_Erythematoxicumtrunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules with central pustules are present.</div><div class=\"graphic_reference\">Photo courtesy of Esther K Chung, MD. From Visual Diagnosis and Treatment in Pediatrics, 1st ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006.</div><div id=\"graphicVersion\">Graphic 78577 Version 4.0</div></div></div>"},"78579":{"type":"graphic_figure","displayName":"Survival revasc vs med rx","title":"Kaplan-Meier long-term survival of all patients and those discharged alive following hospitalization","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier long-term survival of all patients and those discharged alive following hospitalization</div><div class=\"cntnt\"><img style=\"width:526px; height:655px;\" src=\"images/CARD/78579_Survival_revasc_vs_med_rx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among all patients, the survival rates in the early revascularization (ERV) and initial medical stabilization (IMS) groups, respectively, were 41.4 versus 28.3 percent at three years and 32.8 versus 19.6 percent at six years. With exclusion of eight patients with aortic dissection, tamponade, or severe mitral regurgitation identified shortly after randomization, the survival curves remained significantly different (P = .02), with a 14.0 percent absolute difference at six years. Among hospital survivors, the survival rates in the ERV and IMS groups, respectively, were 78.8 versus 64.3 percent at three years and 62.4 versus 44.4 percent at six years.</div><div class=\"graphic_reference\">Reproduced with permission from: Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511. Copyright &#169;2006 American Medical Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 78579 Version 2.0</div></div></div>"},"78580":{"type":"graphic_figure","displayName":"Model of the AChR","title":"Model of the acetylcholine receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Model of the acetylcholine receptor</div><div class=\"cntnt\"><img style=\"width:435px; height:659px;\" src=\"images/NEURO/78580_Model_AChR_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Model of the acetylcholine receptor (AChR) showing a transverse section (top panel), a top view (middle panel) and the alpha-subunit in the membrane (bottom panel). In the top panel, the extracellular and smaller intracellular vestibules that surround the transmembrane ion pore are lined with negative charges. The main immunogenic region (MIR) of the AChR is located at the top of the extracellular portion of the AChR. The transmembrane pore is formed by the M1 and M2 segments of each subunit. The narrowing of the transmembrane ion pore results from bending of the M2 segment. The narrowest part of the pore is the selectivity filter. In the middle panel, &quot;ACh&quot; indicates the alpha/delta and alpha/epsilon or alpha/gamma agonist-binding sites. The lower panel shows the arrangement of the alpha-subunit within the membrane. The subunits are homologous. Each subunit has four transmembrane segments, called M1-M4. The dots on the N-terminal extracellular segment represent the location of amino acids that contribute to the alpha-subunit agonist binding site. The binding site amino acids of the alpha-subunit are tyrosines at alpha 93, alpha 190, and alpha 198, cysteines at alpha 192 and alpha 193, and tryptophan at alpha 149. The MIR is alpha 61 to alpha 76. Note that both the N-terminal and C-terminal portions of the subunit are extracellular. The configurations of the other subunits are similar to that of the alpha-subunit.</div><div class=\"graphic_reference\">Reproduced with permission from: Kaminski HJ, Suarez JI, Ruff RL. Neuromuscular junction physiology in myasthenia gravis. Neurology 1997; 48 Suppl 5:8S. Copyright Â© 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78580 Version 4.0</div></div></div>"},"78581":{"type":"graphic_picture","displayName":"Stasis dermatitis with bulla formation","title":"Stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78581_Stasis_derm_w_bulla_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bulla is present within an area of stasis dermatitis on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78581 Version 1.0</div></div></div>"},"78584":{"type":"graphic_figure","displayName":"Visceral surface spleen","title":"Visceral surface spleen","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Visceral surface spleen</div><div class=\"cntnt\"><img style=\"width:493px; height:315px;\" src=\"images/SURG/78584_Visceral_surface_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78584 Version 2.0</div></div></div>"},"78585":{"type":"graphic_picture","displayName":"Allergic conjunctivitis with chemosis","title":"Allergic conjunctivitis with chemosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic conjunctivitis with chemosis</div><div class=\"cntnt\"><img style=\"width:360px; height:301px;\" src=\"images/EM/78585_Allrgcconjnctvtschemosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the swollen conjunctiva extending up to the border of the cornea (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin MN. Ophthalmic and otolaryngologic emergencies. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78585 Version 10.0</div></div></div>"},"78586":{"type":"graphic_figure","displayName":"Dietary sources vitamin D PI","title":"Foods and drinks with vitamin D","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foods and drinks with vitamin D</div><div class=\"cntnt\"><img style=\"width:355px; height:473px;\" src=\"images/PI/78586_Dietary-sources-vitamin-D-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foods rich in vitamin D include milk, canned tuna fish, cod liver oil, yogurt, ready-to-eat-cereals, cooked salmon, canned sardines, mackerel, and eggs.</div><div id=\"graphicVersion\">Graphic 78586 Version 1.0</div></div></div>"},"78587":{"type":"graphic_picture","displayName":"Liver biopsy II - jaundice and weight loss","title":"Liver biopsy from a 60-year-old man with erythropoietic protophorphyria (high power, H&E stain exposed to polarized light)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver biopsy from a 60-year-old man with erythropoietic protophorphyria (high power, H&amp;E stain exposed to polarized light)</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/GAST/78587_Liver_biopsy_II_jaun_weight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note several red &quot;Maltese crosses&quot;.</div><div class=\"graphic_reference\">Courtesy of Marshall M. Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 78587 Version 3.0</div></div></div>"},"78590":{"type":"graphic_table","displayName":"Equipment for arterial line insertion","title":"Equipment for arterial line insertion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment for arterial line insertion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cannulation</td> </tr> <tr> <td>Intravascular catheter</td> </tr> <tr> <td>Guidewire appropriate for arterial site</td> </tr> <tr> <td>Lidocaine solution (1 percent) and syringe</td> </tr> <tr> <td>Suture material</td> </tr> <tr> <td>Maximal sterile-barrier precautions (drape, gown, mask, gloves,and cap; antiseptic handwash) </td> </tr> <tr> <td>Materials to securely immobilize and expose the arterial site (eg, armboard, tape)</td> </tr> <tr> <td class=\"subtitle1_single\">Monitoring</td> </tr> <tr> <td>Fluid filled noncompliant tubing with stopcocks</td> </tr> <tr> <td>Transducer and dome</td> </tr> <tr> <td>Constant flush device</td> </tr> <tr> <td>Electronic monitoring equipment</td> </tr> <tr> <td>Connecting cable</td> </tr> <tr> <td>Monitor with amplifier</td> </tr> <tr> <td>Oscilloscope display screen</td> </tr> <tr> <td>Recorder</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78590 Version 3.0</div></div></div>"},"78591":{"type":"graphic_figure","displayName":"HIV with pulmonary symptoms","title":"Approach to HIV-positive patients with pulmonary symptoms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to HIV-positive patients with pulmonary symptoms</div><div class=\"cntnt\"><img style=\"width:433px; height:431px;\" src=\"images/PULM/78591_HIV_with_pulmonary_symptoms.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* See text for comment on expectorated versus induced sputum.<br>&#8226; For example, if bacterial pneumonia, TB, or PCP are suspected based on clinical presentation.<br> &#916; Can include chest computed tomography, exercise oximetry, DLCO, or gallium scan. If patient is critically ill, procede with bronchoscopy and/or other invasive procedure.</div><div id=\"graphicVersion\">Graphic 78591 Version 1.0</div></div></div>"},"78592":{"type":"graphic_table","displayName":"V/Q scan results and diagnosis of pulmonary embolism","title":"V/Q scan results andÂ diagnosis ofÂ pulmonary embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">V/Q scan results and&nbsp;diagnosis of&nbsp;pulmonary embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">V/Q Scan Result</td> <td class=\"subtitle1\" colspan=\"3\">Clinical probability of emboli</td> </tr> <tr> <td class=\"subtitle2\">High</td> <td class=\"subtitle2\">Intermediate</td> <td class=\"subtitle2\">Low</td> </tr> <tr> <td>High</td> <td>96</td> <td>88</td> <td>56</td> </tr> <tr> <td>Intermediate</td> <td>66</td> <td>28</td> <td>16</td> </tr> <tr> <td>Low</td> <td>40</td> <td>16</td> <td>4</td> </tr> <tr> <td>Normal or near normal</td> <td>0</td> <td>6</td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All numbers are percentages.</div><div class=\"graphic_footnotes\">V/Q: ventilation/perfusion.</div><div class=\"graphic_reference\">Data from: PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263:2753.</div><div id=\"graphicVersion\">Graphic 78592 Version 4.0</div></div></div>"},"78595":{"type":"graphic_picture","displayName":"Well diff squamous CA Light","title":"Keratinizing (well-differentiated) squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratinizing (well-differentiated) squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/ONC/78595_Well_diff_squamous_CA_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A keratinizing squamous cell carcinoma showing keratin pearls (arrows) and well-defined tumor cell outlines with slender cytoplasmic connections (intercellular bridges). Nuclear pleomorphism is mild and the mitotic rate is low.</div><div class=\"graphic_reference\">Courtesy of Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 78595 Version 6.0</div></div></div>"},"78596":{"type":"graphic_table","displayName":"Definition positive TST in children","title":"Definitions of positive tuberculin skin test (TST) results in infants, children, and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of positive tuberculin skin test (TST) results in infants, children, and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Induration 5 mm or greater</td> </tr> <tr> <td>Children in close contact with known or suspected contagious people with tuberculosis disease</td> </tr> <tr> <td>Children suspected to have tuberculosis disease: <ul> <li>Findings on chest radiograph consistent with active or previous tuberculosis disease </li> <li>Clinical evidence of tuberculosis disease<sup>&#182;</sup></li> </ul> </td> </tr> <tr> <td>Children receiving immunosuppressive therapy<sup>&#916;</sup> or with immunosuppressive conditions, including human immunodeficiency (HIV) infection</td> </tr> <tr> <td class=\"subtitle1_single\">Induration 10 mm or greater</td> </tr> <tr> <td>Children at increased risk of disseminated tuberculosis disease: <ul> <li>Children younger than&nbsp;four years of age </li> <li>Children with other medical conditions, including Hodgkin disease, lymphoma, diabetes mellitus, chronic renal failure, or malnutrition </li> </ul> </td> </tr> <tr> <td>Children with likelihood of increased exposure to tuberculosis disease: <ul> <li>Children born in high-prevalence regions of the world </li> <li>Children who travel to high-prevalence regions of the world </li> <li>Children frequently exposed to adults who are HIV infected, homeless, users of illicit drugs, residents of nursing homes, incarcerated, or institutionalized </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Induration 15 mm or greater</td> </tr> <tr> <td>Children age&nbsp;four years or older without any risk factors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These definitions apply regardless of previous Bacille Calmette-GuÃ©rin immunization; erythema alone at TST site does not indicate a positive test result. Tests should be read at 48 to 72 hours after placement.&nbsp;<br />Â¶ Evidence by physical examination or laboratory assessment that would include tuberculosis in the working differential diagnosis (eg, meningitis).&nbsp;<br />Î Including immunosuppressive doses of corticosteroids or tumor necrosis factor-alpha antagonists.</div><div class=\"graphic_reference\">From: American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright Â© 2012. The contents of this table remain unchanged in the Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed.</div><div id=\"graphicVersion\">Graphic 78596 Version 11.0</div></div></div>"},"78597":{"type":"graphic_table","displayName":"Important immunosuppresive drug interactions","title":"Important interactions for immunosuppressive drugs used in cardiac transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important interactions for immunosuppressive drugs used in cardiac transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Drugs that increase levels of cyclosporine, tacrolimus, and sirolimus</td> </tr> <tr> <td>Calcium channel blockers</td> <td> <p>Diltiazem</p> <p>Nifedipine</p> <p>Nicardipine</p> <p>Verapamil</p> </td> </tr> <tr> <td>Antifungal drugs</td> <td> <p>Itraconazole</p> <p>Fluconazole</p> <p>Ketoconazole</p> <p>Voriconazole</p> <p>Posaconazole</p> </td> </tr> <tr> <td>Macrolide antibiotics</td> <td>All</td> </tr> <tr> <td>Fluoroquinolone antibiotics</td> <td>Ciprofloxacin</td> </tr> <tr> <td>HIV-protease inhibitors</td> <td>All</td> </tr> <tr> <td>Antiarrhythmic agents</td> <td>Amiodarone</td> </tr> <tr> <td>Gastrointestinal agents</td> <td>Metoclopramide</td> </tr> <tr> <td>Miscellaneous</td> <td>Grapefruit juice</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Drugs that decrease levels of cyclosporine, tacrolimus, and sirolimus</td> </tr> <tr> <td>Anti-tubercular drugs</td> <td>Rifampin</td> </tr> <tr> <td>Anti-seizure drugs</td> <td> <p>Phenytoin</p> <p>Phenobarbital</p> </td> </tr> <tr> <td>Gastrointestinal drugs</td> <td>Octreotide</td> </tr> <tr> <td>Miscellaneous</td> <td>St. John's wort</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Drugs with synergistic nephrotoxicity when used with cyclosporine or tacrolimus</td> </tr> <tr> <td colspan=\"2\">Aminoglycoside antibiotics</td> </tr> <tr> <td colspan=\"2\">Amphotericin B</td> </tr> <tr> <td colspan=\"2\">Non-steroidal anti-inflammatory agents (NSAIDs)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Drugs whose concentrations are increased when used with cyclosporine or tacrolimus</td> </tr> <tr> <td colspan=\"2\">Lovastatin</td> </tr> <tr> <td colspan=\"2\">Simvastatin</td> </tr> <tr> <td colspan=\"2\">Atorvastatin</td> </tr> <tr> <td colspan=\"2\">Ezetimibe</td> </tr> <tr> <td colspan=\"2\">Colchicine*&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based upon newer understanding of drug interactions, colchicine has been moved from \"Drugs with synergistric nephrotoxicity\" to \"Drugs whose concentration are increased when used with cyclosporine or tacrolimus.\"</div><div class=\"graphic_reference\">Reproduced with permission from: Pham MX, Chen JM, Berry GJ, Rose EA, Schroeder JS. Surgical Treatment of Heart Failure, Cardiac Transplantation, and Mechanical Ventricular Support. In: Hurst's The Heart, 12th ed, V, Fuster R, O'Rourke R, Walsh P, Poole-Wilson (eds). McGraw-Hill, New York 2007. Copyright Â© 2007 McGraw-Hill Companies Inc.</div><div id=\"graphicVersion\">Graphic 78597 Version 10.0</div></div></div>"},"78598":{"type":"graphic_picture","displayName":"Neonatal herpes simplex virus eye vesicles","title":"Eye vesicles in neonate with herpes simplex virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eye vesicles in neonate with herpes simplex virus infection</div><div class=\"cntnt\"><img style=\"width:380px; height:230px;\" src=\"images/PEDS/78598_Neonatal_HSV_eye_vesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neonate with herpes simplex virus (HSV) infection of the eye, showing characteristic coalescing vesicles on an erythematous base on eyelid and surrounding skin. Ophthalmologic evaluation of the eye should also be performed to determine if keratitis or keratoconjunctivitis is present.</div><div class=\"graphic_reference\">Courtesy of Jenny Ravenscroft, MD, and Gail J Demmler-Harrison, MD, Department of Pediatrics, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 78598 Version 3.0</div></div></div>"},"78599":{"type":"graphic_table","displayName":"Wilms tumor staging","title":"Staging systems for renal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging systems for renal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Stage</td>\n\t\t\t\t\t<td class=\"subtitle1\">NWTSG (before chemotherapy)</td>\n\t\t\t\t\t<td class=\"subtitle1\">SIOP (after chemotherapy)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">I</td>\n\t\t\t\t\t<td>Tumor is limited to the kidney and completely excised</td>\n\t\t\t\t\t<td>Tumor is limited to kidney or surrounded with fibrous pseudocapsule if outside of the normal ontours of the kidney, the renal capsule or pseudocapsule may be infiltrated with the tumor, but it does not reach the outer surface, and is completely resected (resection margins \"clear\")</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>The tumor was not ruptured before or during removal</td>\n\t\t\t\t\t<td>The tumor may be protruding into the pelvic system and \"dipping\" into the ureter (but it is not infiltrating their walls)</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>The vessels of the renal sinus are not involved beyond 2 mm</td>\n\t\t\t\t\t<td>The vessels of the renal sinus are not involved</td>\n\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>There is no residual tumor apparent beyond the margins of excision</td>\n\t\t\t\t\t<td>Intrarenal vessel involvement may be present</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">II</td>\n\t\t\t\t\t<td>Tumor extends beyond the kidney but is completely excised</td>\n\t\t\t\t\t<td>The tumor extends beyond kidney or penetrates through the renal capsule and/or fibrous pseudocapsule into perirenal fat but is completely resected (resection margins \"clear\")</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>No residual tumor is apparent at or beyond the margins of excision</td>\n\t\t\t\t\t<td>The tumor infiltrates the renal sinus and/or invades blood and lymphatic vessels outside the renal parenchyma but is completely resected</td>\n\t\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tumor thrombus in vessels outside the kidney is stage II if the thrombus is removed en bloc with the tumor</td>\n\t\t\t\t\t<td>The tumor infiltrates adjacent organs or vena cava but is completely resected</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Although tumor biopsy or local spillage confined to the flank were considered stage II by NWTSG in the past, such events will be considered stage III in upcoming COG studies.</td>\t<td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"8\"><p>III</p><p> Residual tumor confined to the abdomen</p></td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor</td>\n\t\t\t\t\t<td>Incomplete excision of the tumor, which extends beyond resection margins (gross or microscopical tumor remains postoperatively)</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diffuse peritoneal contamination by the tumor</td>\n\t\t\t\t\t<td>Any abdominal lymph nodes are involved</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Implants are found on the peritoneal surfaces</td>\n\t\t\t\t\t<td>Tumor rupture before or intraoperatively (irrespective of other criteria for staging)</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tumor extends beyond the surgical margins either microscopically or grossly</td>\n\t\t\t\t\t<td>The tumor has penetrated through the peritoneal surface</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tumor is not completely resectable because of local infiltration into vital structures</td>\n\t\t\t\t\t<td>Tumor thrombi present at resection margins of vessels or ureter, transsected or removed piecemeal by surgeon</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t\t<td>The tumor has been surgically biopsied (wedge biopsy) prior to preoperative chemotherapy or surgery</td>\n\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\n\t\t\t\t\t\t<td>&nbsp;</td><td>Regional lymph node involvement was considered stage II in the previous SIOP staging system.</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>IV</td>\n\t\t\t\t\t<td>Presence of hematogenous metastases or metastases to distant lymph nodes</td>\n\t\t\t\t\t<td>Hematogenous metastases (lung, liver, bone, brain, etc.) or lymph node metastases outside the abdomino-pelvic region</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>V</td>\n\t\t\t\t\t<td>Bilateral renal involvement at the time of initial diagnosis</td>\n\t\t\t\t\t<td>Bilateral renal tumors at diagnosis</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">COG: Children's Oncology Group; NWTSG: National Wilms Tumor Study Group; SIOP: International Society of Pediatric Oncology.</div><div class=\"graphic_reference\">Reproduced with permission from: Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815. Copyright &#169;2005 AlphaMed Press.</div><div id=\"graphicVersion\">Graphic 78599 Version 3.0</div></div></div>"},"78602":{"type":"graphic_waveform","displayName":"ECG atrial flutter preexcitation","title":"12-lead electrocardiogramÂ showing atrial flutter in preexcitation syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram&nbsp;showing atrial flutter in preexcitation syndrome</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/78602_Atrialflutterpreexcitatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial flutter is generated within the right atrium and the atrial impulses in this case are conducted to the ventricle by an accessory pathway. There is 1:1 conduction with a ventricular rate of 300 beats/min. The QRS complexes are widened or aberrant and have a bundle branch block morphology and a left axis deviation, suggesting the presence of an atriofascicular (Mahaim) accessory pathway.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 78602 Version 4.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"78603":{"type":"graphic_picture","displayName":"Genital herpes","title":"Genital herpes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Genital herpes</div><div class=\"cntnt\"><img style=\"width:380px; height:252px;\" src=\"images/ID/78603_Genital_herpes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple grouped vesicles of genital herpes on the shaft of the penis. These lesions are frequently painful.</div><div class=\"graphic_reference\">Courtesy of Larry Millikan. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 78603 Version 5.0</div></div></div>"},"78604":{"type":"graphic_diagnosticimage","displayName":"Nocardial brain abscess MRI","title":"Nocardial brain abscess on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nocardial brain abscess on MRI</div><div class=\"cntnt\"><img style=\"width:256px; height:516px;\" src=\"images/ID/78604_Nocardial_brain_abscess_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This noncontrast T1-weighted magnetic resonance imaging (MRI) sequence shows peripherally enhancing necrotic masses in the right cerebellum measuring 18 mm (arrow) and left occipital lobe supratentorially measuring 11 mm (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Nocardial brain abscesses mimicking metastatic lung cancer. Infections in Medicine 2008; 25(11):520. Copyright &copy;2008, Infections in Medicine, CMPMedica. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78604 Version 4.0</div></div></div>"},"78605":{"type":"graphic_table","displayName":"Specimen collection methods I","title":"Microbiology specimen handling and collection - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology specimen handling and collection - I</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Volume</td> <td class=\"subtitle1\">Storage temperature*</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Refer to&nbsp;UpToDate topic review</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Blood</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Routine</td> <td rowspan=\"2\">Blood culture vials</td> <td>Adults: 20 to 30 mL</td> <td rowspan=\"2\">25&#176;C</td> <td rowspan=\"2\">Obtain 2 to 3 sets</td> <td rowspan=\"2\">Technique of obtaining blood cultures for the detection of bacteremia</td> </tr> <tr> <td>Children: 1 to 5 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Dimorphic fungi</td> <td rowspan=\"2\">Lysis centrifugation tube</td> <td rowspan=\"2\">10 to 20 mL</td> <td rowspan=\"2\">25&#176;C</td> <td>Lysis centrifugation tubes should be processed within eight hours</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Yeasts (eg, <em>Candida</em>) should be detectable using many modern routine media and blood culture systems</td> </tr> <tr> <td class=\"indent1\">Mycobacterial</td> <td>BacT/ALERT MP, Bactec MycoF/Lytic, VersaTREK Myco,&nbsp;or lysis centrifugation tube</td> <td>10 to 20 mL</td> <td>25&#176;C</td> <td>Obtain one specimen</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td><strong>Catheter (vascular)</strong></td> <td>Cleanse skin around insertion site with alcohol. Send catheter tip (5 cm) in sterile container</td> <td>&nbsp;</td> <td>4&#176;C</td> <td>Also obtain two peripheral blood cultures</td> <td>Diagnosis and management of central venous catheter-related infections</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Cerebrospinal fluid</strong></td> <td rowspan=\"5\">Sterile tube</td> <td class=\"sublist1_start\">At least 1 to 5 mL per test:</td> <td rowspan=\"5\">4&#176;C</td> <td rowspan=\"5\"> <p>Transport routine cultures at 25&#176;C, viral cultures at 4&#176;C (on ice). Also send extra fluid to store for possible future testing.</p> <p>If volume is limited, prioritize tests requested.</p> <p>Some labs may utilize multiplex polymerase chain reaction for rapid diagnosis.<sup>&#182;</sup></p> </td> <td rowspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Bacterial &#8805;1 mL</td> </tr> <tr> <td class=\"sublist1\">Viral &#8805;1 mL</td> </tr> <tr> <td class=\"sublist1\">Acid-fast bacilli&nbsp;&#8805;2 mL</td> </tr> <tr> <td class=\"sublist1\">Fungal &#8805;2 mL</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"6\">Other fluid</td> </tr> <tr> <td class=\"indent1\">Peritoneal, pericardial, pleural, synovial</td> <td>Sterile container or direct inoculation to blood culture vials</td> <td>At least 1 to 10 mL, but send as much fluid as possible</td> <td>4&#176;C</td> <td>Never send swab dipped in fluid</td> <td>Joint aspiration or injection: Technique and indications</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If immediate processing is not possible.<br />Â¶ Refer to the UpToDate topic on molecular diagnosis of central nervous system infections for additional information.</div><div id=\"graphicVersion\">Graphic 78605 Version 8.0</div></div></div>"},"78606":{"type":"graphic_table","displayName":"Hepatobiliary diseases in IBD","title":"Hepatobiliary diseases associated with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hepatobiliary diseases associated with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Diseases of the liver</td>\n\n</tr>\n<tr>\n<td>Pericholangitis</td>\n\n</tr>\n<tr>\n<td>Steatosis</td>\n\n</tr>\n<tr>\n<td>Fibrosis and cirrhosis</td>\n\n</tr>\n<tr>\n<td>Chronic hepatitis</td>\n\n</tr>\n<tr>\n<td>Hepatic granulomas</td>\n\n</tr>\n<tr>\n<td>Amyloidosis</td>\n\n</tr>\n<tr>\n<td>Hepatic abscess</td>\n\n</tr>\n<tr>\n<td>Drug-induced hepatotoxicity</td>\n\n</tr><tr><td class=\"subtitle1_single\">Diseases of the biliary tract</td></tr><tr><td>Primary sclerosing cholangitis</td></tr><tr><td>Cholelithiasis</td></tr><tr><td>Cholangiocarcinoma</td></tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78606 Version 1.0</div></div></div>"},"78607":{"type":"graphic_table","displayName":"Predictors repeat ulcer bleed","title":"Endoscopic predictors of recurrent peptic ulcer hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic predictors of recurrent peptic ulcer hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Endoscopic stigmata of recent hemorrhage</td>\r\n                    <td class=\"subtitle1\">Prevalence, percent</td>\r\n                    <td class=\"subtitle1\">Risk of rebleeding on medical management, percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Active arterial bleeding (Forrest Ia)</td>\r\n                    <td>10</td>\r\n                    <td>90</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Oozing without visible vessel (Forrest Ib)</td>\r\n                    <td>10</td>\r\n                    <td>10 to 20</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Non-bleeding visible vessel (Forrest IIa)</td>\r\n                    <td>25</td>\r\n                    <td>50</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Adherent clot (Forrest IIb)</td>\r\n                    <td>10</td>\r\n                    <td>25 to 30</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Flat spot (Forrest IIc)</td>\r\n                    <td>10</td>\r\n                    <td>7 to 10</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clean ulcer base (Forrest (III)</td>\r\n                    <td>35</td>\r\n                    <td>3 to 5</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from: Katschinski B, Logan R, Davies J, et al. Dig Dis Sci 1994; 39:706.</div><div id=\"graphicVersion\">Graphic 78607 Version 5.0</div></div></div>"},"78608":{"type":"graphic_picture","displayName":"Cohen cannula","title":"Cohen cannula for uterine manipulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cohen cannula for uterine manipulation</div><div class=\"cntnt\"><img style=\"width:421px; height:241px;\" src=\"images/OBGYN/78608_Cohen_cannula.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78608 Version 1.0</div></div></div>"},"78609":{"type":"graphic_figure","displayName":"Paramedian incision of the abdominal wall","title":"Paramedian incision of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Paramedian incision of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:452px; height:574px;\" src=\"images/SURG/78609_Paramedian_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anterior rectus sheath is opened for the full length of the incision 2 to 3 cm from the midline. The rectus muscle is retracted laterally and the posterior sheath is incised longitudinally under the muscle bed. (B) The lateral paramedian incision is placed near the lateral border of the rectus. When the muscle is retracted laterally, the inferior deep epigastric artery is seen. Finally, the posterior sheath is closed.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 78609 Version 3.0</div></div></div>"},"78610":{"type":"graphic_table","displayName":"Causes of neutropenia in HIV","title":"Common causes of neutropenia in HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of neutropenia in HIV-infected patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Drugs</td>\n</tr>\n<tr>\n<td>Zidovudine</td>\n</tr>\n<tr>\n<td>Other antiretroviral agents (much less common)</td>\n</tr>\n<tr>\n<td>Ganciclovir/Valganciclovir</td>\n</tr>\n<tr>\n<td>Foscarnet</td>\n</tr>\n<tr>\n<td>Trimethoprim-sulfamethoxazole</td>\n</tr>\n<tr>\n<td>Other sulfonamides</td>\n</tr>\n<tr>\n<td>Pyrimethamine</td>\n</tr>\n<tr>\n<td>Acyclovir</td>\n</tr>\n<tr>\n<td>Pentamidine</td>\n</tr>\n<tr>\n<td>Amphotericin B</td>\n</tr>\n<tr>\n<td>5-flucytosine</td>\n</tr>\n<tr>\n<td>Interferon alfa</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Infections</td>\n</tr>\n<tr>\n<td>HIV</td>\n</tr>\n<tr>\n<td>Cytomegalovirus</td>\n</tr>\n<tr>\n<td>Epstein-Barr virus</td>\n</tr>\n<tr>\n<td>Influenza</td>\n</tr>\n<tr>\n<td>Infectious hepatitis</td>\n</tr>\n<tr>\n<td>Dengue fever</td>\n</tr>\n<tr>\n<td>Salmonella infection</td>\n</tr>\n<tr>\n<td>Tularemia</td>\n</tr>\n<tr>\n<td>Brucellosis</td>\n</tr>\n<tr>\n<td>Kala-azar</td>\n</tr>\n<tr>\n<td>Disseminated mycobacterial infection</td>\n</tr>\n<tr>\n<td>Disseminated fungal infections</td>\n</tr>\n<tr>\n<td>Bacteremia/sepsis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Malignancy</td>\n</tr>\n<tr>\n<td>Lymphoma (small, non-cleaved cell non-Hodgkin's lymphoma most common)</td>\n</tr>\n<tr>\n<td>Other malignancies with metastatic bone marrow involvement</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78610 Version 1.0</div></div></div>"},"78611":{"type":"graphic_table","displayName":"Prevention of GVHD with drugs","title":"Efficacy of drug prophylaxis for acute graft-versus-host disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Efficacy of drug prophylaxis for acute graft-versus-host disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug(s)</td>\n\n      <td class=\"subtitle1\">GVHD, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>None</td>\n\n      <td>52-100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Methotrexate</td>\n\n      <td>56-70</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cyclosporine</td>\n\n      <td>33-54</td>\n\n    </tr>\n\n    <tr>\n\n      <td>ATG-methotrexate-prednisone</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cyclosporine-methotrexate</td>\n\n      <td>15-33</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cyclosporine-prednisone</td>\n\n      <td>12-21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cyclosporine-methotrexate-prednisone</td>\n\n      <td>9-32</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">None of these regimens improve disease-free survival.</div><div id=\"graphicVersion\">Graphic 78611 Version 1.0</div></div></div>"},"78612":{"type":"graphic_figure","displayName":"Forearm anatomy 1","title":"Forearm anatomy: Interosseous membrane","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Forearm anatomy: Interosseous membrane</div><div class=\"cntnt\"><img style=\"width:527px; height:228px;\" src=\"images/EM/78612_Interosseousmembraneedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Force applied to one bone is transmitted to the other bone by the interosseous membrane. The attachment and the fibers of the interosseous membrane are such that there is no attachment to the distal radius.</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker JG, Bae DS. Fractures of the Distal Radius and Ulna. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78612 Version 13.0</div></div></div>"},"78613":{"type":"graphic_figure","displayName":"Temporal bone fx","title":"Temporal bone fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temporal bone fracture</div><div class=\"cntnt\"><img style=\"width:374px; height:293px;\" src=\"images/EM/78613_Temporal_bone_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial cuts of a CT scan demonstrating a temporal-zygomatic (TMZ) fracture with dislocation posteriorly into the external auditory canal (EAC) and the middle ear (ME) space. Note the opacification of the mastoid air cells, suggestive of fluid such as blood.</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 78613 Version 1.0</div></div></div>"},"78615":{"type":"graphic_figure","displayName":"Systemic mastocytosis: Bone marrow mast cells - Tryptase stain","title":"Systemic mastocytosis: Bone marrow mast cells - Tryptase staining","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systemic mastocytosis: Bone marrow mast cells - Tryptase staining</div><div class=\"cntnt\"><img style=\"width:432px; height:389px;\" src=\"images/ALLRG/78615_Sys_masto_BM_tryptase.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bone marrow shows multifocal dense infiltrates (arrow) of abnormal appearing spindle-shaped mast cells, which&nbsp;are typically located near thickened bony trabeculae. Tryptase staining (brown) is positive.</div><div class=\"graphic_reference\">Courtesy of Mariana C Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78615 Version 5.0</div></div></div>"},"78616":{"type":"graphic_diagnosticimage","displayName":"Thin endo EFP","title":"Ultrasonography of the uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasonography of the uterus</div><div class=\"cntnt\"><img style=\"width:383px; height:264px;\" src=\"images/ENDO/78616_Thin_endo_EFP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin endometrium in the early follicular phase.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 78616 Version 2.0</div></div></div>"},"78617":{"type":"graphic_diagnosticimage","displayName":"Crohn disease stomach UGI","title":"Crohn disease of the stomach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease of the stomach</div><div class=\"cntnt\"><img style=\"width:344px; height:252px;\" src=\"images/GAST/78617_Crohns_disease_stomach_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This upper gastrointestinal series, performed in a young man with known Crohn disease of the terminal ileum, shows numerous rounded filling defects in the stomach produced by edematous mucosa. In some of these areas, small central collections of barium are demonstrated (arrow), resulting from superficial erosions. These features are suggestive of Crohn disease, but may also be seen in patients with peptic ulcer disease and in those with viral gastritis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78617 Version 4.0</div></div></div>"},"78618":{"type":"graphic_picture","displayName":"Giant ventral hernia following open abdomen","title":"Giant ventral hernia following open abdomen","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Giant ventral hernia following open abdomen</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/78618_Giant_ventr_hernia_open_abd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mature skin over a giant ventral hernia.</div><div id=\"graphicVersion\">Graphic 78618 Version 1.0</div></div></div>"},"78619":{"type":"graphic_diagnosticimage","displayName":"Fetal microcephaly","title":"Fetal microcephaly","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fetal microcephaly</div><div class=\"cntnt\"><img style=\"width:504px; height:463px;\" src=\"images/PEDS/78619_Fetal_microcephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetus with microcephaly at 18 weeks gestational age. Note the small brain and sloping appearance of the forebrain.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 78619 Version 1.0</div></div></div>"},"78620":{"type":"graphic_picture","displayName":"Pancreatic duct stone pancreatoscopy","title":"Pancreatic duct stone seen on pancreatoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic duct stone seen on pancreatoscopy</div><div class=\"cntnt\"><img style=\"width:400px; height:368px;\" src=\"images/GAST/78620_Pancr_stone_pancreatosc_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatoscopy showing a stone in the main pancreatic duct.</div><div id=\"graphicVersion\">Graphic 78620 Version 2.0</div></div></div>"},"78621":{"type":"graphic_table","displayName":"Treatment options in nontoxic multinodular goiter","title":"Advantages and disadvantages of the treatment options in nontoxic multinodular goiter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of the treatment options in nontoxic multinodular goiter</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td><strong>Surgery</strong></td> <td> <p>Significant goiter reduction</p> <p>Rapid decompression of trachea</p> <p>Prompt relief of symptoms</p> <p>Definite histologic diagnosis</p> </td> <td> <p>Inpatient</p> <p>High cost</p> <p>Surgical risk</p> <p>Vocal cord paralysis: approximately 1%</p> <p>Hypoparathyroidism: approximately 1%</p> <p>Risk of hypothyroidism dependent of resection</p> <p>Risk of recurrence dependent of resection</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Radioiodine</strong></td> <td> <p>Most often outpatient</p> <p>If outpatient: low cost</p> <p>Few subjective side effects</p> <p>Goiter reduction: 50% within&nbsp;one year</p> <p>Improves inspiratory capacity in long term</p> <p>Can be repeated successfully</p> </td> <td> <p>Limitation of administrated radioactivity</p> <p>Restricted proximity to other persons</p> <p>Contraceptives needed in fertile women</p> <p>Gradual reduction of the goiter</p> <p>Decreasing effect with increasing size</p> <p>Small risk of acute goiter enlargement</p> <p>Risk of thyroiditis: 3%</p> <p>Risk of transition into Graves' disease: 5%</p> <p>One-year risk of hypothyroidism: 15 to 20%</p> <p>Long-term cancer risk unknown</p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Levothyroxine</strong></td> <td> <p>Outpatient</p> <p>Low cost</p> <p>May prevent new nodule formation</p> </td> <td> <p>Low efficacy</p> <p>Lifelong treatment</p> <p>Adverse effects (bone, heart)</p> <p>Not feasible when TSH is suppressed</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating horomone.</div><div class=\"graphic_reference\">Reproduced with permission from: HegedÃ¼s L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24:102. Copyright Â© 2003 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 78621 Version 4.0</div></div></div>"},"78623":{"type":"graphic_algorithm","displayName":"Approach otorrhea","title":"Approach to otorrhea in children","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Approach to otorrhea in children</div><div class=\"cntnt\"><img style=\"width:578px; height:528px;\" src=\"images/EM/78623_Approach_otorrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AOM: acute otitis media; CSF: cerebrospinal fluid.<br />* Meningitis, brain abscess, epidural abscess, subdural empyema, lateral or cavernous sinus thrombosis, or carotid artery thrombosis.</div><div id=\"graphicVersion\">Graphic 78623 Version 2.0</div></div></div>"},"78624":{"type":"graphic_figure","displayName":"Histology phyllodes tumor","title":"Cellular stroma with leaf-like process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cellular stroma with leaf-like process</div><div class=\"cntnt\"><img style=\"width:400px; height:264px;\" src=\"images/SURG/78624_Histology_phyllodes_tumor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78624 Version 1.0</div></div></div>"},"78625":{"type":"graphic_picture","displayName":"Acrochodae - axilla","title":"Acrochordae (skin tags) in the axilla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrochordae (skin tags) in the axilla</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/78625_Acrochodae_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pedunculated papules are present in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78625 Version 5.0</div></div></div>"},"78626":{"type":"graphic_algorithm","displayName":"Management pancreatic injury","title":"Management pancreatic injury","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Management pancreatic injury</div><div class=\"cntnt\"><img style=\"width:511px; height:290px;\" src=\"images/SURG/78626_Algo_pancreatic_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Patients with significant injury to the head of the pancreas involving the proximal ducts may require debridement, or, rarely, more extensive surgery such as pancreaticoduodenectomy or pyloric exclusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Patton JH Jr, Lyden SP, Croce MA, et al. Pancreatic trauma: A simplified management guideline. J Trauma 1997; 43:234. Copyright &copy; 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78626 Version 5.0</div></div></div>"},"78627":{"type":"graphic_table","displayName":"Common congenital anomalies","title":"Common congenital anomalies per 10,000 live births","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common congenital anomalies per 10,000 live births</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Lesion</td> <td class=\"subtitle1\">Average</td> </tr> <tr> <td>Ventricular septal defect</td> <td>36</td> </tr> <tr> <td>Patent ductus arteriosus</td> <td>8</td> </tr> <tr> <td>Atrial septal defect</td> <td>9</td> </tr> <tr> <td>Atrioventricular septal defect</td> <td>4</td> </tr> <tr> <td>Pulmonary stenosis</td> <td>7</td> </tr> <tr> <td>Aortic stenosis</td> <td>4</td> </tr> <tr> <td>Coarctation of the aorta</td> <td>4</td> </tr> <tr> <td>Tetralogy of Fallot</td> <td>4</td> </tr> <tr> <td>d-Transposition of the great arteries</td> <td>3</td> </tr> <tr> <td>Bicuspid aortic valve</td> <td>136</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 32:1890.</div><div id=\"graphicVersion\">Graphic 78627 Version 2.0</div></div></div>"},"78628":{"type":"graphic_diagnosticimage","displayName":"Radiograph of gibbus deformity","title":"Lateral spine radiograph of acutely angled kyphosis (gibbus deformity) in a patient with type 3 Gaucher disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral spine radiograph of acutely angled kyphosis (gibbus deformity) in a patient with type 3 Gaucher disease</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/ALLRG/78628_Radiogr_gibbus_deformity.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78628 Version 2.0</div></div></div>"},"78629":{"type":"graphic_picture","displayName":"Extended meatoplasty repair of meatal stricture","title":"Extended meatoplasty repair of meatal stricture","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Extended meatoplasty repair of meatal stricture</div><div class=\"cntnt\"><img style=\"width:544px; height:317px;\" src=\"images/SURG/78629_Ext_meatoplasty_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To repair a meatal stricture that has not responded to minimally invasive procedures (dilation, urethrotomy), an extended meatoplasty can be performed in the following manner: the ventral surface of the penis and urethra are incised to just proximal to the stricture, a triangle of tissue is removed, and the edges of the urethra are sutured to the penile skin.</div><div id=\"graphicVersion\">Graphic 78629 Version 3.0</div></div></div>"},"78630":{"type":"graphic_figure","displayName":"Intracranial pressure monitors","title":"Intracranial pressure monitors","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Intracranial pressure monitors</div><div class=\"cntnt\"><img style=\"width:513px; height:389px;\" src=\"images/PULM/78630_Intracranial_pressure_monit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventriculostomy allows both ICP monitoring and therapeutic drainage of cerebrospinal fluid (CSF). Subdural and intraparenchymal monitors cannot be used to drain CSF.</div><div id=\"graphicVersion\">Graphic 78630 Version 1.0</div></div></div>"},"78631":{"type":"graphic_diagnosticimage","displayName":"Paratracheal mass MRI I","title":"Paratracheal mass due to primary lung adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal mass due to primary lung adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:356px; height:301px;\" src=\"images/PULM/78631_Paratracheal_mass_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1-weighted section demonstrates a right paratracheal mass (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78631 Version 2.0</div></div></div>"},"78632":{"type":"graphic_diagnosticimage","displayName":"Sarcoidosis stage II PA","title":"Sarcoidosis, stage 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis, stage 2</div><div class=\"cntnt\"><img style=\"width:340px; height:346px;\" src=\"images/PULM/78632_Sarcoidosis_stage_II_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph. Bilateral enlarged hilar lymph nodes as well as right paratracheal and aortopulmonary window lymph nodes are visible. Fine linear and reticular opacities are present in the perihilar lung parenchyma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78632 Version 4.0</div></div></div>"},"78633":{"type":"graphic_figure","displayName":"Age at onset RPC","title":"Age at onset of relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age at onset of relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:339px; height:230px;\" src=\"images/RHEUM/78633_Age_at_onset_RPC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The age at onset compiled from 572 patients with relapsing polychondritis. The majority of cases occur between the ages of 40 and 60.</div><div id=\"graphicVersion\">Graphic 78633 Version 1.0</div></div></div>"},"78635":{"type":"graphic_figure","displayName":"Predictors stent restenosis","title":"Incidence of restenosis increases with the number of risk factors","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Incidence of restenosis increases with the number of risk factors</div><div class=\"cntnt\"><img style=\"width:496px; height:292px;\" src=\"images/CARD/78635_Predictors_stent_restenosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rate of stent restenosis and the need for target lesion revascularization (TLR) increases as more of the strongest risk factors are present. Risk factors include diabetes, multiples stents, and minimum luminal diameter after stenting &lt;3 mm.</div><div class=\"graphic_reference\">Data from Kastrati A, Schomig A, Elezi S, et al. J Am Coll Cardiol 1997; 30:1428.</div><div id=\"graphicVersion\">Graphic 78635 Version 2.0</div></div></div>"},"78637":{"type":"graphic_table","displayName":"External otitis microbiology B","title":"Acute external otitis microbiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute external otitis microbiology</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Percent*</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Organism</td></tr><tr>\n\n      <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">Aerobic bacteria</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Pseudomonas</td>\n\n      <td>41</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">S. aureus</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">Anaerobic bacteria</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Peptostreptococcus</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Bacteroides</td>\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3_left\">Fungal</td>\n\n      <td>6.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Mixture of organisms</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Aerobic only</td>\n\n      <td>67</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Anaerobic only</td>\n\n      <td>17</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mixed aerobic and anaerobic</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Number of organisms</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Single organism</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Two organisms</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">More than three organisms</td>\n\n      <td>11</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Percent of total patients with bacterial who had growth of this organism (n = 46).</div><div class=\"graphic_reference\">Data from Brook, I. Acta Otolaryngol 1980; 91:285.</div><div id=\"graphicVersion\">Graphic 78637 Version 1.0</div></div></div>"},"78638":{"type":"graphic_picture","displayName":"Palpation of flexor tendon","title":"Palpation of the flexor tendons of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the flexor tendons of the hand</div><div class=\"cntnt\"><img style=\"width:347px; height:292px;\" src=\"images/RHEUM/78638_Palpation_of_flexor_tendon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flexor tendon is palpated for tenderness or cyst formation. The hand is placed with the palm up on the exam table and with the fingers extended. The flexor tendon is palpated along its entire course from the distal interphalangeal (DIP) joint through the palm to the wrist. If a cyst is felt, passive movement of the finger is performed to determine if the cyst is intratendinous (cyst moves with finger movement) or peritendinous (cyst does not move). The arrow indicates the site of maximal tenderness over the first annular (A1) pulley of the tendon sheath.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 78638 Version 4.0</div></div></div>"},"78639":{"type":"graphic_figure","displayName":"Tonsil blood supply","title":"Vessels supplying the palatine tonsil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vessels supplying the palatine tonsil</div><div class=\"cntnt\"><img style=\"width:430px; height:458px;\" src=\"images/PC/78639_Tonsil_blood_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tonsillar vascular supply is from branches of the external carotid artery. Superior pole: Descending palatine artery. Mid-fossa: Ascending pharyngeal artery. Inferior pole: Tonsillar branch of the lingual artery and ascending palatine branch of the facial artery.</div><div id=\"graphicVersion\">Graphic 78639 Version 1.0</div></div></div>"},"78641":{"type":"graphic_table","displayName":"Drugs interact theophylline II","title":"Clinically significant drug interactions with theophylline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically significant drug interactions with theophylline</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Type of interaction</td>\n\n      <td class=\"subtitle1\">Effect on theophylline serum\nconcentrations or pharmacologic effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interferon, human recombinant alpha-A</td>\n\n      <td>Decreases theophylline clearance</td>\n\n      <td>100 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Isoproterenol (IV)</td>\n\n      <td>Increases theophylline clearance </td>\n\n      <td>20 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ketamine</td>\n\n      <td>Pharmacologic</td>\n\n      <td>May lower theophylline seizure threshold </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lithium</td>\n\n      <td>Theophylline increases lithium renal clearance</td>\n\n      <td>Lithium dose required to achieve a therapeutic serum\nconcentration increased an average of 60 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lorazepam</td>\n\n      <td>Similar to diazepam</td>\n\n      <td>Similar to diazepam</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Methotrexate (MTX)</td>\n\n      <td>Decreases theophylline clearance</td>\n\n      <td>20 percent increase after low-dose MTX, higher dose MTX\nmay have a greater effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mexiletine</td>\n\n      <td>Similar to disulfiram</td>\n\n      <td>80 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Midazolam</td>\n\n      <td>Similar to diazepam</td>\n\n      <td>Similar to diazepam</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Moricizine</td>\n\n      <td>Increases theophylline clearance</td>\n\n      <td>25 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pancuronium</td>\n\n      <td>Theophylline may antagonize non-depolarizing\nneuromuscular blocking effects; possibly due to phosphodiesterase\ninhibition</td>\n\n      <td>Larger dose of pancuronium may be required to achieve\nneuromuscular blockade</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pentoxifylline</td>\n\n      <td>Decreases theophylline clearance</td>\n\n      <td>30 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Phenobarbital (PB)</td>\n\n      <td>Similar to aminoglutethimide</td>\n\n      <td>25 percent decrease after more than two weeks of\nconcurrent PB</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Phenytoin</td>\n\n      <td>Phenytoin increases theophylline clearance by\nincreasing microsomal enzyme activity</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Serum theophylline and phenytoin concentrations\ndecrease about 40 percent</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td>Theophylline decreases phenytoin absorption</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Propafenone</td>\n\n      <td>Decreases theophylline clearance and pharmacologic\ninteraction</td>\n\n      <td>40 percent increase. Beta-2-blocking effect may\ndecrease efficacy of theophylline</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Propranolol</td>\n\n      <td>Similar to cimetidine and pharmacologic interaction</td>\n\n      <td>100 percent increase. Beta-2-blocking effect may\ndecrease efficacy of theophylline</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rifampin</td>\n\n      <td>Increases theophylline clearance by increasing\ncytochrome P450 1A2 and 3A3 activity </td>\n\n      <td>20 to 40 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sulfinpyrazone</td>\n\n      <td>Increases theophylline clearance by increasing\ndemethylation and hydroxylation. Decreases renal clearance of\ntheophylline</td>\n\n      <td>20 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tacrine</td>\n\n      <td>Similar to cimetidine, also increases renal clearance\nof theophylline</td>\n\n      <td>90 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thiabendazole</td>\n\n      <td>Decreases theophylline clearance</td>\n\n      <td>190 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ticlopidine</td>\n\n      <td>Decreases theophylline clearance</td>\n\n      <td>60 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Troleandomycin</td>\n\n      <td>Similar to erythromycin</td>\n\n      <td>33 to 100 percent increase depending on troleandomycin\ndose</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Verapamil</td>\n\n      <td>Similar to disulfiram</td>\n\n      <td>20 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zafirlukast</td>\n\n      <td>Mechanism not studied; theophylline decreases either\nbioavailability or\nclearance of zafirlukast. Zafirlukast has no effect on theophylline\nclearance</td>\n\n      <td>Zafirlukast blood levels decrease an average of 40\npercent, which is likely to render it ineffective</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zileuton</td>\n\n      <td>Zileuton inhibits cytochrome P-450 1A2 and, thus,\ndecreases theophylline clearance</td>\n\n      <td>100 percent increase</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.</div><div id=\"graphicVersion\">Graphic 78641 Version 1.0</div></div></div>"},"78642":{"type":"graphic_table","displayName":"Complementary and alternative medicine resources","title":"Complementary and alternative medicine resources for pediatric health care professionals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complementary and alternative medicine resources for pediatric health care professionals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Books</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Culbert T, Olness K. Integrative Pediatrics (Weil Integrative Medicine Library).</strong></p> Oxford University Press 2010.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Kemper KJ. The Holistic Pediatrician.</strong></p> HarperCollins 2002.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Kemper KJ. Mental Health Naturally.</strong></p> American Academy of Pediatrics 2010.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Langler A, Mansky PJ, Seifert G. Integrative Pediatric Cardiology.</strong></p> Springer 2012.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Loo M. Integrative Medicine for Children.</strong></p> Saunders 2008.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Misra S, Verissimo AM. A Guide to Integrative Pediatrics for the Healthcare Professional.</strong></p> Springer Briefs in Public Health 2014.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Rakel D. Integrative Medicine.</strong></p> Saunders 2012.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p><strong>Rosen L, Cohen J. Treatment Alternatives for Children.</strong></p> ALPHA 2012.</td> </tr> <tr> <td class=\"subtitle1_single\">Internet</td> </tr> <tr> <td class=\"indent1\"> <p><strong>American Academy of Pediatrics, Section on Integrative Medicine</strong></p> <a href=\"https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Section-on-Integrative-Medicine\" spellcheck=\"true\" target=\"_blank\">https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Section-on-Integrative-Medicine</a></td> </tr> <tr> <td class=\"indent1\"> <p><strong>The Canadian Pediatric CAM Network</strong></p> <a href=\"http://www.pedcam.ca/\" target=\"_blank\">www.pedcam.ca</a></td> </tr> <tr> <td class=\"indent1\"> <p><strong>The National Center for Complementary and Integrative Health </strong></p> <p><strong>National Institutes of Health</strong></p> <p><a href=\"https://nccih.nih.gov/\" target=\"_blank\"><span style=\"color: #0066cc;\">https://nccih.nih.gov/</span></a></p> <p>Includes a list of tips on complementary health practices</p> <p><a href=\"https://nccih.nih.gov/health/tips\" spellcheck=\"true\" id=\"https://nccih.nih.gov/health/tips\" target=\"_blank\"><span style=\"color: #0066cc;\">https://nccih.nih.gov/health/tips</span></a></p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78642 Version 9.0</div></div></div>"},"78643":{"type":"graphic_figure","displayName":"Duodenojejunal rotation","title":"Normal rotation of the duodenojejunal loop","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Normal rotation of the duodenojejunal loop</div><div class=\"cntnt\"><img style=\"width:549px; height:576px;\" src=\"images/PEDS/78643_Duodenojejunal_rotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The midgut forms a slight bend ventrally.<br />(B) The duodenojejunal junction rotates 90 degrees counterclockwise (to the right of the superior mesentery artery [SMA]). <br />(C) The duodenojejunal junction continues to rotate counterclockwise around the SMA (now 180 degrees from its original position). <br />(D) In its final position, the duodenojejunal junction has rotated 270 degrees and lies to the left of the SMA.</div><div id=\"graphicVersion\">Graphic 78643 Version 2.0</div></div></div>"},"78644":{"type":"graphic_table","displayName":"Indications exercise testing","title":"Indications for pediatric exercise testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for pediatric exercise testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Evaluate specific symptoms or signs that may be induced or aggravated by exercise</td> </tr> <tr> <td>Identify abnormal adaptive responses occurring in children with cardiac or other disorders</td> </tr> <tr> <td>Assess the effectiveness of specific medical and surgical treatments</td> </tr> <tr> <td>Estimate levels of functional capacity for vocational, recreational, and athletic recommendations</td> </tr> <tr> <td>Estimate prognosis for a given disease (eg, cystic fibrosis)</td> </tr> <tr> <td>Evaluate fitness levels</td> </tr> <tr> <td>Establish baseline data and follow-up on effectiveness of cardiac rehabilitation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Paridon SM, Alpert BS, Boas SR, et al. Clinical stress testing in the pediatric age group: a statement from the American Heart Association Council on Cardiovascular Disease in the Young, Committee on Atherosclerosis, Hypertension, and Obesity in Youth. Circulation 2006; 113:1905.</div><div id=\"graphicVersion\">Graphic 78644 Version 2.0</div></div></div>"},"78645":{"type":"graphic_diagnosticimage","displayName":"Osteoblastoma xray","title":"Plain radiograph of osteoblastoma in the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of osteoblastoma in the proximal humerus</div><div class=\"cntnt\"><img style=\"width:430px; height:434px;\" src=\"images/PEDS/78645_Osteoblastoma_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographic findings of osteoblastoma are variable. Above, an expansile, eccentric mass in the proximal humerus causes thinning of the cortex (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78645 Version 2.0</div></div></div>"},"78646":{"type":"graphic_figure","displayName":"Speech sound development","title":"Average age estimates and upper age limits of customary consonant production","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Average age estimates and upper age limits of customary consonant production</div><div class=\"cntnt\"><img style=\"width:373px; height:584px;\" src=\"images/PEDS/78646_Speech_sound_development.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The solid bar corresponding to each sound starts at the median age of customary articulation; it stops at an age level at which 90 percent of all children are customarily producing sound. (From Templin, 1957; Wellman et al, 1931.)</div><div class=\"graphic_footnotes\">&#920;: th as in &quot;those&quot;; &#948;: th as in &quot;thin&quot;.</div><div class=\"graphic_reference\">Reprinted with permission from: When are speech sounds learned? by E K Sander. Journal of Speech and Hearing Disorders, 37, 55. Copyright &#169; 1972 American Speech-Language-Hearing Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78646 Version 4.0</div></div></div>"},"78647":{"type":"graphic_picture","displayName":"Arsenical hyperkeratosis","title":"Arsenical hyperkeratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arsenical hyperkeratosis</div><div class=\"cntnt\"><img style=\"width:160px; height:213px;\" src=\"images/PC/78647_Arsenical_hyperkeratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had extensive hyperkeratosis on the soles of the feet and died of lung cancer.</div><div class=\"graphic_reference\">Reproduced with permission from Chowdhury, UK, Biswas, BK, Chowdhury, TR, et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect 2000; 108:393.</div><div id=\"graphicVersion\">Graphic 78647 Version 1.0</div></div></div>"},"78648":{"type":"graphic_table","displayName":"Moms who deliver at home","title":"Characteristics of mothers giving birth in home and hospitals, United States, 47 states, 2014","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of mothers giving birth in home and hospitals, United States, 47 states, 2014</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Planned home<br /> (percent)</td> <td class=\"subtitle1\">Hospital<br /> (percent)</td> </tr> <tr> <td><strong>White, non-Hispanic</strong></td> <td class=\"centered\">90.8</td> <td class=\"centered\">53.9</td> </tr> <tr> <td><strong>Age 30+</strong></td> <td class=\"centered\">54.3</td> <td class=\"centered\">42.7</td> </tr> <tr> <td><strong>Parity 3+</strong></td> <td class=\"centered\">52.7</td> <td class=\"centered\">28.8</td> </tr> <tr> <td><strong>Foreign born</strong></td> <td class=\"centered\">6.6</td> <td class=\"centered\">22.1</td> </tr> <tr> <td><strong>Gestation 37+ weeks</strong></td> <td class=\"centered\">97.8</td> <td class=\"centered\">88.6</td> </tr> <tr> <td><strong>County &#60;100,000 population</strong></td> <td class=\"centered\">34.8</td> <td class=\"centered\">20.9</td> </tr> <tr> <td><strong>No reported prenatal care</strong></td> <td class=\"centered\">2.7</td> <td class=\"centered\">1.5</td> </tr> <tr> <td><strong>Nonsmoker</strong></td> <td class=\"centered\">99.1</td> <td class=\"centered\">91.5</td> </tr> <tr> <td><strong>16+ years of education</strong></td> <td class=\"centered\">37.6</td> <td class=\"centered\">30.0</td> </tr> <tr> <td><strong>Prepregnancy body mass index 25+</strong></td> <td class=\"centered\">11.6</td> <td class=\"centered\">25.0</td> </tr> <tr> <td><strong>Self-pay for birth</strong></td> <td class=\"centered\">67.1</td> <td class=\"centered\">3.4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: National Center for Health Statistics. VitalStats website. Birth data 2014 state and county files. <A href=\"http://www.cdc.gov/nchs/VitalStats.htm\" target=_blank>http://www.cdc.gov/nchs/VitalStats.htm</A> (Accessed January 5, 2016).</div><div id=\"graphicVersion\">Graphic 78648 Version 16.0</div></div></div>"},"78649":{"type":"graphic_waveform","displayName":"ECG sinus node dysfunction","title":"ECG of sinus node dysfunction","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">ECG of sinus node dysfunction</div><div class=\"cntnt\"><img style=\"width:515px; height:221px;\" src=\"images/CARD/78649_ECG_sinus_node_dysfunction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continuous lead V2 rhythm strip shows evidence of sinus node dysfunction. Following the third sinus beat (*) there is a pause followed by the occurrence of an escape junctional rhythm at a slower rate. P waves reappear (arrows), which are initally dissociated from the QRS complex, but ultimately they become associated with the QRS, resulting in 1:1 conduction.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 78649 Version 2.0</div></div></div>"},"78650":{"type":"graphic_picture","displayName":"High grade squamous intraepithelial lesion (HSIL) of the vulva","title":"High-grade squamous intraepithelial lesion (HSIL) of the vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High-grade squamous intraepithelial lesion (HSIL) of the vulva</div><div class=\"cntnt\"><img style=\"width:278px; height:411px;\" src=\"images/OBGYN/78650_VIN_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 78650 Version 4.0</div></div></div>"},"78652":{"type":"graphic_table","displayName":"Radiation fields in HL","title":"Definition of radiation fields in Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of radiation fields in Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Radiation field definitions<sup>*</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Involved-site radiation therapy (ISRT)</td> </tr> <tr> <td class=\"indent1\">ISRT uses three-dimensional based simulation.&nbsp;The clinical target volume (CTV) encompasses the pre-chemotherapy volume but excludes initially uninvolved, displaced organs after disease regression.&nbsp;Fusion with pre-chemotherapy PET imaging can enhance the CTV definition.&nbsp;Expansion from CTV to internal target volume to planning target volume depends on internal motion and daily setup uncertainties.</td> </tr> <tr> <td class=\"subtitle2_single\">Involved-node radiation therapy (INRT)</td> </tr> <tr> <td class=\"indent1\">INRT can be regarded as a special case of ISRT wherein upfront PET-CT is acquired with the patient in the treatment position, using the same breathing instructions and immobilization devices that will be used later for RT.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Involved-field radiation therapy (IFRT), extended-field radiation therapy (EFRT), mantle field RT, inverted-Y field RT, and total nodal irradiation (TNI) were larger RT fields used in the past before availability of 3D-based planning, and they are no longer used in current practice.</div><div class=\"graphic_footnotes\">* ISRT is the most commonly used RT field in North America since optimal pre-chemotherapy imaging in the RT position is typically not available.<br />PET: positron emission tomography; CT: computed tomography; RT: radiation therapy. </div><div id=\"graphicVersion\">Graphic 78652 Version 4.0</div></div></div>"},"78654":{"type":"graphic_movie","displayName":"TEE PFO","title":"TEE of PFO","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TEE of PFO</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78654_TEEPFOvid.mp4\" style=\"width:324px;height:236px\"></div><img style=\"width:266px; height:432px;\" src=\"images/CARD/78654_TEEPFOimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systolic and diastolic views from a transesophageal echocardiogram (TEE) showing a \"flap\" of atrial septal tissue covering the patent foramen ovale (PFO). In early systole, the flap opens and the foramen ovale becomes patent, allowing right-to-left shunting of blood. In diastole, the flap closes, preventing left-to-right shunting.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 78654 Version 3.0</div></div></div>"},"78657":{"type":"graphic_algorithm","displayName":"PET and ultrafiltration failure","title":"Utility of peritoneal equilibration test in ultrafiltration failure","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Utility of peritoneal equilibration test in ultrafiltration failure</div><div class=\"cntnt\"><img style=\"width:483px; height:410px;\" src=\"images/NEPH/78657_PET_and_ultrafiltration_fai.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PET: peritoneal equilibration test; D/P: dialysate and plasma ratio.</div><div id=\"graphicVersion\">Graphic 78657 Version 4.0</div></div></div>"},"78658":{"type":"graphic_table","displayName":"Genetic causes parkinsonism","title":"Genetic forms of parkinsonism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic forms of parkinsonism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PARK and OMIM designation</td> <td class=\"subtitle1\">Gene (protein) locus</td> <td class=\"subtitle1\">Mode of inheritance and gene alteration</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Neuropathology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Established</td> </tr> <tr> <td class=\"indent1\"> <p>PARK1</p> <p>MIM 168601</p> <p><strong>and</strong></p> <p>PARK4</p> <p>MIM 605543</p> </td> <td> <p>SNCA</p> <p>(Alpha-synuclein)</p> <p>4q21</p> </td> <td> <p>AD</p> <p>Missense mutations (PARK1)</p> <p>Whole gene multiplications (PARK4)</p> </td> <td>Young onset PD with atypical features, dementia with Lewy bodies</td> <td>Nigral degeneration with Lewy bodies</td> </tr> <tr> <td class=\"indent1\"> <p>PARK2</p> <p>MIM 602544</p> </td> <td> <p>Parkin</p> <p>6q25.2-q27</p> </td> <td> <p>AR</p> <p>Gene dosage alterations and small sequence changes</p> </td> <td>Young onset PD with dystonia, dyskinesia, sleep benefit, autonomic symptoms</td> <td>Nigral degeneration; most but not all cases lack Lewy bodies</td> </tr> <tr> <td class=\"indent1\"> <p>PARK6</p> <p>MIM 605909</p> </td> <td> <p>PINK1</p> <p>1p35-36</p> </td> <td> <p>AR</p> <p>Small sequence changes, rarely large deletions</p> </td> <td>Young onset PD</td> <td>Nigral degeneration; variable&nbsp;Lewy bodies in the brainstem and Meynert nucleus</td> </tr> <tr> <td class=\"indent1\"> <p>PARK7</p> <p>MIM 602533</p> </td> <td> <p>DJ-1</p> <p>1p36</p> </td> <td> <p>AR</p> <p>Point mutations and large deletions</p> </td> <td>Young onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK8</p> <p>MIM 607060</p> </td> <td> <p>LRRK2</p> <p>(Dardarin)</p> <p>12q12</p> </td> <td> <p>AD</p> <p>Point mutations</p> </td> <td>Middle to late onset PD, resembles typical PD, responsive to levodopa</td> <td>Nigral degeneration with variable Lewy body, alpha-synuclein, and tau pathology</td> </tr> <tr> <td class=\"indent1\"> <p>PARK9</p> <p>MIM 606693</p> </td> <td> <p>ATP13A2</p> <p>1p36</p> </td> <td>AR</td> <td>Early onset atypical parkinsonism, rapid progression, transient levodopa responsiveness, pyramidal signs, dementia</td> <td>None reported</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>PARK14</p> <p>MIM 612953</p> </td> <td> <p>PLA2G6</p> <p>22q13.1</p> </td> <td>AR</td> <td>Adult onset dystonia-parkinsonism</td> <td>None reported</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tentative</td> </tr> <tr> <td class=\"indent1\"> <p>PARK3</p> <p>MIM 602404</p> </td> <td> <p>?</p> <p>2p13</p> </td> <td>AD</td> <td>Onset juvenile to ninth decade, prominent dementia may be present</td> <td>Nigral degeneration with Lewy bodies; plaques and tangles in some</td> </tr> <tr> <td class=\"indent1\"> <p>PARK5</p> <p>MIM 191342</p> </td> <td> <p>UCHL1</p> <p>4p14</p> </td> <td>AD?</td> <td>Limited clinical information, relevance to PD unclear</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK10</p> <p>MIM 606852</p> </td> <td> <p>?</p> <p>Possible susceptibility locus at 1p32</p> </td> <td>AD?</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK11</p> <p>MIM 607688</p> </td> <td> <p>GIGYF2</p> <p>2q37</p> </td> <td>?</td> <td>Relevance to PD unclear</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK12</p> <p>MIM 300557</p> </td> <td> <p>?</p> <p>Possible susceptibility locus at Xq21-q25</p> </td> <td>X-linked</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK13</p> <p>MIM 610297</p> </td> <td> <p>HTRA2</p> <p>(Omi/HtrA2)</p> <p>2p12</p> </td> <td>AD?</td> <td>Relevance to PD unclear</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK15</p> <p>MIM 260300</p> </td> <td> <p>FBXO7</p> <p>22q12-q13</p> </td> <td>AR</td> <td>Onset juvenile to sixth decade, progressive pyramidal tract signs and parkinsonism</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK16</p> <p>MIM 613164</p> </td> <td> <p>PARK16</p> <p>1q32</p> </td> <td>?</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>PARK17</p> <p>MIM 614203</p> </td> <td> <p>VPS35</p> <p>16q11.2</p> </td> <td>AD</td> <td>Late onset PD</td> <td>Nigral degeneration without Lewy bodies</td> </tr> <tr> <td class=\"indent1\"> <p>PARK21</p> <p>MIM 616361</p> </td> <td> <p>TMEM230</p> <p>3q22</p> </td> <td>AD</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>Not assigned</p> <p>MIM 603779</p> </td> <td> <p>SNCAIP</p> <p>(Synphilin-1)</p> <p>5q23.1-q23.3</p> </td> <td>?</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>Not assigned</p> <p>MIM 601828</p> </td> <td> <p>NR4A2</p> <p>(Nurr1)</p> <p>2q22-q23</p> </td> <td>?</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>Not assigned</p> <p>MIM 174763</p> </td> <td> <p>POLG</p> <p>(DNA polymerase gamma)</p> <p>15q25</p> </td> <td> <p>?</p> <p>Compound heterozygous mutations</p> </td> <td>Young onset, atypical parkinsonism, sensory-motor axonal neuropathy</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\"> <p>Not assigned</p> <p>MIM 605558</p> </td> <td> <p>FGF20</p> <p>(Fibroblast growth factor 20)</p> <p>8p22-p21.3</p> </td> <td>?</td> <td>Late onset PD</td> <td>None reported</td> </tr> <tr> <td class=\"indent1\">MIM 611867</td> <td>Chromosome 22q11.2 deletion syndrome</td> <td>Mainly sporadic</td> <td>Increased risk of early onset PD</td> <td>Variable alpha-synuclein positive&nbsp;Lewy body</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; OMIM: Online Mendelian Inheritance in Man.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to \"PARK\" genes and beyond. Mov Disord 2009; 24:2042.</LI>&#xD;&#xA;<LI>Wider C, Ross OA, Wszolek ZK. Genetics of Parkinson disease and essential tremor. Curr Opin Neurol 2010; 23:388.</LI>&#xD;&#xA;<LI>Shi CH, Tang BS, Wang L, et al. PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology 2011; 77:75.</LI>&#xD;&#xA;<LI>Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012; 27:831.</LI>&#xD;&#xA;<LI>Mok KY, Sheerin U, SimÃ³n-SÃ¡nchez J, et al. Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol 2016; 15:585.</LI>&#xD;&#xA;<LI><A href=\"http://www.ncbi.nlm.nih.gov/omim\" target=_blank>Online Mendelian Inheritance in Man</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 78658 Version 10.0</div></div></div>"},"78659":{"type":"graphic_table","displayName":"Cerebral palsy rate by pleurality","title":"Cerebral palsy rate in Western Australia by pleurality, 1980-1989","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cerebral palsy rate in Western Australia by pleurality, 1980-1989</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Singleton</td> <td class=\"subtitle1\" colspan=\"2\">Twin</td> <td class=\"subtitle1\" colspan=\"2\">Triplet</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Standardized</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Standardized</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Standardized</td> </tr> <tr> <td><strong>Per 1000 live births</strong></td> <td class=\"centered\">1.60</td> <td class=\"centered\">1</td> <td class=\"centered\">7.40</td> <td class=\"centered\">4.6</td> <td class=\"centered\">26.67</td> <td class=\"centered\">16.6</td> </tr> <tr> <td><strong>Per 1000 1st-year survivors</strong></td> <td class=\"centered\">1.60</td> <td class=\"centered\">1</td> <td class=\"centered\">7.32</td> <td class=\"centered\">4.6</td> <td class=\"centered\">27.91</td> <td class=\"centered\">17.4</td> </tr> <tr> <td><strong>Per 1000 pregnancies</strong></td> <td class=\"centered\">1.59</td> <td class=\"centered\">1</td> <td class=\"centered\">13.24</td> <td class=\"centered\">8.3</td> <td class=\"centered\">75.95</td> <td class=\"centered\">47</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith DM, Keith LG. Twin and triplet birth: facts, figures, and costs. Female Patient 2003; 28:11. Copyright &copy; 2003 Jaroslaw J Oleszczuk, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78659 Version 3.0</div></div></div>"},"78660":{"type":"graphic_figure","displayName":"Map of East Asia","title":"Map of East Asia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Map of East Asia</div><div class=\"cntnt\"><img style=\"width:360px; height:261px;\" src=\"images/ID/78660_Map_of_East_Asia.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78660 Version 1.0</div></div></div>"},"78661":{"type":"graphic_figure","displayName":"Relationship between BPP and perinatal mortality and morbidity","title":"Relationship between biophysical profile score and perinatal mortality and morbidity","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Relationship between biophysical profile score and perinatal mortality and morbidity</div><div class=\"cntnt\"><img style=\"width:578px; height:376px;\" src=\"images/OBGYN/78661_BPS_and_PNM_and_morbidity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The relationship betwen the biophysical profile (BPP)&nbsp;score result and the occurance of various perinatal morbidities. The incidence of fetal distress in labor (FD), cesarean&nbsp;delivery for fetal distress (LSCS-FD), low 5-minute Apgar score, and venous cord blood acidemia exhibit a very significant linear inverse relationship to test score. These data are based on observations made in more than 26,000 high-risk fetuses.<br />(B) The relationship betwen the&nbsp;BPP score&nbsp;and perinatal death (PNM), both gross and corrected for fatal anomalies. Unlike morbidity, the mortality rate increases in an inverse exponential fashion as the BPP score decreases.</div><div class=\"graphic_reference\">Data from: Manning FA. Dynamic ultrasound-based fetal assessment: The fetal biophysical profile score. Clin Obstet Gynecol 1995; 38:26.</div><div id=\"graphicVersion\">Graphic 78661 Version 3.0</div></div></div>"},"78662":{"type":"graphic_figure","displayName":"Distal radioulnar joint compression test","title":"Distal radioulnar joint (DRUJ) compression test for DRUJ instability","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal radioulnar joint (DRUJ) compression test for DRUJ instability</div><div class=\"cntnt\"><img style=\"width:430px; height:437px;\" src=\"images/PEDS/78662_DRUJ_compression_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the DRUJ compression test, the examiner compresses the radial and ulnar heads together and then rotates the forearm. Pain with the maneuver suggests DRUJ instability, acute intraarticular injury, or arthritis.</div><div id=\"graphicVersion\">Graphic 78662 Version 5.0</div></div></div>"},"78663":{"type":"graphic_picture","displayName":"Tuberoeruptive xanthomata","title":"Tuberoeruptive xanthomata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberoeruptive xanthomata</div><div class=\"cntnt\"><img style=\"width:409px; height:250px;\" src=\"images/PC/78663_Tuberoeruptive_xanthomata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberoeruptive xanthomata on the elbow and extensor surface of the arm in a patient with type III hyperlipoproteinemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 78663 Version 1.0</div></div></div>"},"78664":{"type":"graphic_diagnosticimage","displayName":"Normal adult wrist lateral radiograph","title":"Lateral view of wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral view of wrist</div><div class=\"cntnt\"><img style=\"width:346px; height:504px;\" src=\"images/RHEUM/78664_Normal_adult_wrist_lat_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of a normal adult wrist shows the outlines of scaphoid, lunate, and capitate bones.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 78664 Version 4.0</div></div></div>"},"78666":{"type":"graphic_picture","displayName":"Ferning of amniotic fluid","title":"Ferning of amniotic fluid","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Ferning of amniotic fluid</div><div class=\"cntnt\"><img style=\"width:550px; height:416px;\" src=\"images/OBGYN/78666_Ferning_amniotic_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Typical ferning pattern of dried amniotic fluid (400).<br> (B, C) Urine and amniotic fluid can be distinguished by microscopic examination of a droplet of the fluid spread and dried on a microscope slide. The proteins in amniotic fluid give the appearance of ferning (B) that is not observed with urine (C).<br> (D) Ferning pattern from amniotic fluid.</div><div class=\"graphic_reference\">Reproduced with permission from:<br> (A) Courtesy of Dr. Dwight Rouse.<br> (B) McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002.<br> (C) McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002.<br> (D) Beckmann CRB, Ling FW, Smith RP, et al. Obstetrics and Gynecology, 5th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006.</div><div id=\"graphicVersion\">Graphic 78666 Version 3.0</div></div></div>"},"78667":{"type":"graphic_picture","displayName":"Porokeratosis of Mibelli extremity","title":"Porokeratosis of Mibelli","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis of Mibelli</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78667_Porokeratosis_Mibelli_extr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-defined erythematous patch with a fine keratotic rim (cornoid lamella) is present.</div><div id=\"graphicVersion\">Graphic 78667 Version 1.0</div></div></div>"},"78668":{"type":"graphic_movie","displayName":"Dilated cardiomyopathy four chamber echocardiogram","title":"Dilated cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78668_4chdilcmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:242px; height:375px;\" src=\"images/CARD/78668_4chdilcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows a very dilated left ventricle which is diffusely hypokinetic. There is also enlargement of the right ventricle and right and left atria.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 78668 Version 2.0</div></div></div>"},"78670":{"type":"graphic_figure","displayName":"New Ballard Score 1","title":"New Ballard score","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">New Ballard score</div><div class=\"cntnt\"><img style=\"width:569px; height:437px;\" src=\"images/PEDS/78670_New_Ballard_Score_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The New Ballard Score is used to estimate gestational age from neuromuscular and physical features. The scores of each feature are added to calculate a maturity rating that correlates with gestational age.</div><div class=\"graphic_reference\">Adapted with permission from: Ballard JL, Khoury JC, Wedig K, et al. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991; 119:417. Copyright &copy; 1991 Elsevier.</div><div id=\"graphicVersion\">Graphic 78670 Version 3.0</div></div></div>"},"78671":{"type":"graphic_figure","displayName":"Montelukast in acute asthma","title":"Effect of intravenous montelukast versus standard therapy in acute asthma","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Effect of intravenous montelukast versus standard therapy in acute asthma</div><div class=\"cntnt\"><img style=\"width:454px; height:354px;\" src=\"images/PULM/78671_Montelukast_in_acute_asthma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients received standard therapy plus either intravenous montelukast or placebo infused over 5 minutes; FEV<SUB>1</SUB> responses were determined at the indicated times. Results are expressed as the percentage changes from the preallocation baseline FEV<SUB>1</SUB>. Montelukast at either dose caused a rapid improvement in FEV<SUB>1</SUB> compared with placebo. There were no differences between the montelukast treatment groups.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second; SE: standard error; IV: intravenous.<br />* p&lt;0.05 for montelukast versus placebo.<br />Â¶ p&lt;0.01 for montelukast versus placebo.</div><div class=\"graphic_reference\">Data from: Camargo CA Jr, Smithline HA, Malice M, et al. Montelukast in acute asthma. Am J Resp Crit Care Med 2003; 167:528.</div><div id=\"graphicVersion\">Graphic 78671 Version 3.0</div></div></div>"},"78673":{"type":"graphic_picture","displayName":"Donut mastopexy","title":"Donut mastopexy","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Donut mastopexy</div><div class=\"cntnt\"><img style=\"width:461px; height:728px;\" src=\"images/SURG/78673_DonutmastopexyPR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Donut mastopexy lumpectomy, medial breast lesion.<br> (A) Preoperative marking including marking of region to be removed based on preoperative bracketing wires and concentric circles for skin donut excision.<br> (B) Initial skin incision.<br> (C) Elevation of skin envelope dissecting in mastectomy plane.<br> (D) Mobilization of full-thickness wedge of disease-bearing ï¬broglandular tissue.<br> (E) Excised specimen and resulting ï¬broglandular defect.<br> (F) Mastopexy closure.<br> (G) Skin closure.<br> (H) Postoperative result.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78673 Version 7.0</div></div></div>"},"78674":{"type":"graphic_picture","displayName":"Gram stain of Campylobacter jejuni in stool","title":"Gram stain of <EM>Campylobacter jejuni </EM>in stool","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of <EM>Campylobacter jejuni </EM>in stool</div><div class=\"cntnt\"><img style=\"width:368px; height:240px;\" src=\"images/ID/78674_Campylobacterinstool.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of stool (x1000) can, in some cases, show <EM>Campylobacter jejuni</EM>, which are small, faint gram-negative curved rods&nbsp;that may be gull-winged in shape. This finding may provide presumptive evidence of<EM> Campylobacter </EM>infection prior to the results of stool culture. Optimal atmospheric condition is 85 percent nitrogen, 10 percent carbon dioxide, and 5 percent oxygen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 78674 Version 3.0</div></div></div>"},"78676":{"type":"graphic_diagnosticimage","displayName":"Plain radiographs - necrotizing enterocolitis in preterm infants","title":"Radiograph of necrotizing enterocolitis in premature infants","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Radiograph of necrotizing enterocolitis in premature infants</div><div class=\"cntnt\"><img style=\"width:523px; height:353px;\" src=\"images/PEDS/78676_NEC_preterm_Plain_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiographs in premature infants with necrotizing enterocolitis. Left panel: There is marked abdominal distention due in part to dilated bowel loops, and bubbles of gas in the bowel wall due to extensive pneumatosis intestinalis (arrow). An orogastric tube is in place. Right panel: There is marked abdominal distention, pneumatosis intestinalis, and a suspicion of portal venous (arrow) and/or free intraperitoneal air.</div><div id=\"graphicVersion\">Graphic 78676 Version 4.0</div></div></div>"},"78677":{"type":"graphic_figure","displayName":"The hypothalamic-pituitary-cortisol system in depression","title":"The hypothalamic-pituitary-cortisol system in depression","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">The hypothalamic-pituitary-cortisol system in depression</div><div class=\"cntnt\"><img style=\"width:480px; height:674px;\" src=\"images/PSYCH/78677_HPC_system_depression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hypothalamic-pituitary-cortisol hypothesis of depression postulates that abnormalities in the cortisol response to stress may underlie depression. The&nbsp;blue arrows show that in response to stress, which is perceived by the brain cortex and the amygdala and transmitted to the hypothalamus, corticotropin-releasing hormone (CRH) is released, inducing the anterior pituitary gland to secrete corticotropin into the bloodstream. Corticotropin stimulates the adrenal cortexes to secrete the glucocorticoid hormone cortisol. The red&nbsp;arrows show that cortisol, in turn, induces feedback inhibition in the hypothalamus and the pituitary, suppressing the production of CRH and corticotropin, respectively. Findings in patients with depression that support the hypothalamic-pituitary-cortisol hypothesis include the following: cortisol levels may be elevated, suppression of cortisol by exogenous corticosteroids may be reduced, the size of the anterior pituitary and adrenal cortex is increased, and CRH levels in the cerebrospinal fluid and CRH expression in the limbic brain regions are increased. Hippocampal size and the numbers of neurons and glia are decreased, possibly reflecting reduced neurogenesis due to elevated cortisol levels or due to reduced brain-derived neurotrophic factor.</div><div id=\"graphicVersion\">Graphic 78677 Version 5.0</div></div></div>"},"78679":{"type":"graphic_diagnosticimage","displayName":"Common hepatic duct stricture","title":"Common hepatic duct stricture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Common hepatic duct stricture</div><div class=\"cntnt\"><img style=\"width:504px; height:500px;\" src=\"images/GAST/78679_Common_hepatic_duct_strict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing a stricture of the common hepatic duct and hepatic duct bifurcation.</div><div id=\"graphicVersion\">Graphic 78679 Version 2.0</div></div></div>"},"78681":{"type":"graphic_picture","displayName":"Broth microdilution antimicrobial susceptibility testing","title":"Broth microdilution antimicrobial susceptibility testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Broth microdilution antimicrobial susceptibility testing</div><div class=\"cntnt\"><img style=\"width:344px; height:531px;\" src=\"images/ID/78681_Microdilution_MIC_testing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Commercially prepared serial dilutions of commonly used antimicrobials are added to a 96-well plate. After incubation with a standardized inoculum of a bacterial isolate, minimum inhibitory concentrations are determined and classified as susceptible, intermediate, or resistant based on the&nbsp;Clinical and Laboratory Standards Institute (CLSI), the European&nbsp;Committee on Antimicrobial Susceptibility Testing&nbsp;(EUCAST), or United States Food and Drug Administration&nbsp;(FDA) breakpoints.</div><div class=\"graphic_reference\">Courtesy of Mary Jane Ferraro, PhD, MPH.</div><div id=\"graphicVersion\">Graphic 78681 Version 4.0</div></div></div>"},"78682":{"type":"graphic_picture","displayName":"Mechanics hands PI","title":"Mechanic's hands in a patient with polymyositis and the anti-synthetase syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanic's hands in a patient with polymyositis and the anti-synthetase syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/PI/78682_Mechanics_hands_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H. Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 78682 Version 2.0</div></div></div>"},"78684":{"type":"graphic_picture","displayName":"Desmosomes squamous CA","title":"Intercellular bridges in a squamous cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intercellular bridges in a squamous cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:399px; height:258px;\" src=\"images/PULM/78684_Desmosomes_squamous_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification photomicrograph showing intercellular bridges (desmosomes), which appear as refractile striations between distinct cytoplasmic borders (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 78684 Version 2.0</div></div></div>"},"78685":{"type":"graphic_diagnosticimage","displayName":"Part patella tendon tear","title":"Partial thickness patellar tendon tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partial thickness patellar tendon tear</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/RHEUM/78685_Part_patella_tendon_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee demonstrates intermediate signal of the distal patellar tendon with discontinuity of some fibers (arrow) consistent with a partial thickness tear.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 78685 Version 2.0</div></div></div>"},"78686":{"type":"graphic_figure","displayName":"TPO physiology","title":"Thrombopoietin physiology","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Thrombopoietin physiology</div><div class=\"cntnt\"><img style=\"width:459px; height:209px;\" src=\"images/HEME/78686_TPOphysiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mechanism by which TPO regulates platelet production from megakaryocytes. TPO (size of large arrows indicates relative concentration) is produced constitutively by the liver and enters the circulation. Left side: When the platelet count is normal, high affinity TPO receptors on the platelets clear most of the TPO and produce a normal plasma TPO concentration, thereby providing basal stimulation of bone marrow megakaryocytes and a normal rate of platelet production. Right side: When platelet production and the platelet count are low, the overall clearance of TPO is reduced, subsequently increasing the plasma TPO concentration and megakaryocyte and platelet production.</div><div class=\"graphic_footnotes\">TPO: thrombopoietin.</div><div class=\"graphic_reference\">Courtesy of David Kuter, MD, DPhil.</div><div id=\"graphicVersion\">Graphic 78686 Version 3.0</div></div></div>"},"78688":{"type":"graphic_picture","displayName":"TSC forehead plaque","title":"Tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:402px; height:236px;\" src=\"images/PEDS/78688_TS_forehead_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical&nbsp;forehead fibrous plaque in a child with tuberous sclerosis.</div><div id=\"graphicVersion\">Graphic 78688 Version 3.0</div></div></div>"},"78690":{"type":"graphic_diagnosticimage","displayName":"Mesothelioma MRI II","title":"Mesothelioma with thickened fissures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesothelioma with thickened fissures</div><div class=\"cntnt\"><img style=\"width:354px; height:317px;\" src=\"images/PULM/78690_Mesothelioma_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2-weighted image shows high signal caused by tumor extending from the diaphragmatic pleura into the thickened major and minor fissures.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78690 Version 2.0</div></div></div>"},"78691":{"type":"graphic_picture","displayName":"Papular sarcoidosis - face","title":"Papular sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/78691_Papular_sarcoid_upper_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular sarcoidosis. Multiple round papules are present on the eyelids and central face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.</div><div id=\"graphicVersion\">Graphic 78691 Version 5.0</div></div></div>"},"78692":{"type":"graphic_picture","displayName":"Fingertip avulsion repair","title":"Repair of a fingertip avulsion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a fingertip avulsion</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/EM/78692_Fingertip_avulsion_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First, carefully approximate and suture the wound where it intersects with the nail folds and then suture the skin of the finger pad.</div><div class=\"graphic_reference\">Courtesy Richard A Saladino, MD.</div><div id=\"graphicVersion\">Graphic 78692 Version 3.0</div></div></div>"},"78693":{"type":"graphic_figure","displayName":"BNP and survival ValHeFT","title":"Plasma BNP concentration predicts survival in patients with HF","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Plasma BNP concentration predicts survival in patients with HF</div><div class=\"cntnt\"><img style=\"width:532px; height:423px;\" src=\"images/CARD/78693_BNP_and_survival_ValHeFT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of brain natriuretic peptide (BNP). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma BNP.</div><div class=\"graphic_reference\">Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.</div><div id=\"graphicVersion\">Graphic 78693 Version 2.0</div></div></div>"},"78695":{"type":"graphic_picture","displayName":"Straight leg raise PI","title":"Straight leg raises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Straight leg raises</div><div class=\"cntnt\"><img style=\"width:432px; height:231px;\" src=\"images/PI/78695_Straight_leg_raise_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on a bed or the floor. Bend the &quot;good&quot; knee and keep the foot on the floor. Keep the injured leg straight. On the injured side, tighten the quadriceps (as above), keep the leg straight, and lift the leg about 18 inches off the floor. Slowly lower the leg back to the bed or floor. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 78695 Version 2.0</div></div></div>"},"78696":{"type":"graphic_table","displayName":"Disorders with cataracts","title":"Pediatric disorders associated with cataracts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric disorders associated with cataracts</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Craniofacial syndromes </td> </tr> <tr> <td><a href=\"http://omim.org/entry/234100\" spellcheck=\"true\" target=\"_blank\">Hallermann-Streiff syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/270400\" spellcheck=\"true\" target=\"_blank\">Smith-Lemli-Opitz syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/101200\" spellcheck=\"true\" target=\"_blank\">Apert syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/123500\" spellcheck=\"true\" target=\"_blank\">Crouzon syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/261800\" spellcheck=\"true\" target=\"_blank\">Pierre-Robin syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/249000\" spellcheck=\"true\" target=\"_blank\">Meckel-Gruber syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic disease </td> </tr> <tr> <td><a href=\"http://omim.org/entry/213700\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #0000ff;\">Cerebrotendinous Xanthomatosis</span></a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/301500\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #0000ff;\">Fabry disease</span></a>&nbsp;</td> </tr> <tr> <td><a href=\"http://omim.org/entry/230400\" spellcheck=\"true\" target=\"_blank\">Galactosemia</a></td> </tr> <tr> <td>Hypoparathyroidism</td> </tr> <tr> <td>Infantile hypoglycemia</td> </tr> <tr> <td>Maternal diabetes</td> </tr> <tr> <td><a href=\"http://omim.org/entry/248500\" spellcheck=\"true\" target=\"_blank\">Mannosidosis</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/266500\" spellcheck=\"true\" target=\"_blank\">Refsum disease</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/214100\" spellcheck=\"true\" target=\"_blank\">Zellweger syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Skeletal disorders </td> </tr> <tr> <td><a href=\"http://omim.org/entry/108300\" spellcheck=\"true\" target=\"_blank\">Stickler syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/302960\" spellcheck=\"true\" target=\"_blank\">Chondrodysplasia punctata</a> (Conradi syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous system disorders </td> </tr> <tr> <td><a href=\"http://omim.org/entry/248800\" spellcheck=\"true\" target=\"_blank\">Marinesco-Sjogren syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/236670\" spellcheck=\"true\" target=\"_blank\">Walker-Warburg syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous </td> </tr> <tr> <td><a href=\"http://omim.org/entry/310600\" spellcheck=\"true\" target=\"_blank\">Norrie disease</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/154780\" spellcheck=\"true\" target=\"_blank\">Marshall syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/161200\" spellcheck=\"true\" target=\"_blank\">Nail-patella syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Intrauterine infection </td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td><a href=\"http://wwwn.cdc.gov/nndss/conditions/rubella-congenital-syndrome/case-definition/2010\" spellcheck=\"true\" target=\"_blank\">Rubella</a></td> </tr> <tr> <td><a href=\"http://www.cdc.gov/cmv/congenital-infection.html\" spellcheck=\"true\" target=\"_blank\">Cytomegalovirus</a></td> </tr> <tr> <td>Herpes simplex and varicella</td> </tr> <tr> <td><a href=\"http://www.cdc.gov/std/tg2015/congenital.htm\" spellcheck=\"true\" target=\"_blank\">Syphilis</a></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Dermatologic disorders </td> </tr> <tr> <td><a href=\"http://omim.org/entry/305100\" spellcheck=\"true\" target=\"_blank\">Ectodermal dysplasia</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/308300\" spellcheck=\"true\" target=\"_blank\">Incontinentia pigmenti</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/268400\" spellcheck=\"true\" target=\"_blank\">Rothmund-Thomson syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/277700\" spellcheck=\"true\" target=\"_blank\">Werner syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/242300\" spellcheck=\"true\" target=\"_blank\">Congenital ichthyosis</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/216400\" spellcheck=\"true\" target=\"_blank\">Cockayne syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/176670\" spellcheck=\"true\" target=\"_blank\">Progeria</a></td> </tr> <tr> <td class=\"subtitle1_single\">Renal disease </td> </tr> <tr> <td><a href=\"http://omim.org/entry/309000\" spellcheck=\"true\" target=\"_blank\">Lowe syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/301050\" spellcheck=\"true\" target=\"_blank\">Alport syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Muscular disorders </td> </tr> <tr> <td><a href=\"http://omim.org/entry/160900\" spellcheck=\"true\" target=\"_blank\">Myotonic dystrophy</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/236670\" spellcheck=\"true\" target=\"_blank\">Walker-Warburg syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Apical syndromes </td> </tr> <tr> <td><a href=\"http://omim.org/entry/180849\" spellcheck=\"true\" target=\"_blank\">Rubinstein-Taybi syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/209900\" spellcheck=\"true\" target=\"_blank\">Bardet-Biedl syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/164200\" spellcheck=\"true\" target=\"_blank\">Oculodentodigital dysplasia</a></td> </tr> <tr> <td class=\"subtitle1_single\">Chromosomal anomalies </td> </tr> <tr> <td><a href=\"http://omim.org/entry/190685\" spellcheck=\"true\" target=\"_blank\">Down syndrome</a> (Trisomy 21)</td> </tr> <tr> <td><a href=\"http://ghr.nlm.nih.gov/condition/trisomy-18\" spellcheck=\"true\" target=\"_blank\">Edward syndrome</a> (Trisomy 18)</td> </tr> <tr> <td><a href=\"http://ghr.nlm.nih.gov/condition/trisomy-13\" spellcheck=\"true\" target=\"_blank\">Patau syndrome</a> (Trisomy 13)</td> </tr> <tr> <td><a href=\"http://omim.org/entry/194190\" spellcheck=\"true\" target=\"_blank\">Wolf-Hirschhorn syndrome</a> (4p-syndrome)</td> </tr> <tr> <td><a href=\"http://ghr.nlm.nih.gov/condition/turner-syndrome\" spellcheck=\"true\" target=\"_blank\">Turner syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/123450\" spellcheck=\"true\" target=\"_blank\">Cri du chat syndrome</a> (5p-syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Ocular disease </td> </tr> <tr> <td>Retinopathy of prematurity</td> </tr> <tr> <td><a href=\"http://omim.org/entry/221900\" spellcheck=\"true\" target=\"_blank\">Persistent Hyperplastic Primary Vitreous</a> (PHPV)</td> </tr> <tr> <td><a href=\"http://omim.org/entry/108300\" spellcheck=\"true\" target=\"_blank\">Stickler syndrome</a></td> </tr> <tr> <td><a href=\"http://omim.org/entry/106210\" spellcheck=\"true\" target=\"_blank\">Aniridia</a></td> </tr> <tr> <td>Uveitis</td> </tr> <tr> <td><a href=\"http://omim.org/entry/607379\" spellcheck=\"true\" target=\"_blank\">Neurofibromatosis type 2</a></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78696 Version 4.0</div></div></div>"},"78697":{"type":"graphic_picture","displayName":"Leukocytoclastic vasculitis","title":"Leukocytoclastic vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukocytoclastic vasculitis</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/78697_Leukocytoclastic_vasculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leukocytoclastic vasculitis appearing as raised purpura. This lesion can occur with any vasculitic syndrome and in the collagen vascular diseases.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 78697 Version 2.0</div></div></div>"},"78698":{"type":"graphic_diagnosticimage","displayName":"Teratoma PA and CT","title":"Teratoma","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Teratoma</div><div class=\"cntnt\"><img style=\"width:458px; height:235px;\" src=\"images/PULM/78698_Teratoma_PA_and_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PA radiograph (left panel) demonstrates a mass to the right of the trachea (arrow). Both the hilum and spine are well seen, suggesting that the mass may be anterior. A CT scan obtained just above the level of the right pulmonary artery (right panel) demonstrates an anterior mediastinal mass with multiple distinct densities. The rounded area of low attenuation in the middle of the mass indicates the presence of fat and is highly suggestive of a teratoma.</div><div class=\"graphic_footnotes\">PA: posterioranterior; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 78698 Version 4.0</div></div></div>"},"78699":{"type":"graphic_figure","displayName":"Mitochondrial metabolism","title":"Mitochondrial metabolism","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Mitochondrial metabolism</div><div class=\"cntnt\"><img style=\"width:601px; height:387px;\" src=\"images/RHEUM/78699_Mitochondrial_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation showing the steps within the mitochondria in which energy stored in fatty acids, pyruvate, and amino acids is transformed into ATP. Energy substrates are first transported into the mitochondria where, after conversion into acetyl CoA, they enter the tricarboxylic acid cycle (TCA). The reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD) are formed from the citric acid cycle and the beta-oxidation of fatty acids in the mitochondrial matrix. Subsequently, oxidative phosphorylation or the respiratory chain, which is composed of four multi-subunit complexes (I, II, III, and IV) linked by the mobile electron carriers coenzyme Q and cytochrome c. The respiratory chain transfers electrons from NADH (via complex I) and from reduced flavoproteins (via complex II and electron transfer flavoprotein-coenzyme Q oxidoreductase [ETF-Qo]) to coenzyme Q10, then complex III, cytochrome c and finally complex IV, where they combine with molecular oxygen to form water.</div><div class=\"graphic_footnotes\">CoQ: Coenzyme Q; NADH: Nicotinamide adenine dinucleotide reduced; FMN: Flavin mononucleotide; FES: Non-heme iron-sulfur protein; Pi: Inorganic phosphate; TCA: Tricarboxylic acid cycle.</div><div class=\"graphic_reference\">Redrawn with permission from: DiMauro, S, De Vivo, D. Diseases of carbohydrate, fatty acid, and mitochondrial metabolism. In: Basic Neurochemistry, Seigel, G, et al (Eds), Raven, New York, 1989, p. 647.</div><div id=\"graphicVersion\">Graphic 78699 Version 1.0</div></div></div>"},"78700":{"type":"graphic_picture","displayName":"External hemorrhoid thrombosed","title":"Thrombosed external hemorrhoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Thrombosed external hemorrhoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/78700_Ext_hemorrhoid_thrombos_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts a classic thrombosed external hemorrhoid.</div><div class=\"graphic_reference\">Courtesy of W Brian Sweeney, MD.</div><div id=\"graphicVersion\">Graphic 78700 Version 1.0</div></div></div>"},"78701":{"type":"graphic_table","displayName":"Required purification processes","title":"Purification processes required to reduce contaminant levels by different amounts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Purification processes required to reduce contaminant levels by different amounts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Group</td> <td class=\"subtitle1\" colspan=\"3\">Reduction ratio</td> </tr> <tr> <td class=\"subtitle2\">0 to 1</td> <td class=\"subtitle2\">1 to 10</td> <td class=\"subtitle2\">10 to 100</td> </tr> <tr> <td class=\"centered\">A</td> <td>No treatment</td> <td>RO</td> <td>RO + DI or DI or Two-stage RO</td> </tr> <tr> <td class=\"centered\">B</td> <td>No treatment</td> <td>RO</td> <td>Carbon + RO or Two-stage RO</td> </tr> <tr> <td class=\"centered\">C</td> <td>No treatment</td> <td>DI or RO</td> <td>RO + DI or DI or Two-stage RO</td> </tr> <tr> <td class=\"centered\">D</td> <td>No treatment</td> <td>Softener or RO</td> <td>Softener + RO or DI or Softener</td> </tr> <tr> <td class=\"centered\">E</td> <td>No treatment</td> <td>Carbon</td> <td>Carbon</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Purification processes based upon required reduction ratios. Appropriate purification processes are selected using the maximum reduction ratio for each contaminant group. For the example given in this table, Group A requires reverse osmosis (reduction ratio of 9.5 for fluoride); Group B requires no treatment (reduction ratio of 0.5 for mercury); Group C requires reverse osmosis or deionization (reduction ratio of 4.0 for aluminum); Group D requires softening, with or without reverse osmosis, or deionization (reduction ratio of 31 for calcium); and Group E requires carbon filtration (reduction ratio of 21 for total chlorine). This list can then be used to select a final purification cascade.</div><div class=\"graphic_footnotes\">RO: reverse osmosis; DI: deionization.</div><div id=\"graphicVersion\">Graphic 78701 Version 5.0</div></div></div>"},"78702":{"type":"graphic_figure","displayName":"Plaque formation PI","title":"Plaque formation","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Plaque formation</div><div class=\"cntnt\"><img style=\"width:537px; height:329px;\" src=\"images/PI/78702_Plaque_formation_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78702 Version 3.0</div></div></div>"},"78703":{"type":"graphic_table","displayName":"Normal MAC and MAMC males","title":"Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian boys in the US Health and Nutrition Examination Survey I of 1971-1974","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian boys in the US Health and Nutrition Examination Survey I of 1971-1974</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Age, years males</td>\r\n            <td class=\"subtitle1\" colspan=\"4\">Mid arm circumference (MAC) percentiles</td>\r\n            <td class=\"subtitle1\" colspan=\"4\">Mid arm muscle circumference (MAMC)&nbsp;percentiles</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">5th</td>\r\n            <td class=\"subtitle2\">50th</td>\r\n            <td class=\"subtitle2\">90th</td>\r\n            <td class=\"subtitle2\">95th</td>\r\n            <td class=\"subtitle2\">5th</td>\r\n            <td class=\"subtitle2\">50th</td>\r\n            <td class=\"subtitle2\">90th</td>\r\n            <td class=\"subtitle2\">95th</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1-1.9</td>\r\n            <td>142</td>\r\n            <td>159</td>\r\n            <td>176</td>\r\n            <td>183</td>\r\n            <td>138</td>\r\n            <td>156</td>\r\n            <td>172</td>\r\n            <td>177</td>\r\n        </tr>\r\n        <tr>\r\n            <td>2-2.9</td>\r\n            <td>141</td>\r\n            <td>162</td>\r\n            <td>178</td>\r\n            <td>185</td>\r\n            <td>142</td>\r\n            <td>160</td>\r\n            <td>176</td>\r\n            <td>184</td>\r\n        </tr>\r\n        <tr>\r\n            <td>3-3.9</td>\r\n            <td>150</td>\r\n            <td>167</td>\r\n            <td>184</td>\r\n            <td>190</td>\r\n            <td>143</td>\r\n            <td>167</td>\r\n            <td>183</td>\r\n            <td>189</td>\r\n        </tr>\r\n        <tr>\r\n            <td>4-4.9</td>\r\n            <td>149</td>\r\n            <td>171</td>\r\n            <td>186</td>\r\n            <td>192</td>\r\n            <td>149</td>\r\n            <td>169</td>\r\n            <td>184</td>\r\n            <td>191</td>\r\n        </tr>\r\n        <tr>\r\n            <td>5-5.9</td>\r\n            <td>153</td>\r\n            <td>175</td>\r\n            <td>195</td>\r\n            <td>204</td>\r\n            <td>153</td>\r\n            <td>175</td>\r\n            <td>203</td>\r\n            <td>211</td>\r\n        </tr>\r\n        <tr>\r\n            <td>6-6.9</td>\r\n            <td>155</td>\r\n            <td>179</td>\r\n            <td>209</td>\r\n            <td>228</td>\r\n            <td>156</td>\r\n            <td>176</td>\r\n            <td>204</td>\r\n            <td>201</td>\r\n        </tr>\r\n        <tr>\r\n            <td>7-7.9</td>\r\n            <td>162</td>\r\n            <td>187</td>\r\n            <td>223</td>\r\n            <td>230</td>\r\n            <td>164</td>\r\n            <td>183</td>\r\n            <td>216</td>\r\n            <td>231</td>\r\n        </tr>\r\n        <tr>\r\n            <td>8-8.9</td>\r\n            <td>162</td>\r\n            <td>190</td>\r\n            <td>220</td>\r\n            <td>245</td>\r\n            <td>168</td>\r\n            <td>195</td>\r\n            <td>247</td>\r\n            <td>261</td>\r\n        </tr>\r\n        <tr>\r\n            <td>9-9.9</td>\r\n            <td>175</td>\r\n            <td>200</td>\r\n            <td>249</td>\r\n            <td>257</td>\r\n            <td>178</td>\r\n            <td>211</td>\r\n            <td>251</td>\r\n            <td>260</td>\r\n        </tr>\r\n        <tr>\r\n            <td>10-10.9</td>\r\n            <td>181</td>\r\n            <td>210</td>\r\n            <td>262</td>\r\n            <td>274</td>\r\n            <td>174</td>\r\n            <td>210</td>\r\n            <td>251</td>\r\n            <td>265</td>\r\n        </tr>\r\n        <tr>\r\n            <td>11-11.9</td>\r\n            <td>186</td>\r\n            <td>223</td>\r\n            <td>261</td>\r\n            <td>280</td>\r\n            <td>185</td>\r\n            <td>224</td>\r\n            <td>276</td>\r\n            <td>303</td>\r\n        </tr>\r\n        <tr>\r\n            <td>12-12.9</td>\r\n            <td>193</td>\r\n            <td>232</td>\r\n            <td>282</td>\r\n            <td>303</td>\r\n            <td>194</td>\r\n            <td>237</td>\r\n            <td>282</td>\r\n            <td>294</td>\r\n        </tr>\r\n        <tr>\r\n            <td>13-13.9</td>\r\n            <td>194</td>\r\n            <td>247</td>\r\n            <td>286</td>\r\n            <td>301</td>\r\n            <td>202</td>\r\n            <td>243</td>\r\n            <td>301</td>\r\n            <td>338</td>\r\n        </tr>\r\n        <tr>\r\n            <td>14-14.9</td>\r\n            <td>220</td>\r\n            <td>253</td>\r\n            <td>303</td>\r\n            <td>322</td>\r\n            <td>214</td>\r\n            <td>252</td>\r\n            <td>304</td>\r\n            <td>322</td>\r\n        </tr>\r\n        <tr>\r\n            <td>15-15.9</td>\r\n            <td>222</td>\r\n            <td>264</td>\r\n            <td>311</td>\r\n            <td>320</td>\r\n            <td>208</td>\r\n            <td>254</td>\r\n            <td>30</td>\r\n            <td>322</td>\r\n        </tr>\r\n        <tr>\r\n            <td>16-16.9</td>\r\n            <td>244</td>\r\n            <td>278</td>\r\n            <td>324</td>\r\n            <td>343</td>\r\n            <td>218</td>\r\n            <td>258</td>\r\n            <td>312</td>\r\n            <td>325</td>\r\n        </tr>\r\n        <tr>\r\n            <td>17-17.9</td>\r\n            <td>246</td>\r\n            <td>285</td>\r\n            <td>336</td>\r\n            <td>347</td>\r\n            <td>220</td>\r\n            <td>264</td>\r\n            <td>324</td>\r\n            <td>350</td>\r\n        </tr>\r\n        <tr>\r\n            <td>18-18.9</td>\r\n            <td>245</td>\r\n            <td>297</td>\r\n            <td>353</td>\r\n            <td>379</td>\r\n            <td>222</td>\r\n            <td>258</td>\r\n            <td>312</td>\r\n            <td>325</td>\r\n        </tr>\r\n        <tr>\r\n            <td>19-24.9</td>\r\n            <td>262</td>\r\n            <td>308</td>\r\n            <td>355</td>\r\n            <td>372</td>\r\n            <td>221</td>\r\n            <td>265</td>\r\n            <td>319</td>\r\n            <td>345</td>\r\n        </tr>\r\n        <tr>\r\n            <td>25-34.9</td>\r\n            <td>271</td>\r\n            <td>319</td>\r\n            <td>363</td>\r\n            <td>374</td>\r\n            <td>241</td>\r\n            <td>290</td>\r\n            <td>356</td>\r\n            <td>378</td>\r\n        </tr>\r\n        <tr>\r\n            <td>35-44.9</td>\r\n            <td>278</td>\r\n            <td>326</td>\r\n            <td>363</td>\r\n            <td>374</td>\r\n            <td>241</td>\r\n            <td>290</td>\r\n            <td>356</td>\r\n            <td>378</td>\r\n        </tr>\r\n        <tr>\r\n            <td>45-54.9</td>\r\n            <td>267</td>\r\n            <td>322</td>\r\n            <td>362</td>\r\n            <td>376</td>\r\n            <td>242</td>\r\n            <td>299</td>\r\n            <td>362</td>\r\n            <td>384</td>\r\n        </tr>\r\n        <tr>\r\n            <td>55-64.9</td>\r\n            <td>258</td>\r\n            <td>317</td>\r\n            <td>355</td>\r\n            <td>369</td>\r\n            <td>243</td>\r\n            <td>303</td>\r\n            <td>367</td>\r\n            <td>385</td>\r\n        </tr>\r\n        <tr>\r\n            <td>65-74.9</td>\r\n            <td>248</td>\r\n            <td>307</td>\r\n            <td>344</td>\r\n            <td>355</td>\r\n            <td>240</td>\r\n            <td>299</td>\r\n            <td>356</td>\r\n            <td>373</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Adapted from: Frisancho AR. Am J Clin Nut 1981; 34:2540.</div><div id=\"graphicVersion\">Graphic 78703 Version 3.0</div></div></div>"},"78706":{"type":"graphic_diagnosticimage","displayName":"MRI of internal hernia","title":"Magnetic resonance imaging (MRI) of internal hernia","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) of internal hernia</div><div class=\"cntnt\"><img style=\"width:542px; height:256px;\" src=\"images/SURG/78706_MRI_internal_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both MRI views obtained in a pregnant patient show stretching of the mesenteric vessels to the patient's left.</div><div id=\"graphicVersion\">Graphic 78706 Version 4.0</div></div></div>"},"78707":{"type":"graphic_figure","displayName":"Construction of an ileostomy - segment through abdominal wall","title":"Construction of an ileostomy - segment through abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of an ileostomy - segment through abdominal wall</div><div class=\"cntnt\"><img style=\"width:447px; height:680px;\" src=\"images/SURG/78707_Ileostomy-segment-through-wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts pulling the proximal end of the ileum through the abdominal wall to construct an ileostomy.</div><div id=\"graphicVersion\">Graphic 78707 Version 2.0</div></div></div>"},"78708":{"type":"graphic_table","displayName":"Vitamin K foods","title":"Amount of vitamin K in different foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amount of vitamin K in different foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food name</td> <td class=\"subtitle1\">Serving size</td> <td class=\"subtitle1\">Vitamin K (micrograms)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High vitamin K foods</td> </tr> <tr> <td class=\"indent1\">Brussels sprouts, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>110</td> </tr> <tr> <td class=\"indent1\">Brussels sprouts, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>150</td> </tr> <tr> <td class=\"indent1\">Greens, beet, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>350</td> </tr> <tr> <td class=\"indent1\">Greens, collard, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>530</td> </tr> <tr> <td class=\"indent1\">Greens, collard, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>365</td> </tr> <tr> <td class=\"indent1\">Greens, mustard, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>415</td> </tr> <tr> <td class=\"indent1\">Greens, turnip, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>265</td> </tr> <tr> <td class=\"indent1\">Greens, turnip, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>425</td> </tr> <tr> <td class=\"indent1\">Kale, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>530</td> </tr> <tr> <td class=\"indent1\">Kale, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>565</td> </tr> <tr> <td class=\"indent1\">Spinach, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>444</td> </tr> <tr> <td class=\"indent1\">Spinach, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>514</td> </tr> <tr> <td class=\"indent1\">Spinach, fresh (raw)</td> <td>1 cup</td> <td>150</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Medium vitamin K foods</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Asparagus, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>72</td> </tr> <tr> <td>4 spears</td> <td>48</td> </tr> <tr> <td class=\"indent1\">Asparagus, fresh (cooked, drained)</td> <td>4 spears</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Beans, green or yellow, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Broccoli, fresh (cooked, drained)</td> <td>1 spear</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Broccoli, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Broccoli, raw</td> <td>1/2 cup</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Cabbage (cooked, drained)</td> <td>1/2 cup</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Cabbage, Chinese bok choy (cooked, drained)</td> <td>1/2 cup</td> <td>28</td> </tr> <tr> <td class=\"indent1\">Cabbage, green (raw)</td> <td>1/2 cup</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Cabbage, red (raw)</td> <td>1/2 cup</td> <td>14</td> </tr> <tr> <td class=\"indent1\">Cabbage, Savoy (raw)</td> <td>1/2 cup</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Calcium soft chews (brand name Viactiv with D) see note below about other vitamin pills</td> <td>1 chew</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Carrots, fresh or frozen (cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Cauliflower, fresh or frozen (raw or cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Celery, raw</td> <td>1/2 cup </td> <td>17</td> </tr> <tr> <td class=\"indent1\">Coleslaw (fast food-type)</td> <td>1/2 cup</td> <td>37</td> </tr> <tr> <td class=\"indent1\">Endive</td> <td>1/2 cup</td> <td>60</td> </tr> <tr> <td class=\"indent1\">Lettuce (butterhead, Boston, Bibb)</td> <td>1/2 head</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Lettuce (iceberg, crisphead)</td> <td>1/2 head</td> <td>65</td> </tr> <tr> <td class=\"indent1\">Lettuce (romaine, cos)</td> <td>1 cup</td> <td>57</td> </tr> <tr> <td class=\"indent1\">Lettuce (green leaf)</td> <td>1 cup</td> <td>97</td> </tr> <tr> <td class=\"indent1\">Oil, canola</td> <td>1 tablespoon</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Okra, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>32</td> </tr> <tr> <td class=\"indent1\">Okra, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>44</td> </tr> <tr> <td class=\"indent1\">Peas, frozen, with pod (cooked, drained)</td> <td>1/2 cup</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Peas, fresh, with pod (cooked, drained)</td> <td>1/2 cup</td> <td>20</td> </tr> <tr> <td class=\"indent1\">Peas, green, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>18</td> </tr> <tr> <td class=\"indent1\">Pickle relish, sweet</td> <td>1 tablespoon</td> <td>13</td> </tr> <tr> <td class=\"indent1\">Pickles, cucumber dill or kosher dill</td> <td>1 pickle</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Sauerkraut, canned</td> <td>1/2 cup</td> <td>56</td> </tr> <tr> <td class=\"indent1\">Vegetables, mixed frozen or canned (cooked, drained)</td> <td>1/2 cup</td> <td>20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Low vitamin K foods</td> </tr> <tr> <td class=\"indent1\">Avocado</td> <td>1 ounce</td> <td rowspan=\"12\">All of these foods have less than 10 micrograms of vitamin K per serving</td> </tr> <tr> <td class=\"indent1\">Bananas</td> <td>1 banana</td> </tr> <tr> <td class=\"indent1\">Chickpeas (garbanzo beans)</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Corn</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Fruit (fresh, frozen or canned including apples, nectarines, peaches, watermelon)</td> <td>Whole piece of fresh fruit, 1 wedge of watermelon, or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Mayonnaise</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Oil, olive</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Oil, other (including peanut, sesame, safflower, corn, sunflower, soybean)</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Peppers, green or red</td> <td>1/2 pepper or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Potatoes</td> <td>1 potato or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Seaweed, kelp (raw)</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Tomatoes</td> <td>1 tomato or 1/2 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Foods very low in vitamin K, but have been occasionally implicated in warfarin or other drug interactions</td> </tr> <tr> <td class=\"indent1\">Cranberry juice</td> <td>4 ounces juice</td> <td rowspan=\"4\">We suggest limiting the amount of these to one or two servings per day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Grapefruit</td> <td>4 ounces juice</td> </tr> <tr> <td>1/2 grapefruit</td> </tr> <tr> <td class=\"indent1\">Green tea, brewed</td> <td>4 ounces</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For patients&nbsp;on anticoagulant therapy&nbsp;with warfarin or other vitamin K antagonists, the goal is to take in similar amounts of vitamin K daily rather than to eliminate sources of high vitamin K intake. Note that vitamins, herbs, and supplements such as calcium soft chews may contain vitamin K.<br />A separate version of this table with additional information specifically for patients is available in UpToDate. Refer to patient information on medicines to prevent blood clots (warfarin) and the table included.</div><div class=\"graphic_reference\">Data from: US Department of Agriculture, Agricultural Research Service. 2013. USDA Nutrient Database for Standard Reference, Release 25. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/nutrientdata. Accessed August 7, 2013.</div><div id=\"graphicVersion\">Graphic 78708 Version 5.0</div></div></div>"},"78709":{"type":"graphic_figure","displayName":"Classification of synthetic materials","title":"Classification of synthetic materials","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Classification of synthetic materials</div><div class=\"cntnt\"><img style=\"width:494px; height:498px;\" src=\"images/OBGYN/78709_Synthetic_mesh_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">1. Davol, Inc., Cranston, RI.<br>2. WL Gore, Inc., Flagstaff, AZ.<br>3. Dupont, Inc., Wilmington, DE.<br>4. Ethicon, Inc., Somerville, NJ.</div><div id=\"graphicVersion\">Graphic 78709 Version 3.0</div></div></div>"},"78710":{"type":"graphic_figure","displayName":"Insulin injection sites","title":"Diabetic injection sites","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Diabetic injection sites</div><div class=\"cntnt\"><img style=\"width:498px; height:607px;\" src=\"images/PC/78710_Insulin_injection_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded areas may be used for insulin injections. Injection sites should be rotated. Insulin is absorbed more rapidly when injected into the abdomen, as compared to the arms or legs.</div><div id=\"graphicVersion\">Graphic 78710 Version 2.0</div></div></div>"},"78712":{"type":"graphic_figure","displayName":"T cell regulation by cytokines","title":"T cell regulation by cytokines","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">T cell regulation by cytokines</div><div class=\"cntnt\"><img style=\"width:485px; height:608px;\" src=\"images/ALLRG/78712_Tcellregulationbycytokines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts the cytokine pathways that regulate the differentiation of T cells into effector lineages of Th1, Th2, and Th17 phenotype. These in turn mediate distinct functions in regulating cell-mediated and humoral immunity.</div><div class=\"graphic_footnotes\">DC: dendritic cell; CD: cluster of differentiation; MHC: major histocompatibility complex; L: ligand; TCR: T cell receptor; ICOSLG: inducible T cell costimulator ligand;Th: T helper cell; IL: interleukin; IFN-gamma: interferon gamma; TNF-alpha: tumor necrosis factor alpha.</div><div id=\"graphicVersion\">Graphic 78712 Version 7.0</div></div></div>"},"78715":{"type":"graphic_picture","displayName":"Chorionic villi1","title":"Chorionic villi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chorionic villi</div><div class=\"cntnt\"><img style=\"width:253px; height:166px;\" src=\"images/OBGYN/78715_Chorionic_villi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One method of distinguishing placenta from organized clot is to rinse with water and then float the tissue in a dish of water, preferably with a good light source underneath. Villi have a frond-like appearance, which has been described as similar to seaweed floating in the ocean</div><div class=\"graphic_reference\">Courtesy of Errol R Norwitz, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78715 Version 1.0</div></div></div>"},"78716":{"type":"graphic_picture","displayName":"Piper forceps","title":"Piper forceps","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Piper forceps</div><div class=\"cntnt\"><img style=\"width:462px; height:246px;\" src=\"images/OBGYN/78716_Piper_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &#169;1980 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 78716 Version 1.0</div></div></div>"},"78717":{"type":"graphic_diagnosticimage","displayName":"Pilocytic astrocytoma MRI","title":"Pilocytic astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Pilocytic astrocytoma</div><div class=\"cntnt\"><img style=\"width:549px; height:322px;\" src=\"images/ONC/78717_Pilocytic_astrocytoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cervical spine MRI postenhancement in a 20-year-old male.<br />(A) The sagittal image demonstrates a contrast-enhancing, circumscribed lesion at the C6-7 level (arrow).<br />(B) Axial images confirm this finding (arrows). The lesion was completely excised without causing neurological deficit and no radiation was administered.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of William Welch, MD.</div><div id=\"graphicVersion\">Graphic 78717 Version 3.0</div></div></div>"},"78718":{"type":"graphic_table","displayName":"Paramedic scope of practice","title":"Scope of practice for Paramedic*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scope of practice for Paramedic*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td> Orotracheal intubation of children and adults</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Nasotracheal intubation of adults</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Surgical airway</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Intravenous and intraosseous access</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Chest decompression</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Advanced rhythm interpretation</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Manual ventricular defibrillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Ventricular defibrillation of children</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Vagal maneuvers</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Synchronized cardioversion</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Transcutaneous pacing</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Comprehensive pharmacologic intervention</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Administration of nebulized albuterol</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Central line infusions</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Advanced triage</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Straightening of select fractures and reducing dislocations if neurovascular compromise is evident</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td> Advanced burn/ingestion management</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Advanced newborn resuscitation</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52010&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>EMT-P_scope_of_practice.htm</title></head></div><div class=\"graphic_footnotes\">* In addition to skills and procedures of EMT-Basic.</div><div id=\"graphicVersion\">Graphic 78718 Version 3.0</div></div></div>"},"78720":{"type":"graphic_picture","displayName":"Isolating and positioning the vas during vasectomy","title":"Isolating and positioning the vas during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isolating and positioning the vas during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:337px;\" src=\"images/PC/78720_Vas_isolation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vas deferens is positioned to lie as superficially as possible. A \"three-finger technique\" is used to manipulate the vas within the scrotum using the nondominant hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright Â©1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 78720 Version 3.0</div></div></div>"},"78721":{"type":"graphic_figure","displayName":"Voiding history question","title":"Voiding history questionaire","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Voiding history questionaire</div><div class=\"cntnt\"><img style=\"width:591px; height:586px;\" src=\"images/OBGYN/78721_Voiding_history_question.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78721 Version 1.0</div></div></div>"},"78725":{"type":"graphic_table","displayName":"Weight categories","title":"Weight categories for adults and youth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weight categories for adults and youth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Adults<br /> (18 years and older)<sup>[1]</sup></td> <td class=\"subtitle1\">Youth (2 to 18 yrs)<br /> CDC, AAP, IOM, ES, IOTF<sup>[2,3]</sup></td> </tr> <tr> <td>Underweight</td> <td>BMI &#60;18.5</td> <td>BMI &#60;5<sup>th</sup> percentile for age</td> </tr> <tr> <td>Normal weight</td> <td>BMI 18.5-24.9</td> <td>BMI &#8805;5<sup>th</sup> to &#60;85<sup>th</sup> percentile</td> </tr> <tr> <td>Overweight</td> <td>BMI 25-29.9</td> <td>BMI &#8805;85<sup>th</sup> to &#60;95<sup>th</sup> percentile</td> </tr> <tr> <td>Obesity</td> <td>BMI &#8805;30</td> <td>BMI &#8805;95<sup>th</sup> percentile</td> </tr> <tr> <td rowspan=\"2\">Severe obesity</td> <td>BMI &#8805;35 (class II obesity)</td> <td>BMI &#8805;120 percent of the 95<sup>th</sup> percentile, or a BMI &#8805;35 (whichever is lower)<sup>*[4,5]</sup></td> </tr> <tr> <td>BMI &#8805;40 (class III obesity)</td> <td>BMI &#8805;140 percent of the 95<sup>th</sup> percentile, or a BMI &#8805;40 (whichever is lower)<sup>[5]&nbsp;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AAP: American Academy of Pediatrics; IOM: Institute of Medicine; ES: Endocrine society; CDC: Centers for Disease Control; IOTF: International obesity task force; BMI: body mass index.<br />* In children, several definitions of severe obesity have been used. The most widely accepted is BMI â¥120 percent of the 95<SUP>th</SUP> percentile, <STRONG>or</STRONG> a BMI â¥35 (whichever is lower).<SUP>[3]</SUP> This corresponds to approximately the 99<SUP>th</SUP> percentile, or BMI Z-score â¥2.33 (ie, 2.33 standard deviations above the mean).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S.</LI>&#xD;&#xA;<LI>Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 Suppl 4:S164.</LI>&#xD;&#xA;<LI>Wang Y. Cross-national comparison of childhood obesity: the epidemic and the relationship between obesity and socioeconomic status. Int J Epidemiol 2001; 30:1129.</LI>&#xD;&#xA;<LI>Kelly AS, Barlow SE, Rao G, et al. Severe Obesity in Children and Adolescents: Identification, Associated Health Risks, and Treatment Approaches: A Scientific Statement From the American Heart Association. Circulation 2013.</LI>&#xD;&#xA;<LI>Skinner AC, Skelton JA. Prevalence and Trends in Obesity and Severe Obesity Among Children in the United States, 1999-2012. JAMA Pediatr 2014.</LI></OL></div><div id=\"graphicVersion\">Graphic 78725 Version 10.0</div></div></div>"},"78727":{"type":"graphic_table","displayName":"Criteria for pulmonary metastatic disease in Ewings sarcoma","title":"Criteria for pulmonary/pleural metastatic disease as used in the EURO-E.W.I.N.G.99 Ewing sarcoma trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for pulmonary/pleural metastatic disease as used in the EURO-E.W.I.N.G.99 Ewing sarcoma trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">CT chest finding</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td class=\"centered\"> <p>One or more pulmonary/pleural nodule(s) &#62;1 cm</p> <p><strong>OR</strong></p> <p>More than one nodule &#62;0.5 cm</p> </td> <td class=\"centered\">Clear evidence of metastatic disease (in the absence of other clear medical explanation for these lesions).</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\"> <p>Solitary nodule of 0.5-1 cm</p> <p><strong>OR</strong></p> <p>Multiple nodules 0.3-0.5 cm</p> </td> <td class=\"centered\">Questionable evidence of metastatic disease; biopsy proof recommended.</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\"> <p>Solitary nodule &#60;0.5 cm</p> <p><strong>OR</strong></p> <p>Several nodules &#60;0.3 cm</p> </td> <td class=\"centered\">Not clear evidence of lung disease. Individual decision-making regarding biopsy.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78727 Version 2.0</div></div></div>"},"78729":{"type":"graphic_table","displayName":"Minor congenital malformations","title":"Minor congenital malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minor congenital malformations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Head and craniofacial structures</td> </tr> <tr> <td class=\"subtitle2_single\">Skull</td> </tr> <tr> <td class=\"indent1\">Abnormal hair whorls (absence, more than two)</td> </tr> <tr> <td class=\"indent1\">Frontal bossing</td> </tr> <tr> <td class=\"indent1\">Plagiocephaly</td> </tr> <tr> <td class=\"indent1\">Flat occiput</td> </tr> <tr> <td class=\"indent1\">Metopic fontanel</td> </tr> <tr> <td class=\"subtitle2_single\">Eyes</td> </tr> <tr> <td class=\"indent1\">Epicanthal folds</td> </tr> <tr> <td class=\"indent1\">Hypotelorism</td> </tr> <tr> <td class=\"indent1\">Hypertelorism</td> </tr> <tr> <td class=\"indent1\">Upslanting or downslanting palpebral fissures</td> </tr> <tr> <td class=\"indent1\">Short palpebral fissures</td> </tr> <tr> <td class=\"indent1\">Synophrys</td> </tr> <tr> <td class=\"indent1\">Ptosis</td> </tr> <tr> <td class=\"subtitle2_single\">Ears</td> </tr> <tr> <td class=\"indent1\">Ear lobe - attached, creases, notches, or bifid</td> </tr> <tr> <td class=\"indent1\">Small ears</td> </tr> <tr> <td class=\"indent1\">Lop ear</td> </tr> <tr> <td class=\"indent1\">Cup-shaped ear</td> </tr> <tr> <td class=\"indent1\">Protruding ear</td> </tr> <tr> <td class=\"indent1\">Ear tags</td> </tr> <tr> <td class=\"indent1\">Preauricular sinuses</td> </tr> <tr> <td class=\"subtitle2_single\">Nose</td> </tr> <tr> <td class=\"indent1\">Flat bridge</td> </tr> <tr> <td class=\"indent1\">Anteverted nostrils</td> </tr> <tr> <td class=\"indent1\">Philtrum long, short, flat</td> </tr> <tr> <td class=\"subtitle2_single\">Mouth and jaw</td> </tr> <tr> <td class=\"indent1\">Microstomia</td> </tr> <tr> <td class=\"indent1\">Macrostomia</td> </tr> <tr> <td class=\"indent1\">Bifid uvula</td> </tr> <tr> <td class=\"indent1\">Multiple frenula</td> </tr> <tr> <td class=\"indent1\">Micrognathia</td> </tr> <tr> <td class=\"subtitle1_single\">Neck</td> </tr> <tr> <td class=\"indent1\">Short neck</td> </tr> <tr> <td class=\"indent1\">Webbing</td> </tr> <tr> <td class=\"indent1\">Redundant skin</td> </tr> <tr> <td class=\"indent1\">Branchial sinuses</td> </tr> <tr> <td class=\"subtitle1_single\">Chest</td> </tr> <tr> <td class=\"indent1\">Extra nipples</td> </tr> <tr> <td class=\"subtitle1_single\">Back</td> </tr> <tr> <td class=\"indent1\">Sacral dimple</td> </tr> <tr> <td class=\"subtitle1_single\">Genitalia</td> </tr> <tr> <td class=\"indent1\">Shawl scrotum</td> </tr> <tr> <td class=\"indent1\">Vaginal tags</td> </tr> <tr> <td class=\"indent1\">Minor hypospadias</td> </tr> <tr> <td class=\"subtitle1_single\">Extremities</td> </tr> <tr> <td class=\"subtitle2_single\">Arms</td> </tr> <tr> <td class=\"indent1\">Cubitus valgus</td> </tr> <tr> <td class=\"indent1\">Dimples over major joints</td> </tr> <tr> <td class=\"subtitle2_single\">Hands</td> </tr> <tr> <td class=\"indent1\">Fifth finger clinodactyly</td> </tr> <tr> <td class=\"indent1\">Single transverse palmar crease</td> </tr> <tr> <td class=\"indent1\">Bridge crease</td> </tr> <tr> <td class=\"indent1\">Tapered fingers</td> </tr> <tr> <td class=\"indent1\">Nail hypoplasia</td> </tr> <tr> <td class=\"indent1\">Persistent finger pads (fetal pads)</td> </tr> <tr> <td class=\"subtitle2_single\">Feet</td> </tr> <tr> <td class=\"indent1\">Partial syndactyly between two to three toes</td> </tr> <tr> <td class=\"indent1\">Nail hypoplasia</td> </tr> <tr> <td class=\"indent1\">Prominence of the heels</td> </tr> <tr> <td class=\"indent1\">Overlapping digits</td> </tr> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td class=\"indent1\">Nevi</td> </tr> <tr> <td class=\"indent1\">Hypo- or hyperpigmented macules</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78729 Version 4.0</div></div></div>"},"78731":{"type":"graphic_diagnosticimage","displayName":"LUL atelectasis Lateral","title":"Left upper lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:384px; height:360px;\" src=\"images/PULM/78731_LUL_atelectasis_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of left upper lobe atelectasis. The left hemithorax is occupied mostly by the hyperexpanded left lower lobe. The major fissure is markedly displaced anteriorly and delineates the collapsed left upper lobe, which is pancaked ventrally (arrows). Anterior to the collapsed left upper lobe, the hyperexpanded anterior segment of the right upper lobe is accounting for the retrosternal lucency (arrowhead) and for the clear outline of the ascending aorta.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78731 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"78732":{"type":"graphic_table","displayName":"Techniques of the initial phase of Interpersonal Psychotherapy","title":"Techniques of the initial phase of Interpersonal Psychotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques of the initial phase of Interpersonal Psychotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Diagnose major depression</td> <td>Conduct psychiatric interview, including current and past psychiatric symptoms, prior treatment history, medical history, and family psychiatric history.</td> <td>Diagnosis is essential to prescribing appropriate treatment. This information is also used to select the IPT problem area.</td> </tr> <tr> <td>Give the sick role</td> <td>Assign the patient a temporary social role that relieves him of his usual social obligations because of his medical condition (depression), while requiring him to focus on obligations associated with treatment.</td> <td>The concept of the sick role follows from the medical model in which depression is likened to other medical illness such as diabetes and asthma.</td> </tr> <tr> <td>Take an interpersonal inventory</td> <td>Evaluate important interpersonal relationships and recent significant changes that have occurred in these relationships and in psychosocial functioning.</td> <td>The clinician focuses on the quality of current interpersonal relationships and recent changes in the patient's life.</td> </tr> <tr> <td>Establish a depression timeline</td> <td>Establish the time of onset of current depressive episode (or exacerbation of depressive symptoms) and temporal relationship between changes in mood and changes in interpersonal functioning.</td> <td>Identifying the temporal relationship between current mood symptoms and onset of interpersonal problem will enable clinician to select a relevant treatment focus.</td> </tr> <tr> <td>Select an interpersonal problem area and formulate the case</td> <td>Propose a treatment focus (interpersonal problem area) that links current mood symptoms to affectively meaningful change in life circumstances.</td> <td>Patient must agree to treatment focus; if there is disagreement, clinician revises the treatment formulation.</td> </tr> <tr> <td>Provide hope</td> <td>Maintain optimism.</td> <td>Providing hope is a nonspecific therapeutic factor that is common across different psychotherapies.</td> </tr> <tr> <td>Discuss the treatment contract</td> <td>Negotiate treatment logistics including number of sessions, meeting times, fees, and procedures for managing issues that occur between sessions.</td> <td>The time-limited nature of acute IPT requires that treatment duration be specified from the outset.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78732 Version 1.0</div></div></div>"},"78733":{"type":"graphic_picture","displayName":"India ink persistent staining","title":"India ink staining","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">India ink staining</div><div class=\"cntnt\"><img style=\"width:497px; height:204px;\" src=\"images/GAST/78733_India_ink_persistent_staini.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent India ink staining is visible on colonoscopy two years after polypectomy.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 78733 Version 1.0</div></div></div>"},"78735":{"type":"graphic_table","displayName":"Classify problematic uter sarc","title":"Classification of problematic uterine smooth muscle tumors based on pathologic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of problematic uterine smooth muscle tumors based on pathologic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Group </td> <td class=\"subtitle1\">MI (per 10 HPF) </td> <td class=\"subtitle1\">Atypia </td> <td class=\"subtitle1\">Coagulatve tumor cell necrosis </td> <td class=\"subtitle1\">Designation </td> <td class=\"subtitle1\">Metastatic or recurrent disease </td> </tr> <tr> <td>I</td> <td>&#8805;5 to &#60;20</td> <td>None or mild</td> <td>None</td> <td>Leiomyoma with increased MI</td> <td>1/89</td> </tr> <tr> <td>IIA</td> <td>&#60;10</td> <td>Diffuse, moderate or severe</td> <td>None</td> <td>Atypical leiomyoma with low risk percent or recurrence</td> <td>2/46</td> </tr> <tr> <td>IIB</td> <td>&#8805;10</td> <td>Diffuse, moderate or severe</td> <td>None</td> <td>Leiomyosarcoma</td> <td>4/10</td> </tr> <tr> <td>III</td> <td>&#8804;20</td> <td>Diffuse, moderate to severe</td> <td>Present</td> <td>Leiomyosarcoma</td> <td>19/33</td> </tr> <tr> <td>IVA</td> <td>&#60;10</td> <td>None to mild</td> <td>Present</td> <td>Smooth muscle tumors of low malignant potential, limited experience</td> <td>1/4</td> </tr> <tr> <td>IVB</td> <td>&#8805;10</td> <td>None to mild</td> <td>Present</td> <td>Leiomyosarcoma</td> <td>3/4</td> </tr> <tr> <td>V</td> <td>&#8805;1 to &#8804;20</td> <td>Multifocal, moderate to severe</td> <td>None</td> <td>Atypical leiomyoma, limited experience</td> <td>0/5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: mitotic index; HPF: high power fields.</div><div class=\"graphic_reference\">Data from: Bell SW, Kempson RL, Hendrickson MR.&nbsp;Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.</div><div id=\"graphicVersion\">Graphic 78735 Version 4.0</div></div></div>"},"78736":{"type":"graphic_table","displayName":"NCI CTCAE v5 neurotoxicity","title":"NCI CTCAE v5.0 neurotoxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 neurotoxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Paresthesia</td> <td>Mild symptoms</td> <td>Moderate symptoms; limiting instrumental ADL*</td> <td>Severe symptoms; limiting self-care ADL*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Peripheral motor neuropathy</td> <td>Asymptomatic; clinical or diagnostic observations only</td> <td>Moderate symptoms; limiting instrumental ADL*</td> <td>Severe symptoms; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> <tr> <td>Peripheral sensory neuropathy</td> <td>Asymptomatic</td> <td>Moderate symptoms; limiting instrumental ADL*</td> <td>Severe symptoms; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Paresthesia is characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a stimulus. Peripheral motor neuropathy is characterized by inflammation or degeneration of the peripheral motor nerves. Peripheral sensory neuropathy is characterized by inflammation or degeneration of the peripheral sensory nerves.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 78736 Version 14.0</div></div></div>"},"78737":{"type":"graphic_table","displayName":"OI clinical features","title":"Clinical features of osteogenesis imperfecta (OI) by type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of osteogenesis imperfecta (OI) by type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type<br /> (MIM#)</td> <td class=\"subtitle1\">Inheritance<br /> (gene)</td> <td class=\"subtitle1\">Severity</td> <td class=\"subtitle1\">Fractures</td> <td class=\"subtitle1\">Bone deformity</td> <td class=\"subtitle1\">Stature</td> <td class=\"subtitle1\">DI</td> <td class=\"subtitle1\">Sclerae</td> <td class=\"subtitle1\">Hearing loss</td> </tr> <tr> <td>I<br /> (#166200)</td> <td>AD (COL1A1 or COL1A2)</td> <td>Mild</td> <td>Few to 100</td> <td>Uncommon</td> <td>Normal or slightly short for family</td> <td>Rare</td> <td>Blue</td> <td>Present in&nbsp;approximately 50%</td> </tr> <tr> <td>II<br /> (IIA - #166210, IIB - #610854)</td> <td> <p>AD (IIA - CO1A1 or COL1A2)</p> AR (IIB - CRTAP)</td> <td>Perinatal lethal</td> <td>Multiple</td> <td>Severe</td> <td>Severely short stature</td> <td>+</td> <td> <p>IIA - Dark blue</p> IIB - Light blue</td> <td>&ndash;</td> </tr> <tr> <td>III<br /> (#259420)</td> <td>AD; (COL1A1 or COL1A2)</td> <td>Severe</td> <td>Multiple</td> <td>Moderate to severe</td> <td>Very short</td> <td>+</td> <td>Blue at birth, becoming normal with age</td> <td>Frequent</td> </tr> <tr> <td>IV<br /> (#166220)</td> <td>AD (COL1A1 or COL1A2)</td> <td>Moderate to mild</td> <td>Multiple</td> <td>Mild to moderate</td> <td>Variably short stature</td> <td>+/&ndash;</td> <td>Normal to gray</td> <td>Some</td> </tr> <tr> <td>V<br /> (#610967)</td> <td>AD (IFITM5)</td> <td>Moderate</td> <td>Multiple with hypertrophic callus</td> <td>Moderate</td> <td>Variable</td> <td>No</td> <td>Normal</td> <td>No</td> </tr> <tr> <td>VI<br /> (#610968)</td> <td>AR (SERPINF1); rarely AD with parental mosaicism</td> <td>Moderate</td> <td>Multiple</td> <td>Rhizomelic shortening</td> <td>Mild short stature</td> <td>No</td> <td>Normal to faintly blue</td> <td>No</td> </tr> <tr> <td>VII<br /> (#610682)</td> <td>AR (CRTAP)</td> <td>Moderate</td> <td>Multiple</td> <td>Yes</td> <td>Mild short stature</td> <td>No</td> <td>Normal to faintly blue</td> <td>No</td> </tr> <tr> <td>VIII<br /> (#610915)</td> <td>AR (LEPRE1)</td> <td>Lethal/severe</td> <td>Multiple</td> <td>Moderate to severe; bulbous \"popcorn\" sepiphyses</td> <td>Short-limbed dwarfism</td> <td>No</td> <td>Normal</td> <td>Not reported</td> </tr> <tr> <td>IX<br /> (#259440)</td> <td>AR (PPIB)</td> <td>Lethal/severe</td> <td>Multiple</td> <td>Moderate to severe</td> <td>Short-limbed dwarfism</td> <td>+</td> <td>Blue</td> <td>No</td> </tr> <tr> <td>X (#613848)</td> <td>AR (SERPINH1)</td> <td>Lethal/severe</td> <td>Multiple</td> <td>Severe</td> <td>Severe short stature</td> <td>+</td> <td>Blue</td> <td>Not reported</td> </tr> <tr> <td>XI (#607063)</td> <td>AR (FKBP10)</td> <td>Severe</td> <td>Multiple</td> <td>Severe</td> <td>Severe short stature</td> <td>No</td> <td>Normal</td> <td>Not reported</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DI: dentinogenesis imperfecta; AD: autosomal dominant; AR: autosomal recessive; COL1A1: collagen, type I, alpha-1; COL1A2: collagen, type I, alpha-2;&nbsp;CRTAP: cartilage-associated protein; IFITM5: interferon-induced transmembrane protein 5; SERPINF1: serpin peptidase inhibitor, clade F, member 1;&nbsp;LEPRE1: leucine- and proline-enriched proteoglycan 1; PPIB: peptidyl-prolyl isomerase B; SERPINH1: serpin peptidase inhibitor, clade H, member 1; FKBP10: FK506-binding protein 10.</div><div class=\"graphic_reference\">Modified and updated from: Steiner RD, Pepin MG, Byers PH. Osteogenesis Imperfecta. GeneReviews at GeneTests: Medical Genetics Information Resource, January 2005.</div><div id=\"graphicVersion\">Graphic 78737 Version 14.0</div></div></div>"},"78738":{"type":"graphic_diagnosticimage","displayName":"Foraminal encroachment radiograph","title":"Oblique neck film for foraminal encroachment","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Oblique neck film for foraminal encroachment</div><div class=\"cntnt\"><img style=\"width:455px; height:433px;\" src=\"images/PC/78738_Foraminal_encroachment_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique views are primarily used to determine the role of foraminal encroachment. This 54-year-old patient presented with a gradual onset of numbness and tingling of the middle fingers of the right hand. Symptoms waxed and waned over a period of several months. The triceps reflex and muscle strength were normal. The oblique film demonstrates C6-7 foraminal encroachment.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 78738 Version 3.0</div></div></div>"},"78739":{"type":"graphic_diagnosticimage","displayName":"Central lung tumor PET","title":"Central bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Central bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:531px; height:450px;\" src=\"images/PULM/78739_Central_lung_tumor_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two coronal (top) and one axial PET scan (left) show marked glucose uptake in the central region of the collapsed lung as well as cirumferential uptake in the periphery of the lung. The glucose avid lymph node (arrow) in the left axilla was biopsied and proved to be inflammatory.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78739 Version 3.0</div></div></div>"},"78740":{"type":"graphic_diagnosticimage","displayName":"Hand arthritis in HH","title":"Hand arthritis in hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand arthritis in hemochromatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:233px;\" src=\"images/RHEUM/78740_Hand_arthritis_in_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial radiographs, five years apart, of the metacarpophalangeal joints in a patient with hereditary hemochromatosis. The second film shows loss of joint space at the metacarpophalangeal articulations, cyst formation, and a hook-like osteophyte on the radial aspect of the metacarpal head of the middle finger.</div><div class=\"graphic_reference\">Courtesy of John S Axford, BSc, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 78740 Version 2.0</div></div></div>"},"78743":{"type":"graphic_picture","displayName":"Testes in phenotypic female","title":"Perineoscrotal hypospadias with palpable gonads","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perineoscrotal hypospadias with palpable gonads</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/PEDS/78743_Testes_in_phenotypic_female.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had a 46,XY karyotype, micropenis, palpable testes, perineoscrotal hypospadias, and a bifid scrotum.</div><div class=\"graphic_reference\">Courtesy Christopher P Houk, MD and Lynne L Levitsky, MD.</div><div id=\"graphicVersion\">Graphic 78743 Version 1.0</div></div></div>"},"78744":{"type":"graphic_table","displayName":"Management anaphylaxis reaction","title":"Pharmacologic management of anaphylactic reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic management of anaphylactic reactions</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Initial management</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Epinephrine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intravenous fluids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diphenhydramine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cimetidine or other H2 blocker</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrocortisone or equivalent steroid</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aerosolized beta-agonists and epinephrine</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Persistent hypotension and/or bronchospasm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vasopressors (epinephrine, dopamine, norepinephrine, phenylephrine)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glucagon (for those patients on beta-blockers)</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=66304&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Management_anaphylaxis_reac.htm</title></head></div><div id=\"graphicVersion\">Graphic 78744 Version 1.0</div></div></div>"},"78745":{"type":"graphic_diagnosticimage","displayName":"Rounded atelectasis CT","title":"CT scan of rounded atelectasis in the right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of rounded atelectasis in the right lower lobe</div><div class=\"cntnt\"><img style=\"width:324px; height:290px;\" src=\"images/PULM/78745_Rounded_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows a subpleural mass in the right lower lobe with tentacle-like extensions towards the hilum (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78745 Version 3.0</div></div></div>"},"78746":{"type":"graphic_figure","displayName":"Thermal relaxation time in skin","title":"Thermal relaxation time","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thermal relaxation time</div><div class=\"cntnt\"><img style=\"width:398px; height:389px;\" src=\"images/DERM/78746_Thermal-relaxation-time.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thermal relaxation time is the amount of time that it takes an object to return to the ambient temperature following heating. When continuous wave lasers heat targets for longer than the thermal relaxation time, heat diffuses to adjacent tissues, where it can induce collateral damage. When light is emitted in pulses that are shorter than the target's thermal relaxation time, diffusion of heat to adjacent tissues is limited.</div><div id=\"graphicVersion\">Graphic 78746 Version 6.0</div></div></div>"},"78747":{"type":"graphic_picture","displayName":"Rosacea papules and pustules","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/78747_Rosaceapapspustules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory papules and pustules are present on the nose and cheeks.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78747 Version 4.0</div></div></div>"},"78748":{"type":"graphic_algorithm","displayName":"Management of a small parapneumonic effusion in children","title":"Management of a small parapneumonic effusion in children","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Management of a small parapneumonic effusion in children</div><div class=\"cntnt\"><img style=\"width:596px; height:313px;\" src=\"images/PEDS/78748_Manag_mild_parapneum_2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* A small effusion is defined as &lt;10 mm on a lateral decubitus radiograph, or one that opacifies less than one-fourth of the hemithorax.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Courtesy of Khoulood Fakhoury.&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 78748 Version 2.0</div></div></div>"},"78749":{"type":"graphic_table","displayName":"Antiemetics by etiology","title":"Selection of antiemetics by clinical situation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of antiemetics by clinical situation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Situation</td> <td class=\"subtitle1\">Associated neurotransmitters</td> <td class=\"subtitle1\">Recommended antiemetic</td> </tr> <tr> <td rowspan=\"2\">Migraine headache</td> <td rowspan=\"2\">Dopamine (probably a primary mediator)</td> <td>For headache and nausea: metoclopramide or prochlorperazine </td> </tr> <tr> <td>For nausea: oral antiemetics, metoclopramide, prochlorperazine, serotonin antagonists</td> </tr> <tr class=\"divider_top\"> <td>Vestibular nausea</td> <td>Histamine, acetylcholine</td> <td>Antihistamines and anticholinergics (equally effective)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Pregnancy-induced nausea</td> <td rowspan=\"2\">Unknown</td> <td>For nausea: ginger, vitamin B6</td> </tr> <tr> <td>For hyperemesis gravidarum: promethazine (first-line agent); serotonin antagonists and corticosteroids (second-line agents)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Gastroenteritis</td> <td rowspan=\"3\">Dopamine, serotonin</td> <td>First-line agents: dopamine antagonists</td> </tr> <tr> <td>Second-line agents: serotonin antagonists</td> </tr> <tr> <td>Use in children is controversial</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Postoperative nausea and vomiting</td> <td rowspan=\"2\">Dopamine, serotonin</td> <td>Prevention: serotonin antagonists, droperidol, dexamethasone</td> </tr> <tr> <td>Treatment: dopamine antagonists, serotonin antagonists, dexamethasone</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.</div><div id=\"graphicVersion\">Graphic 78749 Version 4.0</div></div></div>"},"78751":{"type":"graphic_diagnosticimage","displayName":"Unstable lateral malleolar fracture","title":"Unstable lateral malleolar fracture","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Unstable lateral malleolar fracture</div><div class=\"cntnt\"><img style=\"width:540px; height:400px;\" src=\"images/EM/78751_Unstable_lat_malleolar_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In addition to the displaced, oblique fracture of the lateral malleolus (black arrows), widening of the medial joint space (white arrow), indicating ligament disruption, is also evident on this x-ray. This unstable injury requires surgical fixation.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 78751 Version 2.0</div></div></div>"},"78752":{"type":"graphic_figure","displayName":"Heel pocket out method","title":"Heel-pocket-out method of putting on compression stockings","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Heel-pocket-out method of putting on compression stockings</div><div class=\"cntnt\"><img style=\"width:456px; height:611px;\" src=\"images/PC/78752_Heel_pocket_out_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stockings can be applied by turning the leg portion of the stocking inside-out down to the heel(A). The foot is slipped into the stretched stocking and pulled onto the foot by its folded edge (B). Once the stocking is over the heel, the remainder of the stocking can be gathered and progressively turned right-side out and gently worked up the leg (C).</div><div id=\"graphicVersion\">Graphic 78752 Version 1.0</div></div></div>"},"78753":{"type":"graphic_figure","displayName":"Structure amino acids","title":"Chemical structure of amino acids","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Chemical structure of amino acids</div><div class=\"cntnt\"><img style=\"width:491px; height:707px;\" src=\"images/PC/78753_Structure_amino_acids.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78753 Version 1.0</div></div></div>"},"78755":{"type":"graphic_picture","displayName":"Fusarium finger cellulitis","title":"<EM>Fusarium </EM>finger cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium </EM>finger cellulitis</div><div class=\"cntnt\"><img style=\"width:141px; height:189px;\" src=\"images/ID/78755_Fusarium_finger_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Fusarium</EM> onychomycosis of the fingernail showing whitish discoloration of the proximal nail and brownish discoloration of the middle region of the nail in association with paronychia of the adjacent skin.</div><div class=\"graphic_reference\">This research was originally published in Blood. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematolotic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999. Copyright Â© 1997 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 78755 Version 2.0</div></div></div>"},"78757":{"type":"graphic_figure","displayName":"Pediatric hip fracture classification","title":"Delbet classification of hip fractures in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delbet classification of hip fractures in children</div><div class=\"cntnt\"><img style=\"width:396px; height:546px;\" src=\"images/EM/78757_Hipfxchildclassification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Delbet classification of hip fractures in children. I: transepiphyseal with (IB) or without (IA) dislocation from the acetabulum; II: transcervical; III: cervicotrochanteric; and IV: intertrochanteric.</div><div class=\"graphic_reference\">Reproduced with permission from: McCarthy J, Noonan K. Fractures and traumatic dislocations of the hip in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. &nbsp;</div><div id=\"graphicVersion\">Graphic 78757 Version 11.0</div></div></div>"},"78758":{"type":"graphic_table","displayName":"Clindamycin dosing for adults","title":"Dosing of clindamycin for adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of clindamycin for adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indication </td> <td class=\"subtitle1\">Dose/formulation</td> </tr> <tr> <td>Acne rosacea</td> <td>1% lotion, apply to affected area twice daily</td> </tr> <tr> <td>Acne vulgaris</td> <td>1% lotion, apply to affected area twice daily</td> </tr> <tr> <td>Toxoplasma encephalitis</td> <td>900 mg IV every 8 hours or 600 mg orally every 6 hours for&nbsp;3 to&nbsp;6 weeks, then 300 to 450 mg orally every 6 to 12 hours (plus pyrimethamine 50 to 75 mg orally daily)</td> </tr> <tr> <td><em>Pneumocystis carinii </em>pneumonia</td> <td>900 mg IV every 8 hours initially, then 450 mg orally every 6 hours (plus primaquine 30 mg&nbsp;orally once daily)</td> </tr> <tr> <td>Babesiosis</td> <td>300 to 600 mg IV or IM every 6 hours (plus quinine 650 mg every 4 to 6 hours)</td> </tr> <tr> <td>Pelvic inflammatory disease</td> <td>900 mg IV every 8 hours (plus gentamicin) followed by 450 mg orally every&nbsp;6 hours for a total of 14 days</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Bacterial vaginosis</td> </tr> <tr> <td class=\"sublist1\">Nonpregnant women</td> <td class=\"sublist_other\">2% cream, one full applicator intravaginally at bedtime for&nbsp;7 days; (alternative regimen) 300 mg orally twice daily for&nbsp;7 days</td> </tr> <tr> <td class=\"sublist1\">Pregnant women</td> <td class=\"sublist_other\">300 mg orally twice daily for&nbsp;7 days; topical cream should <strong>not</strong> be used in pregnant women</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Prophylaxis</td> </tr> <tr> <td class=\"sublist1\">Surgical - head and neck</td> <td class=\"sublist_other\">600 mg IV 1 to 2 hours preoperatively and continued every 8 hours for&nbsp;4 doses</td> </tr> <tr> <td class=\"sublist1\">Bacterial endocarditis </td> <td class=\"sublist_other\">600 mg&nbsp;orally 1 hour prior to the procedure or 600 mg IV within 30 minutes of the procedure</td> </tr> <tr> <td><em>Plasmodium falciparum </em>malaria</td> <td>(Alternative regimen) 900 mg&nbsp;orally&nbsp;3 times per day for&nbsp;3 to&nbsp;5 days (plus quinine)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: intravenously; IM: intramuscularly.</div><div id=\"graphicVersion\">Graphic 78758 Version 4.0</div></div></div>"},"78759":{"type":"graphic_table","displayName":"Standard PD solution","title":"Standard peritoneal dialysis solution","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standard peritoneal dialysis solution</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Volume (liters)</td> <td>0.25, 0.5, 1, 1.5, 2.5, 3, 5, 6</td> </tr> <tr> <td>Sodium (mEq/L)</td> <td>132</td> </tr> <tr> <td>Potassium (mEq/L)</td> <td>0 to 2, mostly 0</td> </tr> <tr> <td>Glucose (g/dL)</td> <td>1.5, 2.5, 4, 25</td> </tr> <tr> <td>Calcium (mEq/L)</td> <td>2.5 to 3.5</td> </tr> <tr> <td>Magnesium (mEq/L)</td> <td>0.5 to 1.5</td> </tr> <tr> <td>Lactate (mEq/L)</td> <td>35 to 40</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dinesh Chatoth, MD.</div><div id=\"graphicVersion\">Graphic 78759 Version 3.0</div></div></div>"},"78760":{"type":"graphic_diagnosticimage","displayName":"MRI imaging to measure the airway and related structures","title":"MRI imaging to measure the airway and related structures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI imaging to measure the airway and related structures</div><div class=\"cntnt\"><img style=\"width:407px; height:483px;\" src=\"images/PEDS/78760_Anatomical_outline_T1_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI) of a healthy subject. A) Anatomical outlines of an axial T1 image at the level of the maximal tonsillar area. Transverse red arrow represents the intermandibular distance. B) Anatomical outlines of a midsagittal T1 image. Oblique red arrow represents the mental spine-clivus oblique distance.</div><div class=\"graphic_reference\">Reproduced with permission from Arens R, McDonough JM, Costarino A, et al. Magnetic resonance imaging of the upper airway structure of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2001; 164:6998. Official Journal of the American Thoracic Society. Copyright Â© 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 78760 Version 3.0</div></div></div>"},"78761":{"type":"graphic_figure","displayName":"Strep throat PI","title":"Strep throat","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Strep throat</div><div class=\"cntnt\"><img style=\"width:534px; height:383px;\" src=\"images/PI/78761_Strep_throat_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strep throat can make the roof of your mouth turn red and your tonsils white. It can also make your uvula swell.</div><div id=\"graphicVersion\">Graphic 78761 Version 6.0</div></div></div>"},"78762":{"type":"graphic_diagnosticimage","displayName":"Cylindrical bronchiectasis RML","title":"Cylindrical bronchiectasis in the right middle lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cylindrical bronchiectasis in the right middle lobe</div><div class=\"cntnt\"><img style=\"width:338px; height:283px;\" src=\"images/PULM/78762_Cylindrical_bronchiectasi2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple circular lucencies (arrow) are seen in the contracted middle lobe, most likely as part of a so-called right middle lobe syndrome.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78762 Version 2.0</div></div></div>"},"78763":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis lung transplant","title":"Antimicrobial prophylaxis after lung transplantation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis after lung transplantation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bacterial<sup>&#182;</sup>:</td> </tr> <tr> <td>Ceftazidime 2 g IV 60 minutes before incision, then 1 g IV every 8 hours<sup>&#916;&#9674;&#167;</sup></td> </tr> <tr> <td>Vancomycin 15 mg/kg IV 120 minutes before incision, then&nbsp;15 mg/kg&nbsp;IV every 12 hours<sup>&#916;&#167;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Fungal:</td> </tr> <tr> <td>Inhaled nebulized amphotericin B lipid complex (ABLC) 50 mg daily for extubated patients and 100 mg daily for intubated patients; regimen should continue for four days following transplantation, then weekly while hospitalized</td> </tr> <tr> <td>Nystatin suspension 100,000 units per mL; 5 mL swish &#38; swallow four times per day for 6 months post-transplant</td> </tr> <tr> <td>Voriconazole 6 mg/kg IV (or 400 mg orally) every 12 hours for two doses, then 4 mg/kg IV (or 200 mg orally) every 12 hours for up to 4 months post-transplant<sup>&#165;&#135;&#134;</sup></td> </tr> <tr> <td class=\"subtitle1_single\"><em>Pneumocystis jirovecii </em>(formerly <em>P. carinii</em>):</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole 1 double-strength tablet orally daily or three times per week or 1 single-strength tablet orally daily&nbsp;starting within one week postoperatively, continuing indefinitely<sup>&#916;,</sup>**<sup>,&#182;&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_left\"><span class=\"subtitle1_left\">Cytomegalovirus:</span></td> </tr> <tr> <td>Valganciclovir 900 mg orally once daily<sup>&#916;,&#916;&#916; <strong></strong></sup><strong>or</strong></td> </tr> <tr> <td>Ganciclovir 5 mg/kg IV once daily<sup>&#916;,&#916;&#916;</sup></td> </tr> <tr> <td class=\"subtitle1_left\">Herpes simplex virus and varicella-zoster virus<sup>&#9674;&#9674;</sup>:</td> </tr> <tr> <td>Acyclovir 400 or 800 mg orally twice daily<sup>&#916;</sup> <strong>or</strong></td> </tr> <tr> <td>Valacyclovir 500 mg orally twice daily<sup>&#916;</sup> <strong>or</strong></td> </tr> <tr> <td>Famciclovir 500 mg orally twice daily<sup>&#916;</sup> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />*&nbsp;The approach to antimicrobial prophylaxis varies by transplant center and by the patient's individual risk factors. Some examples of agents for prophylaxis are listed above. Refer to the appropriate UpToDate&nbsp;topic reviews for specific prophylaxis indications and recommendations.<br />Â¶&nbsp;The standard regimen should be adjusted as indicated to include coverage for any other known preoperative pathogens in the recipient. This is particularly indicated for recipients with cystic fibrosis, bronchiectasis, and other septic lung diseases. Coverage should also be modified to include any additional organisms identified from donor bronchial washings.<br />Î Doses should be adjusted for renal insufficiency.<br />â&nbsp;If ceftazidime is not available, alternative beta-lactams with anti-pseudomonal activity include cefepime and piperacillin-tazobactam. Patients who are allergic to beta-lactams should receive levofloxacin 750 mg IV 120 minutes before incision, then 750 mg every 24 hours.<br />Â§&nbsp;The optimal duration of antimicrobial prophylaxis is uncertain, varies at different transplant centers, and is determined based upon several patient-specific factors. For patients without septic lung disease (eg, cystic fibrosis) who have an uncomplicated course following transplantation, we typically continue systemic antibacterial prophylaxis for 72 hours to allow time to determine whether donor cultures are positive. For patients with septic lung disease or complicating factors such as a chest that remains open following transplantation, longer durations are appropriate.<br />Â¥&nbsp;Systemic antifungal prophylaxis with voriconazole is given to selected patients at increased risk for invasive fungal infections. Refer to the topic review on fungal infections in lung transplant recipients for indications for systemic antifungal prophylaxis with voriconazole.<br />â¡&nbsp;When voriconazole (or another azole) is used, the clinician must be aware of its significant interactions with tacrolimus, cyclosporine, and sirolimus and reduce the dose of the immunosuppressant agent accordingly.<br />â &nbsp;Intravenous voriconazole should generally be avoided in patients with renal insufficiency (CrCl &lt;50 mL/min) due to accumulation of the cyclodextrin vehicle; oral voriconazole does not contain the cyclodextrin vehicle. Refer to the UpToDate topic review on pharmacology of azoles for additional details.&nbsp;<br />**&nbsp;Alternate choices for patients with sulfonamide hypersensitivity: Atovaquone 1500 mg orally once daily with food or dapsone 50 mg or 100 mg orally once daily&nbsp;or aerosolized pentamidine 300 mg monthly or 4 mg/kg pentamidine IV monthly, continuing indefinitely.<br />Â¶Â¶&nbsp;For<EM> Toxoplasma gondii</EM>&nbsp;mismatch (donor seropositive/recipient seronegative), trimethoprim-sulfamethoxazole should be dosed at 1 double-strength tablet orally once daily.<br />ÎÎ&nbsp;The duration of cytomegalovirus (CMV) prophylaxis varies. Refer to the UpToDate topic review on prevention of CMV in lung transplant recipients for detailed recommendations.&nbsp;&nbsp;<br />ââ CMV prophylaxis with valganciclovir or ganciclovir will effectively prevent most cases of herpes simplex virus (HSV) and varicella-zoster virus (VZV). Specific HSV and VZV prophylaxis is therefore indicated only for patients not receiving CMV prophylaxis. HSV and VZV prophylaxis is typically given for three to six months following transplantation and during periods of lymphodepletion for the treatment of rejection. </div><div id=\"graphicVersion\">Graphic 78763 Version 6.0</div></div></div>"},"78764":{"type":"graphic_figure","displayName":"Fluence formula","title":"Energy fluence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Energy fluence</div><div class=\"cntnt\"><img style=\"width:450px; height:188px;\" src=\"images/DERM/78764_Fluence_formula.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78764 Version 1.0</div></div></div>"},"78765":{"type":"graphic_picture","displayName":"Ependymoma","title":"Ependymoma","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Ependymoma</div><div class=\"cntnt\"><img style=\"width:503px; height:376px;\" src=\"images/ONC/78765_Ependymoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A true ependymal rosette is present in the upper left portion of the photomicrograph and a perivascular pseudorosette in the lower right-- both cardinal histological features of ependymoma.</div><div class=\"graphic_reference\">Courtesy of Dr. David Louis.</div><div id=\"graphicVersion\">Graphic 78765 Version 1.0</div></div></div>"},"78766":{"type":"graphic_waveform","displayName":"ECG atypical Mobitz type I AV block","title":"Electrocardiogram (ECG) showing atypical Mobitz type I (Wenckebach) atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing atypical Mobitz type I (Wenckebach) atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:391px; height:150px;\" src=\"images/CARD/78766_Atypical_Wenckebach_AV_bloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single lead electrocardiogram (ECG) strip showing an atypical Mobitz type I&nbsp;(Wenckebach) AV block with 18:17 ratio. The last three cycles of the group, the skipped beat (with the P wave lost in the T wave; arrow), and the first three cycles of the next group are shown. The last three cycles had a PR interval of 0.36 sec while the first three cycles showed PR intervals of 0.23, 0.32 and 0.34 sec with a decreasing R-R interval. This demonstrates the importance of comparing the PR interval of the last beat before the dropped QRS to the PR interval of the first and second beats of the new cycle. The PR interval is the longest in the beat before the dropped beat, shortest in the first beat of the cycle, and increases in the second beat.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 78766 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"78767":{"type":"graphic_figure","displayName":"Frameshift mutation","title":"Frameshift mutation","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Frameshift mutation</div><div class=\"cntnt\"><img style=\"width:496px; height:269px;\" src=\"images/ALLRG/78767_Frameshift_mutation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: United States National Library of Medicine. Available online at: http://ghr.nlm.nih.gov/handbook/illustrations/frameshift (Accessed on 1/12/2009).</div><div id=\"graphicVersion\">Graphic 78767 Version 1.0</div></div></div>"},"78768":{"type":"graphic_movie","displayName":"Fistula tract","title":"Fistula tract","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fistula tract</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/78768_fistulatractconv.mp4\" style=\"width:354px;height:256px\"></div><img style=\"width:349px; height:291px;\" src=\"images/CARD/78768_fistulatract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air within the fistula tract (arrow) seen during endorectal ultrasonography.</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 78768 Version 2.0</div></div></div>"},"78770":{"type":"graphic_picture","displayName":"Cat scratch disease typical papular lesion","title":"Typical papular lesion on the finger of a child with cat scratch disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical papular lesion on the finger of a child with cat scratch disease</div><div class=\"cntnt\"><img style=\"width:371px; height:278px;\" src=\"images/PEDS/78770_CSD_typical_papular_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 78770 Version 2.0</div></div></div>"},"78772":{"type":"graphic_figure","displayName":"Glucocorticoid cellular effects","title":"Cellular effects of glucocorticoids","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Cellular effects of glucocorticoids</div><div class=\"cntnt\"><img style=\"width:542px; height:354px;\" src=\"images/PULM/78772_Steroid_cellular_effects.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78772 Version 2.0</div></div></div>"},"78773":{"type":"graphic_diagnosticimage","displayName":"Labral tear MR arthrogram","title":"Superior glenoid labral tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior glenoid labral tear</div><div class=\"cntnt\"><img style=\"width:399px; height:456px;\" src=\"images/RHEUM/78773_Labral_tear_MR_arthogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1 fat suppressed MR arthrogram of the left shoulder shows a tear of the superior glenoid labrum (arrow).</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Shahla Modaressi, MD, and Cecilia Jude, MD.</div><div id=\"graphicVersion\">Graphic 78773 Version 6.0</div></div></div>"},"78774":{"type":"graphic_table","displayName":"Pattern analysis","title":"Pattern analysis (modified)<sup>[1-6]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pattern analysis (modified)<sup>[1-6]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Global features</td> </tr> <tr> <td class=\"subtitle2\">Pattern</td> <td class=\"subtitle2\">Pigment distribution/variant</td> <td class=\"subtitle2\">Diagnostic associations</td> </tr> <tr> <td><strong>Reticular pattern</strong></td> <td> <ol> <li>Diffuse </li> <li>Patchy </li> <li>Central hyperpigmentation </li> <li>Central hypopigmentation </li> <li>Central globules </li> </ol> </td> <td>Acquired melanocytic nevus or congenital melanocytic nevus</td> </tr> <tr> <td><strong>Globular pattern</strong></td> <td>Cobblestone pattern</td> <td>Usually congenital melanocytic nevi</td> </tr> <tr> <td rowspan=\"3\"><strong>Homogeneous pattern</strong></td> <td>Gray-blue</td> <td>Blue nevus</td> </tr> <tr> <td>Brown</td> <td>Usually congenital melanocytic nevi</td> </tr> <tr> <td>Tan-pink</td> <td>Nevi in fair skin</td> </tr> <tr> <td><strong>Starburst pattern</strong></td> <td>Peripheral globules</td> <td>Spitz/Reed nevus</td> </tr> <tr> <td><strong>Two component pattern</strong></td> <td>&nbsp;</td> <td>Acquired of congenital melanocytic nevi</td> </tr> <tr> <td><strong>Multicomponent pattern</strong></td> <td>&nbsp;</td> <td> <p>Melanoma</p> <p>Congenital nevi or acquired dysplastic nevi</p> </td> </tr> <tr> <td><strong>Parallel pattern</strong></td> <td>&nbsp;</td> <td> <p>Nevi on volar skin</p> <p>Melanoma</p> </td> </tr> <tr> <td><strong>Non-specific pattern</strong></td> <td>&nbsp;</td> <td>Melanoma must be ruled out</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Local features</td> </tr> <tr> <td class=\"subtitle2\">Criteria</td> <td class=\"subtitle2\">Variants</td> <td class=\"subtitle2\">Diagnostic associations</td> </tr> <tr> <td rowspan=\"2\"><strong>Pigment network</strong></td> <td><em>Typical</em><br /> Light to dark-brown network with uniformly pigmented lines and hypopigmented holes. Network tends to fade at the periphery.</td> <td>Benign melanocytic lesion</td> </tr> <tr> <td><em>Atypical</em><br /> Increased variability in the width of the network lines, their color and distribution. The holes sizes also have increased variability. May end abruptly at the periphery.<sup>[6]</sup></td> <td> <p>Dysplastic nevi</p> <p>Melanoma/Spitz</p> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Negative network</strong></td> <td><em>Regular</em><br /> Symmetrically located within the lesion.</td> <td>CMN, Spitz nevi</td> </tr> <tr> <td><em>Irregular</em><br /> Diffuse throughout the lesion or focally located.</td> <td>Melanoma/Spitz</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Dots</strong></td> <td><em>Regular</em><br /> Located on top of the pigmented network or at the center of the lesion.</td> <td>Benign melanocytic lesion</td> </tr> <tr> <td><em>Irregular</em><br /> Not associated with the pigmented network or located at the periphery of the lesion.</td> <td>Melanoma/Spitz</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Globules</strong></td> <td><em>Regular</em><br /> Multiple globules regularly distributed within the lesion or symmetrically located in the center or around the entire periphery.</td> <td>Benign melanocytic lesion</td> </tr> <tr> <td><em>Irregular</em><br /> Multiple globules of different size, shape, and color. Asymmetrically and/or focally distributed within the lesion.</td> <td>Melanoma/Spitz<sup>[7]</sup></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Streaks</strong> (pseudopods and radial streaming)</td> <td><em>Regular</em><br /> Radial projections at the periphery of the lesion, distributed around the entire perimeter of the lesion, extending from the tumor toward the surrounding normal skin.<sup>[8]</sup></td> <td>Spitz/Reed nevus</td> </tr> <tr> <td><em>Irregular</em><br /> Radial projections at the periphery of the lesion; irregularly, asymmetric and focally distributed.<sup>[8]</sup></td> <td>Melanoma/Spitz</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Blue-white veil over papular areas</strong></td> <td><em>Regular</em><br /> Tend to be centrally located or homogeneous throughout the lesion.</td> <td>Blue nevi/Spitz</td> </tr> <tr> <td><em>Irregular</em><br /> Tends to be asymmetrically located or diffuse throughout the lesion, but with different hues.</td> <td>Melanoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Regression structures</strong> (consists of granularity and scar-like areas. When both are present together, it gives the appearance of a blue-white veil over macular areas)<sup>[9]</sup></td> <td><em>Regular</em><br /> Tend to be symmetrically located and cover less than 10 percent of the lesion.</td> <td>Nevus</td> </tr> <tr> <td><em>Irregular</em><br /> Tends to be asymmetrically located and often involves more than 50 percent of the lesion.</td> <td>Melanoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Hypopigmented areas</strong> (structureless/homogeneous)</td> <td><em>Regular</em><br /> Centrally located with peripheral network.</td> <td>Nevus</td> </tr> <tr> <td><em>Irregular</em><br /> Structureless light brown area, located at the periphery of the lesion, larger than 10 percent of a lesion<sup>[10]</sup>.</td> <td>Melanoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Blotch</strong></td> <td><em>Regular</em><br /> One blotch located in the center of the lesion.</td> <td>Acquired melanocytic nevus</td> </tr> <tr> <td><em>Irregular</em><br /> Asymmetrically and/or focally located at the periphery. Eccentric peripheral hyperpigmentation is often found in melanoma.<sup>[4]</sup></td> <td>Melanoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Vascular structures</strong>*</td> <td><em>Regular</em><br /> Comma vessels.</td> <td> <p>Dermal nevi</p> <p>Congenital melanocytic nevi<sup>[11]</sup></p> </td> </tr> <tr> <td> <p><em>Irregular</em><br /> Dotted vessels: over milky-red background suggests melanoma/Spitz. Over tan background suggest Clark nevi.</p> <p>Serpentine (linear irregular) vessels.</p> <p>Polymorphous vessels.</p> <p>Corkscrew vessels: usually seen in nodular melanoma, desmoplastic melanoma or melanoma metastases.</p> </td> <td> <p>Melanoma/Spitz</p> <p>Dysplastic or Clark nevus<sup>[11,12]</sup></p> </td> </tr> <tr class=\"divider_top\"> <td><strong>Crystalline structures</strong> (also known as chrysalis or shiny white streaks)</td> <td>&nbsp;</td> <td> <p>Melanoma<sup>[13,14]</sup></p> <p>Spitz nevi<sup>[13,14]</sup></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The presence of a given vessel morphology is not exclusive to a particular diagnosis. For example, dotted vessels can be seen in melanocytic tumors and also in nonmelanocytic lesions such as squamous cell carcinoma<sup>[12]</sup>, basal cell carcinoma<sup>[15]</sup>, porokeratosis<sup>[16]</sup>, or clear cell acanthoma<sup>[17]</sup>. Polymorphous vessels are commonly associated with melanoma, but they can also be seen in BCC<sup>[15]</sup> or stasis dermatitis.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571. </li>&#xD;&#xA;    <li>Malvehy J, Puig S, Argenziano G, et al. Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. J Am Acad Dermatol 2007; 57:84. </li>&#xD;&#xA;    <li>Argenziano G, Chimenti S, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679. </li>&#xD;&#xA;    <li>Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol 2001; 137:1575. </li>&#xD;&#xA;    <li>Marghoob AA, Korzenko AJ, Changchien L, et al. The beauty and the beast sign in dermoscopy. Dermatol Surg 2007; 33:1388. </li>&#xD;&#xA;    <li>Salopek TG, Kopf AW, Stefanato CM, et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001; 19:337. </li>&#xD;&#xA;    <li>Xu J, Stoecker WV, Krishnamurthy Y, et al. Analysis of globule types in malignant melanoma. Arch Dermatol 2009; 145:1245. </li>&#xD;&#xA;    <li>Pizzichetta MA, Stanganelli I, Bono R, et al. Dermoscopic features of difficult melanoma. Dermatol Surg 2007; 33:91. </li>&#xD;&#xA;    <li>Braun RP, Gaide O, Oliviero M, et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007; 157:907. </li>&#xD;&#xA;    <li>Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759. </li>&#xD;&#xA;    <li>Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485. </li>&#xD;&#xA;    <li>Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75. </li>&#xD;&#xA;    <li>Di Stefani A, Campbell TM, Malvehy J, et al. Shiny white streaks: An additional dermoscopic finding in melanomas viewed using contact polarised dermoscopy. Australas J Dermatol 2010; 51:295. </li>&#xD;&#xA;    <li>Balagula Y, Braun RP, Rabinovitz HS, et al.The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2011. Epub ahead of print. </li>&#xD;&#xA;    <li>Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67. </li>&#xD;&#xA;    <li>Pizzichetta MA, Canzonieri V, Massone C, Soyer HP. Clinical and dermoscopic features of porokeratosis of Mibelli. Arch Dermatol 2009; 145:91. </li>&#xD;&#xA;    <li>Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy: Part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 78774 Version 7.0</div></div></div>"},"78775":{"type":"graphic_table","displayName":"CARG model for predicting chemotherapy toxicity in older adults","title":"CARG model for predicting chemotherapy toxicity in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CARG model for predicting chemotherapy toxicity in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factor</td> <td class=\"subtitle1\" colspan=\"2\">Prevalence</td> <td class=\"subtitle1\" colspan=\"2\">Grades 3 to 5 toxicity</td> <td class=\"subtitle1\" rowspan=\"2\">OR</td> <td class=\"subtitle1\" rowspan=\"2\">95% CI</td> <td class=\"subtitle1\" rowspan=\"2\">Score</td> </tr> <tr> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> </tr> <tr> <td>Age &#8805;72 years</td> <td>270</td> <td>54</td> <td>163</td> <td>60</td> <td>1.85</td> <td>1.22 to 2.82</td> <td>2</td> </tr> <tr> <td>Cancer type GI or GU</td> <td>185</td> <td>37</td> <td>120</td> <td>65</td> <td>2.13</td> <td>1.39 to 3.24</td> <td>2</td> </tr> <tr> <td>Chemotherapy dosing, standard dose</td> <td>380</td> <td>76</td> <td>204</td> <td>54</td> <td>2.13</td> <td>1.29 to 3.52</td> <td>2</td> </tr> <tr> <td>Number of chemotherapy drugs, polychemotherapy</td> <td>351</td> <td>70</td> <td>192</td> <td>55</td> <td>1.69</td> <td>1.08 to 2.65</td> <td>2</td> </tr> <tr> <td>Hemoglobin &#60;11 g/dL (male), &#60;10 g/dL (female)</td> <td>62</td> <td>12</td> <td>46</td> <td>74</td> <td>2.31</td> <td>1.15 to 4.64</td> <td>3</td> </tr> <tr> <td>Creatinine clearance (Jelliffe, ideal weight) &#60;34 mL/min</td> <td>44</td> <td>9</td> <td>34</td> <td>77</td> <td>2.46</td> <td>1.11 to 5.44</td> <td>3</td> </tr> <tr> <td>Hearing, fair or worse</td> <td>123</td> <td>25</td> <td>76</td> <td>62</td> <td>1.67</td> <td>1.04 to 2.69</td> <td>2</td> </tr> <tr> <td>Number of falls in last six months, one or more</td> <td>91</td> <td>18</td> <td>61</td> <td>67</td> <td>2.47</td> <td>1.43 to 4.27</td> <td>3</td> </tr> <tr> <td>IADL: Taking medications, with some help/unable</td> <td>39</td> <td>8</td> <td>28</td> <td>72</td> <td>1.50</td> <td>0.66 to 3.38</td> <td>1</td> </tr> <tr> <td>MOS: Walking one block, somewhat limited/limited a lot</td> <td>109</td> <td>22</td> <td>69</td> <td>63</td> <td>1.71</td> <td>1.02 to 2.86</td> <td>2</td> </tr> <tr> <td>MOS: Decreased social activity because of physical/emotional health, limited at least sometimes</td> <td>218</td> <td>44</td> <td>126</td> <td>58</td> <td>1.36</td> <td>0.90 to 2.06</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CARG: Cancer and Aging Research Group; OR: odds ratio; GI: gastrointestinal; GU: genitourinary; IADL: instrumental activities of daily living; MOS: Medical Outcomes Study.</div><div class=\"graphic_reference\">From: Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457. Reprinted with permission. Copyright Â© 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78775 Version 4.0</div></div></div>"},"78776":{"type":"graphic_figure","displayName":"Valsalva blood pressure response","title":"Normal blood pressure responses to the Valsalva maneuver","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Normal blood pressure responses to the Valsalva maneuver</div><div class=\"cntnt\"><img style=\"width:560px; height:312px;\" src=\"images/CARD/78776_Valsalva_response_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal Valsalva response:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Normal changes in systolic blood pressure during 10 seconds of straining (shaded).</li>&#xD;&#xA;    <li>Phase 1 - systolic blood pressure rises with initiation of the maneuver.</li>&#xD;&#xA;    <li>Phase 2 - systolic blood pressure returns to baseline after several seconds.</li>&#xD;&#xA;    <li>Phase 3 - systolic blood pressure drops below normal after strain is released.</li>&#xD;&#xA;    <li>Phase 4 - systolic blood pressure rises transiently before returning to baseline.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 78776 Version 4.0</div></div></div>"},"78777":{"type":"graphic_diagnosticimage","displayName":"Conduit leak A","title":"Leaking conduit at urethral anastomosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leaking conduit at urethral anastomosis</div><div class=\"cntnt\"><img style=\"width:281px; height:363px;\" src=\"images/OBGYN/78777_Conduit_leak_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph showing conduit leak at urethral anastomosis.</div><div id=\"graphicVersion\">Graphic 78777 Version 3.0</div></div></div>"},"78779":{"type":"graphic_table","displayName":"Unusual pathogens for pneumonia","title":"Unusual pathogens causing nonresolving or progressive pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unusual pathogens causing nonresolving or progressive pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathogen (related disease)</td> <td class=\"subtitle1\">Populations at risk</td> </tr> <tr> <td><em>Mycobacterium tuberculosis</em> (tuberculosis)</td> <td>Older adults, immigrants, HIV-positive</td> </tr> <tr> <td>Nontuberculous&nbsp;mycobacteria (bronchiectasis)</td> <td>Chronic obstructive pulmonary disease (COPD), HIV-positive</td> </tr> <tr> <td><em>Nocardia</em> spp (nocardiosis)</td> <td>Immunocompromised host</td> </tr> <tr> <td><em>Actinomyces israelii</em> (actinomycosis)</td> <td>Aspiration risk, chest wall involvement</td> </tr> <tr> <td><em>Aspergillus</em> spp (aspergillosis)</td> <td>Immunocompromised host, evidence of vascular invasion</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Endemic fungi:</td> </tr> <tr> <td class=\"sublist1\"><em>Histoplasma capsulatum</em> (histoplasmosis)</td> <td class=\"sublist_other\">Mississippi River Valley</td> </tr> <tr> <td class=\"sublist1\"><em>Coccidioides immitis</em> (coccidioidomycosis)</td> <td class=\"sublist_other\">Southwestern United States</td> </tr> <tr> <td class=\"sublist1\"><em>Blastomyces dermatitidis</em> (blastomycosis)</td> <td class=\"sublist_other\">Southeast and midwest United States</td> </tr> <tr> <td><em>Coxiella burnetii</em> (Q fever)</td> <td>Exposure to cats, cattle, or sheep</td> </tr> <tr> <td><em>Francisella tularensis</em> (tularemia)</td> <td>Exposure to rabbits or ticks</td> </tr> <tr> <td><em>Chlamydia psittaci</em> (psittacosis)</td> <td>Avian sources</td> </tr> <tr> <td><em>Yersinia pestis</em> (plague)</td> <td>Exposure to rats</td> </tr> <tr> <td><em>Leptospira interrogans</em> (leptospirosis)</td> <td>Exposure to rats</td> </tr> <tr> <td><em>Pseudomonas pseudomallei</em> (melioidosis)</td> <td>Southeast Asia (rodent exposure), mimics tuberculosis</td> </tr> <tr> <td><em>Paragonimus westermani</em> (paragonimiasis)</td> <td>Asia/Africa/Central and South America</td> </tr> <tr> <td>Hantavirus</td> <td>Southwestern United States with exposure to mice</td> </tr> <tr> <td><em>Bacillus anthracis</em> (anthrax)</td> <td>More common in Asia Minor, Iran, Turkey, Greece, South Africa; contact with infected animal carcasses or hides</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78779 Version 3.0</div></div></div>"},"78780":{"type":"graphic_figure","displayName":"Repair sphincter third degr lac","title":"Repair of the anal sphincter after a third-degree perineal laceration","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Repair of the anal sphincter after a third-degree perineal laceration</div><div class=\"cntnt\"><img style=\"width:526px; height:372px;\" src=\"images/OBGYN/78780_Repair_sphincter_third_degr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A third degree laceration extends not only through the skin, mucous membrane, and perinal body, but includes the anal sphincter. Interrupted figure-of-eight sutures should be placed in the capsule of the sphincter muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL. Closure of 2nd degree laceration. In: Obstetrics: Normal &amp; problem pregnancies, 3rd ed, Churchill Livingstone Inc., New York 1996. Copyright &#169; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 78780 Version 2.0</div></div></div>"},"78781":{"type":"graphic_diagnosticimage","displayName":"Inflicted subdural hematomas","title":"Inflicted subdural hematomas","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Inflicted subdural hematomas</div><div class=\"cntnt\"><img style=\"width:510px; height:509px;\" src=\"images/EM/78781_Inflicted_SDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three month old child presented with altered mental status and bulging fontanelle. There was no significant antecedent history given by the caretakers. Computed tomography images (Figures A and B) reveal hemorrhage within the subdural space extending both around the hemisphere and interhemispherically. There is also the question of ischemic changes. Diffusion weighted magnetic resonance imaging (Figure C) performed a few hours later confirm significant ischemic changes. The gradient echo magnetic resonance image (Figure D), sensitive to blood, further defines the hemorrhage in the subdural space. The child was found to have severe bilateral retinal hemorrhages and non-accidental trauma was suspected.</div><div id=\"graphicVersion\">Graphic 78781 Version 3.0</div></div></div>"},"78782":{"type":"graphic_table","displayName":"Activity of OC preparations","title":"Level of androgenic activity of progestins in contraceptive pills","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Level of androgenic activity of progestins in contraceptive pills</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Level of activity</td> <td class=\"subtitle1\">Androgenic brand name(s)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">High</td> <td>Norgestrel</td> </tr> <tr class=\"divider_bottom\"> <td>Levonorgestrel</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Middle</td> <td>Norethindrone</td> </tr> <tr> <td class=\"divider_bottom\">Norethindrone acetate</td> </tr> <tr> <td rowspan=\"5\">Low</td> <td>Ethynodiol</td> </tr> <tr> <td>Norgestimate</td> </tr> <tr> <td>Desogestrel</td> </tr> <tr> <td>Drospirenone</td> </tr> <tr> <td>Dienogest</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78782 Version 5.0</div></div></div>"},"78783":{"type":"graphic_picture","displayName":"Serum sickness foot","title":"Foot serum sickness","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Foot serum sickness</div><div class=\"cntnt\"><img style=\"width:504px; height:214px;\" src=\"images/ALLRG/78783_Serum_sickness_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mark H Wener, MD.</div><div id=\"graphicVersion\">Graphic 78783 Version 1.0</div></div></div>"},"78785":{"type":"graphic_table","displayName":"Torg system classfication","title":"Torg system for classification of stress fractures of the proximal fifth metatarsal","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Torg system for classification of stress fractures of the proximal fifth metatarsal</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Type I fractures (early)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>No intramedullary sclerosis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Sharp, well-delineated fracture line</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Minimal cortical hypertrophy</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Fracture line generally involves only the lateral cortex (ie, does not extend to opposite cortex).</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Type II fractures (delayed)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Widened fracture line that usually involves both cortices</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Periosteal new bone adjacent to fracture line is prominent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Some intramedullary sclerosis present</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Type III fractures (non-union)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Wide fracture line with periosteal new bone</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Complete obliteration of medullary canal at the fracture site by sclerotic bone</td>\n\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13459&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Torg_system_classfication.htm</title></head></div><div class=\"graphic_reference\">Adapted from Strayer, SM, Reece, SG, Petrizzi, MJ. Fractures of the Proximal Fifth Metatarsal. American Family Physician 1999; 59: 9.</div><div id=\"graphicVersion\">Graphic 78785 Version 2.0</div></div></div>"},"78786":{"type":"graphic_figure","displayName":"Sphincter of Oddi","title":"Sphincter of Oddi in relation to the ampulla of Vater","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Sphincter of Oddi in relation to the ampulla of Vater</div><div class=\"cntnt\"><img style=\"width:514px; height:497px;\" src=\"images/GAST/78786_Sphincter_of_Oddi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the anatomy of the sphincter of Oddi and ampulla of Vater. The muscle fibers of the sphincter of Oddi surround the intraduodenal segment of the common bile duct and the ampulla of Vater. A circular aggregate of muscle fibers, known as the sphincter choledochus (or sphincter of Boyden), keeps resistance to bile flow high, and thereby permits filling of the gallbladder during fasting and prevents retrograde reflux of duodenal contents into the biliary tree. A separate structure, called the sphincter pancreaticus, encircles the distal pancreatic duct. The muscle fibers of the sphincter pancreaticus are interlocked with those of the sphincter choledochus in a figure eight pattern.</div><div id=\"graphicVersion\">Graphic 78786 Version 3.0</div></div></div>"},"78789":{"type":"graphic_diagnosticimage","displayName":"Salter Harris II fracture of the radial neck","title":"Salter Harris II fracture of the radial neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter Harris II fracture of the radial neck</div><div class=\"cntnt\"><img style=\"width:366px; height:586px;\" src=\"images/EM/78789_SH_II_frac_rad_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior and oblique views of the right elbow show a Salter Harris II fracture of the proximal radial neck.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 78789 Version 3.0</div></div></div>"},"78790":{"type":"graphic_figure","displayName":"Paranasal sinus anatomy","title":"Paranasal sinus anatomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Paranasal sinus anatomy</div><div class=\"cntnt\"><img style=\"width:538px; height:369px;\" src=\"images/ONC/78790_Paranasal_sinus_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing showing location of the frontal, ethmoid, maxillary, and sphenoid sinuses.</div><div id=\"graphicVersion\">Graphic 78790 Version 6.0</div></div></div>"},"78791":{"type":"graphic_figure","displayName":"Hiatal hernia PI","title":"Hiatal hernia","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Hiatal hernia</div><div class=\"cntnt\"><img style=\"width:486px; height:635px;\" src=\"images/PI/78791_Hiatal_hernia_PI_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sliding hernia happens when the top of the stomach squeezes up into the space above the diaphragm. This is the most common type of hiatal hernia.<br />A paraesophageal hernia happens when the top of the stomach folds up against the esophagus, creating a pouch. This is not very common, but it can be serious.</div><div id=\"graphicVersion\">Graphic 78791 Version 4.0</div></div></div>"},"78792":{"type":"graphic_figure","displayName":"Kaplan-Meier analysis extranodal NK-T cell lymphoma nasal type","title":"Nasal NK/T-cell lymphoma overall survival","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Nasal NK/T-cell lymphoma overall survival</div><div class=\"cntnt\"><img style=\"width:477px; height:298px;\" src=\"images/HEME/78792_KM_analysis_extra_NK_T_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The overall survival from a study of 92 patients with nasal NK/T-cell lymphoma collected from multiple institutions as part of an international retrospective analysis.</div><div class=\"graphic_reference\">Data from: Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.</div><div id=\"graphicVersion\">Graphic 78792 Version 3.0</div></div></div>"},"78793":{"type":"graphic_diagnosticimage","displayName":"Aqueductal stenosis due to a tectal lesion","title":"Aqueductal stenosis due to a tectal lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aqueductal stenosis due to a tectal lesion</div><div class=\"cntnt\"><img style=\"width:387px; height:369px;\" src=\"images/PEDS/78793_Aqueductl_stnss_tctl_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1-weighted magnetic resonance imaging (MRI) showing aqueductal stenosis due to a tectal lesion. There is dilation of the third ventricle (arrow), while the size of the fourth ventricle (thick arrow) remains relatively normal. The hydrocephalus was treated with a third ventriculostomy.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 78793 Version 3.0</div></div></div>"},"78794":{"type":"graphic_diagnosticimage","displayName":"Frykman I radius fracture oblique view","title":"Frykman I radius fracture oblique view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frykman I radius fracture oblique view</div><div class=\"cntnt\"><img style=\"width:288px; height:432px;\" src=\"images/EM/78794_Frykman_I_oblique_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oblique view of the same fracture highlights the loss of radial height.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 78794 Version 3.0</div></div></div>"},"78795":{"type":"graphic_table","displayName":"Causes of acquired PRCA","title":"CausesÂ of acquired pure red cell aplasia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes&nbsp;of acquired pure red cell aplasia in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"sublist2_start\">Transient erythroblastopenia of childhood (TEC)*</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary</td> </tr> <tr> <td class=\"subtitle2_single\">Thymoma and malignancy</td> </tr> <tr> <td class=\"indent1\">Thymoma</td> </tr> <tr> <td class=\"indent1\">Lymphoid malignancies</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic syndrome with solid tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune disorders<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus (SLE)</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis (JIA)</td> </tr> <tr> <td class=\"subtitle2_single\">Infections*</td> </tr> <tr> <td class=\"indent1\">Parvovirus*</td> </tr> <tr> <td class=\"indent1\">Hepatitis A, B, C</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (EBV)</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6 (HHV6)</td> </tr> <tr> <td class=\"indent1\">Echovirus 11</td> </tr> <tr> <td class=\"subtitle2_single\">Pregnancy</td> </tr> <tr> <td class=\"subtitle2_single\">Malnutrition/protein deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Radiation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs probably associated</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide</td> </tr> <tr> <td class=\"indent1\">Valproic acid</td> </tr> <tr> <td class=\"indent1\">Chloramphenicol and thiamphenicol</td> </tr> <tr> <td class=\"indent1\">Sulfonamides</td> </tr> <tr> <td class=\"indent1\">Procainamide</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs possibly associated</td> </tr> <tr> <td class=\"indent1\">Allopurinol</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Chloroquine</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> </tr> <tr> <td class=\"indent1\">Fenoprofen</td> </tr> <tr> <td class=\"indent1\">Penicillamine</td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common causes of acquired&nbsp;pure red cell aplasia&nbsp;in the pediatric population.<br />Â¶ Autoimmune disorders more commonly cause autoimmune hemolytic anemia; pure red cell aplasia is rare.</div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>Shimamura A, Williams DA. Acquired aplastic anemia and pure red cell aplasia. In: Nathan and Oski's hematology and oncology of infancy and childhood, 8th, Orkin SH, Fisjer DE, Ginsburg D, et al.&nbsp; (Eds), Saunders, Philadelphia 2015. Vol 1, p.161.</LI>&#xD;&#xA;<LI>Thompson DF, Gales MA, Pharmacotherapy 1996; 16:1002.</LI>&#xD;&#xA;<LI>Lin YW, Okazaki S, Hamahata K, et al, Am J Hematol 1999; 61:209.</LI></OL></div><div id=\"graphicVersion\">Graphic 78795 Version 10.0</div></div></div>"},"78796":{"type":"graphic_table","displayName":"Public awareness thalassemia","title":"Public awareness of thalassemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Public awareness of thalassemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>93 percent were aware of thalassemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>90 percent were aware of the need for blood transfusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>89 percent knew that thalassemia is not infectious</td>\n\n    </tr>\n\n    <tr>\n\n      <td>80 percent knew about the hereditary nature of thalassemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>69 percent believed that thalassemia is presently incurable</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Number interviewed: 3478.</div><div class=\"graphic_reference\">Data from: Politis C. The psychosocial impact of chronic illness. Ann N Y Acad Sci 1998; 850:349.</div><div id=\"graphicVersion\">Graphic 78796 Version 2.0</div></div></div>"},"78798":{"type":"graphic_figure","displayName":"Testicular descent","title":"Testicular descent","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Testicular descent</div><div class=\"cntnt\"><img style=\"width:510px; height:362px;\" src=\"images/PEDS/78798_Testicular_descent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The testes appear on the urogenital ridge (second month).<br />(B) The coelomic cavity evaginates into the scrotal swelling where it forms the processus vaginalis (middle of the third month).<br />(C) Testes begin descent into the scrotum guided by the gubernaculum (seventh month).<br />(D) The processus vaginalis obliterates spontaneously (shortly after birth).</div><div class=\"graphic_reference\">Adapted from: Langman J. Urogenital System. In: Medical Embryology, 4th ed, Williams and Wilkins, Baltimore 1981. p.263.</div><div id=\"graphicVersion\">Graphic 78798 Version 4.0</div></div></div>"},"78799":{"type":"graphic_picture","displayName":"Flea bites ankle","title":"Flea bites ankle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flea bites ankle</div><div class=\"cntnt\"><img style=\"width:413px; height:323px;\" src=\"images/ALLRG/78799_Flea_bites_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four flea bites clustered on an ankle.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78799 Version 1.0</div></div></div>"},"78800":{"type":"graphic_table","displayName":"Management of asbestosis","title":"Recommendations for management after diagnosis of asbestosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for management after diagnosis of asbestosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">1. Patient notification</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1.1. Inform patient of work-related illness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1.2. Report to appropriate authority as occupational\ndisease, as required by law</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1.3. Inform patient that there are options for\ncompensation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">2. Impairment\nassessment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2.1. Conduct an assessment of functional impairment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2.2. Rate impairment in accordance with ATS criteria,\nwhich are incorporated into the AMA Guides</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">3. Tertiary\nprevention</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3.1. Smoking cessation (primary prevention for\nsmoking-related disorders)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3.2. Withdrawal from further excessive exposure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3.3. Immunization (pneumococcal pneumonia, influenza)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3.4. Management of concurrent respiratory and other\ndiseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">4. Monitoring</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4.1. Chest film and pulmonary function testing should\nbe conducted every 3 to 5 years</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4.2. Active monitoring (periodic screening) for colon\ncancer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4.3. Observation and elevated index of suspicion but\nnot screening for lung cancer, mesothelioma, gastrointestinal cancers\n(other than colon)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">5. Development of a\npatient-specific management plan for symptomatic disease</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">AMA: American Medical Association; ATS: American Thoracic Society.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 78800 Version 1.0</div></div></div>"},"78802":{"type":"graphic_figure","displayName":"Removal of vulvar skin","title":"Skinning vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skinning vulvectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:344px;\" src=\"images/OBGYN/78802_Removal_of_vulvar_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vulva skin is dissected off the underlying fat.</div><div id=\"graphicVersion\">Graphic 78802 Version 1.0</div></div></div>"},"78804":{"type":"graphic_diagnosticimage","displayName":"Comminuted femoral shaft fracture","title":"Comminuted femoral shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted femoral shaft fracture</div><div class=\"cntnt\"><img style=\"width:446px; height:343px;\" src=\"images/EM/78804_Comminuted_femur_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 78804 Version 3.0</div></div></div>"},"78806":{"type":"graphic_algorithm","displayName":"Level of care matching","title":"Level of care treatment matching according to the American Society of Addiction Medicine patient placement criteria","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Level of care treatment matching according to the American Society of Addiction Medicine patient placement criteria</div><div class=\"cntnt\"><img style=\"width:521px; height:526px;\" src=\"images/PC/78806_Level_of_care_matching.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Gastfriend, D, and McLellan, A. Treatment matching: Theoretical basis and practical implications. Med Clin North Am 1997; 81:945. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78806 Version 2.0</div></div></div>"},"78807":{"type":"graphic_diagnosticimage","displayName":"SLE pulmonary fibrosis PA","title":"Interstitial lung disease with systemic lupus erythematosus (SLE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interstitial lung disease with systemic lupus erythematosus (SLE)</div><div class=\"cntnt\"><img style=\"width:358px; height:277px;\" src=\"images/PULM/78807_SLE_pulmonary_fibrosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systemic lupus erythematosus with bibasal pulmonary fibrosis producing loss of volume and partial obscuration of the diaphragmatic contour.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78807 Version 6.0</div></div></div>"},"78809":{"type":"graphic_diagnosticimage","displayName":"Carotid-cavernous fistula","title":"MRI of a carotid-cavernous fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of a carotid-cavernous fistula</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/NEURO/78809_Carotid-cavernous-fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal postcontrast fat-suppressed T1-weighted image shows enlargement of the extraocular muscles in both orbits. Note the prominent right superior ophthalmic vein (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78809 Version 5.0</div></div></div>"},"78811":{"type":"graphic_table","displayName":"Monitoring of FTM transgender persons on cross-hormone therapy","title":"Monitoring of female-to-male transgender persons on cross-hormone therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of female-to-male transgender persons on cross-hormone therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Evaluate patient every&nbsp;two to&nbsp;three months in the first year and then&nbsp;one to&nbsp;two times per year to monitor for appropriate signs of virilization and for development of adverse reactions.</td> </tr> <tr> <td class=\"sublist1_start\">2. Measure serum testosterone every&nbsp;two to&nbsp;three months until levels are in the normal physiological male range:</td> </tr> <tr> <td class=\"sublist2\">a. For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. If the level is &#62;700 ng/dL or &#60;350 ng/dL, adjust dose accordingly.</td> </tr> <tr> <td class=\"sublist2\">b. For parenteral testosterone undecanoate, testosterone should be measured just before the next injection.</td> </tr> <tr> <td class=\"sublist2\">c. For transdermal testosterone, the testosterone level can be measured at any time after&nbsp;one week.</td> </tr> <tr> <td class=\"sublist2\">d. For oral testosterone undecanoate, the testosterone level should be measured three to five&nbsp;hours after ingestion.</td> </tr> <tr> <td class=\"sublist2\">e. Note: During the first&nbsp;three to nine&nbsp;months of testosterone treatment, total testosterone levels may be high, although free testosterone levels are normal, due to high SHBG levels in some biological women.</td> </tr> <tr> <td>3. Measure estradiol levels during the first&nbsp;six months of testosterone treatment or until there has been no uterine bleeding for&nbsp;six months. Estradiol levels should be &#60;50 pg/mL.</td> </tr> <tr> <td>4. Measure complete blood count and liver function tests at baseline and every&nbsp;three months for the first year and then&nbsp;one to two&nbsp;times a year. Monitor weight, blood pressure, lipids, fasting blood sugar (if family history of diabetes), and hemoglobin A1c (if diabetic) at regular visits.</td> </tr> <tr> <td>5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (eg, previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy.</td> </tr> <tr> <td>6. If cervical tissue is present, an annual pap smear is recommended by the American College of Obstetricians and Gynecologists.</td> </tr> <tr> <td>7. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SHBG: sex hormone-binding globulin; BMD: bone mineral density.</div><div class=\"graphic_reference\">Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright Â© 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 78811 Version 5.0</div></div></div>"},"78813":{"type":"graphic_figure","displayName":"Unicornuate uter and xtra horn","title":"Unicornuate uterus with uterine horn (not containing an endometrial cavity) not fused to unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus with uterine horn (not containing an endometrial cavity) not fused to unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:383px; height:322px;\" src=\"images/OBGYN/78813_Unicornuateuterandxtrah.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78813 Version 15.0</div></div></div>"},"78814":{"type":"graphic_table","displayName":"Calcium content of supplements","title":"Elemental calcium content per pill of different calcium supplements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elemental calcium content per pill of different calcium supplements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Elemental Ca/tablet</td> <td class=\"subtitle1\">Ca compound</td> <td class=\"subtitle1\">Vitamin D</td> </tr> <tr> <td><strong>Caltrate 600 + D3</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Soft Chews</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate Gummy Bites</strong></td> <td>250 mg</td> <td>Tribasic calcium phosphate</td> <td>400 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Plus Minerals Chewables</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Plus Minerals Minis</strong></td> <td>300 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Citracal Petites</strong></td> <td>200 mg</td> <td>Citrate</td> <td>250 units</td> </tr> <tr> <td><strong>Citracal Maximum</strong></td> <td>315 mg</td> <td>Citrate</td> <td>250 units</td> </tr> <tr> <td><strong>Citracal Plus Magnesium &#38; Minerals</strong></td> <td>250 mg</td> <td>Citrate</td> <td>125 units</td> </tr> <tr> <td><strong>Citracal + D Slow Release</strong></td> <td>600 mg</td> <td>Citrate + carbonate blend</td> <td>500 units</td> </tr> <tr> <td><strong>Citracal Calcium Gummies</strong></td> <td>250 mg</td> <td>Tricalcium phosphate</td> <td>500 units</td> </tr> <tr> <td><strong>Citracal Calcium Pearls</strong></td> <td>200 mg</td> <td>Carbonate</td> <td>500 units</td> </tr> <tr> <td><strong>OsCal Calcium + D3</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>200 units</td> </tr> <tr> <td><strong>Oscal Extra + D3</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>600 units</td> </tr> <tr> <td><strong>Oscal Ultra</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>500 units</td> </tr> <tr> <td><strong>Oscal Chewable</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>600 units</td> </tr> <tr> <td><strong>Tums</strong></td> <td>200 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Extra Strength</strong></td> <td>300 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Ultra Strength</strong></td> <td>400 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Chewy Delights</strong></td> <td>400 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Viactiv Calcium plus D + K</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>500 units (or 1000 units in sugar-free)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ca: calcium; units: international units.</div><div id=\"graphicVersion\">Graphic 78814 Version 7.0</div></div></div>"},"78815":{"type":"graphic_diagnosticimage","displayName":"Acute portal vein thrombus CT","title":"Acute portal vein thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute portal vein thrombus</div><div class=\"cntnt\"><img style=\"width:360px; height:254px;\" src=\"images/GAST/78815_Acute_portal_vein_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan of the liver in a 27-year-old woman with a systemic coagulation disorder demonstrates a large thrombus in the portal vein (arrow) which is preventing contrast from entering the main portal vein. The liver is being perfused via hepatic arteries (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Krukal, MD.</div><div id=\"graphicVersion\">Graphic 78815 Version 3.0</div></div></div>"},"78821":{"type":"graphic_table","displayName":"Cleaning lead dust PI","title":"Ways to clean to decrease exposure to lead in dust","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to clean to decrease exposure to lead in dust</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cleaning hard surfaces</td> </tr> <tr> <td>Mop floors once a week with soapy water</td> </tr> <tr> <td>Clean window sills and the area around the windows once a week with soapy water</td> </tr> <tr> <td>Use paper towels or set aside a sponge for lead cleaning only</td> </tr> <tr> <td>Use separate buckets for wash and rinse water</td> </tr> <tr> <td>Lightly spray floors with water before sweeping</td> </tr> <tr> <td>Seal wood floors to provide a smooth, easy-to-clean surface</td> </tr> <tr> <td>Put a blanket or rug on bare floors where children play</td> </tr> <tr> <td>Keep children and their clothes and toys away from windows</td> </tr> <tr> <td>Open double-hung windows from the top</td> </tr> <tr> <td class=\"subtitle1_single\">Cleaning carpeted surfaces</td> </tr> <tr> <td class=\"sublist1_start\">Use a HEPA* vacuum for cleaning if possible, or</td> </tr> <tr> <td class=\"sublist1\">- Use a \"HEPA-type\" or \"allergy\" filter bag, or</td> </tr> <tr> <td class=\"sublist1\">- Lightly coat new vacuum bags by spreading and vacuuming flour or cornstarch</td> </tr> <tr> <td>Use a vacuum with an agitator head</td> </tr> <tr> <td>Be thorough when you vacuum</td> </tr> <tr> <td>When steam cleaning carpets, consider adding Calgon to the cleaning solution. (It has a chemical that can improve cleaning.)</td> </tr> <tr> <td>Be careful when removing older carpets that already have a lot of lead dust trapped in them</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* High-efficiency particulate air.</div><div class=\"graphic_reference\">Adapted from: Environmental Protection Agency. Additional information available at: <a href=\"http://www.epa.gov/lead/\" target=\"_blank\">http://www.epa.gov/lead/</a>.</div><div id=\"graphicVersion\">Graphic 78821 Version 4.0</div></div></div>"},"78822":{"type":"graphic_table","displayName":"Diagnosis of Wiskott-Aldrich syndrome","title":"Diagnostic criteria for Wiskott-Aldrich syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Wiskott-Aldrich syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with congenital thrombocytopenia (less than 70,000 platelets/mm<sup>3</sup>), small platelets, and at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Deleterious mutation in the <em>WAS </em>gene (other than the mutation that causes XLN).</td> </tr> <tr> <td class=\"sublist1\">2. Absent WAS messenger RNA (mRNA) on Northern blot analysis of lymphocytes.</td> </tr> <tr> <td class=\"sublist1\">3. Absent WAS protein (WASp) in lymphocytes.</td> </tr> <tr> <td class=\"sublist1\">4. Maternal male<span style=\"color: #ff0000;\"> </span>cousins, uncles, or nephews with small platelets and thrombocytopenia.</td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with congenital thrombocytopenia (less than 70,000 platelets/mm<sup>3</sup>), small platelets, and at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Eczema.</td> </tr> <tr> <td class=\"sublist1\">2. Abnormal antibody response to polysaccharide antigens.</td> </tr> <tr> <td class=\"sublist1\">3. Recurrent bacterial or viral infections.</td> </tr> <tr> <td class=\"sublist1\">4. Autoimmune diseases.</td> </tr> <tr> <td class=\"sublist1\">5. Lymphoma, leukemia, or other malignancies.</td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with thrombocytopenia (less than 70,000 platelets/mm<sup>3</sup>) and small platelets, or male patient splenectomized for thrombocytopenia, who has at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Eczema.</td> </tr> <tr> <td class=\"sublist1\">2. Abnormal antibody response to polysaccharide antigens.</td> </tr> <tr> <td class=\"sublist1\">3. Recurrent bacterial or viral infections.</td> </tr> <tr> <td class=\"sublist1\">4. Autoimmune diseases.</td> </tr> <tr> <td class=\"sublist1\">5. Lymphoma, leukemia, or other malignancies.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WAS: Wiskott-Aldrich syndrome; XLN: X-linked neutropenia.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some, but not all of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From: Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 78822 Version 8.0</div></div></div>"},"78823":{"type":"graphic_diagnosticimage","displayName":"Esophageal foreign body CPC","title":"Esophageal foreign body","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Esophageal foreign body</div><div class=\"cntnt\"><img style=\"width:535px; height:266px;\" src=\"images/GAST/78823_Esophageal_foreign_body_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Postero-anterior radiology image showing the crucifix portion of the necklace lodged in the distal esophagus with extension of the chain into the stomach. There are multiple healed left rib fractures and metallic foreign body from previous gunshot wound in the left chest. (B) Lateral view.</div><div class=\"graphic_reference\">Courtesy of Christopher W. Duncan MD, MPP and Lehel, Somogyi MD, PhD.</div><div id=\"graphicVersion\">Graphic 78823 Version 2.0</div></div></div>"},"78825":{"type":"graphic_picture","displayName":"Light microscopy gonadoblastoma","title":"Gonadoblastoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gonadoblastoma</div><div class=\"cntnt\"><img style=\"width:388px; height:258px;\" src=\"images/ONC/78825_Light_microscopy_gonadoblas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of an ovarian gonadoblastoma. Cells with small round, dark nuclei resemble immature Sertoli cells and are arrayed around spherical collections of eosinophilic material. Larger seminoma-like cells with clear cytoplasm are scattered about in the lower half of the field. The arrowhead points to a calcification that is typical of this neoplasm.</div><div class=\"graphic_reference\">Courtesy of Dr. Marisa Nucci, Department of Pathology, Brigham and Womens Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 78825 Version 1.0</div></div></div>"},"78826":{"type":"graphic_picture","displayName":"Acral lentiginous melanoma","title":"Acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:288px; height:193px;\" src=\"images/PC/78826_Acral_lentiginous_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An acral lentiginous melanoma shows the asymmetry and color variegation of typical melanomas. They are distinguished clinically by their location on the palms, soles, or nails.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 78826 Version 2.0</div></div></div>"},"78827":{"type":"graphic_diagnosticimage","displayName":"Inspissated stool","title":"Plain abdominal radiograph showing inspissated stool which might be mistaken for drug packets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain abdominal radiograph showing inspissated stool which might be mistaken for drug packets</div><div class=\"cntnt\"><img style=\"width:432px; height:525px;\" src=\"images/PULM/78827_Inspissated_stool.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stool predominantly in upper left quadrant of radiograph. Body packing was not suspected. Pellets of stool lack the geometric appearance of drug packets.</div><div class=\"graphic_reference\">Courtesy of Stephen Traub, MD.</div><div id=\"graphicVersion\">Graphic 78827 Version 2.0</div></div></div>"},"78828":{"type":"graphic_figure","displayName":"Mechanism organophos pralidox","title":"Mechanism of action: Organophosphate and pralidoxime","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Mechanism of action: Organophosphate and pralidoxime</div><div class=\"cntnt\"><img style=\"width:523px; height:435px;\" src=\"images/PULM/78828_Mechanism_organophos_pralid.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78828 Version 1.0</div></div></div>"},"78829":{"type":"graphic_figure","displayName":"Transverse recovery in MRI","title":"Rate of recovery during transverse relaxation in MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rate of recovery during transverse relaxation in MRI</div><div class=\"cntnt\"><img style=\"width:332px; height:228px;\" src=\"images/PULM/78829_Transverse_recovery_in_MRI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following 90Â° radiofrequency relaxation, transverse magnetization is initially maximal and then decays exponentially due to dipolar interactions among spins (spin-spin relaxation) with a time constant T2.</div><div id=\"graphicVersion\">Graphic 78829 Version 2.0</div></div></div>"},"78830":{"type":"graphic_form","displayName":"Example of SCIT prescription form in use","title":"Example of SCIT prescription form in use","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Example of SCIT prescription form in use</div><div class=\"cntnt\"><img style=\"width:646px; height:802px;\" src=\"images/ALLRG/78830_SCIT_prescript_form_com_ED2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maintenance concentration and subsequent dilutions reported as volume/volume (v/v) dilutions with maintenance concentration 1:1 v/v.</div><div class=\"graphic_footnotes\">SCIT: subcutaneous immunotherapy; AU: allergy unit; BAU: bioequivalent allergy unit; w/v: weight per volume ratio; PNU: protein nitrogen unit; 50% G: 50% glycerinated; Aq: aqueous; Ly: lyophilized; AP: alum-precipitated; AcP: acetone-precipitated; HSA: normal saline with 0.03% human serum albumin.<br />* Volume to add = (maintenance concentration/concentration of manufacturer's extract) Ã total volume.<br />Â¶ Target maintenance dose volume is 0.5 mL per injection.</div><div class=\"graphic_reference\">Reproduced from: Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 78830 Version 9.0</div></div></div>"},"78831":{"type":"graphic_table","displayName":"Stages of chronic kidney disease","title":"Stages of chronic kidney disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of chronic kidney disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">GFR (mL/min per 1.73 m<sup>2</sup> body surface area)</td> </tr> <tr> <td>1</td> <td>Kidney damage* with normal or increased GFR</td> <td>&#8805;90</td> </tr> <tr> <td>2</td> <td>Kidney damage* with mildly decreased GFR</td> <td>60 to 89</td> </tr> <tr> <td>3</td> <td>Moderately decreased GFR</td> <td>30 to 59</td> </tr> <tr> <td>4</td> <td>Severely decreased GFR</td> <td>15 to 29</td> </tr> <tr> <td>5</td> <td>Kidney failure</td> <td>&#60;15 or dialysis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate.<br />* Kidney damage defined as abnormalities on pathologic, urine, blood, or imaging tests.</div><div class=\"graphic_reference\">Copyright &copy; 2007 American Diabetes Association From Diabetes Care Vol 30, Supplement 1, 2007. Reprinted with permission from: The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 78831 Version 4.0</div></div></div>"},"78832":{"type":"graphic_table","displayName":"Nasal irrigation for atrophic rhinosinusitis","title":"Nasal irrigation for atrophic rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nasal irrigation for atrophic rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Buffered normal saline nasal irrigation</td> </tr> <tr> <td class=\"subtitle2_single\">The benefits</td> </tr> <tr> <td class=\"indent1\">1. When you irrigate, the saline (saltwater) acts as a solvent and washes the mucus crusts and other debris from your nose.</td> </tr> <tr> <td class=\"indent1\">2. The sinus passages are moisturized.</td> </tr> <tr> <td class=\"indent1\">3. Studies have also shown that a nasal irrigation improves cell function (the cells that have fine filaments to move the mucus out work better).</td> </tr> <tr> <td class=\"subtitle2_single\">The recipe</td> </tr> <tr> <td class=\"indent1\">Choose a one-quart glass jar that is thoroughly cleansed.</td> </tr> <tr> <td class=\"indent1\">Fill with water that has been distilled, previously boiled, or otherwise sterilized.</td> </tr> <tr> <td class=\"indent1\">Add 1 to 1 <span style=\"font-size: 16px; font-family: calibri;\">&#189; </span>heaping teaspoons of pickling/canning salt, NOT table salt, as it contains a large number of additives.</td> </tr> <tr> <td class=\"indent1\">Add 1 teaspoon baking soda (pure bicarbonate).</td> </tr> <tr> <td class=\"indent1\">Mix ingredients together and store at room temperature. Discard after&nbsp;one week.</td> </tr> <tr> <td class=\"subtitle2_single\">The instructions</td> </tr> <tr> <td class=\"indent1\">You should plan to irrigate your nose with buffered saline two to three times per day. You may use a bulb/ear syringe, large medical syringe (30 cc), or water pick with an irrigation tip. Always pour the amount of fluid you plan to use into a clean bowl. Do NOT put your used syringe back into the quart, because it contaminates your solution. Many people prefer to warm the solution slightly in the microwave, but be sure that the solution is NOT HOT. Bend over the sink (some people do this in the shower), and squirt the solution into each side of your nose, aiming the stream toward the back of your head, NOT the top of your head. It will not harm you if you swallow a little.</td> </tr> <tr> <td class=\"indent1\">Some people experience a little burning sensation the first few times they use buffered saline solution, but this usually goes away after they adapt to it.</td> </tr> <tr> <td class=\"indent1\">After irrigating, apply a lubricant (such as petrolatum or KY liquid) to the inside of the nose with a clean cotton swab. If told to do so by your health care provider, you may apply mupirocin ointment instead (also with a cotton swab).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Diseases of the Sinuses: Diagnosis and Management. Kennedy DW, Bolger WE, Zinreich SJ (Eds), BC Decker, Hamilton, Ontario 2001. Copyright Â© Kennedy DW, Zinreich SJ.</div><div id=\"graphicVersion\">Graphic 78832 Version 10.0</div></div></div>"},"78834":{"type":"graphic_picture","displayName":"Invasive UC glandular diff","title":"Invasive urothelial carcinoma with glandular differentiation","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Invasive urothelial carcinoma with glandular differentiation</div><div class=\"cntnt\"><img style=\"width:516px; height:198px;\" src=\"images/ONC/78834_Invasive_UC_glandular_diff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A, The presence of true glandular spaces within the urothelial component characterizes the glandular differentiation in urothelial carcinoma (20x). B, Apical cytoplasm and more basally situated nuclei of true glandular differentiation are noted at high power (40x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78834 Version 1.0</div></div></div>"},"78835":{"type":"graphic_table","displayName":"Higher cortical function in children","title":"Assessment of higher cortical function in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of higher cortical function in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Evidence of normal cortical function</td> </tr> <tr> <td rowspan=\"3\">6 to 12 months</td> <td>Awareness of surroundings</td> </tr> <tr> <td>Interaction with examiner (social smile, inquisitiveness, habituation)</td> </tr> <tr> <td>Cooing and gurgling, sometimes making of nonspecific \"mama\" and \"dada\" sounds</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">12 to 20 months</td> <td>Six to eight word vocabulary</td> </tr> <tr> <td>Comprehends one-step commands</td> </tr> <tr> <td>Points to two or three body parts</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">24 months</td> <td>Names two or three body parts</td> </tr> <tr> <td>Uses phrases and simple sentences</td> </tr> <tr class=\"divider_top\"> <td>24 to 36 months</td> <td>Concept of self (referring to self as \"I\", knowledge of name and age)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">36 months</td> <td>Counts three objects</td> </tr> <tr> <td>Understands prepositional concepts (eg, \"over\" and \"under\")</td> </tr> <tr> <td>Asks questions</td> </tr> <tr> <td>Names three colors</td> </tr> <tr class=\"divider_top\"> <td>48 months</td> <td>Copies a square and a cross</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">5 or 6 years</td> <td>Spells monosyllabic words</td> </tr> <tr> <td>Counts to 10</td> </tr> <tr class=\"divider_top\"> <td>6 years</td> <td>Copies a triangle</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">6 or 7 years</td> <td>Does simple addition and subtraction</td> </tr> <tr> <td>Reads polysyllabic words</td> </tr> <tr class=\"divider_top\"> <td>7 years</td> <td>Copies a diamond</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78835 Version 2.0</div></div></div>"},"78837":{"type":"graphic_diagnosticimage","displayName":"CT appearance PPNAD","title":"CT appearance PPNAD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT appearance PPNAD</div><div class=\"cntnt\"><img style=\"width:427px; height:576px;\" src=\"images/ENDO/78837_CT_appearance_PPNAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adrenal CT scan of a 20-year-old female with PPNAD, Cushing's syndrome, and family history of Carney's complex. Note the right adrenal (A) of normal size but with discrete bead-like nodules (arrow). In the left adrenal (B), a larger 1.5 cm nodule was present (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; PPNAD: primary pigmented nodular adrenocortical disease.</div><div class=\"graphic_reference\">Courtesy of Andre Lacroix, MD.</div><div id=\"graphicVersion\">Graphic 78837 Version 3.0</div></div></div>"},"78839":{"type":"graphic_diagnosticimage","displayName":"Angiogram after embolization for postpartum hemorrhage","title":"Right uterine angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right uterine angiogram</div><div class=\"cntnt\"><img style=\"width:420px; height:275px;\" src=\"images/OBGYN/78839_Postpartum_hemorrhage_7b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right uterine angiogram reveals occlusion of the right uterine artery (arrow) after superselective uterine artery embolization. The procedure successfully stopped the bleeding.</div><div id=\"graphicVersion\">Graphic 78839 Version 4.0</div></div></div>"},"78840":{"type":"graphic_diagnosticimage","displayName":"Pontine lesions vanishing white matter disease","title":"Neuropathology of the pons in vanishing white matter disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuropathology of the pons in vanishing white matter disease</div><div class=\"cntnt\"><img style=\"width:288px; height:432px;\" src=\"images/NEURO/78840_Pons_VWM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse section of the pons reveals symmetric lesions in the areas of the central tegmental tracts (arrows), the superior central nuclei (arrowheads), and the dorsal and central parts of the basis pontis (Kliiver stain).</div><div class=\"graphic_reference\">Reproduced with permission from: Van der Knaap MS, Kamphorst W, Barth PG. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998; 51:540. Copyright Â© 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 78840 Version 13.0</div></div></div>"},"78841":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step seven","title":"Standard cricothyrotomy step seven","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step seven</div><div class=\"cntnt\"><img style=\"width:372px; height:298px;\" src=\"images/EM/78841_Cric_standard_step_seven.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red><FONT color=black>Remove the obturator.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 78841 Version 2.0</div></div></div>"},"78842":{"type":"graphic_picture","displayName":"Straddle injury2","title":"Prepubertal child with laceration from straddle injury, after cleaning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prepubertal child with laceration from straddle injury, after cleaning</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/EM/78842_Straddleinjury2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note bleeding out of proportion to size of laceration. Interrupted sutures were placed for hemostasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78842 Version 10.0</div></div></div>"},"78843":{"type":"graphic_picture","displayName":"TM atelectasis","title":"Collapse (atelectasis) of the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collapse (atelectasis) of the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:360px; height:396px;\" src=\"images/PEDS/78843_TM_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Collapse (atelectasis) of the tympanic membrane is caused by poor eustachian tube function.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 78843 Version 1.0</div></div></div>"},"78845":{"type":"graphic_diagnosticimage","displayName":"Drug packet ingestion","title":"Drug packet ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug packet ingestion</div><div class=\"cntnt\"><img style=\"width:217px; height:328px;\" src=\"images/PULM/78845_Drug_packet_ingestion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal radiograph showing radiopaque drug packets ingested by a &quot;body packer.&quot;</div><div class=\"graphic_reference\">Courtesy of Michael J Burns, MD.</div><div id=\"graphicVersion\">Graphic 78845 Version 2.0</div></div></div>"},"78846":{"type":"graphic_table","displayName":"Monitoring drug Rx of RA","title":"Monitoring strategies for drug treatment of rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring strategies for drug treatment of rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Ongoing monitoring via system review and physical examination</td> <td class=\"subtitle1\">Ongoing monitoring via laboratory tests</td> </tr> <tr> <td>Salicylates, NSAIDs</td> <td>Dyspepsia, nausea/vomiting, abdominal pain, edema, blood pressure</td> <td>CBC and&nbsp;complete metabolic panel (electrolytes, creatinine, albumin, transaminases)&nbsp;every six months.</td> </tr> <tr> <td>Glucocorticoids</td> <td>Mood, weight gain, visual changes, weakness, polyuria, polydipsia, edema, infection, blood pressure</td> <td>Diabetes screening, lipids, bone mineral density testing.</td> </tr> <tr> <td>Hydroxychloroquine</td> <td>Visual change, skin color change, paresthesia, periodic visual field testing</td> <td>None after baseline.</td> </tr> <tr> <td>Sulfasalazine</td> <td>Headache, nausea, diarrhea, photosensitivity, symptoms of myelosuppression, hepatotoxicity,&nbsp;rash&nbsp;</td> <td>CBC, aminotransferases and creatinine every&nbsp;two to four&nbsp;weeks for the first&nbsp;three months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks.</td> </tr> <tr> <td>Methotrexate<sup>*</sup></td> <td>Stomatitis, alopecia, diarrhea, nausea/vomiting, flu-like symptoms, shortness of breath, symptoms of myelosuppression, hepatotoxicity,&nbsp;infection,&nbsp;lymph node swelling, pregnancy</td> <td>CBC, aminotransferases, and creatinine every&nbsp;two&nbsp;to four&nbsp;weeks for the first&nbsp;three months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks.</td> </tr> <tr> <td>Leflunomide<sup>*</sup></td> <td>Nausea/vomiting, diarrhea, shortness of breath, paresthesia, hepatotoxicity, weight loss, blood pressure, pregnancy</td> <td>CBC, aminotransferases, and creatinine every&nbsp;two to four&nbsp;weeks for the first&nbsp;three months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks.</td> </tr> <tr> <td>Minocycline</td> <td>Hyperpigmentation, dizziness, falls</td> <td>None after baseline.</td> </tr> <tr> <td>Azathioprine</td> <td>Diarrhea, nausea/vomiting, symptoms of myelosuppression, infection</td> <td>CBC and platelet count every&nbsp;one to two&nbsp;weeks with changes in dosage, every&nbsp;one to three&nbsp;months thereafter.</td> </tr> <tr> <td>Anti-TNF alpha biologics</td> <td>Infection, malignancy, demyelination, congestive heart failure, autoimmune phenomenon</td> <td>CBC every&nbsp;three months, update vaccinations,&nbsp;repeat TB testing in patients at increased risk of&nbsp;or with&nbsp;known exposure and patients treated for latent TB with potential ongoing exposure.</td> </tr> <tr> <td>Tocilizumab</td> <td>Infection, symptoms of myelosuppression (PMNs and platelets), demyelination, hepatotoxicity, gastrointestinal perforations<br /> </td> <td>CBC with differential (neutrophils) and LFTs every month until stable, then every&nbsp;three months.&nbsp;Lipids every&nbsp;six months.</td> </tr> <tr> <td>Rituximab</td> <td>Infection, PML, symptoms of neutropenia</td> <td>CBC every&nbsp;two to four&nbsp;months.</td> </tr> <tr> <td>Abatacept</td> <td>Infection, COPD exacerbation, malignancy&nbsp;</td> <td>CBC every&nbsp;three months.</td> </tr> <tr> <td>Tofacitinib</td> <td>Infection, zoster, symptoms of myelosuppression, hepatotoxicity, malignancy, gastrointestinal perforation</td> <td>CBC with differential, creatinine,&nbsp;liver function tests (transaminases, albumin, bilirubin)&nbsp;every month for three months, then every three months; lipids six to eight weeks after drug start.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs; CBC: complete blood cell count (hematocrit, hemoglobin, white blood cell count, including differential white blood cell count and&nbsp;platelet counts); TB: tuberculosis;&nbsp;PMN: polymorphonuclear leukocytes; PML: progressive multifocal leukoencephalopathy; COPD: chronic obstructive pulmonary disease.<br /><SUP>*</SUP>In patients receiving methotrexate and leflunomide in combination: CBC, creatinine, albumin, and&nbsp;transaminases every two to&nbsp;four weeks for the first three months or following dose increase,&nbsp;every four weeks for the next three months, then every three months. </div><div class=\"graphic_reference\">Adapted from: Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Arthritis Rheum 1996; 39:723; American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis 2002 Update. Arthritis Rheum 2002; 46:328; and Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762; and Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68:1.</div><div id=\"graphicVersion\">Graphic 78846 Version 4.0</div></div></div>"},"78847":{"type":"graphic_table","displayName":"Causes of pericardial effusion","title":"Case series of moderate-large pericardial effusions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Case series of moderate-large pericardial effusions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sagrista-Sauleda, 2000 (N = 322)</td> <td class=\"subtitle1\">Corey, 1993 (N = 57)</td> <td class=\"subtitle1\">Levy, 2003 (N = 204)</td> <td class=\"subtitle1\">Ma, 2012 (N = 140)&nbsp;</td> <td class=\"subtitle1\">Strobbe, 2017 (N = 269)</td> </tr> <tr> <td><strong>Size of effusion, mm</strong></td> <td>&#62;10</td> <td>&#62;10</td> <td>NR</td> <td>&nbsp;&#62;10</td> <td>&nbsp;&#62;10 (98 percent)</td> </tr> <tr class=\"divider_top\"> <td><strong>Tamponade, percent</strong></td> <td>37</td> <td>NR</td> <td>NR</td> <td>&nbsp;100</td> <td>&nbsp;88</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Etiologies, percent</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Idiopathic*</td> <td>29 (9 percent chronic)</td> <td>7</td> <td>48</td> <td>&nbsp;0</td> <td>&nbsp;26</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> <td>13</td> <td>23</td> <td>15</td> <td>&nbsp;38</td> <td>&nbsp;25</td> </tr> <tr> <td class=\"indent1\">Uremia</td> <td>6</td> <td>12</td> <td>2</td> <td>&nbsp;6</td> <td>&nbsp;3</td> </tr> <tr> <td class=\"indent1\">Iatrogenic</td> <td>16</td> <td>0</td> <td>0</td> <td>&nbsp;9</td> <td>&nbsp;21</td> </tr> <tr> <td class=\"indent1\">Post-acute myocardial infarction</td> <td>8</td> <td>0</td> <td>0</td> <td>&nbsp;5</td> <td>&nbsp;1</td> </tr> <tr> <td class=\"indent1\">Infection</td> <td>6</td> <td>27</td> <td>16</td> <td>&nbsp;28</td> <td>&nbsp;7</td> </tr> <tr> <td class=\"indent1\">Collagen vascular disease</td> <td>5</td> <td>12</td> <td>10</td> <td>&nbsp;6</td> <td>&nbsp;3</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td>2</td> <td>0</td> <td>10</td> <td>&nbsp;5</td> <td>&nbsp;0</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>15</td> <td>23</td> <td>0</td> <td>&nbsp;3</td> <td>&nbsp;14</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br> * Includes both acute and chronic pericardial effusions.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Sagrista-Sauleda J, Merce J, Permanyer-Maralda G, et al. Clinical clues to the causes of large pericardial effusions. Am J Med 2000; 109:95. </LI>&#xD;&#xA;<LI>Corey GR, Campbell PT, VanTrigt P, et al. Etiology of large pericardial effusion. Am J Med 1993; 95:209. </LI>&#xD;&#xA;<LI>Levy PY, Corey R, Berger P, et al. Etiologic diagnosis of 204 pericardial effusion. Medicine (Baltimore) 2003; 82:385. </LI>&#xD;&#xA;<LI>Ma W, Liu J, Zeng Y, et al. Causes of moderate to large pericardial effusion requiring pericardiocentesis in 140 Han Chinese patients. Herz 2012; 37: 183.</LI>&#xD;&#xA;<LI>Strobbe A, Adriaenssens T, Bennett J, et al. Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am Heart Assoc 2017; 6: e007598.</LI></OL></div><div id=\"graphicVersion\">Graphic 78847 Version 7.0</div></div></div>"},"78848":{"type":"graphic_algorithm","displayName":"Diarrhea in the seriously ill child","title":"Diarrhea in the seriously ill child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diarrhea in the seriously ill child</div><div class=\"cntnt\"><img style=\"width:363px; height:366px;\" src=\"images/PEDS/78848_Diarrheaseriouslyill.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* More likely in older children and adolescents.<br />&para; More likely in infants and young children.</div><div id=\"graphicVersion\">Graphic 78848 Version 9.0</div></div></div>"},"78849":{"type":"graphic_table","displayName":"Symptoms CMV mononucleosis","title":"Symptoms and signs in nine patients with spontaneous cytomegalovirus mononucleosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs in nine patients with spontaneous cytomegalovirus mononucleosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Number of patients</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Symptoms</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Malaise</td>\n\n\n      <td>9</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Fever</td>\n\n\n      <td>8</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Chills</td>\n\n\n      <td>6</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Myalgia</td>\n\n\n      <td>6</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Sore throat</td>\n\n\n      <td>5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Headache</td>\n\n\n      <td>4</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Anorexia</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Abdominal pain</td>\n\n\n      <td>2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Signs</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Pharyngeal erythema</td>\n\n\n      <td>5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Lymphadenopathy</td>\n\n\n      <td>5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Rash*</td>\n\n\n      <td>5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Splenomegaly</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Hepatomegaly</td>\n\n\n      <td>0</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Exudative pharyngitis</td>\n\n\n      <td>0</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Includes one patient whose rash was associated with ampicillin therapy.</div><div class=\"graphic_reference\">Modified from Jordan, MC, Rousseau, W, Stewart, JA, et al. Spontaneous cytomegalovirus mononucleosis. Clinical and laboratory observations in nine cases. Ann Intern Med 1973; 79:153.</div><div id=\"graphicVersion\">Graphic 78849 Version 1.0</div></div></div>"},"78850":{"type":"graphic_picture","displayName":"Chronic pulm thromboemboli","title":"Chronic pulmonary thromboemboli","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary thromboemboli</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/PULM/78850_Chronic_pulm_thromboemboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic thromboemboli removed by thromboendarterectomy. Note the chronic, fibrotic appearance with extension into multiple lobar and segmental branches.</div><div class=\"graphic_reference\">Courtesy of Peter F Fedullo, MD.</div><div id=\"graphicVersion\">Graphic 78850 Version 2.0</div></div></div>"},"78853":{"type":"graphic_picture","displayName":"Cataracts view PI","title":"How cataracts affect vision","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">How cataracts affect vision</div><div class=\"cntnt\"><img style=\"width:516px; height:262px;\" src=\"images/PI/78853_Cataracts_view_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cataracts blur or dull what you see. Sometimes they also cause a glare.</div><div class=\"graphic_reference\">Reproduced from: National Eye Institute Eye Disease Simulations. <a href=\"http://www.nei.nih.gov/health/examples/\">http://www.nei.nih.gov/health/examples/</a>.</div><div id=\"graphicVersion\">Graphic 78853 Version 2.0</div></div></div>"},"78854":{"type":"graphic_picture","displayName":"Nevus with a two-component pattern","title":"Dermoscopic image of a nevus with a two-component pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a two-component pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/78854_Nevus_two_comp_pattern_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanocytic nevus with a two-component pattern: half of the lesion has a globular pattern and the other half a homogeneous pattern.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 78854 Version 6.0</div></div></div>"},"78855":{"type":"graphic_picture","displayName":"Taenia scolices","title":"<em>Taenia</em> scolices","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\"><em>Taenia</em> scolices</div><div class=\"cntnt\"><img style=\"width:584px; height:209px;\" src=\"images/ID/78855_Taenia_scolices.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Scolex of <em>T. saginata</em>. Note the four large suckers and lack of rostellum and rostellar hooks.<br> (B) Scolex of <em>T. solium</em>. Note the four large suckers and rostellum containing two rows of hooks.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Taeniasis. Available at: <A href=\"http://www.cdc.gov/dpdx/taeniasis/index.html\">http://www.cdc.gov/dpdx/taeniasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 78855 Version 5.0</div></div></div>"},"78856":{"type":"graphic_diagnosticimage","displayName":"Subcostal view HCM","title":"Subcostal long axis view in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcostal long axis view in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:270px; height:216px;\" src=\"images/CARD/78856_Subcostal_view_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subcostal view from the two dimensional echocardiogram shows extremely hypertrophied and asymmetric septum which is 35 mm in thickness. The subcostal view often provides images from which the interventricular septum is most easily measured.</div><div id=\"graphicVersion\">Graphic 78856 Version 2.0</div></div></div>"},"78857":{"type":"graphic_diagnosticimage","displayName":"Vigorous achalasia Ba swallow","title":"Vigorous achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vigorous achalasia</div><div class=\"cntnt\"><img style=\"width:191px; height:310px;\" src=\"images/GAST/78857_Vigorous_achalasia_Ba_swall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow in a patient with &quot;vigorous&quot; achalasia. In addition to the narrowing at the esophagogastric junction, there are multiple, nonperistaltic muscular contractions in the dilated esophagus.</div><div class=\"graphic_reference\">Reprinted, courtesy of the American Gastroenterological AssociationÂ©. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 78857 Version 2.0</div></div></div>"},"78858":{"type":"graphic_picture","displayName":"Black grain histopathology","title":"Eumycetoma: Black grain histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eumycetoma: Black grain histopathology</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ID/78858_Blackgrainhistopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of demonstrating black grain with fungal hyphae and thick-walled chlamidoconidia on the edges (hematoxylin &amp; eosin stain x1000).</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 78858 Version 4.0</div></div></div>"},"78860":{"type":"graphic_picture","displayName":"Tinea versicolor chest","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:382px; height:266px;\" src=\"images/PC/78860_Tineaversicolorchest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple light brown, coalescing macules are present on the chest.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 78860 Version 2.0</div></div></div>"},"78861":{"type":"graphic_picture","displayName":"Granulomatous cheilitis 2","title":"Granulomatous cheilitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomatous cheilitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/78861_Granulomatous_cheilitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granulomatous cheilitis is a rare disorder in which recurrent swelling of the lips leads to permanent areas of enlargement.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78861 Version 4.0</div></div></div>"},"78864":{"type":"graphic_figure","displayName":"Spectral karyotype","title":"Spectral karyotyping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spectral karyotyping</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/HEME/78864_Spectral_karyotype.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a multi-color fluorescence in situ hybridization analysis (M-FISH, spectral karyotyping) of a complex karyotype. In this technique, each chromosome is given a unique color; translocations are easily seen (yellow arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Jalal, SM, et al. Br J Haematol 2001; 112:975. Copyright &#169; 2001 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 78864 Version 1.0</div></div></div>"},"78865":{"type":"graphic_figure","displayName":"Vent responses to hypercapnia","title":"Ventilatory responses to hypercapnia in patients with mild and severe hypothyroidism","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Ventilatory responses to hypercapnia in patients with mild and severe hypothyroidism</div><div class=\"cntnt\"><img style=\"width:491px; height:379px;\" src=\"images/ENDO/78865_Vent_responses_to_hypercapn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ventilatory responses are shown as the relationships between alveolar carbon dioxide (PACO2) and&nbsp;VE (STPD).</div><div class=\"graphic_footnotes\">PACO2: partial pressure of carbon dioxide; STPD: standard temperature and pressure dry; VE: minute ventilation.</div><div class=\"graphic_reference\">Data from: Zwillich AA, Pierson DJ, Hofeldt FD. Ventilatory control in myxedema and hypothyroidism.&nbsp;N Engl J Med 1975; 292:662.</div><div id=\"graphicVersion\">Graphic 78865 Version 3.0</div></div></div>"},"78866":{"type":"graphic_figure","displayName":"Tactile sensibility pathways","title":"Pathways concerned with discriminatory tactile sensibility (A) and crude tactile sensibility (B)","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Pathways concerned with discriminatory tactile sensibility (A) and crude tactile sensibility (B)</div><div class=\"cntnt\"><img style=\"width:464px; height:363px;\" src=\"images/NEURO/78866_Tactile_sensibility_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">L: lower extremity; U: upper extremity; T: trunk.</div><div class=\"graphic_reference\">Reproduced with permission from Widerholt, WC, Neurology for Non- neurologists, 4th ed, WB Sauders, Philadelphia, 2000. Copyright &#169; 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 78866 Version 1.0</div></div></div>"},"78867":{"type":"graphic_table","displayName":"Differential diagnosis of physical findings sexual abuse 1","title":"Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 1)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 1)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Differential diagnosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Perineal area (boys or girls)</td> </tr> <tr> <td class=\"indent1\">Perineal inflammation or erythema</td> <td>Candidal infection, pinworms, perianal cellulitis, contact dermatitis, atopic dermatitis, psoriasis</td> </tr> <tr> <td class=\"indent1\">Perineal ulcer or vesicular rash*</td> <td>Syphilis, herpes simplex virus, varicella, chanchroid, <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Beh&#231;et syndrome</span>, bullous pemphigoid, Epstein-Barr virus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Perineal bruising</td> <td>Mongolian spots, trauma, hemolytic uremic syndrome, Henoch-Schonlein purpura</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Perianal area (boys or girls)</td> </tr> <tr> <td class=\"indent1\">Perianal erythema</td> <td>Encopresis, poor hygiene, pinworms, Group A streptococcal or staphylococcal infection, irritants, trauma</td> </tr> <tr> <td class=\"indent1\">Anal fissures</td> <td>Constipation; perianal irritation</td> </tr> <tr> <td class=\"indent1\">Perianal scar</td> <td>May be caused by medical conditions, such as fissures, or lesions of Crohn disease, or from previous medical procedures</td> </tr> <tr> <td class=\"indent1\">Venous congestion or pooling</td> <td>Usually due to positioning of child; may be seen in constipation</td> </tr> <tr> <td class=\"indent1\">Flattened anal folds</td> <td>May be caused by relaxation of the anal sphincter or swelling of the perianal tissues from infection or trauma</td> </tr> <tr> <td class=\"indent1\">Anogenital warts<sup>&#182;</sup></td> <td>Human papillomavirus, molluscum contagiousum, common warts, skin tags</td> </tr> <tr> <td class=\"indent1\">Rectal bleeding</td> <td>Hemorrhoids, Crohn disease, rectal prolapse, rectal tumors; anal trauma or penetration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anal dilation to less than 2 cm, with or without stool present</td> <td>May be a normal reflex or caused by severe constipation or encopresis, sedation, anesthesia, neuromuscular conditions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Male genitalia</td> </tr> <tr> <td class=\"indent1\">Penile trauma</td> <td>Hair tourniquet, zipper entrapment injury, straddle injury (history is usually readily available for zipper entrapment and straddle injuries; straddle injuries usually affect the anterior structures)</td> </tr> <tr> <td class=\"indent1\">Penile or scrotal erythema</td> <td>Irritants, infection, trauma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cultures for herpes simplex virus type 1 and 2 and syphilis should be obtained.<br />Â¶ May need biopsy to confirm diagnosis.</div><div class=\"graphic_reference\">Adapted from Bays, J, Jenny, C. Genital and anal conditions confused with child sexual abuse trauma. Am J Dis Child<br />1990; 144:1319. Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev<br />1996; 17:236. Adams, JA. Evolution of a classification scale: medical<br />evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31.<br />Adams, JA. Medical evaluation of suspected child sexual abuse. J<br />Pediatr Adolesc Gynecol 2004; 17:191.</div><div id=\"graphicVersion\">Graphic 78867 Version 4.0</div></div></div>"},"78868":{"type":"graphic_diagnosticimage","displayName":"Split pleura sign II CT","title":"Empyema with split pleura sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Empyema with split pleura sign</div><div class=\"cntnt\"><img style=\"width:360px; height:302px;\" src=\"images/PULM/78868_Split_pleura_sign_II_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrates a loculated collection of pleural effusion in the left hemithorax with enhancing visceral and parietal pleura (\"split pleura\" sign) and a few bubbles of gas within the empyema, likely due to a gas forming organism. Larger collections of gas are usually indicative of a bronchopleural fistula. The contralateral right transudative effusion does not show enhancement of the pleura after intravenous contrast material administration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 78868 Version 3.0</div></div></div>"},"78870":{"type":"graphic_picture","displayName":"Dermoscopy seborrheic keratosis","title":"Dermoscopy of seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:549px; height:488px;\" src=\"images/DERM/78870_Dermoscopy_seborr_kerat_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Milia-like cysts (white arrows) and comedo-like openings (dashed black arrows).<br />(B) Network-like structures and fingerprint-like structures (solid square).<br />(C) Hairpin vessels (solid square), milia-like cysts (white arrow), and comedo-like openings (dashed black arrow).<br />(D) Gyri and sulci.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 78870 Version 5.0</div></div></div>"},"78871":{"type":"graphic_picture","displayName":"Acid-fast stain biopsy -  Leprosy","title":"Leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leprosy</div><div class=\"cntnt\"><img style=\"width:366px; height:240px;\" src=\"images/ID/78871_Acidfaststainbiopsyansw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acid-fast stain of skin biopsy (x1000) from a patient with lepromatous leprosy shows numerous red acid-fast bacilli.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 78871 Version 4.0</div></div></div>"},"78872":{"type":"graphic_figure","displayName":"IVUS technique","title":"Technique of intracoronary ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technique of intracoronary ultrasonography</div><div class=\"cntnt\"><img style=\"width:331px; height:189px;\" src=\"images/CARD/78872_IVUS_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intracoronary ultrasound catheter is advanced down the coronary artery, past the stenotic lesion. This visualizes the artery in cross section, perpendicular to the axis of the catheter.</div><div class=\"graphic_reference\">By permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.</div><div id=\"graphicVersion\">Graphic 78872 Version 2.0</div></div></div>"},"78875":{"type":"graphic_table","displayName":"Disorders with stereotypies","title":"Disorders with stereotypies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders with stereotypies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiological</td> </tr> <tr> <td>Mannerisms</td> </tr> <tr> <td class=\"subtitle1_single\">Pathological</td> </tr> <tr> <td>Mental retardation</td> </tr> <tr> <td>Autism spectrum disorder</td> </tr> <tr> <td>Rett syndrome</td> </tr> <tr> <td>Williams syndrome</td> </tr> <tr> <td>Tardive dyskinesia</td> </tr> <tr> <td>Akathisia</td> </tr> <tr> <td>Neuroacanthocytosis</td> </tr> <tr> <td>Schizophrenia</td> </tr> <tr> <td>Catatonia</td> </tr> <tr> <td>Obsessive-compulsive disorder</td> </tr> <tr> <td>Tourette syndrome</td> </tr> <tr> <td>Restless legs syndrome</td> </tr> <tr> <td>Epileptic automatism</td> </tr> <tr> <td>Psychogenic</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Jankovic, J, Lang, AE. Classification of movement disorders. In: Germano, IM, (Ed), Surgical Treatment of Movement Disorders, The American Association of Neurological Surgeons (AANS), Lebanon, NH, 1998. p.3.</div><div id=\"graphicVersion\">Graphic 78875 Version 2.0</div></div></div>"},"78876":{"type":"graphic_table","displayName":"Pro-inflammatory treatment options","title":"Pro-inflammatory treatment options","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pro-inflammatory treatment options</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Ultrasound-guided percutaneous tenotomy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Prolotherapy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Topical nitric oxide application</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Extracorporeal shock wave treatment (ESWT)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acupuncture</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Autologous blood injection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Plasma-rich protein injections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Botulinum injections</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Surgery (with debridement, arthroscopic drilling)</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 78876 Version 2.0</div></div></div>"},"78878":{"type":"graphic_table","displayName":"Bacteriology normal human flora","title":"Bacteriology of the normal human flora","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacteriology of the normal human flora</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anatomic site</td> <td class=\"subtitle1\">Total bacteria (per mL or g)</td> <td class=\"subtitle1\">Anaerobe/aerobe ratio</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Upper airways</td> </tr> <tr> <td class=\"indent1\">Nasal washings</td> <td>10<sup>3</sup> to 10<sup>4</sup></td> <td>3 to 5:1</td> </tr> <tr> <td class=\"indent1\">Saliva</td> <td>10<sup>8</sup> to 10<sup>9</sup></td> <td>1:1 </td> </tr> <tr> <td class=\"indent1\">Tooth surface</td> <td>10<sup>10</sup> to 10<sup>11</sup></td> <td>1:1</td> </tr> <tr> <td class=\"indent1\">Gingival crevice</td> <td>10<sup>11</sup> to 10<sup>12</sup></td> <td>1000:1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Stomach</td> <td>0 to 10<sup>5</sup></td> <td>1:1</td> </tr> <tr> <td class=\"indent1\">Small bowel</td> <td>10<sup>2</sup> to 10<sup>4</sup></td> <td>1:1</td> </tr> <tr> <td class=\"indent1\">Ileum</td> <td>10<sup>4</sup> to 10<sup>7</sup> </td> <td>1:1</td> </tr> <tr> <td class=\"indent1\">Colon</td> <td>10<sup>11</sup> to 10<sup>12</sup></td> <td>1000:1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Female genital tract</td> </tr> <tr> <td class=\"indent1\">Endocervix</td> <td>10<sup>7</sup> to 10<sup>9</sup></td> <td>1 to 5:1</td> </tr> <tr> <td class=\"indent1\">Vagina</td> <td>10<sup>7</sup> to 10<sup>9</sup></td> <td>1 to 5:1</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78878 Version 2.0</div></div></div>"},"78879":{"type":"graphic_picture","displayName":"Preeclampsia light micrograph","title":"Preeclampsia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preeclampsia</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/78879_Preeclampsia_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in preeclampsia showing glomerular endotheliosis. The primary changes are swelling of damaged endothelial cells, leading to partial closure of many of the capillary lumens (arrows). Mitosis within an endothelial cell (short arrow) is a sign of cellular repair.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78879 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"78881":{"type":"graphic_table","displayName":"Grading GI marginal zone lymphoma","title":"Histologic scoring of gastric marginal zoneÂ lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic scoring of gastric marginal zone&nbsp;lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Histologic features</td> </tr> <tr> <td>0</td> <td>Normal</td> <td>Scattered plasma cells in lamina propria; no lymphoid follicles</td> </tr> <tr> <td>1</td> <td>Chronic active gastritis</td> <td>Small clusters of lymphocytes in lamina propria; no lymphoid follicles; no LELs</td> </tr> <tr> <td>2</td> <td>Chronic active gastritis with florid lymphoid follicle formation</td> <td>Prominent lymphoid follicles with surrounding mantle zone and plasma cells; no LELs</td> </tr> <tr> <td>3</td> <td>Suspicious lymphoid infiltrate in lamina propria, probably reactive</td> <td>Lymphoid follicles surrounded by small lymphocytes that infiltrate diffusely in lamina propria and occasionally into epithelium</td> </tr> <tr> <td>4</td> <td>Suspicious lymphoid infiltrate in lamina propria, probably lymphoma</td> <td>Lymphoid follicles surrounded by CCL cells that infiltrate diffusely in lamina propria and into epithelium in small groups</td> </tr> <tr> <td>5</td> <td>Marginal zone lymphoma</td> <td>Presence of dense diffuse infiltrate of CCL cells in lamina propria with prominent LELs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CCL: centrocyte-like lesion; LEL: lymphoepithelial lesion.</div><div class=\"graphic_reference\">Adapted from: Wotherspoon AC, Dogliogi C, Diss TC, et al. Lancet 1993; 342:575.</div><div id=\"graphicVersion\">Graphic 78881 Version 4.0</div></div></div>"},"78884":{"type":"graphic_picture","displayName":"Common warts PI","title":"Common warts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common warts</div><div class=\"cntnt\"><img style=\"width:369px; height:276px;\" src=\"images/PI/78884_Common_warts_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 78884 Version 1.0</div></div></div>"},"78885":{"type":"graphic_table","displayName":"Causes elevated sweat chloride","title":"Conditions other than cystic fibrosis associated with elevated sweat chloride concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions other than cystic fibrosis associated with elevated sweat chloride concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Adrenal insufficiency</td> </tr> <tr> <td>Pseudohypoaldosteronism</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Hypoparathyroidism</td> </tr> <tr> <td>Nephrogenic diabetes insipidus</td> </tr> <tr> <td>Ectodermal dysplasia</td> </tr> <tr> <td> <p>Glycogen storage disease</p> (type I)</td> </tr> <tr> <td>Mucopolysaccharidoses</td> </tr> <tr> <td>Fucosidosis</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td>Mauriac syndrome</td> </tr> <tr> <td>Familial cholestasis syndrome</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Prostaglandin E1 administration</td> </tr> <tr> <td>Hypogammaglobulinemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Welsh MJ, Tsui L-C, Boat T, et al. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, et al (Eds), McGraw-Hill, New York 1995. p.3801.</div><div id=\"graphicVersion\">Graphic 78885 Version 3.0</div></div></div>"},"78888":{"type":"graphic_figure","displayName":"ICD post CABG from CABG-Patch trial","title":"Prophylactic ICD does not improve survival in high-risk patients after CABG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prophylactic ICD does not improve survival in high-risk patients after CABG</div><div class=\"cntnt\"><img style=\"width:300px; height:224px;\" src=\"images/CARD/78888_ICDpostCABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CABG-Patch trial randomized 900 patients with a low ejection fraction and a positive signal-averaged electrocardiogram to an implantable cardioverter-defibrillator or no defibrillator after coronary artery bypass graft surgery. There was no difference in mortality at a mean follow-up of 32 months.</div><div class=\"graphic_reference\">Data from: Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators, N Engl J Med 1997; 337:1569.</div><div id=\"graphicVersion\">Graphic 78888 Version 4.0</div></div></div>"},"78890":{"type":"graphic_table","displayName":"Causes of clubfoot","title":"Etiologies of clubfoot","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of clubfoot</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Intrinsic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Chromosomal\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Trisomy 18\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Deletions of chromosomes 18q, 4p, 7q, 9q, 13q\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Connective tissue\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Arthrogryposis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Collagen defects\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Joint synostosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Neurologic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Anencephaly\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Anterior motor horn cell deficiency\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Hydrancephaly\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Holoprosencephaly\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Myelomeningocele\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Spina bifida\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Muscular\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Myopathy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Myotonic dystrophy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Skeletal dysplasia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Campomelic dysplasia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Chondrodysplasia punctata\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Diastrophic dysplasia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Ellis-van Creveld\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Syndromes\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Escobar syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Hecht syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Larsen syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Meckel-Gruber syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Multiple pterygium\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Pena Shokeir\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Smith-Lemli-Opitz\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Zellweger syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Extrinsic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Amniotic bands or synechiae\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Early amniocentesis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Intrauterine crowding\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Fibroids\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Multiple gestation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Oligohydramnios\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent2\">\n   Potter sequence\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_single\">\n   Malposition\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Breech\n   </td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">Clubfoot may be familial.</div><div class=\"graphic_reference\">Courtesy of Urania Magriples, MD.</div><div id=\"graphicVersion\">Graphic 78890 Version 1.0</div></div></div>"},"78891":{"type":"graphic_picture","displayName":"Multiple atypical nevi","title":"Multiple atypical nevi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple atypical nevi</div><div class=\"cntnt\"><img style=\"width:373px; height:504px;\" src=\"images/PEDS/78891_Multiple_atypical_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple atypical nevi on the posterior trunk of an adolescent.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 78891 Version 1.0</div></div></div>"},"78892":{"type":"graphic_table","displayName":"USPSTF grade C recommendations","title":"Adult screening and prevention recommendations of USPSTF C recommendations (offer or provide this service for selected patients depending on individual circumstances)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult screening and prevention recommendations of USPSTF C recommendations (offer or provide this service for selected patients depending on individual circumstances)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Service</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular disease</td> </tr> <tr> <td class=\"indent1\">Screening for abdominal aortic aneurysm</td> <td>Men ages 65 to 75 who have never smoked</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Aspirin for primary prevention of CVD and CRC</td> <td>Adults ages 60 to 69 with &#8805;10% 10-year CVD risk</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Statins: Discuss and selectively offer low- to moderate-dose statins</td> <td>Adults ages 40 to 75 years with no history of CVD, &#8805;1 CVD risk factor, and calculated 10-year CVD event risk of 7.5 to 10%</td> <td class=\"centered\">2016</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Healthful&nbsp;diet and physical activity for CVD prevention in adults without known risk factors: behavioral counseling </td> <td>Adults without obesity, hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes</td> <td class=\"centered\">2017</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer</td> </tr> <tr> <td class=\"indent1\">Screening for breast cancer by mammography</td> <td>Women ages 40 to 49 years, individualized including patient's risks and patient's values regarding specific benefits and harms</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Aspirin for primary prevention of CVD and CRC</td> <td>Adults ages 60 to 69 with &#8805;10% 10-year CVD risk</td> <td class=\"centered\">2016</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Screening for CRC</td> <td>Adults ages 76 to 85 years</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other conditions</td> </tr> <tr> <td class=\"indent1\">In-depth multifactorial risk assessment and comprehensive management of identified risks to prevent falls</td> <td>Adults &#8805;65 years who live in the community </td> <td class=\"centered\">2012</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table covers recommendations for adults &gt;18 years.</div><div class=\"graphic_footnotes\">USPSTF: US Preventive Services Task Force; CVD: cardiovascular disease; CRC: colorectal cancer.</div><div id=\"graphicVersion\">Graphic 78892 Version 12.0</div></div></div>"},"78893":{"type":"graphic_algorithm","displayName":"Treatment of cutaneous lupus","title":"Algorithm for the initial management of discoid lupus and subacute cutaneous lupus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the initial management of discoid lupus and subacute cutaneous lupus</div><div class=\"cntnt\"><img style=\"width:242px; height:333px;\" src=\"images/DERM/78893_Tx_of_cutaneous_lupus_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78893 Version 1.0</div></div></div>"},"78894":{"type":"graphic_picture","displayName":"PCLBCL- LT Bcl-2 staining","title":"Primary cutaneous diffuse large B-cell lymphoma, leg type Bcl-2 protein expression","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous diffuse large B-cell lymphoma, leg type Bcl-2 protein expression</div><div class=\"cntnt\"><img style=\"width:551px; height:454px;\" src=\"images/HEME/78894_PCLBCL-LT_Bcl-2_SL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous diffuse large B-cell lymphoma, leg type commonly demonstrates strong expression of Bcl-2 protein.</div><div id=\"graphicVersion\">Graphic 78894 Version 1.0</div></div></div>"},"78895":{"type":"graphic_diagnosticimage","displayName":"Long axis hypertrophic CM","title":"Parasternal long axis echocardiogram in a patient with hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram in a patient with hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:304px; height:227px;\" src=\"images/CARD/78895_LongaxishypertrophicCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long-axis view from a two-dimensional echocardiogram in a patient with hypertrophic cardiomyopathy shows significant hypertrophy of the interventricular septum (IVS) as well as the posterior left ventricular wall (PWLV); the echo-free space behind the posterior wall is a pericardial effusion (PE).</div><div class=\"graphic_footnotes\">RV: right ventricle; Ao: aorta; LV: left ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 78895 Version 5.0</div></div></div>"},"78896":{"type":"graphic_table","displayName":"Rare but serious side effects of antiseizure drugs","title":"Rare but serious side effects of antiseizure drugs*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rare but serious side effects of antiseizure drugs*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Side effects*</td> </tr> <tr> <td>Brivaracetam<sup>&#182;</sup></td> <td>Hypersensitivity reactions including bronchospasm and&nbsp;angioedema, leukopenia, neutropenia, psychosis</td> </tr> <tr> <td>Carbamazepine</td> <td>Agranulocytosis, aplastic anemia, SJS/TEN, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, lupus syndrome</td> </tr> <tr> <td>Clobazam</td> <td>Respiratory depression, SJS/TEN</td> </tr> <tr> <td>Eslicarbazepine&nbsp;</td> <td>Prolonged PR interval, atrioventricular block, hyponatremia (rarely severe), SJS/TEN&nbsp;</td> </tr> <tr> <td>Ethosuximide</td> <td>Agranulocytosis, SJS/TEN, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness</td> </tr> <tr> <td>Felbamate</td> <td>Aplastic anemia, liver failure</td> </tr> <tr> <td>Gabapentin</td> <td>Multiorgan hypersensitivity</td> </tr> <tr> <td>Lacosamide</td> <td>Prolonged PR interval, atrioventricular block, multiorgan hypersensitivity, neutropenia</td> </tr> <tr> <td>Lamotrigine</td> <td>SJS/TEN, multiorgan hypersensitivity, aseptic meningitis</td> </tr> <tr> <td>Levetiracetam</td> <td>SJS/TEN, anaphylaxis and angioedema, pancytopenia, psychosis</td> </tr> <tr> <td>Oxcarbazepine</td> <td>SJS/TEN, multiorgan hypersensitivity, agranulocytosis, pancytopenia, leukopenia</td> </tr> <tr> <td>Perampanel&nbsp;</td> <td>Severe neuropsychiatric effects (eg, hostility, aggression)&nbsp;</td> </tr> <tr> <td>Phenytoin</td> <td>Agranulocytosis, SJS/TEN, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, adenopathy, pseudolymphoma, neuropathy, ataxia, lupus syndrome, hirsutism</td> </tr> <tr> <td>Pregabalin</td> <td>Angioedema, hypersensitivity reactions, rhabdomyolysis</td> </tr> <tr> <td>Primidone, phenobarbital</td> <td>Agranulocytosis, SJS/TEN, hepatic failure, dermatitis/rash, serum sickness, connective tissue contractures (eg, Dupuytren)</td> </tr> <tr> <td>Rufinamide</td> <td>SJS/TEN, dermatitis/rash, shortened QT interval</td> </tr> <tr> <td>Tiagabine</td> <td>SJS/TEN, nonconvulsive status epilepticus</td> </tr> <tr> <td>Topiramate</td> <td>Acute myopia and glaucoma; kidney stones; oligohidrosis and hyperthermia which primarily occur in children</td> </tr> <tr> <td>Valproate</td> <td>Agranulocytosis, SJS/TEN, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, polycystic ovary syndrome</td> </tr> <tr> <td>Vigabatrin</td> <td>MRI abnormalities, depression, weight gain</td> </tr> <tr> <td>Zonisamide</td> <td>Rash, SJS/TEN, aplastic anemia, agranulocytosis, nephrolithiasis; in children, fever and hyperhidrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; MRI: magnetic resonance imaging.<br />* As a class, antiseizure drugs have been associated with an increased risk of suicidal ideation and suicidal behavior.<br />Â¶ Based upon limited experience from preapproval clinical trials.</div><div id=\"graphicVersion\">Graphic 78896 Version 19.0</div></div></div>"},"78898":{"type":"graphic_picture","displayName":"Conjunctivitis in Kawasaki","title":"Conjunctivitis in Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conjunctivitis in Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:432px; height:185px;\" src=\"images/PEDS/78898_Conjunctivitis_in_Kawasaki.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert Sundel, MD.</div><div id=\"graphicVersion\">Graphic 78898 Version 2.0</div></div></div>"},"78899":{"type":"graphic_table","displayName":"Ginkgo quality criteria","title":"Examples of Ginkgo biloba brands meeting specified quality criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of Ginkgo biloba brands meeting specified quality criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Product name (manufacturer or distributor) </td> </tr> <tr> <td>Target Up &#38; Up Ginkgo Biloba, 120 mg/capsule (Target Corporation)</td> </tr> <tr> <td>Ginkgoba&#174;, 40 mg/tablet (Alan James Group)</td> </tr> <tr> <td>Finest Natural Ginkgo Biloba, 120 mg/capsule (Walgreen Corporation)</td> </tr> <tr> <td class=\"subtitle1_single\"> <p>Examples of products passing testing. Full report available at www.consumerlabs.com.</p> <p>*To pass testing, products had to meet all of the following criteria:</p> </td> </tr> <tr> <td>1. Product label states a recommended daily dosage considered to provide a clinically appropriate amount of Ginkgo biloba leaf extract (ie, 120 mg per day in divided doses) and standardized to include 22 to 27% total flavonol glycosides and 5 to 7% total terpenelactones.</td> </tr> <tr> <td>2. Products must contain 100 to 150% of the claimed amounts of total flavonol glycosides and total terpene lactones.</td> </tr> <tr> <td>3. Minimum amounts of individual flavonol glycosides must be present as follows: quercetin (&#8805;9.5%), kaempferol (&#8805;10.5%), and isorhamnetin (&#8805;2.0%).</td> </tr> <tr> <td>4. Minimum amounts of individual terpene lactones must be present as follows: ginkgolides A, B, and C (total &#8805;2.8%) and bilobalide (&#8805;2.6%).</td> </tr> <tr> <td>5. USP parameters for disintegration of vitamin supplements.</td> </tr> <tr> <td>6. Contain &#8804;2.0 mcg of lead in a daily recommended serving.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">USP: US Pharmacopeial Convention.</div><div id=\"graphicVersion\">Graphic 78899 Version 3.0</div></div></div>"},"78900":{"type":"graphic_figure","displayName":"Southern blot hybridization","title":"Southern blotting","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Southern blotting</div><div class=\"cntnt\"><img style=\"width:503px; height:599px;\" src=\"images/PC/78900_Southern_blot_hybridization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This representation shows the steps in Southern blotting.<br />Step 1: Genomic DNA is digested by a restriction enzyme.<br />Step 2: DNA is run on an agarose&nbsp;gel, giving a smeared appearance.<br />Step 3: DNA is transferred from the gel to a membrane.<br />Step 4: A radioactive probe is hybridized to the membrane and the membrane is exposed to X-ray film. The bands show the places where the probe hybridized to the patient DNA. If the DNA has a gene deletion or a mutation that eliminates a restriction enzyme site, then one or more bands may be missing. This step can also be performed using a non-radioactive probe.<br />In the final image, normal individuals (Lanes 2 to 4) show the expected pattern, while an individual with a partial gene deletion (Lane 5) is missing one of the bands.</div><div id=\"graphicVersion\">Graphic 78900 Version 2.0</div></div></div>"},"78901":{"type":"graphic_table","displayName":"Incidence childhood arthritis","title":"Incidence of juvenile rheumatoid arthritis in different countries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of juvenile rheumatoid arthritis in different countries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Country</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>Finland</td> <td>9.2/100,000</td> <td>Laaksonen, 1966</td> </tr> <tr> <td>Finland</td> <td>19.6/100,000</td> <td>Kunnamo, 1986</td> </tr> <tr> <td>Sweden</td> <td>10.9/100,000</td> <td>Gare, 1992</td> </tr> <tr> <td>Canada</td> <td>5.3/100,000</td> <td>Oen, 1995</td> </tr> <tr> <td>UK</td> <td>10.0/100,000</td> <td>Symmons, 1996</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78901 Version 3.0</div></div></div>"},"78902":{"type":"graphic_picture","displayName":"Disseminated histoplasmosis - papules","title":"Disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/78902_Dissem_histopl_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules are present on the skin of this patient with histoplasmosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78902 Version 3.0</div></div></div>"},"78903":{"type":"graphic_table","displayName":"Causes of secondary dysmenorrhea","title":"Causes of secondary dysmenorrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary dysmenorrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gynecologic </td> </tr> <tr> <td>Endometriosis</td> </tr> <tr> <td>Adenomyosis</td> </tr> <tr> <td>Fibroids</td> </tr> <tr> <td>Ovarian cysts</td> </tr> <tr> <td>Intrauterine or pelvic adhesions</td> </tr> <tr> <td>Chronic pelvic inflammatory disease</td> </tr> <tr> <td>Obstructive&nbsp;endometrial polyps</td> </tr> <tr> <td>Congenital obstructive m&#252;llerian malformations</td> </tr> <tr> <td>Cervical stenosis</td> </tr> <tr> <td>Use of an intrauterine contraceptive device</td> </tr> <tr> <td>Pelvic congestion syndrome&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Nongynecologic </td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td>Uteropelvic junction obstruction</td> </tr> <tr> <td>Psychogenic disorders</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78903 Version 3.0</div></div></div>"},"78904":{"type":"graphic_table","displayName":"Rx of adrenal insufficiency","title":"Treatment of chronic primary adrenal insufficiency in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of chronic primary adrenal insufficiency in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Glucocorticoid replacement</td> </tr> <tr> <td> <p>Hydrocortisone 15 to 25 mg orally in two or three divided doses (largest dose in morning upon awakening; typically 10 mg upon arising in morning, 5 mg early afternoon, 2.5 mg late afternoon) <strong>or</strong></p> </td> </tr> <tr> <td>Prednisone 5 mg (range: 2.5 to 7.5 mg) orally at bedtime; <strong>or</strong></td> </tr> <tr> <td>Dexamethasone 0.75 mg (range: 0.25 to 0.75 mg) orally at bedtime</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Monitor clinical symptoms and morning plasma ACTH. </span></td> </tr> <tr> <td class=\"subtitle1_single\">2. Mineralocorticoid replacement<sup>*</sup></td> </tr> <tr> <td>Fludrocortisone 0.1 mg (range: 0.05 to 0.2 mg) orally.</td> </tr> <tr> <td>Liberal salt intake.</td> </tr> <tr> <td>Monitor lying and standing blood pressure and pulse, edema, serum potassium, and plasma renin activity.</td> </tr> <tr> <td class=\"subtitle1_single\">3. Androgen replacement</td> </tr> <tr> <td>Dehydroepiandrosterone (DHEA)<sup>&#182;</sup>&nbsp;initially 25 to 50 mg orally&nbsp;(only in women with impaired mood or sense of well-being despite optimal glucocorticoid and mineralocorticoid replacement).</td> </tr> <tr> <td class=\"subtitle1_single\">4. Patient education</td> </tr> <tr> <td>Educate patient about the disease, how to manage minor illnesses and major stresses, and how to inject dexamethasone or other glucocorticoid&nbsp;intramuscularly or subcutaneously.</td> </tr> <tr> <td><span class=\"indent1\"></span><span class=\"indent2\"></span><span class=\"indent1\"></span>Refer to UpToDate patient education topics on adrenal insufficiency (Addison's disease).</td> </tr> <tr> <td class=\"subtitle1_single\">5. Emergency precautions</td> </tr> <tr> <td>Obtain medical alert bracelet/necklace, Emergency Medical Information Card, and prefilled syringes containing dexamethasone 4 mg in 1 mL saline.</td> </tr> <tr> <td class=\"subtitle1_single\">6. Treatment of minor febrile illness or stress</td> </tr> <tr> <td>Increase glucocorticoid dose two- to threefold for the few days of illness. Do not change mineralocorticoid dose.</td> </tr> <tr> <td>Patient is instructed to contact clinician if illness worsens or persists for more than three days.</td> </tr> <tr> <td>No extra supplementation is needed for most uncomplicated, outpatient dental procedures under local anesthesia.</td> </tr> <tr> <td>Glucocorticoid supplement for surgical stress:<br /> <ul> <ul> <li>Minor (eg, herniorrhaphy): hydrocortisone 25 mg IV (or equivalent) on day of procedure </li> <li>Moderate (eg, orthopedic surgery): hydrocortisone 50 to 75 mg IV (or equivalent) on day of surgery and postoperative day 1 </li> <li>Major (eg, cardiac bypass): hydrocortisone 100 to 150 mg IV (or equivalent) in two or three divided doses on day of surgery and postoperative days&nbsp;1 and 2 </li> </ul> </ul> Then return to usual daily glucocorticoid dose.</td> </tr> <tr> <td>General anesthesia or IV sedation should not be performed in the office setting.</td> </tr> <tr> <td class=\"subtitle1_single\">7. Emergency treatment of severe stress or trauma</td> </tr> <tr> <td>Each patient should have an injectable glucocorticoid (eg, 4 mg vials of dexamethasone or 100 mg vials of hydrocortisone) and vials of sterile 0.9% normal saline and syringes.</td> </tr> <tr> <td>Instruct patient/caregivers on how to reconstitute the vial and to inject entire dose intramuscularly or subcutaneously in event of severe stress or trauma and get medical help immediately after injection.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: corticotropin; IV; intravenously.<br />* Hydrocortisone 20 mg and prednisone 50 mg provide a mineralocorticoid effect that is approximately equivalent to 0.1 mg of fludrocortisone, so fludrocortisone replacement (if needed) must be decreased appropriately. Dexamethasone lacks mineralocorticoid effect.<br />Â¶ DHEA is available in the United States and some other countries as a nonprescription dietary supplement, and these products are not well regulated for potency or purity.</div><div class=\"graphic_reference\">Courtesy of Lynette Nieman, MD, with additional data from Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101:364.</div><div id=\"graphicVersion\">Graphic 78904 Version 4.0</div></div></div>"},"78906":{"type":"graphic_table","displayName":"Early postnatal weight","title":"Early postnatal growth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early postnatal growth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Usual pattern</td> <td class=\"subtitle1\">Trigger for action</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Weight loss</strong></td> <td>5 to &#60;7 percent</td> <td>&#62;7 percent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration of weight loss</strong></td> <td>&#60;5 days</td> <td>5 to 10 days</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time to regain birthweight</strong></td> <td>One to two weeks</td> <td>&#62;2 weeks</td> </tr> <tr> <td rowspan=\"5\"><strong>Intervention</strong></td> <td rowspan=\"5\">Routine management</td> <td>Evaluate lactation management</td> </tr> <tr> <td>Rule out primary lactation failure</td> </tr> <tr> <td>Rule out infant oral-motor abnormalities</td> </tr> <tr> <td>Monitor closely, including daily weights</td> </tr> <tr> <td>Consider supplementation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 78906 Version 3.0</div></div></div>"},"78909":{"type":"graphic_picture","displayName":"RTT 20 years of age","title":"Twenty-year-old woman with Rett syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Twenty-year-old woman with Rett syndrome</div><div class=\"cntnt\"><img style=\"width:333px; height:540px;\" src=\"images/NEURO/78909_Twenty_year_old_Rett_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a 20-year-old woman with Rett syndrome and motor problems who continues to ambulate.</div><div id=\"graphicVersion\">Graphic 78909 Version 3.0</div></div></div>"},"78910":{"type":"graphic_picture","displayName":"Bullous pemphigoid axillae","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/78910_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae arising on erythematous plaques, ruptured bullae, and erosions in and around skin of the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78910 Version 2.0</div></div></div>"},"78911":{"type":"graphic_picture","displayName":"Metal gyn speculum","title":"Vaginal speculum types","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Vaginal speculum types</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/OBGYN/78911_Speculum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Pederson speculum. B: Graves speculum.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright Â© Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 78911 Version 3.0</div></div></div>"},"78917":{"type":"graphic_table","displayName":"Adherence improvement HCW","title":"Strategies to improve adherence: clinician and health team-related","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to improve adherence: clinician and health team-related</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>\nEstablish trust.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nServe as educator and information source with ongoing support and\nmonitoring.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nProvide access between visits for questions or problems (eg, by\nproviding a pager number), including during vacations or conferences.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nMonitor ongoing adherence; intensify management during periods of\nsuboptimal adherence (ie, more frequent visits, recruitment of family\nor friends,\ndeployment of other team members, and referral for mental health or\nchemical-dependency services).</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nUse health team for all patients, including patients with special needs\n(eg, use peer educators for adolescents or for injection-drug users).</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nConsider impact of new diagnoses on adherence (eg, depression, liver\ndisease, wasting, or recurrent chemical dependency) and include\nadherence intervention in management.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nUse nurses, pharmacists, peer educators, volunteers, case managers,\ndrug counselors, clinician's assistants, nurse practitioners, and\nresearch nurses to reinforce adherence messages.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nProvide training to support team regarding antiretroviral therapy and\nadherence.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\nAdd adherence interventions to job descriptions of support team\nmembers; add continuity-of-care role to improve patient access.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">http://aidsinfo.nih.gov.</div><div id=\"graphicVersion\">Graphic 78917 Version 1.0</div></div></div>"},"78918":{"type":"graphic_table","displayName":"Medicines to reduce stomach acid PI","title":"Medicines used to reduce stomach acid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines used to reduce stomach acid</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medicine type</td> <td class=\"subtitle1\">Medicine name examples</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antacids*</td> <td>Calcium carbonate (sample brand name: Tums)</td> </tr> <tr class=\"divider_bottom\"> <td>Aluminum hydroxide, magnesium hydroxide, and simethicone (sample brand name: Maalox)</td> </tr> <tr class=\"divider_bottom\"> <td>Surface agents</td> <td>Sucralfate (brand name: Carafate)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Histamine blockers</td> <td>Ranitidine (brand name: Zantac)</td> </tr> <tr> <td>Famotidine (brand name: Pepcid)</td> </tr> <tr class=\"divider_bottom\"> <td>Cimetidine (brand name: Tagamet)</td> </tr> <tr> <td rowspan=\"6\">Proton pump inhibitors</td> <td>Omeprazole (brand name: Prilosec)</td> </tr> <tr> <td>Esomeprazole (brand name: Nexium)</td> </tr> <tr> <td>Pantoprazole (brand name: Protonix)</td> </tr> <tr> <td>Lansoprazole (brand name: Prevacid)</td> </tr> <tr> <td>Dexlansoprazole (brand name: Dexilant)</td> </tr> <tr> <td>Rabeprazole (brand name: AcipHex)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some antacids contain aspirin, which can increase the risk of internal bleeding. Examples of antacids with aspirin include Alka-Seltzer, Medi-Seltzer, and Neutralin. But there are others, too, so it's important to check labels. Talk to your doctor or nurse before taking any medicines that contain aspirin.</div><div id=\"graphicVersion\">Graphic 78918 Version 10.0</div></div></div>"},"78919":{"type":"graphic_table","displayName":"Causes hypoglycemia","title":"Causes of hypoglycemia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypoglycemia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ill or medicated individual</td> </tr> <tr> <td class=\"subtitle2_single\">1. Drugs</td> </tr> <tr> <td class=\"indent1\">Insulin or insulin secretagogue</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Others (refer to UpToDate table on&nbsp;drugs that cause hypoglycemia)</td> </tr> <tr> <td class=\"subtitle2_single\">2. Critical illnesses</td> </tr> <tr> <td class=\"indent1\">Hepatic, renal, or cardiac failure</td> </tr> <tr> <td class=\"indent1\">Sepsis (including malaria)</td> </tr> <tr> <td class=\"indent1\">Inanition</td> </tr> <tr> <td class=\"subtitle2_single\">3. Hormone deficiency</td> </tr> <tr> <td class=\"indent1\">Cortisol</td> </tr> <tr> <td class=\"indent1\">Glucagon and epinephrine (in insulin-deficient diabetes mellitus)</td> </tr> <tr> <td class=\"subtitle2_single\">4. Nonislet cell tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Seemingly well individual</td> </tr> <tr> <td class=\"subtitle2_single\">5. Endogenous hyperinsulinism</td> </tr> <tr> <td class=\"indent1\">Insulinoma</td> </tr> <tr> <td class=\"indent1\">Functional beta cell disorders (nesidioblastosis)</td> </tr> <tr> <td class=\"indent2\">Noninsulinoma pancreatogenous hypoglycemia</td> </tr> <tr> <td class=\"indent2\">Post gastric bypass hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Insulin autoimmune hypoglycemia</td> </tr> <tr> <td class=\"indent2\">Antibody to insulin</td> </tr> <tr> <td class=\"indent2\">Antibody to insulin receptor</td> </tr> <tr> <td class=\"indent1\">Insulin secretagogue</td> </tr> <tr> <td class=\"indent1\">Other</td> </tr> <tr> <td class=\"subtitle2_single\">6. Accidental, surreptitious, or malicious hypoglycemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709. Copyright Â© 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 78919 Version 8.0</div></div></div>"},"78920":{"type":"graphic_picture","displayName":"Black widow spider ventral surface","title":"Black widow spider ventral surface","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Black widow spider ventral surface</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/ALLRG/78920_Spider_bl_widow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 78920 Version 2.0</div></div></div>"},"78922":{"type":"graphic_picture","displayName":"Micro P marneffei","title":"Microscopic examination of <em>Penicillium marneffei</em> mycelia after incubating at 25Â°C on Sabouraud dextrose agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microscopic examination of <em>Penicillium marneffei</em> mycelia after incubating at 25&#176;C on Sabouraud dextrose agar</div><div class=\"cntnt\"><img style=\"width:305px; height:293px;\" src=\"images/ID/78922_Micro_P_marneffei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 78922 Version 1.0</div></div></div>"},"78923":{"type":"graphic_table","displayName":"CYSHCN transition adulthood","title":"Components of transition for adolescents with special health care needs within the medical home model*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of transition for adolescents with special health care needs within the medical home model*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Maintain the adolescent in the home or community whenever possible</td> </tr> <tr> <td>Identify the individual who will be responsible for assessing health status</td> </tr> <tr> <td>Establish a plan for communication with the health care provider</td> </tr> <tr> <td class=\"subtitle1_single\">Organize critical information and make it accessible</td> </tr> <tr> <td>Assess the adolescent's ability to provide an accurate medical history</td> </tr> <tr> <td>Shift the responsibility for information management from the parent to the adolescent or other responsible adult</td> </tr> <tr> <td class=\"subtitle1_single\">Identify the collaborating team</td> </tr> <tr> <td>Reassess the need for specialty and subspecialty care</td> </tr> <tr> <td>Assess the family/adolescent's readiness to make the transition to adult specialist(s)</td> </tr> <tr> <td>Develop a plan for the transition of care to new physicians</td> </tr> <tr> <td>Develop a formal process to say \"goodbye\" to valued, established health care providers</td> </tr> <tr> <td class=\"subtitle1_single\">Coordinate care with family, home, and community providers</td> </tr> <tr> <td>Reassess the developmental appropriateness of current community services</td> </tr> <tr> <td>Determine whether there are unmet needs</td> </tr> <tr> <td>Assess the need for formal evaluation that will help to identify areas of strength and areas where support will be required</td> </tr> <tr> <td class=\"subtitle1_single\">Coordinate subspecialty service of value to the family</td> </tr> <tr> <td>Assess capacity of adolescent to assume responsibility for coordination of care</td> </tr> <tr> <td>Begin to transfer responsibility to the adolescent and allow time for him or her to \"practice\" this responsibility</td> </tr> <tr> <td>Reassign responsibility for areas of needed support</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51299&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* The needs are on a continuum based upon the skills and abilities of the adolescent.</div><div class=\"graphic_reference\">Adapted from: Kelly AM, Kratz B, Bielski M, Rinehart PM. Implementing transitions for youth with complex chronic conditions using the medical home model. Pediatrics 2002; 110:1322.</div><div id=\"graphicVersion\">Graphic 78923 Version 4.0</div></div></div>"},"78924":{"type":"graphic_figure","displayName":"Ankle and foot ligaments lateral view","title":"Ankle and foot ligaments lateral view","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Ankle and foot ligaments lateral view</div><div class=\"cntnt\"><img style=\"width:578px; height:452px;\" src=\"images/EM/78924_Ft_antmy_ltr_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 78924 Version 8.0</div></div></div>"},"78927":{"type":"graphic_figure","displayName":"Anatomy posterior vagina","title":"Anatomy posterior vagina","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Anatomy posterior vagina</div><div class=\"cntnt\"><img style=\"width:451px; height:312px;\" src=\"images/OBGYN/78927_Anatomy_posterior_vagina.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal posterior wall support provided by the levator ani muscles holds the vagina closed. With increased abdominal pressure, the pressure on the posterior vaginal wall is equilibrated by pressure on the anterior vaginal wall (upper arrows), and there is no stress on the connective tissue supports. Distally, the pressure transmitted to the rectum is resisted by the perineal body.</div><div class=\"graphic_footnotes\">ARW: anterior rectal wall; PB: perineal body; PVW: posterior vaginal wall.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters MD, Karram MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 78927 Version 2.0</div></div></div>"},"78928":{"type":"graphic_picture","displayName":"Erysipelas buttock","title":"Erysipelas involving the buttock","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erysipelas involving the buttock</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/78928_Erysipelas_buttock.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 78928 Version 4.0</div></div></div>"},"78935":{"type":"graphic_table","displayName":"Sxs distinguish CFS/SEID FM and TMD","title":"Symptoms that distinguish between chronic fatigue syndrome (systemic exertion intolerance disease), fibromyalgia, and temporomandibular joint disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms that distinguish between chronic fatigue syndrome (systemic exertion intolerance disease), fibromyalgia, and temporomandibular joint disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms common to all three conditions</td> </tr> <tr> <td>Muscle pain, aching, or discomfort</td> </tr> <tr> <td>Problems falling or staying asleep, or sleeping too much</td> </tr> <tr> <td>Wake up feeling tired, unrefreshed after a full night's rest</td> </tr> <tr> <td>Difficulty concentrating or thinking, forgetfulness</td> </tr> <tr> <td>Abdominal pain relieved by a bowel movement</td> </tr> <tr> <td>Hard, loose, or watery stools</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms that distinguish CFS/SEID and FM from TMD</td> </tr> <tr> <td>Fatigue greater than six months</td> </tr> <tr> <td>Fatigue resulting in a 50% reduction of normal activity</td> </tr> <tr> <td>Unexplained muscle weakness</td> </tr> <tr> <td>Migratory arthralgias without redness or swelling</td> </tr> <tr> <td>Burning, shooting, or throbbing muscle pain</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms that distinguish CFS/SEID from FM and TMD</td> </tr> <tr> <td>Mild fever (37.5 to 38.6&#176;C) or chills</td> </tr> <tr> <td>Sore throat</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms that distinguish FM from CFS/SEID and TMD</td> </tr> <tr> <td>Pain made better by heat or massage</td> </tr> <tr> <td>Pain made worse by sitting or standing</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms that distinguish TMD from CFS/SEID and FM</td> </tr> <tr> <td>Pain in jaw muscles, temporomandibular joint, or inside the ear</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFS/SEID: chronic fatigue syndrome, also known as systemic exertion intolerance disease; FM: fibromyalgia; TMD: temporomandibular joint disorder.</div><div class=\"graphic_reference\">Data from: Aaron, LA, Burke, MM, Buchwald, D, Arch Intern Med 2000; 160:221.</div><div id=\"graphicVersion\">Graphic 78935 Version 5.0</div></div></div>"},"78938":{"type":"graphic_waveform","displayName":"ECG strip sinus tachycardia","title":"Electrocardiogram (ECG) showing sinus tachycardia at a rate of 150 beats/min","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing sinus tachycardia at a rate of 150 beats/min</div><div class=\"cntnt\"><img style=\"width:469px; height:176px;\" src=\"images/CARD/78938_Sinus_tachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the difficulty in separating the P waves from the T waves in the standard leads. The P waves are most evident in lead V1 (arrow) where the terminal negativity suggests left atrial enlargement.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 78938 Version 3.0</div></div></div>"},"78941":{"type":"graphic_figure","displayName":"Radical hysterectomy PI","title":"Radical hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Radical hysterectomy</div><div class=\"cntnt\"><img style=\"width:539px; height:476px;\" src=\"images/PI/78941_Radical_hysterectomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a radical hysterectomy, the surgeon removes the uterus and cervix, some of the tissue around the uterus and cervix, and a part of the vagina. It is not always necessary to remove the ovaries. The surgery is usually done through an opening in the belly. But it can also be done \"laparoscopically.\" To do a laparoscopic hysterectomy, the surgeon inserts a tiny camera and tools through small openings in the belly. Then he or she removes the uterus and other tissues through the vagina.</div><div id=\"graphicVersion\">Graphic 78941 Version 6.0</div></div></div>"},"78942":{"type":"graphic_figure","displayName":"Endometriosis pelvis PI","title":"Areas where endometriosis can be found","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Areas where endometriosis can be found</div><div class=\"cntnt\"><img style=\"width:503px; height:618px;\" src=\"images/PI/78942_Endometriosis_pelvis_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows some of the areas in the body (purple spots) where endometriosis can be found. Common areas affected by endometriosis include the ovaries, the tubes connecting the ovaries to the uterus (fallopian tubes), and the bowel. Endometriosis can also grow in front, in back, and to the sides of the uterus. Sometimes the doctor can feel the tissue when doing a pelvic exam.</div><div id=\"graphicVersion\">Graphic 78942 Version 5.0</div></div></div>"},"78943":{"type":"graphic_table","displayName":"Comparative cost effectiveness","title":"Estimated cost effectiveness of various medical interventions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated cost effectiveness of various medical interventions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Cost per year of life gained, in US dollars</td> </tr> <tr> <td>Smoking cessation</td> <td>2587 to 6828</td> </tr> <tr> <td>Pneumonia vaccine in elderly patients</td> <td>1500</td> </tr> <tr> <td>CABG in patients with left main coronary disease and severe angina</td> <td>4329</td> </tr> <tr> <td>Phenylketonuria screening</td> <td>7000</td> </tr> <tr> <td>Kidney transplantation</td> <td>9756</td> </tr> <tr> <td>Cervical cancer screening</td> <td>10,000 to &#62;1,000,000</td> </tr> <tr> <td>Treatment of moderate hypertension (DBP &#62;110 mmHg)</td> <td>11,300</td> </tr> <tr> <td>Heart transplantation</td> <td>16,239</td> </tr> <tr> <td>Treatment of mild hypertension (DBP 90 to 110 mmHg)</td> <td>24,408</td> </tr> <tr> <td>Breast cancer screening</td> <td>26,800</td> </tr> <tr> <td>Treatment of cholesterol &#62;265 mg/dL (6.9 mmol/L) with cholestyramine</td> <td>36,000 to &#62;1,000,000</td> </tr> <tr> <td>Dialysis</td> <td>37,000</td> </tr> <tr> <td>Streptokinase for acute MI in patients &#8805;65 years old</td> <td>55,000</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=63868&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">CABG: coronary artery bypass grafting; DBP: diastolic blood pressure; MI: myocardial infarction.</div><div class=\"graphic_reference\">Adapted from: Croghan IT, Offord KP, Evans RW, et al, Mayo Clin Proc 1997; 72:917.</div><div id=\"graphicVersion\">Graphic 78943 Version 5.0</div></div></div>"},"78946":{"type":"graphic_figure","displayName":"Orofacial clefts","title":"Types of orofacial clefts","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Types of orofacial clefts</div><div class=\"cntnt\"><img style=\"width:542px; height:703px;\" src=\"images/OBGYN/78946_Orofacial_clefts.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78946 Version 1.0</div></div></div>"},"78948":{"type":"graphic_table","displayName":"Classification of retinoblastoma","title":"International classification of intraocular retinoblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International classification of intraocular retinoblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Specific features</td> </tr> <tr> <td>A</td> <td><strong>Very low risk:</strong> Eyes with small discrete tumors away from critical structures</td> <td>Tumor&nbsp;&#8804;3 mm in basal dimension or thickness</td> </tr> <tr> <td>B</td> <td><strong>Low risk:</strong> Eyes with discrete retinal tumor of any size or location without vitreous or subretinal seeding</td> <td class=\"sublist1_start\"> <p>Tumor&nbsp;&#62;3 mm in basal dimension or thickness, or any of the following:</p> <ul class=\"decimal_heading\"> <li>Macular location &#8804;3 mm to foveola </li> <li>Juxtapapillary location &#8804;1.5 mm to disc </li> <li>Clear subretinal fluid &#8804;3 mm from margin </li> </ul> </td> </tr> <tr> <td>C</td> <td><strong>Moderate risk:</strong> Eyes&nbsp;with&nbsp;discrete retinal tumors of any size and location with only focal vitreous or subretinal seeding</td> <td class=\"sublist1_start\"> <p>One of the following:</p> <ul class=\"decimal_heading\"> <li>Subretinal seeds &#8804;3 mm from tumor </li> <li>Vitreous seeds &#8804;3 mm from tumor </li> <li>Both subretinal and vitreous seeds &#8804;3 mm from tumor </li> <li>Less than one quadrant of subretinal fluid in the fundus </li> </ul> </td> </tr> <tr> <td>D</td> <td><strong>High risk:</strong> Eyes with massive nondiscrete tumors and/or diffuse vitreous or subretinal seeding</td> <td class=\"sublist1_start\"> <p>One of the following:</p> <ul class=\"decimal_heading\"> <li>Subretinal seeds &#62;3 mm from tumor </li> <li>Vitreous seeds &#62;3 mm from tumor </li> <li>Both subretinal and vitreous seeds &#62;3 mm from tumor </li> <li>Greater than one quadrant of subretinal fluid in the fundus </li> </ul> </td> </tr> <tr> <td>E</td> <td><strong>Very high risk:</strong> Eyes that have been destroyed anatomically or functionally by the tumor</td> <td class=\"sublist1_start\"> <p>Extensive retinoblastoma&nbsp;or one of the following:</p> <ul class=\"decimal_heading\"> <li><span class=\"decimal_heading\">Neovascular glaucoma</span> </li> <li><span class=\"decimal_heading\">Opaque media from hemorrhage in anterior chamber, vitreous, or subretinal space</span> </li> <li><span class=\"decimal_heading\">Invasion of postlaminar optic nerve, choroid (&#62;2 mm), sclera, orbit, anterior chamber</span> </li> <li><span class=\"decimal_heading\">Tumor anterior to the anterior vitreous face, including the ciliary body or iris</span> </li> <li><span class=\"decimal_heading\">Diffuse infiltrating tumor</span> </li> <li><span class=\"decimal_heading\">Phthisis bulbi or orbital cellulitis</span> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Opthalmol Clin North Am 2005; 18:41.</LI>&#xD;&#xA;<LI>Shields CL, Mashayekhi A, Au AK. The International Classification of Retinoblastoma Predicts Chemoreduction Success. Ophthalmology 2006; 113.2276.</LI>&#xD;&#xA;<LI>Ortize MV, Dunkel IJ. Retinoblastoma. J Child Neurol 2016; 31:227.</LI></OL></div><div id=\"graphicVersion\">Graphic 78948 Version 5.0</div></div></div>"},"78949":{"type":"graphic_figure","displayName":"Mortality metoprolol HF","title":"Metoprolol reduces mortality in patients with heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metoprolol reduces mortality in patients with heart failure</div><div class=\"cntnt\"><img style=\"width:386px; height:363px;\" src=\"images/CARD/78949_Mortality_metoprolol_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MERIT-HF trial randomly assigned 3991 patients with NYHA class II to IV heart failure who were treated with digoxin, angiotensin converting enzyme inhibitors, and digoxin to metoprolol CR/XL or placebo. Kaplan-Meier curves show a significant reduction in total mortality at 12 months with metoprolol (7.2 versus 11 percent for placebo, p = 0.006).</div><div class=\"graphic_reference\">Data from: The MERIT-HF Study Group, Lancet 1999; 353:2001.</div><div id=\"graphicVersion\">Graphic 78949 Version 1.0</div></div></div>"},"78950":{"type":"graphic_figure","displayName":"Posterior superior iliac spine","title":"Posterior superior iliac spine","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Posterior superior iliac spine</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/HEME/78950_Post-sup-iliac-spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration&nbsp;of the posterior pelvis. In most persons, the posterior superior iliac spine&nbsp;can be easily palpated as a bony prominence&nbsp;at the posterior end of the iliac crest. The bone marrow needle should be inserted at the top of this prominence (at the site of the asterisk). As shown by the arrow, it should be angled in the direction of the anterior superior iliac spine, a prominence found at the anterior end of the iliac crest.</div><div id=\"graphicVersion\">Graphic 78950 Version 2.0</div></div></div>"},"78952":{"type":"graphic_figure","displayName":"Implant nasal vest CA","title":"Diagram of an interstitial implant for nasal vestibule carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of an interstitial implant for nasal vestibule carcinoma</div><div class=\"cntnt\"><img style=\"width:401px; height:536px;\" src=\"images/ONC/78952_ImplantnasalvestCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright Â© 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 78952 Version 11.0</div></div></div>"},"78954":{"type":"graphic_picture","displayName":"Hyperacute rejection light","title":"Renal allograft biopsy showing hyperacute rejection by light microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal allograft biopsy showing hyperacute rejection by light microscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/NEPH/78954_Hyperacute_rejection_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a glomerulus in hyperacute rejection. There is a thrombus in the afferent arteriole (arrow) and there is extensive necrosis of the glomerular tuft (which has few cells) and the surrounding parenchyma.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78954 Version 3.0</div></div></div>"},"78957":{"type":"graphic_figure","displayName":"Toupet fundoplication","title":"Toupet fundoplication","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Toupet fundoplication</div><div class=\"cntnt\"><img style=\"width:465px; height:411px;\" src=\"images/GAST/78957_Toupet_fundoplication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Toupet fundoplication is a partial fundoplication creating a collar of approximately 270Â° around the esophagus posteriorly.</div><div id=\"graphicVersion\">Graphic 78957 Version 2.0</div></div></div>"},"78958":{"type":"graphic_picture","displayName":"Ulcerating esoph CA EGD","title":"Ulcerating malignant esophageal mass in distal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerating malignant esophageal mass in distal esophagus</div><div class=\"cntnt\"><img style=\"width:264px; height:247px;\" src=\"images/GAST/78958_Ulcerating_esoph_CA_EGD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerating malignant esophageal mass in distal esophagus seen on endoscopy.</div><div class=\"graphic_reference\">Courtesy of William Brugge, MD.</div><div id=\"graphicVersion\">Graphic 78958 Version 1.0</div></div></div>"},"78959":{"type":"graphic_figure","displayName":"Pathophysiology of DIC","title":"Pathophysiology of the clinical manifestations of disseminated intravascular coagulation","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of the clinical manifestations of disseminated intravascular coagulation</div><div class=\"cntnt\"><img style=\"width:499px; height:438px;\" src=\"images/HEME/78959_Pathophysiology_of_DIC.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 78959 Version 3.0</div></div></div>"},"78960":{"type":"graphic_figure","displayName":"Temporal dispersion","title":"Temporal dispersion motor conduction","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Temporal dispersion motor conduction</div><div class=\"cntnt\"><img style=\"width:484px; height:557px;\" src=\"images/NEURO/78960_Temporal_dispersion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With increasing lengths of nerve segment between stimulating and recording electrodes, temporal dispersion increases and amplitude decreases.<br> <strong>A:</strong> Stimulus onset.<br> <strong>B:</strong> CMAP onset.<br> <strong>C:</strong> Peak amplitude of negative phase.<br> <strong>D:</strong> Return to baseline.<br> <strong>E:</strong> Peak of positive phase.<br> <strong>F:</strong> Return to baseline.<br> <strong>A-B:</strong> Latency.<br> <strong>B-C:</strong> Rise time.<br> <strong>B-C-D:</strong> Area under the curve.<br> <strong>B-D:</strong> Duration of negative phase.<br> <strong>C-E:</strong> Peak-to-peak amplitude.</div><div id=\"graphicVersion\">Graphic 78960 Version 1.0</div></div></div>"},"78961":{"type":"graphic_figure","displayName":"Jabbing method","title":"Techniques for transbronchial penetration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Techniques for transbronchial penetration</div><div class=\"cntnt\"><img style=\"width:310px; height:248px;\" src=\"images/PULM/78961_Jabbing_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram shows the jabbing method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope is held stationary while the needle assembly is jabbed forward.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research- Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 78961 Version 1.0</div></div></div>"},"78962":{"type":"graphic_table","displayName":"Clinical indications for allergen immunotherapy","title":"Clinical indications for allergen immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical indications for allergen immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Symptoms of allergic rhinitis, allergic conjunctivitis, allergic asthma, or any combination of these disorders after natural exposure to aeroallergens</td> </tr> <tr> <td><strong>AND</strong></td> </tr> <tr> <td>Demonstrable evidence of clinically relevant specific IgE</td> </tr> <tr> <td><strong>AND</strong></td> </tr> <tr> <td class=\"sublist1_start\">At least one of the following:</td> </tr> <tr> <td class=\"sublist1\">Poor response to pharmacotherapy, allergen avoidance, or both</td> </tr> <tr> <td class=\"sublist1\">Unacceptable adverse effects of medications</td> </tr> <tr> <td class=\"sublist1\">Wish to reduce or avoid long-term pharmacotherapy and the cost of medication</td> </tr> <tr> <td class=\"sublist1\">Possible prevention of asthma in patients with allergic rhinitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 78962 Version 8.0</div></div></div>"},"78963":{"type":"graphic_diagnosticimage","displayName":"Acute colonic pseudo-obstruction","title":"Acute colonic pseudo-obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute colonic pseudo-obstruction</div><div class=\"cntnt\"><img style=\"width:266px; height:288px;\" src=\"images/GAST/78963_Acute_colonic_pseudoobstruc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiograph in a patient with septic shock and leukemia reveals a massively dilated and air filled right and transverse colon. Haustral markings are normal.</div><div class=\"graphic_reference\">Courtesy of Michael Camilleri, MD.</div><div id=\"graphicVersion\">Graphic 78963 Version 3.0</div></div></div>"},"78964":{"type":"graphic_picture","displayName":"Grade I to II hyphema","title":"Grade I to II hyphema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade I to II hyphema</div><div class=\"cntnt\"><img style=\"width:421px; height:276px;\" src=\"images/EM/78964_Hyphema_grade_I_to_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A layered Grade I to II hyphema inferiorly is seen as well as an area of active bleeding from the superior iris.</div><div class=\"graphic_reference\">Photo courtesy of Kathryn A Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 78964 Version 4.0</div></div></div>"},"78966":{"type":"graphic_table","displayName":"Comparison of coronary diagnostic techniques","title":"Comparison of coronary diagnostic techniques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of coronary diagnostic techniques</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Angioscopy</td> <td class=\"subtitle1\">Coronary arteriography</td> <td class=\"subtitle1\">Intravascular ultrasound</td> <td class=\"subtitle1\">Optical coherence tomography</td> </tr> <tr> <td>Color tone</td> <td>Color</td> <td>Black and white</td> <td>Black and white</td> <td>False color (eg, sepia) or black and white</td> </tr> <tr> <td>Picture expression</td> <td>3-dimension</td> <td>2-dimension</td> <td>2-dimension</td> <td>2-dimension and 3-dimension</td> </tr> <tr> <td>High resolution</td> <td>++</td> <td>+</td> <td>+</td> <td>+++</td> </tr> <tr> <td>Quantification</td> <td>-</td> <td>++</td> <td>++</td> <td>++</td> </tr> <tr> <td>General picture</td> <td>-</td> <td>-</td> <td>++</td> <td>++</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Tissue characterization</td> </tr> <tr> <td class=\"sublist1\">Intraluminal</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> </tr> <tr> <td class=\"sublist1\">Intramural</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">++ </td> <td class=\"sublist_other\">+</td> </tr> <tr> <td class=\"sublist1\">Thrombus</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">+++</td> </tr> <tr> <td class=\"sublist1\">Calcification</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+++</td> </tr> <tr> <td class=\"sublist1\">Plaque characterization</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">++</td> <td class=\"sublist_other\">++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">++: excellent; +: good; -: poor.</div><div id=\"graphicVersion\">Graphic 78966 Version 3.0</div></div></div>"},"78967":{"type":"graphic_picture","displayName":"MPGN Light II","title":"Membranoproliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Membranoproliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/78967_MPGN_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of membranoproliferative glomerulonephritis (MPGN) showing thickening of all capillary walls with double contours (long arrows) and focal areas of cellular proliferation (short arrow). The double-contour or tram-track appearance represents interposition of mesangial cell elements with new glomerular basement membrane synthesis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78967 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"78968":{"type":"graphic_picture","displayName":"P-ANCA pattern on indirect immunofluorescence","title":"P-ANCA pattern on indirect immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">P-ANCA pattern on indirect immunofluorescence</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/78968_P_ANCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Demonstration of perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) by indirect immunofluorescence with normal neutrophils. Staining is limited to the perinuclear region, and the cytoplasm is nonreactive. Among patients with vasculitis, the antibodies are usually directed against MPO. However, a P-ANCA pattern can also be seen with autoantibodies against a number of other antigens including lactoferrin and elastase. Non-MPO P-ANCA can be seen in a variety of nonvasculitic disorders.</div><div class=\"graphic_footnotes\">MPO: myeloperoxidase.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 78968 Version 5.0</div></div></div>"},"78969":{"type":"graphic_table","displayName":"Limb-girdle muscular dystrophies","title":"Limb-girdle muscular dystrophies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Limb-girdle muscular dystrophies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Gene&nbsp;</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Inheritance</td> </tr> <tr> <td>LGMD1A</td> <td>5q31</td> <td>&nbsp;MYOT</td> <td>Myotilin</td> <td>AD</td> </tr> <tr> <td>LGMD1B</td> <td>1q21.2</td> <td>&nbsp;LMNA</td> <td>Lamin A/C</td> <td>AD</td> </tr> <tr> <td>LGMD1C</td> <td>3p25</td> <td>&nbsp;CAV3</td> <td>Caveolin-3</td> <td>AD</td> </tr> <tr> <td>LGMD1D</td> <td>7q36</td> <td>&nbsp;DNAJB6</td> <td>DnaJ homolog subfamily B member 6</td> <td>AD</td> </tr> <tr> <td>LGMD1E</td> <td>2q35</td> <td>&nbsp;DES</td> <td>Desmin</td> <td>AD</td> </tr> <tr> <td>LGMD1F</td> <td>7q32.1</td> <td>&nbsp;TNPO3</td> <td>Transportin 3</td> <td>AD</td> </tr> <tr> <td>LGMD1G</td> <td>4q21.21</td> <td>&nbsp;HNRNPDL </td> <td>Heterogeneous nuclear ribonucleoprotein D-like protein</td> <td>AD</td> </tr> <tr> <td>LGMD1H</td> <td>3p25.1-p23</td> <td>&nbsp;Unknown</td> <td>Unknown</td> <td>AD</td> </tr> <tr> <td>LGMD2A</td> <td>15q15.1-q21.1</td> <td>&nbsp;CAPN3</td> <td>Calpain-3</td> <td>AR</td> </tr> <tr> <td>LGMD2B</td> <td>2p13.3-p13.1</td> <td>&nbsp;DYSF</td> <td>Dysferlin</td> <td>AR</td> </tr> <tr> <td>LGMD2C</td> <td>13q12</td> <td>&nbsp;SGCG</td> <td>Gamma-sarcoglycan</td> <td>AR</td> </tr> <tr> <td>LGMD2D</td> <td>17q12-q21.33</td> <td>&nbsp;SGCA</td> <td>Alpha-sarcoglycan</td> <td>AR</td> </tr> <tr> <td>LGMD2E</td> <td>4q12</td> <td>&nbsp;SGCB</td> <td>Beta-sarcoglycan</td> <td>AR</td> </tr> <tr> <td>LGMD2F</td> <td>5q33-q34</td> <td>&nbsp;SGCD</td> <td>Delta-sarcoglycan</td> <td>AR</td> </tr> <tr> <td>LGMD2G</td> <td>17q12</td> <td>&nbsp;TCAP</td> <td>Telethonin</td> <td>AR</td> </tr> <tr> <td>LGMD2H</td> <td>9q32-9q34.11</td> <td>&nbsp;TRIM32</td> <td>Tripartite motif containing 32</td> <td>AR</td> </tr> <tr> <td>LGMD2I</td> <td>19q13.3</td> <td>&nbsp;FKRP</td> <td>Fukutin related protein</td> <td>AR</td> </tr> <tr> <td>LGMD2J</td> <td>2q24.3</td> <td>&nbsp;TTN</td> <td>Titin</td> <td>AR</td> </tr> <tr> <td>LGMD2K</td> <td>9q34.1</td> <td>&nbsp;POMT1</td> <td>Protein-O-mannosyl transferase 1</td> <td>AR</td> </tr> <tr> <td>LGMD2L</td> <td>11p14.3</td> <td>&nbsp;ANO5</td> <td>Anoctamin 5</td> <td>AR</td> </tr> <tr> <td>LGMD2M</td> <td>9q31</td> <td>&nbsp;FKTN</td> <td>Fukutin</td> <td>AR</td> </tr> <tr> <td>LGMD2N</td> <td>14q24.3</td> <td>&nbsp;POMT2</td> <td>Protein-O-mannosyl transferase 2</td> <td>AR</td> </tr> <tr> <td>LGMD2O</td> <td>1p34-p33</td> <td>&nbsp;POMGnT1</td> <td>Protein O-linked mannose beta1,2-N-acetylglucosaminyl transferase</td> <td>AR</td> </tr> <tr> <td>LGMD2P</td> <td>3p21 </td> <td>&nbsp;DAG1&nbsp; </td> <td>Dystroglycan</td> <td>AR</td> </tr> <tr> <td>LGMD2Q</td> <td>8q24 </td> <td>&nbsp;PLEC1&nbsp; </td> <td>Plectin</td> <td>AR</td> </tr> <tr> <td>LGMD2R</td> <td>2q35 </td> <td>&nbsp;DES&nbsp; </td> <td>Desmin </td> <td>AR</td> </tr> <tr> <td>LGMD2S</td> <td>4q35 </td> <td>&nbsp;TRAPPC11 </td> <td>Transport protein particle complex 11</td> <td>AR</td> </tr> <tr> <td>LGMD2T</td> <td>3p21 </td> <td>&nbsp;GMPPB </td> <td>GDP-mannosepyrophosphorylase B<br /> </td> <td>AR</td> </tr> <tr> <td>LGMD2U</td> <td>7p21 </td> <td>&nbsp;ISPD </td> <td>Isoprenoid synthase domain containing</td> <td>AR</td> </tr> <tr> <td>LGMD2V</td> <td>17q25.3 </td> <td>&nbsp;GAA </td> <td>Alpha-1,4-glucosidase</td> <td>AR</td> </tr> <tr> <td>LGMD2W</td> <td>2q14 </td> <td>&nbsp;LIMS2 </td> <td>Lim and senescent cell antigen-like domains 2</td> <td>AR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; LGMD: limb-girdle muscular dystrophy</div><div class=\"graphic_reference\">Modified from: Darras BT, Jones HR, Jr. Diagnosis of pediatric neuromuscular disorders in the era of DNA analysis. Pediatr Neurol 2000; 23:289.<br />Data from: Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol 2014; 33:1.</div><div id=\"graphicVersion\">Graphic 78969 Version 8.0</div></div></div>"},"78971":{"type":"graphic_table","displayName":"Lab practices to avoid Brucella exposure","title":"Recommendations for safe laboratory practices to avoid exposure to <EM>Brucella</EM> spp","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for safe laboratory practices to avoid exposure to <EM>Brucella</EM> spp</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>When brucellosis is suspected, clinicians or forwarding laboratories should note on the laboratory submission: \"Suspect or rule out brucellosis.\"</td> </tr> <tr> <td>Review laboratory containment methods and microbiologic procedures to ensure compliance with recommendations in the Biosafety in Microbiological and Biomedical Laboratories, Fifth Edition.</td> </tr> <tr> <td>Use primary barriers (ie, safety centrifuge cups, personal protective equipment, and class II or higher biological safety cabinets [BSCs]) for procedures with a high likelihood of producing droplet splashes or aerosols.</td> </tr> <tr> <td>Use secondary barriers: Restrict access to the laboratory when work is being performed and maintain the integrity of the laboratory air-handling system by keeping external doors and windows closed.</td> </tr> <tr> <td>Avoid causing splashes or aerosols when performing procedures on unidentified isolates.</td> </tr> <tr> <td>Prohibit sniffing of open culture plates to assist in the identification of isolates.</td> </tr> <tr> <td>Manipulate isolates of small gram-negative or gram-variable rods initially inside a BSC.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: MMWR Surveill Summ 2008; 57:39.</div><div id=\"graphicVersion\">Graphic 78971 Version 3.0</div></div></div>"},"78972":{"type":"graphic_algorithm","displayName":"Eval Rx malignancy ascites","title":"Evaluation and treatment of malignancy-related ascites","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Evaluation and treatment of malignancy-related ascites</div><div class=\"cntnt\"><img style=\"width:560px; height:848px;\" src=\"images/GAST/78972_Eval_Rx_malignancy_ascites.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SAAG: serum-ascites albumin gradient.</div><div id=\"graphicVersion\">Graphic 78972 Version 2.0</div></div></div>"},"78973":{"type":"graphic_table","displayName":"Skin changes in pregnancy","title":"Pregnancy-related physiologic surface changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy-related physiologic surface changes</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Skin\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperpigmentation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Melasma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Striae</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Telangiectasia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Palmar erythema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nonpitting edema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Varicosities</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pruritus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pyogenic granuloma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Hair\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hirsutism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Postpartum hair loss</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Frontal thinning</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Nails\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Subungual hyperkeratosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Distal onycholysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transverse grooves</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Brittleness</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rapid growth</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Sweat and sebaceous glands\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased eccrine and sebaceous function</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased apocrine function</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Mucous membranes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Gingival hyperemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Gingivitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bluish discoloration of the cervix</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Erythema of the vagina</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=44515&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Skin_changes_in_pregnancy.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Wong RC, Ellis CN. Physiologic skin changes in pregnancy. J Am Acad Dermatol 1984; 10:929.</div><div id=\"graphicVersion\">Graphic 78973 Version 2.0</div></div></div>"},"78974":{"type":"graphic_picture","displayName":"Cystic fibrosis light","title":"Histology of the lung in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of the lung in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/PULM/78974_Cystic_fibrosis_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of an airway in cystic fibrosis demonstrating a plug of mucoid material and inflammatory cells as well as hyperplasia of the submucosal glands.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD.</div><div id=\"graphicVersion\">Graphic 78974 Version 2.0</div></div></div>"},"78975":{"type":"graphic_figure","displayName":"Repeated exercise challenge","title":"Refractoriness to repeated exercise-induced bronchoconstriction","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Refractoriness to repeated exercise-induced bronchoconstriction</div><div class=\"cntnt\"><img style=\"width:488px; height:318px;\" src=\"images/PULM/78975_Repeated_exercise_challenge.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exercise-induced bronchoconstriction (as measured by a fall in FEV1) is attenuated when a second exercise challenge is performed one hour after an initial challenge.</div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in&nbsp;one second.</div><div id=\"graphicVersion\">Graphic 78975 Version 2.0</div></div></div>"},"78976":{"type":"graphic_figure","displayName":"Persistent white coat hypertension","title":"Persistent white coat hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistent white coat hypertension</div><div class=\"cntnt\"><img style=\"width:448px; height:246px;\" src=\"images/NEPH/78976_Persistent_white_coat_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurement of systolic blood pressure by nurses at two screening visits (S1 and S2) and during five-year follow-up in patients from the Medical Research Council Mild Hypertension trial. The measurements made by a doctor are denoted by D; all other measurements were made by nurses. A white coat effect, leading to higher measurements by doctors, is present throughout the study, being most prominent at the entry examination (E).</div><div class=\"graphic_reference\">Redrawn from: Millar JA, Isles CG, Lever AF. J Hypertens 1995; 13:175.</div><div id=\"graphicVersion\">Graphic 78976 Version 3.0</div></div></div>"},"78978":{"type":"graphic_picture","displayName":"Nodules in coccidioidomycosis","title":"Nodular lesions of coccidioido- mycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lesions of coccidioido- mycosis</div><div class=\"cntnt\"><img style=\"width:257px; height:360px;\" src=\"images/ID/78978_Nodules_in_coccidioidomycos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominent raised nodules on the nose and cheek due to disseminated coccidioidomycosis.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 78978 Version 3.0</div></div></div>"},"78979":{"type":"graphic_table","displayName":"Headache causes in children","title":"Life-threatening and common causes of headache in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Life-threatening and common causes of headache in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Bacterial meningitis*</td> </tr> <tr> <td class=\"indent1\">Viral encephalitis*</td> </tr> <tr> <td class=\"indent1\">Orbital or cerebral abscess*</td> </tr> <tr> <td class=\"indent1\">Viral infection, including viral meningitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Lyme meningitis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pharyngitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Otitis media<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Sinusitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Dental infection<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Increased intracranial pressure</td> </tr> <tr> <td class=\"indent1\">Tumor*</td> </tr> <tr> <td class=\"indent1\">Hydrocephalus*</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage*</td> </tr> <tr> <td class=\"indent1\">Idiopathic intracranial hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide poisoning*</td> </tr> <tr> <td class=\"indent1\">Hypertensive encephalopathy*</td> </tr> <tr> <td class=\"indent1\">Temporomandibular joint dysfunction</td> </tr> <tr> <td class=\"indent1\">Cluster headache</td> </tr> <tr> <td class=\"subtitle1_single\">Primary headache</td> </tr> <tr> <td class=\"indent1\">Migraine<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Tension-type headache<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Chronic daily headache</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Life-threatening condition.<br />Â¶ Common condition.</div><div id=\"graphicVersion\">Graphic 78979 Version 6.0</div></div></div>"},"78980":{"type":"graphic_figure","displayName":"Congenital gen lipodystrophy","title":"Patients with congenital generalized lipodystrophies","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Patients with congenital generalized lipodystrophies</div><div class=\"cntnt\"><img style=\"width:476px; height:583px;\" src=\"images/ENDO/78980_Congenitalgenlipodystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This panel shows a woman and a man with CGL types 1 and 2. Type 1 is due to a mutation in the 1-acylglycerol-3-phosphate O-acyltransferase 2 gene. Type 2 is due to a mutation in the seipin gene. Both types are characterized by a generalized lack of fat, extreme muscularity, acanthosis nigricans in the groin and axillae, and acromegaloid features. Patients with CGL2 have a higher prevalence of intellectual impairment and cardiomyopathy than those with CGL1.</div><div class=\"graphic_footnotes\">CGL: congenital generalized lipodystrophy.</div><div id=\"graphicVersion\">Graphic 78980 Version 6.0</div></div></div>"},"78983":{"type":"graphic_table","displayName":"Etiology of lactic acidosis","title":"Etiology of lactic acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of lactic acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased lactate production</td> </tr> <tr> <td class=\"subtitle2_single\">Increased pyruvate production</td> </tr> <tr> <td class=\"indent1\">Enzymatic defects in glycogenolysis or gluconeogenesis (as with type 1 glycogen storage disease)</td> </tr> <tr> <td class=\"indent1\">Respiratory alkalosis, including salicylate intoxication</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Beta-agonists&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sepsis&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Impaired pyruvate utilization</td> </tr> <tr> <td class=\"sublist2_start\">Decreased activity of pyruvate dehydrogenase or pyruvate carboxylase</td> </tr> <tr> <td class=\"sublist2\">&#8226; Congenital</td> </tr> <tr> <td class=\"sublist2\">&#8226; Possibly a role in diabetes mellitus, Reye syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Altered redox state favoring pyruvate conversion to lactate</td> </tr> <tr> <td class=\"sublist2_start\">Enhanced metabolic rate</td> </tr> <tr> <td class=\"sublist2\">&#8226; Grand mal seizure</td> </tr> <tr> <td class=\"sublist2\">&#8226; Severe exercise</td> </tr> <tr> <td class=\"sublist2\">&#8226; Hypothermic shivering</td> </tr> <tr> <td class=\"sublist2\">&#8226; Severe asthma</td> </tr> <tr> <td class=\"sublist2_start\">Decreased oxygen delivery</td> </tr> <tr> <td class=\"sublist2\">&#8226; Shock</td> </tr> <tr> <td class=\"sublist2\">&#8226; Cardiac arrest</td> </tr> <tr> <td class=\"sublist2\">&#8226; Acute pulmonary edema</td> </tr> <tr> <td class=\"sublist2\">&#8226; Carbon monoxide poisoning</td> </tr> <tr> <td class=\"sublist2\">&#8226; Severe hypoxemia (PO<sub>2</sub> &#60;25 to 30 mmHg)</td> </tr> <tr> <td class=\"sublist2\">&#8226; Pheochromocytoma</td> </tr> <tr> <td class=\"sublist2_start\">Reduced oxygen utilization</td> </tr> <tr> <td class=\"sublist2\">&#8226; Cyanide intoxication (decreased oxidative metabolism), which may result from cyanide poisoning or, during a fire, from smoke inhalation of vapors derived from the thermal decomposition of nitrogen-containing materials such as wool, silk, and polyurethane</td> </tr> <tr> <td class=\"sublist2\">&#8226; Drug-induced mitochondrial dysfunction due to zidovudine or stavudine</td> </tr> <tr> <td class=\"sublist2\">&#8226; Sepsis</td> </tr> <tr> <td class=\"subtitle2_single\">D-lactic acidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Primary decrease in lactate utilization</td> </tr> <tr> <td class=\"indent1\">Hypoperfusion and marked acidemia</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"subtitle1_single\">Mechanism uncertain</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus, including metformin in the absence of tissue hypoxia</td> </tr> <tr> <td class=\"indent1\">Acquired immunodeficiency syndrome</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Although this table has been divided into either increased production or decreased utilization of lactate, there is considerable overlap among listed causes.</div><div class=\"graphic_reference\">Modified with permission from: Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.594. Copyright Â© 2001 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 78983 Version 7.0</div></div></div>"},"78986":{"type":"graphic_table","displayName":"Age-related changes in adaptive immunity","title":"Age-related changes in the adaptive immune system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-related changes in the adaptive immune system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Age-related decrease</td> <td class=\"subtitle1\">Age-related increase</td> <td class=\"subtitle1\">No change</td> </tr> <tr> <td>Thymic precursors</td> <td> <p>Thymus size</p> <p>Number of thymic precursors</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>T lymphocytes</td> <td> <p>Number of na&#239;ve T cells</p> <p>Diversity of T cell repertoire</p> <p>Proliferative capacity</p> <p>Signaling intensity</p> <p>Regulatory T cell function</p> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>B lymphocytes</td> <td> <p>B cells precursors in the bone marrow (pre-B cells)</p> <p>Peripheral B cell numbers</p> <p>B cell repertoire</p> <p>Antibody response</p> <p>Opsonizing capacity of immunoglobulins</p> </td> <td>Autoreactive serum antibodies</td> <td>Immunoglobulin levels (may increase)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=86870&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 78986 Version 2.0</div></div></div>"},"78990":{"type":"graphic_figure","displayName":"EEG electrode placement","title":"International electrode placement system","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">International electrode placement system</div><div class=\"cntnt\"><img style=\"width:543px; height:404px;\" src=\"images/RHEUM/78990_EEG_electrode_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The location of electrodes for recording electroencephalograms from the scalp, nasopharyngeal, and external ear sites are shown. The leads placed on the zygomatic arch beneath the eye allow for monitoring of eye movements.</div><div class=\"graphic_reference\">Adapted from: Jasper HH. Report of the committee on methods of clinical examination in electroencephalography: 1957. Electroencephalogr Clin Neurophysiol 1958; 10:370.</div><div id=\"graphicVersion\">Graphic 78990 Version 2.0</div></div></div>"},"78991":{"type":"graphic_picture","displayName":"Gastrointestinal stromal tumor in the small bowel","title":"Gastrointestinal stromal tumor in the small bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal stromal tumor in the small bowel</div><div class=\"cntnt\"><img style=\"width:432px; height:415px;\" src=\"images/GAST/78991_Gastro_stromal_tumor_small_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastrointestinal stromal tumor of the small bowel detected during double balloon enteroscopy.</div><div class=\"graphic_reference\">Courtesy of Hiroto Kita, MD, PhD.</div><div id=\"graphicVersion\">Graphic 78991 Version 2.0</div></div></div>"},"78993":{"type":"graphic_picture","displayName":"Myelokathexis","title":"Myelokathexis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myelokathexis</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/HEME/78993_Myelokathexis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with neutropenia due to myelokathexis. There is an increased number of mature and hypersegmented neutrophils. The myelokathexis morphology is characterized by pyknotic nuclei with lengthening and thinning of intrasegmented filaments and vacuoles.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 78993 Version 1.0</div></div></div>"},"78995":{"type":"graphic_figure","displayName":"Anatomy embryology pancreas div","title":"Anatomy and embryology of pancreas divisum","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Anatomy and embryology of pancreas divisum</div><div class=\"cntnt\"><img style=\"width:548px; height:678px;\" src=\"images/GAST/78995_Anatomy_embryology_pancreas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pancreas develops from two parts whose ducts are in continuity with the common bile duct. One part is ventral and the other dorsal to the intestinal tract before rotation. The rotation brings the two parts together with separate ducts. The duct of the dorsal (larger) part later becomes continuous, enters that of the ventral part which enters the duodenum with the common bile duct. However, in a congenital malformation (pancreas divisum) the other two parts of the pancreas remain distinct, each with its own duct.</div><div id=\"graphicVersion\">Graphic 78995 Version 3.0</div></div></div>"},"78996":{"type":"graphic_picture","displayName":"Hemiretinal vein occlusion","title":"Hemiretinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemiretinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:386px; height:385px;\" src=\"images/PC/78996_Hemiretinal_vein_occlusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraretinal hemorrhages in half of the retina on funduscopic examination.</div><div id=\"graphicVersion\">Graphic 78996 Version 2.0</div></div></div>"},"78997":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray tetralogy Fallot","title":"Tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:468px; height:369px;\" src=\"images/CARD/78997_Chest_xray_tetralogy_Fallot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chest radiograph demonstrates some of the classic findings of tetralogy of Fallot. The lungs are hyperinflated, and there is overall decreased pulmonary vascularity. There is a right aortic arch. The cardiac apex is upturned due to right ventricular enlargement.</div><div class=\"graphic_reference\">Courtesy of Jeanne Chow, MD, and Children's Hospital Boston.</div><div id=\"graphicVersion\">Graphic 78997 Version 3.0</div></div></div>"},"78999":{"type":"graphic_figure","displayName":"Risk of perinatal death in terms of BPP and GA","title":"Comparison of neonatal death rates as predicted by gestational age and fetal death rates as predicted by the fetal biophysical profile (BPP) score","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of neonatal death rates as predicted by gestational age and fetal death rates as predicted by the fetal biophysical profile (BPP) score</div><div class=\"cntnt\"><img style=\"width:425px; height:379px;\" src=\"images/OBGYN/78999_Perinatal_death_by_BPP_and.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The red line represents the probability of neonatal death by gestational age. For example, the risk of fetal death with a BPP score of 2/10 is approximately 20%. Therefore, when the BPP score is 2/10, the risk of neonatal death is less than the risk of fetal death if the gestational age is greater than 28 weeks. This graph should be used for illustration only because the neonatal survival rate shown here from the University of Manitoba in 1995 will differ from other centers and more contemporary data. However, the predictive accuracy of the BPP score is unlikely to vary among centers.</div><div class=\"graphic_reference\">Data from: Manning FA. Dynamic ultrasound-based fetal assessment: The fetal biophysical profile score. Clin Obstet Gynecol 1995; 38:26.</div><div id=\"graphicVersion\">Graphic 78999 Version 3.0</div></div></div>"}};